Peer-Reviewed Journal Tracking and Analyzing Disease Trends
Pages 1609–1784
EDITOR-IN-CHIEF
D. Peter Drotman
Associate Editors
Paul Arguin, Atlanta, Georgia, USA
Charles Ben Beard, Fort Collins, Colorado, USA
Ermias Belay, Atlanta, Georgia, USA
David Bell, Atlanta, Georgia, USA
Sharon Bloom, Atlanta, GA, USA
Mary Brandt, Atlanta, Georgia, USA
Corrie Brown, Athens, Georgia, USA
Charles Calisher, Fort Collins, Colorado, USA
Michel Drancourt, Marseille, France
Paul V. Effler, Perth, Australia
Anthony Fiore, Atlanta, Georgia, USA
David Freedman, Birmingham, Alabama, USA
Peter Gerner-Smidt, Atlanta, Georgia, USA
Stephen Hadler, Atlanta, Georgia, USA
Matthew Kuehnert, Edison, New Jersey, USA
Nina Marano, Atlanta, Georgia, USA
Martin I. Meltzer, Atlanta, Georgia, USA
David Morens, Bethesda, Maryland, USA
J. Glenn Morris, Gainesville, Florida, USA
Patrice Nordmann, Fribourg, Switzerland
Ann Powers, Fort Collins, Colorado, USA
Didier Raoult, Marseille, France
Pierre Rollin, Atlanta, Georgia, USA
Frank Sorvillo, Los Angeles, California, USA
David Walker, Galveston, Texas, USA
J. Todd Weber, Atlanta, Georgia, USA
Managing Editor
Byron Breedlove, Atlanta, Georgia, USA
Copy Editors Kristina Clark, Dana Dolan, Karen Foster,
Thomas Gryczan, Jean Michaels Jones, Michelle Moran, Shannon
O’Connor, Jude Rutledge, P. Lynne Stockton, Deborah Wenger
Production Thomas Eheman, William Hale, Barbara Segal,
Reginald Tucker
Editorial Assistants Kristine Phillips, Susan Richardson
Communications/Social Media Sarah Logan Gregory,
Tony Pearson-Clarke
Founding Editor
Joseph E. McDade, Rome, Georgia, USA
Emerging Infectious Diseases is published monthly by the Centers for Disease Control
and Prevention, 1600 Clifton Rd NE, Mailstop H16-2, Atlanta, GA 30329-4027, USA.
Telephone 404-639-1960, fax 404-639-1954, email eideditor@cdc.gov.
The conclusions, findings, and opinions expressed by authors contributing
to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for
Disease Control and Prevention, or the authors’ affiliated institutions. Use of
trade names is for identification only and does not imply endorsement by any
of the groups named above.
All material published in Emerging Infectious Diseases is in the public
domain and may be used and reprinted without special permission; proper
citation, however, is required.
EDITORIAL BOARD
Timothy Barrett, Atlanta, Georgia, USA
Barry J. Beaty, Fort Collins, Colorado, USA
Martin J. Blaser, New York, New York, USA
Richard Bradbury, Atlanta, Georgia, USA
Christopher Braden, Atlanta, Georgia, USA
Arturo Casadevall, New York, New York, USA
Kenneth C. Castro, Atlanta, Georgia, USA
Benjamin J. Cowling, Hong Kong, China
Vincent Deubel, Shanghai, China
Christian Drosten, Charité Berlin, Germany
Isaac Chun-Hai Fung, Statesboro, Georgia, USA
Kathleen Gensheimer, College Park, Maryland, USA
Duane J. Gubler, Singapore
Richard L. Guerrant, Charlottesville, Virginia, USA
Scott Halstead, Arlington, Virginia, USA
Katrina Hedberg, Portland, Oregon, USA
David L. Heymann, London, UK
Keith Klugman, Seattle, Washington, USA
Takeshi Kurata, Tokyo, Japan
S.K. Lam, Kuala Lumpur, Malaysia
Stuart Levy, Boston, Massachusetts, USA
John S. MacKenzie, Perth, Australia
John E. McGowan, Jr., Atlanta, Georgia, USA
Jennifer H. McQuiston, Atlanta, Georgia, USA
Tom Marrie, Halifax, Nova Scotia, Canada
Nkuchia M. M’ikanatha, Harrisburg, Pennsylvania, USA
Frederick A. Murphy, Bethesda, Maryland, USA
Barbara E. Murray, Houston, Texas, USA
Stephen M. Ostroff, Silver Spring, Maryland, USA
Marguerite Pappaioanou, Seattle, Washington, USA
Johann D. Pitout, Calgary, Alberta, Canada
Mario Raviglione, Geneva, Switzerland
David Relman, Palo Alto, California, USA
Guénaël Rodier, Saône-et-Loire, France
Connie Schmaljohn, Frederick, Maryland, USA
Tom Schwan, Hamilton, Montana, USA
Rosemary Soave, New York, New York, USA
P. Frederick Sparling, Chapel Hill, North Carolina, USA
Robert Swanepoel, Pretoria, South Africa
Phillip Tarr, St. Louis, Missouri, USA
John Ward, Atlanta, Georgia, USA
Jeffrey Scott Weese, Guelph, Ontario, Canada
Mary E. Wilson, Cambridge, Massachusetts, USA
Use of trade names is for identification only and does not imply
endorsement by the Public Health Service or by the U.S. Department of Health
and Human Services.
EMERGING INFECTIOUS DISEASES is a registered service mark of
the U.S. Department of Health & Human Services (HHS).
∞ Emerging Infectious Diseases is printed on acid-free paper that meets the
requirements of ANSI/NISO 239.48-1992 (Permanence of Paper)
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Ve ct or bor n e I n fe ct ion s
Se pt e m be r 2 0 1 8
On the Cover
Paul Klee (1879–1940),
Tropische Dämmerung
(Tropical Twilight), 1921.
Oil on white primer on paper
on cardboard; 13.5 in × 9.1 in/
33.5 cm × 23 cm.
Fondation Beyeler,
Riehen/Basel, Switzerland;
Beyeler Collection;
Photo: Robert Bayer
About the Cover p. 1779
Ca se Re por t a n d Ge n e t ic
Se qu e n ce An a lysis of
Ca n dida t u s Bor r e lia k a la h a r ica ,
Sou t h e r n Afr ica
K. St et e et al.
1659
Related material available online:
http://wwwnc.cdc.gov/eid/
article/24/9/17-1381_article
Re se a r ch
N ove l Or t h opox vir u s a n d
Le t h a l D ise a se in Ca t , I t a ly
G. Lanave et al.
1665
Em e r ge n ce of
Ca r ba pe n e m a se - Pr odu cin g
Enterobacteriaceae,
Sou t h - Ce n t r a l On t a r io, Ca n a da
P.P. Kohler et al.
1674
Related material available online:
http://wwwnc.cdc.gov/eid/
article/24/9/18-0164_article
Pe r spe ct ive
Et h ics of I n fe ct ion Con t r ol
M e a su r e s for Ca r r ie r s of
An t im icr obia l D r u g– Re sist a n t
Or ga n ism s
B. Rum p et al.
1609
Related material available online:
http://wwwnc.cdc.gov/eid/
article/24/9/17-1644_article
Syn opse s
C.C. Porse et al.
1626
D ist in gu ish in g Ja pa n e se
Spot t e d Fe ve r a n d Scr u b Typh u s,
Ce n t r a l Ja pa n , 2 0 0 4 – 2 0 1 5
E. Sando et al.
1633
Related material available online:
http://wwwnc.cdc.gov/eid/
article/24/9/17-1436_article
N at ional Surveillance for
Clostridioides difficile I nfect ion,
Sw eden, 2 0 0 9 – 2 0 1 6
Improved hygiene measures in healthcare
settings likely caused the sustained nationwide
decrease in rates of C. difficile infection.
K. Rizzardi et al.
Tr a ve l- Associa t e d Zik a Ca se s a n d
Th r e a t of Loca l Tr a n sm ission
du r in g Globa l Ou t br e a k ,
Ca lifor n ia , USA
1617
Related material available online:
http://wwwnc.cdc.gov/eid/
article/24/9/17-1658_article
Syst e m a t ic Re vie w a n d
M e t a - a n a lysis of Post e x posu r e
Pr oph yla x is for Cr im e a n - Con go
H e m or r h a gic Fe ve r Vir u s a m on g
H e a lt h ca r e W or k e r s
Ö. Ergönül et al.
1642
Fr om Cu lt u r om ics t o Clin ica l
M icr obiology a n d For w a r d
G. Dubourg et al.
1683
D ispa t ch e s
Associa t ion of Ba t a i Vir u s
I n fe ct ion a n d En ce ph a lit is
in H a r bor Se a ls,
Ge r m a n y, 2 0 1 6
W.K. Jo et al.
1691
Related material available online:
http://wwwnc.cdc.gov/eid/
article/24/9/17-1829_article
Use of Fa vipir a vir t o
Tr e a t La ssa Vir u s I n fe ct ion
in M a ca qu e s
K. Rosenke et al.
1696
Related material available online:
http://wwwnc.cdc.gov/eid/
article/24/9/18-0233_article
Eve n t - Ba se d Su r ve illa n ce a t
Com m u n it y a n d H e a lt h ca r e
Fa cilit ie s, Vie t n a m , 2 0 1 6 – 2 0 1 7
A. Clara et al.
1649
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Aor t ic En dogr a ft I n fe ct ion
w it h Mycobacterium chimaera
a n d Granulicatella adiacens,
Sw it ze r la n d, 2 0 1 4
A. Plat e et al.
1700
Related material available online:
http://wwwnc.cdc.gov/eid/
article/24/9/18-0247_article
Est im a t in g Fr e qu e n cy of
Pr oba ble Au t och t h on ou s Ca se s
of D e n gu e , Ja pa n
A. Senda et al.
1705
Related material available online:
http://wwwnc.cdc.gov/eid/
article/24/9/17-0408_article
Cor r e la t ion of Se ve r it y of
H u m a n Tick - bor n e En ce ph a lit is
Vir u s D ise a se a n d
Pa t h oge n icit y in M ice
C. Kurhade et al.
1709
I n cr e a sin g Pr e va le n ce of
Bor r e lia bu r gdor fe r i se n su
st r ict o– I n fe ct e d Bla ck le gge d
Tick s in Te n n e sse e Va lle y,
Te n n e sse e , USA
G.J. Hickling et al.
1713
Su sce pt ibilit y of W h it e - Ta ile d
D e e r t o Rift Va lle y Fe ve r Vir u s
W.C. Wilson et al.
1717
Ou t br e a k of Pn e u m ococca l
M e n in git is, Pa ou a Su bpr e fe ct u r e ,
Ce n t r a l Afr ica n Re pu blic,
2016–2017
M.E. Coldiron et al.
1720
Molecular Confirmation of
Rock y M ou n t a in Spot t e d
Fe ve r Epide m ic Age n t in
M e x ica li, M e x ico
L. Tinoco- Gracia et al.
Se pt e m be r 2 0 1 8
1666
Elizabethkingia anophelis a n d
Associa t ion w it h Ta p W a t e r a n d
H a n dw a sh in g, Sin ga por e
C.- F. Yung et al.
1730
M a r ipa Vir u s RN A Loa d a n d
An t ibody Re spon se in H a n t a vir u s
Pu lm on a r y Syn dr om e ,
Fr e n ch Gu ia n a
S. Mat heus et al.
1734
Se ve r e M a n ife st a t ion s of
Ch ik u n gu n ya Fe ve r in Ch ildr e n ,
I n dia , 2 0 1 6
P.K. Sharm a et al.
1737
Zik a Vir u s Se r oposit ivit y
in 1 – 4 - Ye a r - Old Ch ildr e n ,
I n don e sia , 2 0 1 4
R.T. Sasm ono et al.
1740
Related material available online:
http://wwwnc.cdc.gov/eid/
article/24/9/18-0582_article
Re se a r ch Le t t e r s
1723
Fa t a l Tick bor n e Ph le bovir u s
I n fe ct ion in Ca pt ive
Ch e e t a h s, Ja pa n
K. Mat suno et al.
1726
Tr ich odyspla sia Spin u losa
Polyom a vir u s in
Re spir a t or y Tr a ct of
I m m u n ocom pr om ise d Ch ild
A.A. Bagasi et al.
1744
Related material available online:
http://wwwnc.cdc.gov/eid/
article/24/9/18-0829_article
Wohlfahrtiimonas chitiniclastica
Ba ct e r e m ia in H ospit a lize d
H om e le ss M a n w it h
Squ a m ou s Ce ll Ca r cin om a
Y. Kat anam i et al.
1746
Sym pt om a t ic D e n gu e du r in g
Pr e gn a n cy a n d Con ge n it a l
N e u r ologic M a lfor m a t ion s
E.S. Paixão et al.
1748
Related material available online:
http://wwwnc.cdc.gov/eid/
article/24/9/17-0361_article
Tr a ve le r s’ Act u a l a n d Su bj e ct ive
Kn ow le dge a bou t Risk for
Ebola Vir u s D ise a se
I . Régner et al.
1750
Related material available online:
http://wwwnc.cdc.gov/eid/
article/24/9/17-1343_article
Spr e a d of mcr-1– D r ive n
Colist in Re sist a n ce on
H ospit a l Su r fa ce s, I t a ly
E. Caselli et al.
1752
Tr a n sve r se M ye lit is a n d
Gu illa in - Ba r r é Syn dr om e
Associa t e d w it h Ca t - Scr a t ch
D ise a se , Te x a s, USA, 2 0 1 1
R. Zakhour et al.
1754
1701
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Co- Cir cu la t ion of 4 D e n gu e
Vir u s Se r ot ype s a m on g
Tr a ve le r s En t e r in g Ch in a fr om
M ya n m a r , 2 0 1 7
B. Wang et al.
1756
Ca se of M icr oce ph a ly a ft e r
Con ge n it a l I n fe ct ion w it h
Asia n Lin e a ge Zik a Vir u s,
Th a ila n d
T. Wongsurawat et al.
Se pt e m be r 2 0 1 8
1762
1758
Dirofilaria repens N e m a t ode
Infection with Microfilaremia
in Tr a ve le r Re t u r n in g t o
Be lgiu m fr om Se n e ga l
I . Pot t ers et al.
1761
Ru be lla Vir u s Ge n ot ype 1 E in
Tr a ve le r s Re t u r n in g t o Ja pa n
fr om I n don e sia , 2 0 1 7
D. Kanbayashi et al.
1763
Spon dw e n i Vir u s in Fie ldCa u gh t Culex quinquefasciatus
M osqu it oe s, H a it i, 2 0 1 6
S.K. Whit e et al.
1765
Related material available online:
http://wwwnc.cdc.gov/eid/
article/24/9/17-1957_article
Flu con a zole - Re sist a n t Ca n dida
parapsilosis Bloodst r e a m
I sola t e s w it h a Y1 3 2 F M u t a t ion
in ERG1 1 Ge n e , Sou t h Kor e a
Y.J. Choi et al.
1768
Related material available online:
http://wwwnc.cdc.gov/eid/
article/24/9/18-0625_article
Borrelia miyamotoi D ise a se
in a n I m m u n ocom pe t e n t
Pa t ie n t , W e st e r n Eu r ope
D. Hoornst ra et al.
1770
Le t t e r
On lin e Re por t
W orld Health Organization
Methodology to Prioritize Em erging
I nfectious Diseases in Need of
Research and Developm ent
Seroprevalence of
Chikungunya Virus aft er I t s
Em ergence in Brazil
P. Gérardin et al.
1773
An ot h e r D im e n sion
M. Si Mehand et al.
ht t ps: / / wwwnc.cdc.gov/ eid/ art icle/
24/ 9/ 17- 1427_art icle
Cor r e ct ion s
Em e r gin g I n fe ct iou s Lit e r a t u r e s
a n d t h e Zom bie Con dit ion
J. Verran, X.A. Reyes
1774
Abou t t h e Cove r
Vol. 2 4 , N o. 9
Tr opica l Su n se t Blu e s
B. Breedlove, P.M. Arguin
1779
Et ym ologia
Granulicatella
R. Henry
1773
Vol. 2 4 , N o. 8
The author list was incorrect in Death from
Transfusion-Transmitted Anaplasmosis, New
York, USA, 2017 (R. Goel et al.), and a name
was missing from the acknowledgments.
1704
Several corrections to the text were
needed in Phenotypic and Genotypic
Characterization of Enterobacteriaceae
Producing Oxacillinase-48–Like
Carbapenemases, United States
(J.D. Lutgring et al.).
I CEI D Abst r a ct s
I n t e r n a t ion a l Con fe r e n ce
on Em e r gin g I n fe ct iou s
D ise a se s 2 0 1 8 Post e r a n d Or a l
Pr e se n t a t ion Abst r a ct s
https://go.usa.gov/xUshu
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
PERSPECTI VE
Et hics of I nfect ion Cont rol M ea sures
for Ca rriers of Ant im icrobia l
Drug– Resist a nt Orga nism s
Babette Rump, Aura Timen, Marlies Hulscher, Marcel Verweij
Many countries have implemented infection control measures directed at carriers of multidrug-resistant organisms.
To explore the ethical implications of these measures, we
analyzed 227 consultations about multidrug resistance and
compared them with the literature on communicable disease
in general. We found that control measures aimed at carriers have a range of negative implications. Although moral
dilemmas seem similar to those encountered while implementing control measures for other infectious diseases, 4
distinct features stand out for carriage of multidrug-resistant
organisms: carriage presents itself as a state of being; carriage has limited relevance for the health of the carrier; carriage has little relevance outside healthcare settings; and
antimicrobial resistance is a slowly evolving threat on which
individual carriers have limited effect. These features are of
ethical relevance because they influence the way we traditionally think about infectious disease control and urge us
to pay more attention to the personal experience of the individual carrier.
A
ntimicrobial resistance (AMR) is one of the most serious health threats of the 21st century. It challenges
effective treatment of infectious diseases, now and in the
future. AMR may imply that infections that used to be relatively harmless will pose a severe threat to patients in the
future (1). Many countries have implemented measures to
control AMR, including proper use of antimicrobial drugs
in humans, minimization of antimicrobial drug use in animals, and prevention of further transmission of resistant
microbes within the healthcare system (1–5). AMR raises
a range of ethical questions (6–12). We explored ethical issues that arise in relation to carriage of antimicrobial drug–
resistant organisms (hereafter called carriage).
AMR control measures are directed at carriers. The
types of control measures vary by microorganism and
Author affiliations: The Netherlands National Institute for
Public Health and the Environment, Bilthoven, the Netherlands
(B. Rump, A. Timen); Radboud University Medical Center,
Nijmegen, the Netherlands (M. Hulscher); Wageningen University,
Wageningen, the Netherlands (M. Verweij)
DOI: https://doi.org/10.3201/eid2409.171644
depend on resistance pattern, virulence, and mode of transmission. Measures can include control precautions taken
during patient care, such as use of personal protective
equipment; cleaning and disinfection of the care environment; dedicated single-patient use of rooms and equipment;
eradication treatment, if applicable; and, in exceptional
cases, exclusion of the carrier from work or joint facilities.
The actual control measures recommended by health authorities vary among countries. Countries in northern Europe, for instance, have implemented far-reaching infection
control interventions that include preemptive use of contact precautions at the time of admission until the patient is
proven culture negative and closure of hospital units to new
admissions when applicable. Countries in southern Europe
and North America follow a less aggressive approach, emphasizing contact precautions after detection of multidrugresistant organisms (1–4).
Control measures may effectively control transmission
of multidrug-resistant organisms, but negative effects on
the health and well-being of carriers have been reported
from countries that follow stringent multidrug-resistant
organism policies and from countries that have a less aggressive approach (13–16). These negative effects make
AMR control measures, apart from a technical and medical
challenge, also an ethical issue. Our aim with this study
was to examine the ethical context of multidrug-resistant
organism carriage: what are the negative implications for
carriers, and what is the ethical relevance?
Methods
We analyzed 227 consultations/inquiries associated with
multidrug-resistant organisms registered from January 1,
2008, through January 16, 2016, by the Centre for Infectious Disease Control in the Netherlands (Table 1; Figure).
We looked for potentially negative implications on freedom,
well-being, and other ethical values and assessed the respects
in which the ethically relevant features of carriage differ
from those of infectious disease in general. The Netherlands
follows a strict multidrug-resistant organism search-and-destroy policy (Table 2) (2,17,18). Estimated prevalence rates
for multidrug-resistant organisms in the Netherlands are low
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1609
PERSPECTIVE
Table 1. Detailed information from 227 consultations about antimicrobial-resistant organisms, Centre for Infectious Disease Control,
Bilthoven, the Netherlands, January 1, 2008–January 16, 2016*
Characteristic
No. (%)
Type of multidrug-resistant organism
Methicillin-resistant Staphylococcus aureus
177 (78)
Vancomycin-resistant Enterococci
18 (8)
Extended-spectrum β-lactamase
9 (4)
Klebsiella pneumoniae carbapenemase-producing Enterobactericeae
5 (2)
Unknown
18 (8)
Setting
Long-term care facilities
61 (27)
Paramedical facilities
23 (10)
Home-care facilities
14 (6)
Rehabilitation centers
5 (2)
Carriage among healthcare workers
50 (22)
Social interaction of healthcare workers
32 (14)
Other
42 (19)
*In the Netherlands, 25 regional Public Health Services (PHS) are in charge of communicable disease control. Healthcare institutions such as hospitals
and nursing homes have a responsibility to detect, monitor, and control outbreaks within their facility and report these to the PHS. The PHS assists
healthcare institutions and professionals and provides advice on the basis of national guidelines. In turn, the Centre for Infectious Disease Control of the
National Institute of Public Health and the Environment (RIVM) acts as national public health authority; it develops and publishes national guidelines and
offers support in outbreak management including a 24-hour consultation helpdesk for PHS and other health professionals. The center is consulted by
PHS professionals >1,000 times/y about a variety of cases of notifiable diseases, outbreaks, and incidents that occur in the community (15,17,18). Since
2008, all consultations have been anonymously registered in a database. During the 8-year study period, RIVM registered 227 consultations associated
with carriage of multidrug-resistant organisms that needed national guidance.
(online Technical Appendix, https://wwwnc.cdc.gov/EID/
article/24/9/17-1644-Techapp1.pdf) (2,19–21).
Results
Negative Implications of Control Measures for Carriers
Problems with Access to Healthcare
A clear implication of AMR control measures involves
problems with access to healthcare. During their consultations, several carriers asked about being faced with postponement of planned surgery, about cancellation of admission to rehabilitation, and about being denied access
to dental clinics. A nursing home, for instance, wanted to
deprioritize a person at the top of the waiting list because
this person was carrying a multidrug-resistant organism. A
medical daycare center refused to admit a child because of
persistent carriage.
Restrictions within Healthcare Facilities
Another distinct implication of AMR control measures involves restrictions within healthcare facilities. Several consultations involved questions about carriers of methicillinresistant Staphylococcus aureus (MRSA) in care facilities
in which elderly carriers were banned from organized social activities or not allowed to dine at the same table with
fellow residents. In medical daycare facilities, children
who were carriers were banned from group activities or
kept away from their peers, and in a psychiatric institution,
a group of patients was placed in a closed ward because of
carriage. Other inquiries concerned privileges that carriers
received; for instance, carriers in nursing homes were allocated a single room or a private bathroom.
1610
Negative Implications for Daily Life
The control measures also affected daily life. One inquiry
concerned a MRSA-positive child who faced restrictions
after returning to school because a classmate was a cystic fibrosis patient for whom acquiring a MRSA infection
would constitute a health risk. Another inquiry was about
adoption of a child with special health needs; the family had
already adopted their first child with a previous diagnosis
of persistent MRSA carriage, and they hesitated to adopt
a second child because the MRSA would most likely be
transmitted to that child, bringing extra MRSA-associated
health risks. Also, parents of a healthy MRSA toddler were
confronted with a daycare center caregiver who refused to
attend to their child for fear of transmitting MRSA to her
newborn baby at home. Some inquiries concerned interaction with animals; for instance, a family struggled with persistent MRSA carriage and 1 of their children was denied
access to a medical daycare center. They were advised to
relocate or abandon their cats, which were thought to be the
source of reinfection.
Negative Implications for Carriers Who Work in Healthcare
Control measures can also have negative implications for
those who work in healthcare. We found cases of healthcare workers (HCWs) who were restricted at work, banned
from work, and faced income loss. For example, a nurse
who was a carrier was assigned administrative tasks instead
of patient care, thereby missing out on the substantial financial benefits that come along with performing patient care
during night and weekend shifts. A temporary employee’s
contract was not renewed because of past carriage, and a
fifth-year medical student discontinued training because
of a chronic MRSA infection. HCWs were also pressed to
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Ethics of Infection Control Measures
Figure. Methods used in study
of ethics of infection control
measures for carriers of
antimicrobial-resistant organisms,
the Netherlands, January 1,
2008–January 16, 2016. MDRO,
multidrug-resistant organism.
cooperate with testing and treatment. A temporary healthcare employee was asked to show proof of being MRSA
negative, and MRSA-positive nurses were pressed to cooperate with intensive eradication treatment consisting of
daily scrubbing of the skin and taking of oral antimicrobial
drugs. In several instances, MRSA-negative HCWs were
excluded from healthcare work because in their private life
they cared for a MRSA-positive child or parent.
Negative Implications for Close Contacts of HCWs
Infection control measures for HCWs can also affect their
family members and other contacts. For example, HCWs
with MRSA were asked to disclose the names of their
close contacts outside the hospital. Contacts needed to
cooperate with MRSA screening and, if test results were
positive, undergo eradication treatment. In some instances, such measures had far-reaching consequences for family members. For instance, in a single-income household,
young children were subjected to very intensive MRSA
eradication in order for the main breadwinner to be able
to secure employment. In another case, contact screening started by the employer of a nurse who was a carrier included screening of the nurse’s children. One child
was physically handicapped and visited a medical daycare
center. When results indicated that he was a carrier, he
was denied access to this medical daycare center for several months.
The negative implications for carriers of multidrug-resistant organisms were not only defined by the outcome of
the control measures advised in the policies but also were
further enhanced by focus on collective benefits with less
emphasis on harm for carriers (1) and by strong concerns
with communication and disclosure when applying the
policy (2). Several inquiries resulted in implementation of
control measures that were more stringent than those prescribed by national policies.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1611
PERSPECTIVE
Table 2. Indications for routine screening for multidrug-resistant organisms, the Netherlands*
Healthcare setting
Indication†
Hospital
Patients at high risk of carrying an MDRO (e.g., patients transferred from a hospital in a foreign country
or patients working in animal husbandry)
Patients at high risk of acquiring infection with an MDRO
Patients with signs of clinical infection with an MDRO
Patients for whom empiric treatment failed
Patients with recurrent infection
Family members of hospital patient known to carry an MDRO
Personnel with unprotected exposure to a person known to carry MRSA
General practice
Patients for whom empiric treatment failed
Patients with recurrent infection
Nursing home/care facility
Patients for whom empiric treatment failed
Patients with recurrent infection
Patient with unprotected exposure (e.g., shared a room, shared medical equipment) to a person with
MRSA or carbapenemase-producing Enterobacteriaceae
Personnel with unprotected exposure to a person known to carry MRSA
Home
Personnel with unprotected exposure to a person known to carry MRSA
*MDRO, multidrug-resistant organism; MRSA, methicillin-resistant Staphylococcus aureus.
†As advised by the Werkgroep Infectie Preventie guideline on measures against transmission of highly resistant microorganisms in hospitals (2,19,20).
Negative Implications because of Overemphasis on
Collective Benefits
Inquiries reflected a strong focus on the benefits of AMR
control measures and ignoring of the potential harm for
carriers. Several inquiries reported control measures that
went beyond the already stringent national policies. For example, in 2015–2016, a large influx of war refugees from
Syria to the Netherlands caused some hospitals to demand
that their employees refrain from volunteer work with refugees outside their working hours because of the possibility
that they could be exposed to a multidrug-resistant organism by doing such work. In addition, a pig farmer who had
undergone heart valve surgery was advised not to go back
to work on the farm because of the small risk of contracting
livestock-associated MRSA, which would make follow-up
visits more complicated to schedule for the hospital.
Negative Implications because of Concerns about
Communication and Disclosure
Some inquiries reflected outcomes that were motivated
by concerns about disclosure and communication rather
than actual risk for transmission of the multidrug-resistant
organisms. For instance, a MRSA-positive child was not
allowed access to a medical daycare facility, not because
of the risk to other children, which was considered to be
small, but because the facility felt an obligation to inform
all other parents. The parents of the carrier, however, insisted on nondisclosure for fear of stigma. Another inquiry
concerned a nurse who lived on a livestock farm and was
therefore at high risk of contracting MRSA, a risk that was
well-known and had been accepted by her employer for
years. When, by accident, the nurse was screened and carriage was confirmed, she was no longer allowed to work at
that facility. This response was not motivated by the risk
for transmission—the employer acknowledged that she
presumably had been carrying MRSA for a long time and
1612
had never caused an outbreak—but because the institution
was concerned about the consequences should MRSA carriage of a hospital employee become public.
Ethical Features Unique to Being a
Multidrug-Resistant Organism Carrier
Inquiries concerned questions about AMR control measures that primarily aimed to reduce further transmission
of antimicrobial-resistant pathogens. In doing so, these
measures resulted in negative implications that raised
moral dilemmas.
In the inquiries explored, the exact nature of the moral
dilemmas remained implicit. However, for almost all cases,
it could be assumed that the control measures had negative
effects on the carrier’s well-being, autonomy, and (healthassociated) justice. Well-being was affected because carriers were limited in their opportunities to work or to engage
in social contacts. Autonomy may have been at stake when
carriers were requested to disclose their medical condition
or when they were pressed to undergo tests and eradication
therapy they might have preferred to avoid. Their sense of
dignity may have been affected when carriers were stigmatized because of their condition. The various implications also seemed to be involve injustices: health inequity
if carriers were excluded from certain medical treatment
or faced a delay in care, and social injustice if they were
excluded from (the benefits of) going to work.
Although challenging, the moral dilemmas at hand—
and the values at stake—seem not fundamentally different
from dilemmas that arise in infectious disease control in
general (22–25). Health equity issues, for instance, occur in many contexts of infectious disease control. In Europe, while the 2014–2015 Ebola outbreak was occurring
in West Africa, persons suspected of having Ebola virus
disease were banned from hospital emergency rooms (26).
Often at the heart of outbreak management are quarantine,
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Ethics of Infection Control Measures
isolation, and social distancing measures, which clearly
involve tensions with respect to autonomy and deprive
persons from contact with their loved ones and otherwise
undermine their quality of life (25). Restrictions to healthcare staff (e.g., a surgeon who seems to be a hepatitis B
virus carrier) are well-accepted ways to prevent bloodborne
nosocomial infections (27). However, 4 differences stood
out, suggesting that there is something ethically noteworthy about carriage of multidrug-resistant organisms.
Relevance of Carriage for the Carriers
Patients in this study were asymptomatic carriers for whom
carriage did not affect their health. Some might have had
other health conditions, but they were not ill from the drugresistant microorganism they carried. Thus, carriage differs
from most communicable diseases, in which the health of
the persons carrying the microorganism is threatened or affected by the infection. Ebola virus infection, for instance,
forms an acute threat to the health of the patient, who is in
immediate need of treatment and medication while threatening the health of others, including health personnel.
Other infectious diseases can also involve asymptomatic
carriage; moreover, multidrug-resistant organisms can certainly also cause infections and thus illness. In fact, the proactive screening and preemptive use of control measures
that are common in the Netherlands probably caused an
overrepresentation of inquiries concerning these “carriers
without multidrug-resistant organism infection” (2,19,20).
What remains ethically noteworthy and relevant for preemptive and reactive AMR control strategies is that, although all carriers are at risk for their carriage resulting in
clinical infection, multidrug-resistant organisms primarily
threaten a specific subgroup of vulnerable patients in hospital settings. The extent to which multidrug-resistant organisms contribute to death has been debated and seems to
remain limited to those with severe illness and concurrent
conditions (28–30). Studies addressing multidrug-resistant
gram-negative infections, for instance, show substantial diversity in the outcomes. It can be concluded that mortality
rates are higher among those infected by multidrug-resistant gram-negative bacteria; however, concurrent conditions and severity scores are more commonly identified as
predictors of death (28–30). From a broader public health
perspective, the health threat of multidrug-resistant organism carriage thus appears limited.
Healthcare-Associated Relevance
A noteworthy finding is that carriage became relevant
almost exclusively in healthcare-associated settings. In
schoolchildren, for example, carriage was problematic because a classmate had a chronic illness and needed regular hospital checkups. A MRSA-positive family member
is only problematic in the context of work in healthcare.
Again, most outbreaks of infectious diseases are problematic within healthcare-associated settings, because these
outbreaks lead to high morbidity and mortality rates, putting pressure on limited resources and putting HCWs in
direct danger of contracting disease. Control measures
for most communicable diseases therefore aim to regulate
these threats (25). Outbreaks of multidrug-resistant organism infections, however, do not cause high morbidity and
mortality rates (21,28–30). Public health measures aim to
prevent introduction and further transmission of multidrugresistant organisms in (some) healthcare-associated settings
(2). Whether a carrier is subject to control measures does
not depend on the severity of the pathogen but only on the
likelihood that the resistant pathogen will be transmitted to
a healthcare setting where vulnerable patients are cared for.
Multidrug-Resistant Organism Carriage as a State of Being
A salient feature of the inquiries was that carriage could
last for a long time, making implementation of control
measures even more burdensome. Some persons were colonized for such a long period, some even starting at birth,
that it could be argued that the resistant microorganism was
now part of their regular flora. The inquiries showed that,
after a person receives a diagnosis of being a carrier, the
label persists. It was often very difficult to eradicate the
bacteria; moreover, there was no standard for determining
whether a person was no longer a carrier. From an ethical
perspective, persistence is particularly salient because inevitably, within the open population but also in healthcare
settings, there will be a substantial group of unidentified
asymptomatic carriers. Therefore, the severe restrictions
faced by known carriers may not only be burdensome and
stigmatizing but may also be considered unfair.
The Carrier as a Nondefining Factor in a Slowly
Evolving Threat
In all cases analyzed for this study, the individual carrier
was a possible link in the chain of transmission but certainly was not a central factor in the emergence and spread
of multidrug-resistant organisms. The long-term clinical
effect of multidrug-resistant organisms may be high, but it
was not obvious that imposing restrictions, either preemptive or reactive, on individual carriers played a crucial role
in controlling and mitigating that effect. The immediate
threat posed by individual carriers was limited, certainly if
compared with the role of conditions caused by other microorganisms, such as Ebola virus disease or meningococcal meningitis, for which devastating effects become evident in days, weeks, or months (25).
Discussion
We have shown how multidrug-resistant organism control measures undermine the well-being of asymptomatic
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1613
PERSPECTIVE
carriers. Although set in a country at the highest end of
the spectrum with regard to strict AMR control measures,
this finding is relevant to countries with all types of policies. The unique ethical features of multidrug-resistant
organism carriage challenge the way we think about infectious disease control.
Traditionally, epidemics have been portrayed as an
enemy attack of foreign microbes on human life, describing the carrier as “patient” or “victim” (25,31). However,
multidrug-resistant organism carriers are not ill from carriage and can remain colonized for a long time. Any role
as victim results more from the control measures than from
the pathogen.
AMR control measures that may seem reasonable at
first can easily lead to stigmatization. Stigma is defined as
a social process characterized by exclusion, rejection, or
blame resulting from experience, perception, or anticipation of adverse social judgments (32). In infectious disease control, the line between reasonable precaution measures and stigmatization has always been thin (32–35),
but when carriage resembles a state of being, with limited
relevance outside healthcare, the line also becomes vague
and ambiguous (33).
Still, the dilemma of multidrug-resistant organism
carriage represents one of the universal ethical challenges
of public health: balancing the protection of the public
while respecting individual well-being. Various public
health ethics frameworks to guide decision-making have
been suggested in this trade-off (24,36–38). Those frameworks have in common that they, explicitly or implicitly,
call for clarity about the goals of a program and evaluation of effectiveness and proportionality. Such clarity
is indeed valuable, but for multidrug-resistant organism
control measures, the ultimate goals are not obvious. Of
course, control measures are meant to control further
spread of AMR, yet at the same time, overall mortality
rates caused by multidrug-resistant organisms are still
low and limited to vulnerable patients. Moreover, AMR is
not a single epidemic; rather, it is a complex problem that
slowly evolves and continually reemerges. Types of microorganisms displaying resistance and resistance mechanisms are constantly evolving. How AMR will emerge
and what implications it will have in the next decades has
yet to be determined (39). Although the control of AMR is
of utmost importance, it is not obvious that strict control
measures imposed on carriers will make a big difference
in the overall objective.
AMR resembles a “wicked problem,” a policy challenge that is not solvable by traditional policy instruments and to which no singular solution exists (8,9).
Our analysis shows that control measures can be highly
burdensome to carriers and that the magnitude of burden depends largely on the carrier’s personal situation.
1614
Tailoring control measures to individual carriers’ needs
and values may therefore offer a way to deal with the
wicked complexity.
Rather than asking whether it is justified to impose
strict control measures to prevent antimicrobial resistance
transmission from carriers, we propose asking, “How can
we best care for this person’s carriage and well-being in
ways that do not imply unacceptable risk (for transmission)
for other patients?” This question essentially takes an individualistic and contextual approach, acknowledging that
different carriers can have different needs and values. For
instance, some carriers enjoy the privacy that comes with
isolation, many dislike the solitude, and others are most
concerned about the quality of care and are relatively indifferent to isolation.
The question touches on the idea of patient-centered
care, which involves caring for patients (and their families) in ways that are meaningful and valuable to each
patient (40). At the same time, the problem goes beyond
the scope of healthcare. Often the primary needs of carriers are not so much healthcare needs but rather are protection of the possibility that they can live a good life
according to their own personal values. From this perspective, frameworks that use a rich account of quality of
life may be helpful for evaluating the justice of control
measures (41–45).
The question also requires critical reflection on the
assessment of the risks of possible transmission of AMR
to others in this specific context, ruling out that control
measures imposed on individual persons are (implicitly)
justified by appeal to the general (long-term) public health
threat of AMR. A specific level of risk may be acceptable
in a hospital in a region where baseline prevalence is high
yet problematic in one where prevalence is low.
Especially when strict control measures are justified,
an individualistic approach can help lower the individual
burden. A nurse carrying multidrug-resistant organisms
can be given other tasks instead of being sent home, some
carriers could be compensated for financial consequences,
and others could be helped by provision of childcare or
extra support at home. Relieving the burdens of control
measures on carriers will often come with financial costs
for society or healthcare institutions, but it would be unreasonable if burdens of public health measures are borne by
carriers individually.
In summary, AMR is one of the most severe threats
of this century and control measures are needed; however,
these measures are highly burdensome for carriers and of
only limited benefit to the overall problem. Tailoring measures to personal needs and values of carriers may offer
a new way to prevent carriers’ transmission of multidrugresistant organisms while minimizing compromises to their
well-being.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Ethics of Infection Control Measures
This work was supported by the Ministry of Health, Welfare and
Sport, the Netherlands (V/150013/18/ED), and the Netherlands
Organisation for Health Research and Development (ZonMW
731010011).
About the Author
Dr. Rump is a medical doctor who works at the National
Coordination Centre for Communicable Disease Control in the
Netherlands. She specializes in prevention of infectious diseases
and has a special interest in public health ethics. Her research
focuses on the development and implementation of a normative
framework for ethical decision-making, addressing special
treatment of persons carrying multidrug-resistant organisms.
15.
16.
17.
18.
19.
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
World Health Organization. Global action plan on antimicrobial
resistance. Report no. WHA68/2015/REC/1. Geneva: The
Organization; 2015.
Kluytmans-VandenBergh MF, Kluytmans JA, Voss A. Dutch
guideline for preventing nosocomial transmission of highly
resistant microorganisms (HRMO). Infection. 2005;33:309–13.
http://dx.doi.org/10.1007/s15010-005-5079-z
Siegel JD, Rhinehart E, Jackson M, Chiarello L; Health Care
Infection Control Practices Advisory Committee. 2007 guideline
for isolation precautions: preventing transmission of infectious
agents in health care settings. Am J Infect Control. 2007;35(Suppl
2):S65–164. http://dx.doi.org/10.1016/j.ajic.2007.10.007
Siegel JD, Rhinehart E, Jackson M, Chiarello L; Healthcare
Infection Control Practices Advisory Committee. Management of
multidrug-resistant organisms in health care settings, 2006.
Am J Infect Control. 2007;35(Suppl 2):S165–93. http://dx.doi.org/
10.1016/j.ajic.2007.10.006
Shlaes DM, Gerding DN, John JF Jr, Craig WA, Bornstein DL,
Duncan RA, et al. Society for Healthcare Epidemiology of America
and Infectious Diseases Society of America Joint Committee on
the Prevention of Antimicrobial Resistance: guidelines for the
prevention of antimicrobial resistance in hospitals. Clin Infect Dis.
1997;25:584–99. http://dx.doi.org/10.1086/513766
Leibovici L, Paul M. Ethical dilemmas in antibiotic treatment:
focus on the elderly. Clin Microbiol Infect. 2015;21:27–9.
http://dx.doi.org/10.1016/j.cmi.2014.10.013
Leibovici L, Paul M, Ezra O. Ethical dilemmas in antibiotic
treatment. J Antimicrob Chemother. 2012;67:12–6.
http://dx.doi.org/10.1093/jac/dkr425
Littmann J. Antimicrobial resistance and distributive justice
[doctoral thesis]. London: University College London; 2014.
Littmann J, Viens AM. The ethical significance of antimicrobial
resistance. Public Health Ethics. 2015;8:209–24.
Millar M. Can antibiotic use be both just and sustainable... or
only more or less so? J Med Ethics. 2011;37:153–7.
http://dx.doi.org/10.1136/jme.2010.038042
Millar M. Constraining the use of antibiotics: applying
Scanlon’s contractualism. J Med Ethics. 2012;38:465–9.
http://dx.doi.org/10.1136/medethics-2011-100256
Selgelid MJ. Ethics and drug resistance. Bioethics. 2007;21:218–
29. http://dx.doi.org/10.1111/j.1467-8519.2006.00542.x
Abad C, Fearday A, Safdar N. Adverse effects of isolation in
hospitalised patients: a systematic review. J Hosp Infect.
2010;76:97–102. http://dx.doi.org/10.1016/j.jhin.2010.04.027
Barratt RL, Shaban R, Moyle W. Patient experience of source
isolation: lessons for clinical practice. Contemp Nurse.
2011;39:180–93. http://dx.doi.org/10.5172/conu.2011.180
20.
21.
22.
23.
24.
25.
26.
27.
28.
Morgan DJ, Diekema DJ, Sepkowitz K, Perencevich EN.
Adverse outcomes associated with contact precautions: a
review of the literature. Am J Infect Control. 2009;37:85–93.
http://dx.doi.org/10.1016/j.ajic.2008.04.257
Mutsonziwa GA, Green J. Colonised and isolated: a qualitative
metasynthesis of patients’ experiences of being infected with
multiple drug resistant organisms and subsequent isolation.
Healthc Infect. 2011;16:147–55. http://dx.doi.org/10.1071/
HI11020
Bijkerk P, Fanoy EB, van der Sande MA. When should notification
of an infectious disease be mandatory? A decision aid to determine
whether mandatory notification is justified [in Dutch]. Ned Tijdschr
Geneeskd. 2016;160:A9768.
van Vliet JA, Haringhuizen GB, Timen A, Bijkerk P. Changes in
the duty of notification of infectious diseases via the Dutch Public
Health Act [in Dutch]. Ned Tijdschr Geneeskd. 2009;153:B79.
Altorf-van der Kuil W, Schoffelen AF, de Greeff SC, Thijsen SF,
Alblas HJ, Notermans DW, et al.; The National AMR
Surveillance Study Group. National laboratory-based
surveillance system for antimicrobial resistance: a successful
tool to support the control of antimicrobial resistance in the
Netherlands. Euro Surveill. 2017;22. http://dx.doi.org/10.2807/
1560-7917.ES.2017.22.46.17-00062
de Greeff SC, Mouton JW. NethMap 2017: consumption of
antimicrobial agents and antimicrobial resistance among
medically important bacteria in the Netherlands/MARAN 2017:
monitoring of antimicrobial resistance and antibiotic usage in
animals in the Netherlands in 2016 [cited 2018 Jun 26].
https://www.rivm.nl/Documenten_en_publicaties/Wetenschappelijk/
Rapporten/2017/Juni/NethMap_2017_Consumption_of_
antimicrobial_agents_and_antimicrobial_resistance_among_
medically_important_bacteria_in_the_Netherlands_
MARAN_2017_Monitoring_of_antimicrobial_resistance_and_
antibiotic_usage_in_animals_in_the_Netherlands_in_2016
The European Centre for Disease Prevention and Control. Data
from the ECDC Surveillance Atlas—antimicrobial resistance [cited
2018 Feb 25]. https://ecdc.europa.eu/en/antimicrobial-resistance/
surveillance-and-disease-data/data-ecdc
Verweij M. Infectious disease control, Section 2, Chapter 6.
In: Dawson A, editor. Public Health Ethics: Key Concepts and
Issues in Policy and Practice. New York: Cambridge University
Press; 2011. p. 100–17.
Selgelid MJ. Ethics and infectious disease. Bioethics. 2005;
19:272–89. http://dx.doi.org/10.1111/j.1467-8519.2005.00441.x
Barrett DH, Ortmann LW, Dawson A, Saenz C, Reis A,
Bolan GA. Public health ethics: cases spanning the globe.
New York: Springer; 2016.
Battin MP, Francis LP, Jacobson JA, Smith CB. Characteristics of
infectious disease that raise distinctive challenges for bioethics. In:
Battin MP, Francis LP, Jacobson JA, Smith CB, editors. The patient
as victim and vector: ethics and infectious disease. New York:
Oxford University Press; 2009. p. 26–40.
Blais CM, White JL. Bioethics in practice—a quarterly column
about medical ethics: Ebola and medical ethics—ethical challenges
in the management of contagious infectious diseases. Ochsner J.
2015;15:5–7.
Daha TJ, Bilkert-Mooiman MA, Ballemans C, Frijstein G,
Keeman JN, de Man RA, et al. Hepatitis B virus infected health
care workers in the Netherlands, 2000–2008. Eur J Clin Microbiol
Infect Dis. 2009;28:1041–4. http://dx.doi.org/10.1007/
s10096-009-0744-2
Jarrell AS, Kruer RM, Berescu LD, Pronovost PJ, Trivedi JB.
Factors associated with in-hospital mortality among critically ill
surgical patients with multidrug-resistant Gram-negative
infections. J Crit Care. 2018;43:321–6. http://dx.doi.org/
10.1016/j.jcrc.2017.10.035
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1615
PERSPECTIVE
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
Patel SJ, Oliveira AP, Zhou JJ, Alba L, Furuya EY, Weisenberg SA,
et al. Risk factors and outcomes of infections caused by extremely
drug-resistant gram-negative bacilli in patients hospitalized in
intensive care units. Am J Infect Control. 2014;42:626–31.
http://dx.doi.org/10.1016/j.ajic.2014.01.027
Vardakas KZ, Rafailidis PI, Konstantelias AA, Falagas ME.
Predictors of mortality in patients with infections due to multi-drug
resistant Gram negative bacteria: the study, the patient, the bug or
the drug? J Infect. 2013;66:401–14. http://dx.doi.org/10.1016/
j.jinf.2012.10.028
Washer P, Joffe H. The “hospital superbug”: social representations
of MRSA. Soc Sci Med. 2006;63:2141–52. http://dx.doi.org/
10.1016/j.socscimed.2006.05.018
Weiss MG, Ramakrishna J, Somma D. Health-related stigma:
rethinking concepts and interventions. Psychol Health Med.
2006;11:277–87. http://dx.doi.org/10.1080/13548500600595053
Rump B, De Boer M, Reis R, Wassenberg M, Van Steenbergen J.
Signs of stigma and poor mental health among carriers of
MRSA. J Hosp Infect. 2017;95:268–74. http://dx.doi.org/
10.1016/j.jhin.2016.09.010
Van Brakel WH. Measuring health-related stigma—a literature
review. Psychol Health Med. 2006;11:307–34. http://dx.doi.org/
10.1080/13548500600595160
Scambler G, Heijnders M, van Brakel WH. ICRAAS.
Understanding and tackling health-related stigma. Psychol Health
Med. 2006;11:269–70. http://dx.doi.org/10.1080/13548500600594908
Kass NE. An ethics framework for public health. Am J Public
Health. 2001;91:1776–82. http://dx.doi.org/10.2105/
AJPH.91.11.1776
Petrini C, Ricciardi G. Ethical issues in public health surveillance:
drawing inspiration from ethical frameworks. Ann Ist Super Sanita.
2015;51:270–6.
Schröder-Bäck P, Duncan P, Sherlaw W, Brall C, Czabanowska K.
Teaching seven principles for public health ethics: towards a
curriculum for a short course on ethics in public health
programmes. BMC Med Ethics. 2014;15:73. http://dx.doi.org/
10.1186/1472-6939-15-73
D’Andrea MM, Arena F, Pallecchi L, Rossolini GM.
CTX-M-type β-lactamases: a successful story of antibiotic
resistance. Int J Med Microbiol. 2013;303:305–17.
http://dx.doi.org/10.1016/j.ijmm.2013.02.008
Picker Institute. Principles of patient-centered care [cited 2018 Feb
25]. http://pickerinstitute.org/about/picker-principles/
Entwistle VA, Watt IS. Treating patients as persons: a capabilities
approach to support delivery of person-centered care. Am J
Bioeth. 2013;13:29–39. http://dx.doi.org/10.1080/
15265161.2013.802060
Stanford Encyclopedia of Philosophy Archive. The capability
approach [cited 2018 Feb 25] https://plato.stanford.edu/archives/
win2016/entries/capability-approach
Nussbaum MC. In defense of universal values. In: Nussbaum MC,
editor. Women and Human Development. Cambridge: Cambridge
University Press; 2000. p. 24–100.
Sen A. Equality of what? In: McMurrin S, editor. Tanner Lectures
on Human Values, Vol 1. Cambridge: Cambridge University
Press; 1980.
Millar MR. A capabilities perspective on healthcare associated
infection. Am J Bioeth. 2013;13:53–4. http://dx.doi.org/10.1080/15
265161.2013.802063
May 2017:
An t im icr obia l Re sist a n ce
• Exposure Characteristics of Hantavirus Pulmonary
Syndrome Patients, United States, 1993–2015
• Increased Neurotropic Threat from Burkholderia
pseudomallei Strains with a B. mallei–like Variation in
the bimA Motility Gene, Australia
• Population Genomics of Legionella longbeachae and
Hidden Complexities of Infection Source Attribution
• Prevention of Chronic Hepatitis B after 3 Decades of
Escalating Vaccination Policy, China
• Lack of Durable Cross-Neutralizing Antibodies against
Zika Virus from Dengue Virus Infection
• Use of Blood Donor Screening Data to Estimate Zika
Virus Incidence, Puerto Rico, April–August 2016
• Invasive Nontuberculous Mycobacterial Infections
among Cardiothoracic Surgical Patients Exposed to
Heater–Cooler Devices
• Anthrax Cases Associated with Animal-Hair
Shaving Brushes
• Increasing Macrolide and Fluoroquinolone Resistance
in Mycoplasma genitalium
• Population Responses during the Pandemic Phase
of the Influenza A(H1N1)pdm09 Epidemic,
Hong Kong, China
https://wwwnc.cdc.gov/eid/articles/
issue/23/5/table-of-contents
Address for correspondence: Babette Rump or Aura Timen,
National Coordination Centre for Communicable Disease Control,
RIVM–Centre for Communicable Diseases, PO Box 1, 3720 BA,
Bilthoven, the Netherlands; email: babette.rump@rivm.nl or
aura.timen@rivm.nl
1616
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
SYN OPSI S
N a t ion a l Su r ve illa n ce for
Clostridioides difficile I n fe ct ion ,
Sw e de n , 2 0 0 9 – 2 0 1 6
Kristina Rizzardi, Torbjörn Norén, Olov Aspevall, Barbro Mäkitalo,
Michael Toepfer, Åsa Johansson, Thomas Åkerlund
In support of improving patient care, this activity has been planned and implemented by
Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council
for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to
provide continuing education for the healthcare team.
Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 AMA PRA Category 1
Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal
CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the
post-test with a 75% minimum passing score and complete the evaluation at http://www.medscape.org/journal/eid;
and (4) view/print certificate. For CME questions, see page 1782.
Release date: August 16, 2018; Expiration date: August 16, 2019
Learning Objectives
Upon completion of this activity, participants will be able to:
• Describe Clostridioides difficile infection (CDI) incidence rates and resistance from 2012 to 2016,
according to the Swedish national surveillance program
• Determine distribution of C. difficile types, including known outbreaks from 2012 to 2016, according to
the Swedish national surveillance program
• Recognize the impact of diagnostic methods on CDI incidence and other possible reasons for changes
in incidence and resistance, according to the Swedish national surveillance program
CME Editor
Jude Rutledge, BA, Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: Jude Rutledge has disclosed
no relevant financial relationships.
CME Author
Laurie Barclay, MD, freelance writer and reviewer, Medscape, LLC. Disclosure: Laurie Barclay, MD, has disclosed
the following relevant financial relationships: owns stock, stock options, or bonds from Pfizer.
Authors
Disclosures: Kristina Rizzardi, PhD; Torbjörn Norén, MD, PhD; Olov Aspevall, MD, PhD; Barbro Mäkitalo, PhD;
Åsa Johansson, BSc; and Thomas Åkerlund, PhD, have disclosed no relevant financial relationships. Michael
Toepfer, MD, has disclosed the following relevant financial relationships: employed by a commercial interest, Unilabs
AB (clinical microbiologist).
Author affiliations: Public Health Agency of Sweden, Solna,
Sweden (K. Rizzardi, O. Aspevall, B. Mäkitalo, T. Åkerlund);
Örebro University, Örebro, Sweden (T. Norén); Unilabs Clinical
Microbiology, Skövde, Sweden (M. Toepfer); Växjö Hospital,
Växjö, Sweden (Å. Johansson)
DOI: https://doi.org/10.3201/eid2409.171658
We report results from a national surveillance program for
Clostridioides difficile infection (CDI) in Sweden, where
CDI incidence decreased by 22% and the proportion of
multidrug-resistant isolates decreased by 80% during
2012–2016. Variation in incidence between counties also
diminished during this period, which might be attributable to
implementation of nucleic acid amplification testing as the
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1617
SYNOPSIS
primary diagnostic tool for most laboratories. In contrast to
other studies, our study did not indicate increased CDI incidence attributable the introduction of nucleic acid amplification testing. Our results also suggest that successful implementation of hygiene measures is the major cause of the
observed incidence decrease. Despite substantial reductions in CDI incidence and prevalence of multidrug-resistant
isolates, Sweden still has one of the highest CDI incidence
levels in Europe. This finding is unexpected and warrants
further investigation, given that Sweden has among the lowest levels of antimicrobial drug use.
I
n a 1995 study assessing incidence of Clostridioides difficile infection (CDI) in Sweden, 5,133 cases were reported, corresponding to an incidence of 58 cases/100,000
inhabitants (1). After the initial reports of outbreaks of
CDI in Europe associated with PCR ribotype 027 (RT027)
in 2005 (2), a second incidence study was conducted in
2007, which showed that CDI incidence had increased to
90 cases/100,000 inhabitants (8,276 new cases). Based
on recommendations from the European Centre for Disease Prevention and Control, a national surveillance program for CDI was initiated in Sweden 2009, aiming to
monitor the apparent nationwide increase in CDI cases,
detect trends and outbreaks, and determine the baseline
incidence of CDI in the catchment areas of local clinical
laboratories (3). The program, conducted by the Public
Health Agency of Sweden, includes voluntary laboratory
reporting of all new and recurring CDI cases as well as
epidemiologic typing and susceptibility testing of isolates
from clinical laboratories.
Countries in Europe have large variations in CDI incidence rates and distribution of prevalent PCR ribotypes,
and the highest incidence rates occur in the northern countries, even though these countries have a low prevalence of
RT027 (4,5). In addition, across Europe, a weak negative
correlation has been observed between CDI incidence rates
and cephalosporin use (5). Here we summarize results of
the national CDI surveillance program in Sweden during
2012–2016, including CDI incidence rates, distribution of
C. difficile types, known CDI outbreaks, and the effect of
changes in diagnostic methods on reported CDI incidence.
Methods
Voluntary Surveillance Program
We collected epidemiologic case data through a voluntary reporting system, in which local laboratories reported the total number of CDI cases each week, including
information of patients who had prior episodes of CDI
within the previous 8 weeks. A new CDI case was defined as a patient with CDI with no prior diagnosis of
CDI within the previous 8-week period. The reporting,
1618
which started during week 43 in 2009, also included
catchment area (i.e., county) and sex and age of the patient. Initially, 16 of 28 laboratories reported CDI data,
and by the end of 2011, all laboratories had joined the
surveillance program. We collected denominator data by
using a separate questionnaire, distributed yearly, which
included the total number of tests and the number of
positive samples per laboratory.
We performed epidemiologic typing and antimicrobial susceptibility testing twice a year on isolates collected
during weeks 11 and 39. We chose these weeks arbitrarily
because there was no reason to assume seasonal variation
of CDI. We asked the local clinical laboratories to culture
samples from all suspected CDI case-patients and to test
the fecal samples and bacterial cultures by using that laboratory’s standard diagnostic algorithm. To ensure that all
isolates were identified during the study weeks, all culturepositive C. difficile isolates (including toxin-negative and
toxin-positive according to the local laboratory’s standard
test algorithm) were sent to the Public Health Agency of
Sweden for PCR ribotyping and antimicrobial susceptibility testing. Approximately 4% of all yearly cases are analyzed by this program. The laboratories also sent information stating their current diagnostic method and the test
results for each isolate sent for testing.
PCR Ribotyping
From week 1 in 2009 through week 11 in 2012, PCR ribotyping was gel-based, as previously described by Stubbs
et al. (6), with minor modifications (7). From week 39 in
2012, we performed PCR ribotyping with capillary gel
electrophoresis and analyzed results with BioNumerics 7.5
(Applied Maths, Sint-Martens-Latem, Belgium) (8). We
conducted identification on the basis of the Cardiff–European Centre for Disease Prevention and Control strain collection and other known types. We gave new types the prefix “x” followed by a chronological number until the strain
was typed by the reference laboratory at Leiden University
Medical Centre (Leiden, the Netherlands).
Antimicrobial Susceptibility Testing
We performed susceptibility testing by using the antimicrobial drugs recommended for treatment (i.e., metronidazole and vancomycin) and common antimicrobial drugs
known to increase risk for acquiring CDI (i.e., moxifloxacin, clindamycin, and erythromycin). We tested all isolates
by using Etest on Brucella agar, as previously described
(9). The breakpoints for resistant isolates were epidemiologic cutoff values according to the European Committee
on Antimicrobial Susceptibility Testing (EUCAST): metronidazole, >2 mg/L; vancomycin, >2 mg/L; moxifloxacin, >4 mg/L; clindamycin, >16 mg/L; and erythromycin,
>2 mg/L.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
National Surveillance for C. difficile, Sweden
Statistical Methods
We analyzed county-level PCR ribotype diversity by using the Simpson reciprocal index, 1/D. We analyzed how
switching diagnostic method affected positivity rates by using the χ2 test. We compared ecologic MIC distributions of
C. difficile isolates in Sweden to EUCAST distributions by
using the Wilcoxon rank-sum test.
Results and Discussion
Incidence of CDI in Sweden during 2012–2016
In 2012, a total of 10,820 cases of CDI were reported, of
which 8,104 (75%) were new cases and 2,716 (25%) were
recurrent cases. Recurrent cases represent a maximum
estimate because the data included a few double samples
from the same patient. The incidence of new cases was
11.8/10,000 patient-days and 85/100,000 inhabitants, results that were almost unchanged compared with those reported in 2007 (11.9/10,000 patient-days and 90/100,000
inhabitants). In 2016, the incidence of new cases had decreased to 10.1/10,000 patient-days (a 15% decrease) and
66/100,000 inhabitants (a 22% decrease) (Figure 1, panel
A and B). The decrease occurred in most counties and
resulted in less geographic variation in incidence (range
4.0–18.7/10,000 patient-days in 2012 compared with 7.1–
15.5/10,000 patient-days in 2016 [online Technical Appendix Figure, https://wwwnc.cdc.gov/EID/article/24/9/171658-Techapp1.pdf]).
CDI incidence decreased in all age groups except for
5–14 years; the largest reductions came in the age groups
0–4 years (25%), 45–64 years (23%), and >85 years (23%)
(Figure 2, panel A). The incidence was reduced similarly
in male and female inhabitants over time, although higher
incidence occurred in male inhabitants 5–14 and >75 years
of age during the entire period (Figure 2, panel B). For female inhabitants 15–64 years of age, higher incidence also
occurred, 33% higher among the 15–44 years age group
and 17% higher among the 45–64 years age group (Figure
2, panel B).
multidrug-resistant (MDR) types were no longer among the
10 most common ribotypes. RT078 prevalence was ≈3% in
Europe during 2012–2013; this ribotype is also common in
pigs and calves (4,10). RT046 is predominant in scouring
piglets in central parts of Sweden (11).
The distribution of PCR ribotypes was more variable
between counties and over time. For example, Östergötland and Uppsala had relatively high levels of RT012 and
RT231 in 2012 (Figure 3, panel A and B); these types are
associated with outbreaks (9,12). By 2016, these types had
diminished, and CDI incidence in these counties had decreased (to 35% in Östergötland and 52% in Uppsala) (online Technical Appendix Figure). An increase occurred in
PCR ribotype diversity over time (Figure 3, panel A and
B). Similarly, a study in England indicated that ribotype
diversity increased as outbreak-prone types decreased (13).
These results (i.e., the disappearance of major types, increase in type diversity, and decrease in incidence) suggest
that hospitals adopted improved infection control during
the study period. In contrast, no change in ribotype diversity was observed in the county of Västernorrland despite an
increased incidence during 2012–2015 (Figure 3, panel C).
PCR Ribotype Distribution
The distribution of the most common PCR ribotypes in
Sweden has, with a few exceptions, been relatively constant since 2009 (online Technical Appendix Table) and is
comparable to that observed in other countries of Northern
Europe (4). RT014 was the most common type throughout
the whole period, except in 2011, when it was the second
most common after RT020. Types frequently associated
with multidrug resistance, such as RT012, RT078, RT046,
and RT017, were among the 10 most common types in
the first years of the surveillance program. In conjunction
with the 7% reduction of incidence rate during 2014–2015,
with the exception of RT078, all of the previously common
Figure 1. National incidence of Clostridioides difficile infection
(CDI), Sweden, 2012–2016. A) CDI cases/10,000 patient-days.
B) CDI cases/100,000 inhabitants. Error bars indicate SD of the
mean county incidence for each year.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1619
SYNOPSIS
Figure 2. National incidence of new Clostridioides difficile infection (CDI) cases, Sweden, 2012–2016. A) Incidence by age group and
year; B) incidence by age group and sex. Error bars indicate SD. *p<0.05; **p<0.01 (both by t-test).
Jämtland was another county that showed strong incidence variation: an increase during 2012–2014 and then
a decrease in 2016 (online Technical Appendix Figure
1). In Jämtland, we observed a change in ribotype diversity, from high diversity in 2012 to low diversity during
2014–2015, then back to high diversity in 2016 (Figure 3,
panel D). However, no clustering of MDR PCR ribotypes
was evident in Västernorrland or Jämtland. Possible explanations for the incidence levels might include polyclonal
outbreaks, changes in diagnostics, and changes in sampling procedures. All 4 counties have changed diagnostic
methods from enzyme immunoassay for toxin A and B (as
Figure 3. Variation in PCR ribotype distribution in 4 counties with large changes in Clostridioides difficile infection incidence rates,
Sweden, 2012–2016. A) Östergötland; B) Uppsala; C) Västernorrland; D) Jämtland. 1/D, Simpson’s reciprocal index 1/D.
1620
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
National Surveillance for C. difficile, Sweden
standalone test) to generally more sensitive nucleic acid
amplification tests (NAATs) (also as standalone test); Uppsala and Jämtland changed in 2012 and Östergötland and
Västernorrland in 2015.
Outbreaks of C. difficile
A geographic clustering of MDR isolates might be explained by a clonal outbreak that is not always apparent
in clinical practice or in infrequent surveillance programs.
One insidious outbreak caused by MDR RT046 was detected in 2011 in the Eksjö catchment area in Jönköping
County (14), where an incidence of 22 CDI cases/10,000
patient-days surfaced in the national surveillance. The
outbreak isolate was predominant in 46% of cases, and
an excess virulence was observed by a 30-day mortality
rate of 30% and a >40% recurrence rate compared with
other ribotypes (T. Norén, unpub. data). Because the geographic clustering of RT046 in Jönköping was obvious
already in 2008 (3), the impact of this outbreak cannot
be fully understood. Antimicrobial drug stewardship and
improved hygiene were implemented stepwise during the
initial 10 months, but the outbreak was not controlled until chlorine disinfection was introduced after this period.
In addition to RT046, significant (p<0.001) geographic
clustering of RT231 was detected in 2008 in the counties of Stockholm and Uppsala (3), and this type spread
between several hospitals during an extended period until
it finally diminished (8).
Another outbreak, caused by toxin A–negative MDR
RT017, was detected late in 2012 at Ystad Hospital in
Skåne County. Considerable clinical impact occurred, similar to outbreaks with this type in other countries in Europe
(15,16). During a 6-month period, 27 patients experienced
severe CDI with this ribotype, and 10 died in spite of treatment. In November 2013, a hospital outbreak of RT027
CDI started at Växjö Hospital in Kronoberg County and
was discovered when isolates from several fulminant cases
were ribotyped. During August 2013–April 2016, a total
of 41 patients had RT027 CDI diagnosed; 6 patients died,
resulting in a 15% 30-day mortality rate for this strain. The
strain was traced back to a patient that had been abroad,
but whether his case was the actual index case was unclear.
Because of the limited periods of strain collection in the
national surveillance program, the smaller outbreaks of
RT017 and RT027 CDI could only be traced retrospectively, and the outbreak alert in these cases was prompted by
clinical awareness of clustering of severe cases.
Increased local incidence of CDI can be polyclonal,
like in Jämtland County, where a sudden increase from
≈2–4 cases/week to 10–20 cases/week occurred during a
few weeks of the 2013–14 winter season. Typing revealed
5–6 different susceptible PCR ribotypes, and although no
clear evidence of transmission could be found, the sudden
increase contributed to a substantially higher incidence in
the county in 2013 and 2014 (online Technical Appendix
Figure 1). Increases of CDI in these scenarios might occur
as a result of changes in diagnostic performance, in antimicrobial drug use, overcrowded wards, or a general decline in hygiene precautions, as opposed to introduction of
a single virulent type.
Sampling and Diagnostic Algorithms
We found a positive correlation between sampling rate
and CDI incidence per 100,000 inhabitants per county for
all 6 years (Figure 4, panel A), consistent with findings in
Figure 4. Correlation between Clostridioides difficile infection
(CDI) cases and sampling rates, Sweden, 2009–2016. A)
Correlation between number of positive CDI cases/100,000
inhabitants per county and sampling rates. B) Correlation between
percentage of CDI cases and sampling rates. Dots indicate
values per county; lines indicate regression analyses (R values
as indicated). C) Mean positivity rate (bars) and mean sampling
frequency (line), by year. Error bars show interlaboratory SD in
positivity rates.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1621
SYNOPSIS
Table. Comparison of CDI positivity rates for clinical laboratories that switched methods during the 2009–2016 study period, Sweden*
Mean no. positive samples (mean
Change in
Local CDI‡ incidence
positivity, %)
Change in testing
Year algorithm
positivity after change 2012–2016,
algorithm
was switched
2 y before switch
2 y after switch
p value†
switch, %
%
EIA to NAAT
Laboratory 1
2011
698 (21)
672 (19)
0.004
9
52
Laboratory 2
2011
176 (13)
355 (16)
<0.001
+24
31
Laboratory 3
2011
101 (12)
168 (16)
<0.001
+36
9
Laboratory 4
2011
635 (22)
506 (19)
<0.001
+6
13
Laboratory 5
2012
322 (15)
312 (17)
0.013
+14
27
Laboratory 6
2013
416 (22)
377 (18)
<0.001
18
34
Laboratory 7
2013
346 (16)
300 (12)
<0.001
27
28§
Laboratory 8
2013
176 (11)
272 (14)
<0.001
+25
28§
Total
359 (18)
370 (17)
<0.001
7
Cytotox to NAAT
Laboratory 9¶
2012
124 (7)
353 (20)
<0.001
+68
+67
Laboratory 10
2013
1,398 (13)
1233(11)
<0.001
18
9§
Total
761 (12)
793 (12)
0.358
2
Cytotox to EIA + GDH
Laboratory 11
2014
294 (17)
273 (13)
<0.001
22
35
NAAT to EIA + NAAT
Laboratory 12
2014
388 (19)
290 (14)
<0.001
27
44
EIA to EIA + NAAT
Laboratory 13
2014
677 (17)
420 (13)
<0.001
21
35
*CDI, Clostridioides difficile infection; EIA, enzyme immunoassay; GDH, glutamate dehydrogenase assay; NAAT, nucleic acid amplification testing.
†By 2 test.
‡CDI incidence/100,000 population. Local incidence data from before 2012 not available.
§Data from >1 laboratory is included in local CDI incidence rates.
¶This laboratory used a nonstandardized cell cytotoxicity assay.
other studies (17,18). Indications for sampling and laboratory testing might differ between regions, and an extensive
sampling might lead to lower positivity rates. However,
sampling rates did not largely affect the diagnostic positivity rates, suggesting that the indications for sampling
were similar among counties (Figure 4, panel B). The positivity rate and the intercounty variation in positivity rate
decreased gradually during 2012–2016 (Figure 4, panel
C), and, because many laboratories changed diagnostic
methods during the period, the reduction in intercounty
variation is most likely attributable to optimization of diagnostic algorithms and methods.
The number of laboratories using NAAT as a standalone method for CDI diagnostics increased from 6/28 in
2011 to 16/26 in 2016. Switching to NAATs as a standalone test has been associated with higher diagnostic
sensitivity and up to a 67% increase in incidence (19–21),
but we did not find any elevated positivity rate attributable
to the increased use of NAAT. On the contrary, the average
positivity rates 2 years after a method switch from enzyme
immunoassay to NAAT decreased by 7% (Table). Moreover, we observed no consistent associations between method switch, positivity rate, and incidence. One explanation
might be that most laboratories already had high sensitivity
in the testing algorithms. Also, improved infection control
and the elimination of certain PCR ribotypes that clustered
in geographic areas during the study period most likely contributed to the lower positivity and incidence rates. Only 1
laboratory (laboratory 9, which serves Västerbotten County)
1622
showed a major increase in positivity and incidence rate after adopting NAAT after switching in 2013. The most likely
explanation for this increase is that the laboratory used an
unusual diagnostic method prior to the switch, including pretreatment of feces with alcohol followed by cell-cytotoxicity
assay. A suboptimal diagnostic method might explain why
this county had the lowest incidence rates in Sweden 2012
(online Technical Appendix Figure 1).
Antimicrobial Resistance
All 3,321 isolates collected during 2009–2016 within the
national surveillance program have been tested for antimicrobial susceptibility to vancomycin, metronidazole, erythromycin, clindamycin, and moxifloxacin. Only 1 isolate
(RT027) was resistant to metronidazole (MIC 4 mg/L), and
no isolate was resistant to vancomycin. The proportion of
isolates resistant to erythromycin, clindamycin, and moxifloxacin was reduced during 2009–2016 (Figure 5, panel
A). The highest proportion of resistant isolates was observed in 2012, when 13% of isolates were MDR (resistant
to moxifloxacin, clindamycin, and erythromycin). During
2012–2016, the proportion of MDR isolates was reduced
by 80%; moxifloxacin-resistant isolates were reduced by
26%, clindamycin-resistant isolates by 51%, and erythromycin-resistant isolates by 46%. During 2009–2012, from
94% to 97% of the MDR isolates belonged to 4 PCR ribotypes (RT012, RT017, RT046, and RT231). In 2016, the
same ribotypes accounted for only 30% of all MDR isolates
(Figure 5, panel B).
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
National Surveillance for C. difficile, Sweden
Figure 5. Resistance of
Clostridioides difficile to
indicator antimicrobial
drugs, Sweden, 2009–2016.
A) Percentage of isolates
resistant and sensitive to
indicator antimicrobial drugs
erythromycin, clindamycin, and
moxifloxacin. B) PCR ribotype
distribution of MDR isolates.
MDR, multidrug-resistant (i.e.,
resistant to erythromycin,
clindamycin, and moxifloxacin);
S, sensitive to erythromycin,
clindamycin, and moxifloxacin.
The MIC distributions of isolates collected in Sweden
during 2009–2016 showed significant differences to those
from EUCAST for all antimicrobial drugs tested except for
clindamycin. The collection from Sweden had a greater
proportion of isolates with lower MICs than did the EUCAST collection (p = <0.001 by Wilcoxon rank-sum test)
(online Technical Appendix Figure 2).
Conclusions
During 2012–2016, a sustained decrease in incidence rates
of CDI has occurred in Sweden, as well as a dramatic
decrease in the proportion of MDR C. difficile isolates.
Although decreased antimicrobial drug consumption or
prudent use might be part of the explanation, we suggest
that the major impact is attributable to improved hygiene
measures in healthcare settings. This hypothesis is supported by 1) the fact that the volume of antimicrobial drugs
typically associated with increased risk for acquiring CDI
sold to hospitals, where CDI is predominant (4), was virtually unchanged during the study period (22); 2) a substantial reduction in CDI cases that occurred among elderly patients, who are known to be hospitalized to a greater extent;
and 3) the apparent disappearance of geographic clusters
of specific C. difficile PCR ribotypes, indicative of reduced
nosocomial spread. However, because CDI cases are not
classified into community- and healthcare-associated CDI,
we cannot entirely rule out the possibility that the observed
incidence reduction occurred mainly in the community,
where antimicrobial drug sales have decreased more compared with sales to inpatient facilities (22).
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1623
SYNOPSIS
The surveillance system in Sweden has several limitations (e.g., the reporting is not mandatory, diagnostic methods vary across the country and over time, and isolates are
collected only twice per year). However, the compliance
of reporting has been rather high, probably because of the
open reporting of information on geographic differences in
incidence and clusters of C. difficile types. This reporting
has in turn led to increased awareness of local epidemiology that is useful for tailoring hospital hygiene measures
and antimicrobial stewardship policies.
Despite the 22% decrease in CDI incidence during
2012–2016, Sweden still has a comparatively high CDI incidence compared with other countries in Europe. Because
only a few outbreaks have been reported and diversity of
types is high in northern Europe, including Sweden (4),
the high incidence is probably not explained by nationwide
outbreaks but is more likely attributable to increased clinical awareness, contributing to correct diagnoses and treatment. Sampling rates for CDI in Sweden are also high (17),
an average of 116 samples/10,000 patient-days in 2016, a
factor that is correlated with higher incidence (19–21). Introduction of highly sensitive methods such as standalone
NAAT has been correlated with higher CDI incidence (17),
but the small effect on positivity rates after adopting NAAT
that we report suggests that previous diagnostic algorithms
were on par with NAAT methods. A high incidence might
also be related to more subtle differences in the population,
such as immunity or susceptibility to CDI, a possibility that
warrants further research.
Acknowledgments
We thank Ingela Alefjord for exceptional laboratory work and
all the clinical laboratories in Sweden that provided isolates
and case data for the national surveillance program. We also
thank Björn Herrmann and Birgitta Lytsy for valuable
comments on the manuscript and Ed Kuijper for supplying the
C. difficile Cardiff–European Centre for Disease Prevention
and Control reference collection and providing valuable
support with strain types.
All work was financially supported by the Public Health Agency
of Sweden.
About the Author
Dr. Rizzardi is a research scientist and analyst at the Public
Health Agency of Sweden. Her research interests include the
epidemiology and molecular typing of Clostridioides difficile.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
References
1.
1624
Karlström O, Fryklund B, Tullus K, Burman LG. A prospective
nationwide study of Clostridium difficile–associated diarrhea
in Sweden. Clin Infect Dis. 1998;26:141–5. http://dx.doi.org/
10.1086/516277
15.
Kuijper EJ, Coignard B, Tüll P; ESCMID Study Group for
Clostridium difficile; EU Member States; European Centre for
Disease Prevention and Control. Emergence of Clostridium
difficile–associated disease in North America and Europe. Clin
Microbiol Infect. 2006;12(Suppl 6):2–18. http://dx.doi.org/10.1111/
j.1469-0691.2006.01580.x
Akerlund T, Alefjord I, Dohnhammar U, Struwe J, Noren T,
Tegmark-Wisell K; Swedish C. difficile Study Group. Geographical
clustering of cases of infection with moxifloxacin-resistant
Clostridium difficile PCR-ribotypes 012, 017 and 046 in
Sweden, 2008 and 2009. Euro Surveill. 2011;16:16.
http://dx.doi.org/10.2807/ese.16.10.19813-en
Davies KA, Ashwin H, Longshaw CM, Burns DA, Davis GL,
Wilcox MH; EUCLID study group. Diversity of Clostridium
difficile PCR ribotypes in Europe: results from the European,
multicentre, prospective, biannual, point-prevalence study of
Clostridium difficile infection in hospitalised patients with
diarrhoea (EUCLID), 2012 and 2013. Euro Surveill. 2016;21:30294.
http://dx.doi.org/10.2807/1560-7917.ES.2016.21.29.30294
Wilcox MH, Chalmers JD, Nord CE, Freeman J, Bouza E.
Role of cephalosporins in the era of Clostridium difficile infection.
J Antimicrob Chemother. 2016;72:1–18.
Stubbs SLJ, Brazier JS, O’Neill GL, Duerden BI. PCR targeted to
the 16S-23S rRNA gene intergenic spacer region of Clostridium
difficile and construction of a library consisting of 116 different
PCR ribotypes. J Clin Microbiol. 1999;37:461–3.
Svenungsson B, Burman LG, Jalakas-Pörnull K, Lagergren A,
Struwe J, Åkerlund T. Epidemiology and molecular
characterization of Clostridium difficile strains from patients
with diarrhea: low disease incidence and evidence of limited
cross-infection in a Swedish teaching hospital. J Clin Microbiol.
2003; 41:4031–7. http://dx.doi.org/10.1128/JCM.41.9.40314037.2003
Rizzardi K, Åkerlund T. High molecular weight typing with
MALDI-TOF MS—a novel method for rapid typing of Clostridium
difficile. PLoS One. 2015;10:e0122457. http://dx.doi.org/10.1371/
journal.pone.0122457
Harvala H, Alm E, Åkerlund T, Rizzardi K. Emergence and
spread of moxifloxacin-resistant Clostridium difficile ribotype
231 in Sweden between 2006 and 2015. New Microbes
New Infect. 2016;14:58–66. http://dx.doi.org/10.1016/
j.nmni.2016.09.002
Keel K, Brazier JS, Post KW, Weese S, Songer JG. Prevalence
of PCR ribotypes among Clostridium difficile isolates from pigs,
calves, and other species. J Clin Microbiol. 2007;45:1963–4.
http://dx.doi.org/10.1128/JCM.00224-07
Norén T, Johansson K, Unemo M. Clostridium difficile PCR
ribotype 046 is common among neonatal pigs and humans in
Sweden. Clin Microbiol Infect. 2014;20:O2–6. http://dx.doi.org/
10.1111/1469-0691.12296
Wüst J, Sullivan NM, Hardegger U, Wilkins TD. Investigation of
an outbreak of antibiotic-associated colitis by various typing
methods. J Clin Microbiol. 1982;16:1096–101.
Fawley WN, Davies KA, Morris T, Parnell P, Howe R, Wilcox MH;
Clostridium difficile Ribotyping Network (CDRN) Working
Group. Enhanced surveillance of Clostridium difficile infection
occurring outside hospital, England, 2011 to 2013. Euro
Surveill. 2016;21:30295. http://dx.doi.org/10.2807/1560-7917.
ES.2016.21.29.30295
Toepfer M, Magnusson C, Norén T, Hansen I, Iveroth P,
Offenbartl K. Insidious and widespread outbreak of Clostridium
difficile. Changed cleaning procedures and frequent evaluations
cut infection rates in half [in Swedish]. Lakartidningen. 2014;
111:24–7.
Cairns MD, Preston MD, Lawley TD, Clark TG, Stabler RA,
Wren BW. Genomic epidemiology of a protracted hospital outbreak
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
National Surveillance for C. difficile, Sweden
16.
17.
18.
19.
caused by a toxin A–negative Clostridium difficile sublineage
PCR ribotype 017 strain in London, England. J Clin Microbiol.
2015;53:3141–7. http://dx.doi.org/10.1128/JCM.00648-15
Arvand M, Hauri AM, Zaiss NH, Witte W, Bettge-Weller G.
Clostridium difficile ribotypes 001, 017, and 027 are associated
with lethal C. difficile infection in Hesse, Germany. Euro Surveill.
2009;14:19403. http://dx.doi.org/10.2807/ese.14.45.19403-en
Davies KA, Longshaw CM, Davis GL, Bouza E, Barbut F,
Barna Z, et al. Underdiagnosis of Clostridium difficile across
Europe: the European, multicentre, prospective, biannual,
point-prevalence study of Clostridium difficile infection in
hospitalised patients with diarrhoea (EUCLID). Lancet
Infect Dis. 2014;14:1208–19. http://dx.doi.org/10.1016/
S1473-3099(14)70991-0
Bauer MP, Notermans DW, van Benthem BH, Brazier JS,
Wilcox MH, Rupnik M, et al.; ECDIS Study Group. Clostridium
difficile infection in Europe: a hospital-based survey. Lancet.
2011;377:63–73. http://dx.doi.org/10.1016/S0140-6736
(10)61266-4
Moehring RW, Lofgren ET, Anderson DJ. Impact of change to
molecular testing for Clostridium difficile infection on healthcare
facility–associated incidence rates. Infect Control Hosp Epidemiol.
2013;34:1055–61. http://dx.doi.org/10.1086/673144
20.
Gould CV, Edwards JR, Cohen J, Bamberg WM, Clark LA,
Farley MM, et al.; Clostridium difficile Infection Surveillance
Investigators, Centers for Disease Control and Prevention.
Effect of nucleic acid amplification testing on population-based
incidence rates of Clostridium difficile infection. Clin
Infect Dis. 2013;57:1304–7. http://dx.doi.org/10.1093/
cid/cit492
21. Crobach MJT, Planche T, Eckert C, Barbut F, Terveer EM,
Dekkers OM, et al. European Society of Clinical Microbiology
and Infectious Diseases: update of the diagnostic guidance
document for Clostridium difficile infection. Clin Microbiol
Infect. 2016;22(Suppl 4):S63–81. http://dx.doi.org/10.1016/
j.cmi.2016.03.010
22. Hellman J, Aspevall O, editors. 2016 SWEDRES/SVARM.
Consumption of antibiotics and occurrence of antibiotic resistance
in Sweden. Solna (Sweden): Public Health Agency of Sweden,
Uppsala (Sweden): National Veterinary Institute; 2016 [cited 2018
Jun 21]. http://www.sva.se/globalassets/redesign2011/pdf/om_sva/
publikationer/swedres_svarm2016.pdf
Address for correspondence: Thomas Åkerlund, Public Health Agency
of Sweden, Unit for Surveillance of Bacterial Pathogens, Nobels väg
18, Solna, Sweden; email: thomas.akerlund@folkhalsomyndigheten.se
August 2017: V e ct or bor n e I n fe ct ion s
• Added Value of Next-Generation Sequencing for
Multilocus Sequence Typing Analysis of a Pneumocystis
jirovecii Pneumonia Outbreak
• Molecular Characterization of Corynebacterium
diphtheriae Outbreak Isolates, South Africa,
March–June 2015
• Bartonella quintana, an Unrecognized Cause of
Infective Endocarditis in Children in Ethiopia
• Clinical Laboratory Values as Early Indicators of Ebola
Virus Infection in Nonhuman Primates
• Characteristics of Dysphagia in Infants with Microcephaly
Caused by Congenital Zika Virus Infection, Brazil, 2015
• Maguari Virus Associated with Human Disease
• Zika Virus Infection in Patient with No Known Risk
Factors, Utah, USA, 2016
• Human Infection with Highly Pathogenic Avian Influenza
A(H7N9) Virus, China
• Human Metapneumovirus and Other Respiratory Viral
Infections during Pregnancy and Birth, Nepal
• Global Spread of Norovirus GII.17 Kawasaki 308,
2014–2016
• Preliminary Epidemiology of Human Infections with
Highly Pathogenic Avian Influenza A(H7N9) Virus,
China, 2017
• Acute Febrile Illness and Complications Due to Murine
Typhus, Texas, USA
• High Infection Rates for Adult Macaques after
Intravaginal or Intrarectal Inoculation with Zika Virus
• Lyme Borreliosis in Finland, 1995–2014
• Characterization of Fitzroy River Virus and Serologic
Evidence of Human and Animal Infection
• Genomic Characterization of Recrudescent
Plasmodium malariae after Treatment with Artemether/
Lumefantrine
• Real-Time Evolution of Zika Virus Disease Outbreak,
Roatán, Honduras
• Clonal
Expansion of
New PenicillinResistant Clade
of Neisseria
meningitidis
Serogroup W
Clonal Complex
11, Australia
https://wwwnc.cdc.gov/eid/articles/issue/23/8/table-of-contents
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1625
SYNOPSIS
Tr a ve l- Associa t e d Zik a Ca se s
a n d Th r e a t of Loca l Tr a n sm ission
du r in g Globa l Ou t br e a k ,
Ca lifor n ia , USA
Charsey Cole Porse, Sharon Messenger, Duc J. Vugia, Wendy Jilek,
Maria Salas, James Watt, Vicki Kramer
Zika and associated microcephaly among newborns were
reported in Brazil during 2015. Zika has since spread across
the Americas, and travel-associated cases were reported
throughout the United States. We reviewed travel-associated Zika cases in California to assess the potential threat of
local Zika virus transmission, given the regional spread of
Aedes aegypti and Ae. albopictus mosquitoes. During November 2015–September 2017, a total of 588 travel-associated Zika cases were reported in California, including 139
infections in pregnant women, 10 congenital infections, and
8 sexually transmitted infections. Most case-patients reported travel to Mexico and Central America, and many returned during a period when they could have been viremic.
By September 2017, Ae. aegypti mosquitoes had spread to
124 locations in California, and Ae. albopictus mosquitoes
had spread to 53 locations. Continued human and mosquito
surveillance and public health education are valuable tools
in preventing and detecting Zika virus infections and local
transmission in California.
Zika virus is endemic, the risk for autochthonous transmission of Zika virus is a concern (4). During 2011–2015,
Ae. aegypti and Ae. albopictus mosquitoes were detected
in 85 cities and census-designated places in 12 counties
of California (5).
In California, patient testing and evaluation focused on
assessment of infection in pregnant women and symptomatic patients, and assessment of potential viremia in these
patients in relation to proximity to known Aedes mosquito
infestations. To describe travel-associated Zika cases and
better assess the potential threat of local Zika transmission
in California, we reviewed all Zika cases reported to the
California Department of Public Health (CDPH) during
November 2015–September 2017. We also summarized
surveillance for Ae. aegypti and Ae. albopictus mosquitoes
in California and laboratory testing for Zika virus during
this time.
T
Methods
Zika cases were reported to CDPH by the 61 local health
departments in California, either through the electronic
California Reportable Disease Information Exchange
(https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/
CalREDIE.aspx) or through paper case report forms. Cases
reviewed by CDPH during November 2015–September
2017 were analyzed for type of Zika disease or infection,
as defined by the 2016 Council of State and Territorial Epidemiologists (CSTE)/Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) criteria and classified
as confirmed or probable (6). Variables examined included
sex, age, race/ethnicity, country where exposure likely took
place, duration of travel, symptoms, symptom onset date,
and pregnancy status and outcomes.
We analyzed data by using SAS for Windows version
9.4 (SAS Institute Inc., Cary, NC, USA). For Zika casepatients with a travel duration of <6 months, we compared
duration of time in Zika-affected areas between pregnant
and all other case-patients by using the Kruskal-Wallis test
he first human cases of Zika virus infection reported
from the Americas were in May 2015 from Brazil (1).
In the span of less than a year, Zika virus spread across
South America, Central America, the Caribbean, and parts
of Mexico. As observed with other mosquitoborne diseases, such as dengue and chikungunya, which have spread
through Central and South America and the Caribbean,
travel-associated cases of Zika were reported throughout
the United States, and local transmission of Zika virus
was eventually detected in Florida and Texas (2,3). Because California has established and expanding infestations of Aedes aegypti and Ae. albopictus mosquitoes, the
main vectors of Zika virus, and is near Mexico, to which
Author affiliations: California Department of Public Health,
Sacramento, California, USA (C.C. Porse, W. Jilek, V. Kramer);
California Department of Public Health, Richmond, California,
USA (S. Messenger, D.J. Vugia, M. Salas, J. Watt)
DOI: https://doi.org/10.3201/eid2409.180203
1626
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Travel-Associated Zika during Global Outbreak
for 2 groups (unequal variances) to retrospectively assess
time at risk between these 2 groups.
California has a network of local vector control agencies that monitors distribution and abundance of Aedes spp.
and other mosquito populations. Mosquito surveillance
typically includes trapping and identifying mosquitoes.
Surveillance might be augmented by submitting mosquito
specimens, especially specimens collected in and around
residences or workplaces of case-patients, to the Davis Arbovirus Research and Training Laboratory at the University
of California (Davis, CA, USA) for Zika virus (7), dengue
virus (DENV) (8), and chikungunya virus (Davis Arbovirus Research and Training Laboratory at the University of
California, unpub. data) testing by multiplex quantitative
reverse transcription PCR (RT-PCR), as described by CDC
(9). Mosquitoes submitted during West Nile virus (WNV)
season (June 1–October 15) are also tested for WNV, St.
Louis encephalitis virus, and western equine encephalitis
virus (10). Agencies enter mosquito surveillance data into
the California Vectorborne Disease Surveillance Gateway
Database (https://gateway.calsurv.org/), which is used to
generate statewide data for mapping of Aedes mosquito locations. We used a geographic information system (ArcGIS
Desktop version 10.5; Esri, Redlands, CA, USA) to generate maps that enabled spatial and temporal mapping of
Aedes mosquito populations in relation to presumed places
of residence of presumed viremic Zika case-patients. We
generated latitude and longitude data by using the Gateway
Database for mosquitoes and determined case-patient place
of residence by using the California Reportable Disease Information Exchange.
Testing of humans for Zika virus was performed by the
CDPH Viral and Rickettsial Disease Laboratory (VRDL),
CDC, local public health laboratories, commercial laboratories, and blood banks. Testing for Zika virus infection
was completed for appropriate tissue, serum, or urine specimens by using Zika virus nucleic acid or serologic tests.
We analyzed symptomology and pregnancy status of those
tested, volume of testing at the CDPH VRDL, types of tests
conducted, and time from symptom onset to specimen collection date. For purposes of local transmission risk assessment, a potentially viremic patient was defined as a Zikapositive case-patient with symptom onset <7 days before or
any time after return from travel to their place of residence.
Results
Descriptive Statistics
During November 2015–September 2017, a total of 588
travel-associated Zika cases were reported in California,
including 139 infections in pregnant women, 10 congenital infections, and 8 sexually transmitted infections. Sixtytwo case-patients were <18 years of age. On the basis of
the 2016 CSTE surveillance case definition for Zika, 410
cases met the confirmed criteria and 178 were probable.
Of these, 466 case-patients had noncongenital Zika disease
with symptoms meeting the 2016 CSTE case definition
for noncongenital Zika (>1 of the following: fever, rash,
arthralgia, or conjunctivitis); 112 had a symptomatic noncongenital Zika infections, 6 had congenital Zika disease
with Zika-associated birth defects (birth defects reported
include those detected in infants infected with Zika virus
before, during, or shortly after birth, including microcephaly, calcium deposits in the brain indicating possible brain
damage, excess fluid in the brain cavities and surrounding
the brain, absent or poorly formed brain structures, abnormal eye development, or other problems resulting from
damage to the brain that affects nerves, muscles, and bones,
such as clubfoot or inflexible joints, and confirmed hearing
loss); and 4 had congenital Zika infections with no Zikaassociated birth defects (6).
A total of 66% (391/588) of case-patients were female;
median age of case-patients was 35 years (range <1–89
years). Of persons with reported ethnicity, 69% (306/443)
were Latino/Latina. For the 139 women pregnant at the
time of diagnosis, median age was 27 years (range 14–44
years), and 78% (87/111) of those with reported ethnicity
were Latina.
Of 570 case-patients who contracted Zika virus while
traveling outside California, most case-patients reported
travel to Mexico (36.4%), Central America (34.3%), or the
Caribbean (13.1%). The top 10 countries and territories for
travel were Mexico (36.4%), Nicaragua (9.6%), Guatemala
(8.4%), El Salvador (7.0%), Dominican Republic (4.4%),
Puerto Rico (4.4%), Honduras (3.9%), Costa Rica (3.7%),
Jamaica (2.5%), and Colombia (1.8%). The timeline for
travel-associated Zika cases reported in California mirrored the spread of the outbreak across the Americas (Figure 1); the number of case-patients with travel to Mexico
increased substantially starting in June 2016 as the number
of Zika cases reported in Mexico steadily increased.
Of 570 case-patients who traveled, 79 (13.9%) lived in
their country of exposure for >6 months before coming to
California, where they were subsequently tested for Zika
virus. When we excluded these 79 persons, women who
were pregnant at the time of Zika diagnosis had a significantly (p = 0.03) longer travel duration (median 14 days
[range 1–153 days]) than all other Zika case-patients (median 11 days [range 1–137 days]).
For 466 case-patients with symptoms, rash was the most
common (89.0%, 415), followed by arthralgia (62.5%, 291),
fever (60.1%, 280), myalgia (36.9%, 172), and conjunctivitis
(35.0%, 161). A rash without any other symptom was seen
in 49 (10.5%) case-patients. For those case-patients with
>1 symptom, the most common combination of symptoms,
reported by 13% of case-patients, was rash, arthralgia, and
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1627
SYNOPSIS
Figure 1. Number of human Zika
virus infections in residents, by
month and year of onset and
country of travel (top 10 countries
shown), California, USA, October
1, 2015–September 1, 2017.
Month was determined by date of
symptom onset for symptomatic
persons or specimen collection
date for asymptomatic persons.
fever. Seven case-patients were hospitalized for a median
of 3 (range 1–8) days. On the basis of symptom onset date,
the number of Zika cases reported in California in 2016
increased from June through August and then decreased
through November (Figure 2).
Of 139 women who were pregnant at the time of
Zika diagnosis, 120 had completed their pregnancies by
September 1, 2017: 114 with live births and 6 with fetal
losses. Fourteen women were still pregnant, and the status
of 5 women was unknown. For live births, 90 (78.9%)
infants were tested for Zika virus at or shortly after birth;
84 (73.7% of live births) infants showed negative results
for Zika virus by nucleic acid and IgM tests, and 6 (5.3%
of live births) showed positive results. Of the remaining 24
live births, 7 infants were not tested, and the testing status
of 17 infants was unknown. In addition to the 6 congenitally
infected infants that were born to Zika virus–positive
mothers, 4 additional infants whose mothers were exposed
to Zika virus but showed negative results by nucleic acid or
IgM tests were positive for Zika virus.
Eight infants were born in California with Zika-associated birth defects. Of these infants, 2 were negative and
6 were positive for Zika virus by PCR and IgM test. Both
Zika virus–negative infants had mothers who were positive
for Zika virus, and 3 of the Zika virus–positive infants had
mothers who had negative results for Zika virus.
Mosquito and Human Case Surveillance
During January 1, 2016–September 1, 2017, we detected
78 new locations for Ae. aegypti mosquitoes and 25 new locations for Ae. albopictus mosquitoes, for a total of 133 cities or census-designated places for Ae. aegypti mosquitoes
and 56 for Ae. albopictus mosquitoes, an increase of 142%
for Ae. aegypti mosquitoes and 81% for Ae. albopictus
1628
mosquitoes in 20 months. In 2017, Ae. aegypti mosquitoes
were detected in 12 counties and Ae. albopictus mosquitoes
in 5 counties, including 2 new counties containing Ae.
aegypti mosquitoes in the Central Valley (11).
As of September 1, 2017, a total of 13,499 Ae. aegypti mosquitoes and 2,719 Ae. albopictus mosquitoes had
been tested by Davis Arbovirus Research and Training for
Zika virus, chikungunya virus, and DENV. None of these
mosquitoes were positive for these arboviruses, although
5 pools of Ae. aegypti mosquitoes and 1 pool of Ae. albopictus mosquitoes were positive for WNV. Of the 588
case-patients reported who had Zika virus infections, 435
(74.6%) were likely viremic while in California. Of those
viremic case-patients, 279 (64.1%) were also residents of
California counties where Ae. aegypti or other Aedes spp.
mosquitoes have been detected; their co-location was more
common in southern California (Figure 3).
Laboratory Testing
Although the VRDL performed most (58.7%; 345/588)
testing for Zika-positive cases in California, commercial
laboratories accounted for 17.5% (103/588), local health
departments for 13.1% (77/588), and CDC for 9.5%
(56/588). Seven Zika cases reported in California were
identified through blood bank screening. Most testing at
VRDL was performed for asymptomatic pregnant women
(7,795 asymptomatic pregnant women/11,603 total patients; 67.2%). Eighty (1.0%) of these asymptomatic pregnant women were positive for Zika virus by quantitative
RT-PCR (1 woman) or IgM test and plaque-reduction neutralization test (PRNT) (79 women).
Of the 120 completed pregnancies for women who
were infected with Zika virus while pregnant, 45 placental tissues (including placenta, membrane, and umbilical
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Travel-Associated Zika during Global Outbreak
Figure 2. Confirmed and
probable symptomatic Zika
virus infections, by symptom
onset month and year,
California, USA, October 2015–
September 2017.
cord) were sent to CDC for testing. Zika virus was detected
by RT-PCR in placental tissues of 8 women. Detection of
Zika virus in the placental tissue provided confirmatory
testing for 5 of these women (3 were already confirmed by
serum PRNT).
Of the 410 confirmed Zika cases reported in California, 319 (77.8%) case-patients had Zika virus detected by
nucleic acid tests in serum, urine, or placental tissue, and
the other 91 were confirmed by detection of neutralizing
antibodies to Zika virus (and not DENV). For symptomatic
case-patients, the median time from illness onset to specimen collection was 5 days (range 1–194 days). For cases
confirmed by serum or urine nucleic acid tests, the time to
collection was shorter, with a median of 3 days (range 1–33
days), than for PRNT, with a median of 16 days (range
1–194 days).
Discussion
Since the global Zika outbreak began in South America
in 2015, many travel-associated Zika cases have been
documented in California, including infections in pregnant
women, congenital infections, and sexually transmitted infections. With the establishment and continuing spread of
Ae. aegypti and Ae. albopictus mosquitoes in California,
prevention of local transmission of Zika virus has been
and continues to be a public health priority. In working to
identify possible local transmission, CDPH used the data
for travel-associated Zika cases described in this article to
develop our Zika testing prioritization. Although CDC recommended specific criteria for travel-associated Zika virus
testing, different criteria were needed when testing persons
without travel history, especially when the number of confirmed Zika cases was increasing in California and local
Zika virus transmission was reported in Florida (2). The
goal of such testing was to identify anyone who potentially
had Zika virus, without testing large numbers of persons at
low risk.
CDPH subsequently provided criteria for local health
departments in California to consider in evaluating whether
suspected persons without travel history should be considered for Zika virus testing, including factors that could
increase risk for local transmission, as well as signs and
symptoms most suggestive of Zika. For example, CDPH
allowed that, for counties where Aedes mosquitoes have
been detected, Zika virus testing could be offered to persons who live in an area containing Aedes spp. mosquitoes
and who came to their healthcare provider with a maculopapular rash and 1 other symptom consistent with Zika (fever, arthralgia, or conjunctivitis), without an alternative explanation, such as a drug reaction or other infection. Rash
was recommended as the primary criterion in this setting
because nearly 90% of Zika case-patients had a rash. This
allowance for Zika virus testing for persons with no travel
or sexual exposure was used in some counties in California and identified several persons suspected of having Zika
who were tested, all of whom showed negative results. This
testing allowance would not be appropriate in areas that did
not contain Aedes spp. mosquitoes and is being reconsidered as the number of Zika cases has decreased.
Although California health officials did not identify
any episodes of local Zika virus transmission, our data
indicate that large numbers of likely viremic travelers returned to areas containing Ae. aegypti and Ae. albopictus
mosquitoes, especially in southern California, as has also
been found for dengue and chikungunya (4). This overlap
of viremic travelers and Aedes spp. mosquito vectors potentially increases the risk for local transmission and will
continue to be a public health concern requiring ongoing mosquito and human case surveillance. CDPH works
closely with local health departments and vector control
agencies to prepare for the potential of a locally transmitted outbreak. The close coordination of mosquito control
programs in California with programs of local health departments, the common use of air conditioning or window
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1629
SYNOPSIS
screens by residents, and the variable distribution of Aedes
spp. mosquitoes in some affected counties in California
would likely limit the extent of a local outbreak should it
occur. Nonetheless, knowledge of co-located vector mosquitoes and infected returned travelers is needed to aid in
rapid investigation of any suspected locally transmitted
case(s) and to limit potential spread.
Mosquito seasonality influences risk for local transmission, and although Aedes spp. mosquitoes can be found
year-round in California, they are most abundant from June
through November, typically peaking in September and
October (5). Large numbers of potentially viremic case-patients returned to California during June–November 2016
(Figure 2), corresponding with the season of high Aedes
spp. mosquito activity in California. This seasonality also
reflects Ae. aegypti mosquito activity in northern Mexico,
where Ae. aegypti mosquitoes are abundant from August
through November.
Similar to the chikungunya outbreak in the Americas
that began in 2013 and rapidly peaked in most locations
before decreasing (12), the number of Zika cases is now
decreasing. This decrease in Zika cases has been observed
both in countries reporting local transmission and in the
number of infected returned travelers reported in the United States and in California (13). Although the level of Zika
virus transmission has decreased, many countries, including Mexico, have continued to report moderate levels of
local Zika virus transmission (14). Given the large number
of travelers between Mexico and California, it is critical
that Zika prevention messaging, surveillance, and outreach continue, especially as it pertains to women traveling
while pregnant.
The large volume of testing for asymptomatic pregnant women reinforces that potential Zika virus exposure incidents were occurring in high numbers even with
extensive provider education and public health messaging in California and nationally. Women who were
pregnant at the time of their Zika diagnosis had a longer
duration of travel in their exposure country than all other
case-patients. Because most infected pregnant women
were Latina, it is possible that many of them had traveled to visit family and therefore had longer stays. Given the health risk to pregnant women and their fetuses,
this finding is of great concern. We need to ensure that
English- and Spanish-language public health messaging
about risks of travel or travel of sexual partners to Zikaaffected countries continues to reach pregnant women
and their healthcare providers. Although a decrease in
reported travel-associated Zika cases was observed in
California in March 2017, we did not detect a decrease in
Figure 3. Locations where Aedes spp. mosquitoes were detected and residences of possibly viremic case-patients infected with Zika
virus, central (A) and southern (B) California, USA, October 2015–September 2017. Insets show larger views of corresponding region.
1630
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Travel-Associated Zika during Global Outbreak
specimens submitted for asymptomatic pregnant women
to VRDL until August 2017.
Laboratory testing for Zika virus has proved challenging throughout the outbreak. Results of assays were difficult to interpret because serologic cross-reactivity with
other flaviviruses, especially DENV, was common (15).
Detection of neutralizing antibodies against Zika virus and
DENV was observed for 178 probable Zika case-patients
reported in California. Thus, the specific flavivirus of the
infection in these case-patients could not be determined.
In addition, Zika IgM has been reported to persist in serum, making timing of infection difficult to determine (16).
The discordant testing results observed in the mother/infant
pairs were equally challenging, suggesting that a negative
test result could rarely rule out a Zika virus infection. All
these factors, in addition to the difficulty of determining
the date of exposure for many case-patients, especially for
women who lived in the area of exposure for an extended
time, made the interpretation of negative results problematic and created challenges for ensuring that affected infants
received appropriate follow-up care.
Our study and data interpretation have several limitations. First, the data included only case-patients who were
positive for Zika virus, not case-patients who were negative but had been potentially exposed to Zika virus. Analysis of such persons who were negative for this virus but
had potentially been exposed would be helpful to further
delineate risk and discriminate symptoms. However, negative results, particularly from commercial laboratories, often have limited associated clinical and demographic data.
Second, some dengue cases might be misclassified as Zika
cases because of cross-reactivity and nonspecific binding
in available serologic assays. Given the large percentage of
case-patients in California with previous exposure to flaviviruses, especially DENV, there is potential for false-positive interpretation of PRNT results. All case-patients with
neutralizing antibodies against DENV and Zika virus were
classified on the basis of the CSTE case definition as having Zika because of the higher risk during pregnancy from
exposure to Zika virus. In addition, low pretest probability,
especially in asymptomatic persons, increases the risk for
misclassification because of type I errors (false-positive results). Third, an estimated 80% of persons infected with
Zika virus are asymptomatic (17), making it difficult to determine when, where, and how many potentially viremic
persons are returning to California. Fourth, there is a clear
testing bias toward pregnant and reproductive-age women,
which skews demographic data.
Although Zika virus transmission and Zika case
numbers have decreased across the Americas, we expect
to see continued, limited, local transmission in some affected countries. Thus, there is still a risk for pregnant
women and all those who travel to these countries, and it
is necessary that prevention messaging remains targeted
and operative. Healthcare providers should continue to
be suspicious of returning travelers with rash, fever, conjunctivitis, or arthralgia, particularly when other diagnoses have been ruled out. The expansion of Ae. aegypti and
Ae. albopictus mosquitoes into 12 counties in California,
especially along the southern border region, increases the
risk for local Zika transmission in California. The large
percentage of potentially viremic travelers returning to
areas that contain Aedes spp. mosquitoes, in addition to
an unknown number of returned travelers who are asymptomatically infected but not detected, makes the risk
for local transmission a continuing threat, albeit low, in
California. Zika has complicated disease manifestations
and transmission dynamics, such as sexual and congenital
transmission, which are not typically observed for other
arboviruses. It is vital that we apply the public health
lessons learned during the Zika outbreak to prepare for
complexities that might arise during future epidemics of
emerging and reemerging arboviruses.
Acknowledgments
We thank the Viral and Rickettsial Disease Laboratory at CDPH;
the Center for Family Health at CDPH, particularly Karen
Ramstrom; the Centers for Disease Control and Prevention; the
University of California, Davis, particularly Christopher Barker;
and local California health departments and vector-control
agencies for their collaborative efforts. We also thank Marco
Metzger and Greg Hacker for providing Aedes spp. mosquito
surveillance data and mapping expertise and Anne Kjemtrup for
detailed manuscript review.
This study was supported by the Epidemiology and Laboratory
Capacity for Infectious Diseases Cooperative Agreement no. 6
NU50CK000410 from the Centers for Disease Control
and Prevention.
About the Author
Dr. Porse is an epidemiologist in the Vector-Borne Disease
Section, Infectious Diseases Branch, Division of Communicable
Disease, California Department of Public Health, Sacramento,
CA. Her research interests include epidemiology, mosquitoborne
diseases, and public health.
References
1.
Zanluca C, Melo VC, Mosimann AL, Santos GI, Santos CN,
Luz K. First report of autochthonous transmission of Zika virus
in Brazil. Mem Inst Oswaldo Cruz. 2015;110:569–72.
http://dx.doi.org/10.1590/0074-02760150192
2. Florida Department of Public Health. Zika virus [cited 2017 Sep
29]. http://www.floridahealth.gov/diseases-and-conditions/
zika-virus/index.html
3. Texas Department of State Health Services. Zika in Texas [cited
2017 Sep 29]. http://texaszika.org/
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1631
SYNOPSIS
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
Porse CC, Kramer V, Yoshimizu MH, Metzger M, Hu R,
Padgett K, et al. Public health response to Aedes aegypti and
Ae. Albopictus mosquitoes invading California, USA. Emerg Infect
Dis. 2015;21:1827–9. http://dx.doi.org/10.3201/eid2110.150494
Metzger ME, Hardstone Yoshimizu M, Padgett KA, Hu R,
Kramer VL. Detection and establishment of Aedes aegypti and
Aedes albopictus (Diptera: Culicidae) mosquitoes in California,
2011–2015. J Med Entomol. 2017;54:533–43. http://dx.doi.org/
10.1093/jme/tjw237
Center for Disease Control and Prevention. National Notifiable
Diseases Surveillance System (NNDSS). Zika virus disease and
Zika virus infection 2016 case definition, approved June
2016. CSTE position statements [cited 2017 Oct 3].
https://wwwn.cdc.gov/nndss/conditions/zika/case-definition/2016/06/
Lanciotti RS, Kosoy OL, Laven JJ, Velez JO, Lambert AJ,
Johnson AJ, et al. Genetic and serologic properties of Zika
virus associated with an epidemic, Yap State, Micronesia, 2007.
Emerg Infect Dis. 2008;14:1232–9. http://dx.doi.org/10.3201/
eid1408.080287
Callahan JD, Wu SJ, Dion-Schultz A, Mangold BE, Peruski LF,
Watts DM, et al. Development and evaluation of serotype- and
group-specific fluorogenic reverse transcriptase PCR (TaqMan)
assays for dengue virus. J Clin Microbiol. 2001;39:4119–24.
http://dx.doi.org/10.1128/JCM.39.11.4119-4124.2001
Centers for Disease Control and Prevention. Trioplex real-time
RT-PCR assay [cited 2018 May 9]. https://www.cdc.gov/zika/pdfs/
trioplex-real-time-rt-pcr-assay-instructions-for-use.pdf
Brault AC, Fang Y, Reisen WK. Multiplex qRT-PCR for the
detection of western equine encephalomyelitis, St. Louis
encephalitis, and West Nile viral RNA in mosquito pools
(Diptera: Culicidae). J Med Entomol. 2015;52:491–9.
http://dx.doi.org/10.1093/jme/tjv021
California Department of Public Health. Zika, what Californians
need to know. Aedes aegypti and Aedes albopictus mosquitoes in
California detection sites by county/city [cited 2017 Sep 1].
https://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20
Document%20Library/AedesDistributionMap.pdf
Pan American Health Organization. Chikungunya. PAHO/WHO
data, maps and statistics. Geographic distribution 2014–2017 [cited
2017 Oct 3]. http://www.paho.org/hq/index.php?option=com_topic
s&view=article&id=343&Itemid=40931
Hills SL, Fischer M, Petersen LR. Epidemiology of Zika virus
infection. J Infect Dis. 2017;216(suppl 10):S868–74.
http://dx.doi.org/10.1093/infdis/jix434
General Directorate of Epidemiology (DEG). National system
of epidemiologic surveillance; unique information system; 2017
[cited 2017 Oct 3]. https://www.gob.mx/cms/uploads/attachment/
file/255100/sem35.pdf
Rabe IB, Staples JE, Villanueva J, Hummel KB, Johnson JA,
Rose L, et al. Interim guidance for interpretation of Zika virus
antibody tests results. MMWR Morb Mortal Wkly Rep.
2016;65:543–6. http://dx.doi.org/10.15585/mmwr.mm6521e1
Oduyebo T, Polen KD, Walke HT, Reagan-Steiner S, Lathrop E,
Rabe IB, et al. Update: interim guidance for health care providers
caring for pregnant women with possible Zika virus exposure—
United States (including U.S. territories), July 2017. MMWR Morb
Mortal Wkly Rep. 2017;66:781–93. http://dx.doi.org/10.15585/
mmwr.mm6629e1
Duffy MR, Chen T-H, Hancock WT, Powers AM, Kool JL,
Lanciotti RS, et al. Zika virus outbreak on Yap Island, Federated
States of Micronesia. N Engl J Med. 2009;360:2536–43.
http://dx.doi.org/10.1056/NEJMoa0805715
Hist ory of
Mosquit oborne
Diseases in t he
Unit ed St at es
Dr. Max Moreno, assistant
professor of environmental health
science at Indiana University,
discusses the history of mosquitoborne diseases in the United States
and the threat of their return.
Visit ou r w e bsit e t o list e n :
h t t ps:/ / t ools.cdc.gov/ m e dia libr a r y/
in de x .a spx # / m e dia / id/ 3 8 1 2 8 4
Address for correspondence: Charsey Cole Porse, California Department
of Public Health, 1616 Capitol Ave, MS-7307, Sacramento CA 95814,
USA; email: charsey.porse@cdph.ca.gov
1632
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
D ist in gu ish in g Ja pa n e se Spot t e d
Fe ve r a n d Scr u b Typh u s,
Ce n t r a l Ja pa n , 2 0 0 4 – 2 0 1 5
Eiichiro Sando, Motoi Suzuki, Shungo Katoh, Hiromi Fujita,
Masakatsu Taira, Makito Yaegashi, Koya Ariyoshi
Japanese spotted fever (JSF) and scrub typhus (ST) are
endemic to Japan and share similar clinical features. To
document the clinical and epidemiologic characteristics that
distinguish these 2 rickettsial diseases, during 2004–2015
we recruited 31 JSF patients, 188 ST patients, and 97 nonrickettsial disease patients from the Southern Boso Peninsula of Japan. JSF occurred during April–October and ST
during November–December. Patients with JSF and ST
were significantly older and more likely to reside in wooded areas than were patients with nonrickettsial diseases.
Spatial analyses revealed that JSF and ST clusters rarely
overlapped. Clinical findings more frequently observed in
JSF than in ST patients were purpura, palmar/plantar rash,
hyponatremia, organ damage, and delayed defervescence
after treatment. Although their clinical features are similar,
JSF and ST differ in seasonality, geographic distribution,
physical signs, and severity. Because a considerable percentage of patients did not notice rash and eschar, many
rickettsial diseases might be underdiagnosed in Japan.
T
wo rickettsial diseases are endemic to Japan, scrub typhus (ST) and Japanese spotted fever (JSF). ST, which
is also called tsutsugamushi disease (1), was first reported
in central Japan in 1878 (2). ST is caused by the miteborne pathogen Orientia tsutsugamushi. According to the
national surveillance data of notifiable diseases in Japan,
during 2004–2015, the number of reported ST cases was
nearly constant; each year on average, 396 ST cases and
2 deaths (case-fatality rate 0.5%) were reported (3). ST
was originally believed to be confined to the Asia–Pacific
region; however, ST has recently been reported in Kenya
(4) and southern Chile (5). In 1984, JSF was identified in
western Japan (6). JSF is caused by the tickborne pathogen
Rickettsia japonica (7). Except for a case reported in South
Author affiliations: Nagasaki University, Nagasaki, Japan
(E. Sando, M. Suzuki, S. Katoh, K. Ariyoshi); Kameda Medical
Center, Kamogawa, Japan (E. Sando, M. Yaegashi); Mahara
Institute of Medical Acarology, Anan, Japan (H. Fujita); Chiba
Prefectural Institute of Public Health, Chiba, Japan (M. Taira)
DOI: https://doi.org/10.3201/eid2409.171436
Korea (8), JSF is endemic nearly exclusively to the central
and western portions of Japan (3). Recently, the number
of reported JSF cases in this region increased, from 66 in
2004 to 215 in 2015, and the case-fatality rate increased
from 1.5% to 2.3% (3); thus, JSF is a public health concern.
Although JSF and ST have been reported in several prefectures in Japan, the areas of endemicity rarely overlap at the
district level (3). One of the rare districts to which both JSF
and ST are endemic is the southern Boso Peninsula, Chiba
Prefecture, in central Japan.
The typical signs and symptoms of JSF and ST are
similar (e.g., fever, rash, and eschar), although in patients
with ST, the frequency of rash varies from 14% to 93% and
of eschar from 8% to 93% (9–13). For a few patients with
JSF and ST, severe conditions develop (14–17). However,
clinical information regarding JSF has been limited by lack
of an appropriate case definition, lack of in-depth information, and studies involving small sample sizes (14,16). The
clinical features observed in patients with JSF and ST are
not comparable across studies because of the different enrollment criteria and nonstandardized case definitions. To
clarify the clinical and epidemiologic characteristics of JSF
and ST patients by using stringent laboratory confirmation
methods and to identify the factors that distinguish the 2
diseases, we conducted a multicenter study in the southern
Boso Peninsula in central Japan, an area of high JSF and
ST endemicity. The study was approved by the institutional
review boards of the Kameda Medical Center and the Awa
Regional Medical Center.
Methods
Study Design and Setting
The southern Boso Peninsula is a predominantly rural
mountainous region with a long coastline facing the Pacific Ocean and Tokyo Bay. According to the census, the
total population in 2015 was 350,000 and 35.4% of the
residents were >65 years of age. We conducted prospective
and retrospective case series reviews at 3 medical facilities:
Kameda Medical Center (865 acute beds), Awa Regional
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1633
SYNOPSIS
Medical Center (149 beds), and Kameda Family Clinic–
Tateyama (no beds).
Study Period and Entry Criteria
We prospectively enrolled patients from January 1, 2011,
through December 31, 2015. We collected clinical, epidemiologic, and laboratory data from the patients who visited
the study hospitals and exhibited signs and symptoms compatible with rickettsial disease. The patients were suspected
to have rickettsial disease if they had any of the following
clinical signs or symptoms without other apparent causes:
fever, rash, eschar, respiratory symptoms, altered mental
status, lymphadenopathy, neurologic abnormalities, systematic pain, chills/rigors, headache, or malaise. Using the
same enrollment criteria, we also retrospectively collected
data from patients who visited the study hospitals from January 1, 2004, through December 31, 2010, and who were
not included in the prospective data collection. We used a
standardized format to extract clinical and epidemiologic
information from electronic medical records.
or immunoperoxidase assay was observed in paired serum
samples (i.e., acute and convalescent phases). A patient’s
status that did not fulfill the criteria for confirmed was defined as probable if the IgM titer of IFA or immunoperoxidase assay was >80 for JSF or ST. A patient’s status was
defined as possible if the clinical course was compatible
with that of JSF or ST but the laboratory test results did
not fulfill the criteria for either confirmed or probable. A
patient was defined as having a nonrickettsial disease if a
diagnosis of an infectious or noninfectious disease other
than a rickettsial disease was confirmed. We excluded from
analysis those patients who were classified as having possible cases or a diagnosis of murine typhus or concurrent
JSF and ST infection.
Traditionally, in Japan, fever, rash, and eschar have been
considered the triad of JSF and ST. We classified the triad
into 3 categories: 1) “chief complaint” if any of the signs
were the reason for the visit; 2) “upon history collection” if
patients noticed the signs but had not complained until the
physician asked; and 3) “physical exam” if the signs were
objectively identified at the initial physical examination.
Laboratory Methods
All blood samples were sent to a commercial laboratory
(SRL, Inc., Tokyo) for an indirect immunofluorescence assay (IFA) to identify the O. tsutsugamushi serotypes Kato,
Karp, and Gilliam; the antigens were provided by Denka
Seiken Co., Ltd. If JSF was suspected, the samples were
sent to the Chiba Prefectural Institute of Public Health for
IFA to identify the O. tsutsugamushi serotypes Kato, Karp,
Gilliam, Irie/Kawasaki, Hirano/Kuroki, and R. japonica
(YH strain). The blood samples collected during 2009 and
2010 were also sent to the Ohara Research Laboratory (Fukushima City, Japan), and samples collected during 2014
were sent to the Mahara Institute of Medical Acarology
(Anan, Japan) for an indirect immunoperoxidase assay to
identify 6 O. tsutsugamushi serotypes (the previously mentioned 5 serotypes plus the serotype Shimokoshi), R. japonica (Aoki strain), and R. typhi (18). The type-specific
whole rickettsial particles were used as antigens in the IFA
and immunoperoxidase assays. Serum samples were diluted from 1:40 to 1:40,960 for immunoperoxidase assays
and from 1:10 (or 20) to 1:10,240 for IFA. The titer was
expressed as the reciprocal of the highest dilution. Nested
PCR assays were performed to identify the 56-kDa antigen
of O. tsutsugamushi and the 17-kDa genus-common antigen of R. japonica from eschars at the Chiba Prefectural
Institute of Public Health (Chiba, Japan) or Kameda Medical Center (Kamogawa, Japan) (19,20).
Case Definitions and Data Collection
A patient’s rickettsial status was defined as confirmed if
the PCR result from the eschar was positive for any rickettsiae or if a >4-fold increase in the IgM or IgG titer of IFA
1634
Statistical Analyses
The clinical and epidemiologic characteristics of the patients were summarized and compared according to the 3
categories (i.e., JSF, ST, and nonrickettsial diseases). We
used χ2 or Fisher exact tests to compare characteristics of
the patients by disease category. We computed odds ratios
(ORs) with 95% CIs by using logistic regression models.
The patients’ home addresses were geocoded and
plotted on maps by using ArcGIS version 10.4.1 (Esri,
Redlands, CA, USA). We calculated the population density and land use percentage within a radius of 500 m based
on the census data and compared the 3 categories by using the Mann-Whitney U test. The Kulldorff scan statistics tool (SaTScan version 9.4.4) was used to identify the
geographic clusters of JSF and ST (21). All tests were
2-tailed, and p<0.05 was considered statistically significant. All clinical data analyses were performed by using
STATA version 13.0 (StataCorp LLC, College Station,
Texas, USA).
Results
Laboratory Confirmation
A total of 661 patients were enrolled in the study: 303
by prospective and 358 by retrospective data collection.
Overall, 42% of the patients were female, and the mean
age was 60 years. Of the 50 patients whose eschars were
tested by nested PCR, 8 were positive for R. japonica
DNA and 29 were positive for O. tsutsugamushi DNA.
The O. tsutsugamushi serotypes were identified in 22
patients; 16 were the Irie/Kawasaki type and 6 were the
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Japanese Spotted Fever and Scrub Typhus
Hirano/Kuroki type. All patients were tested by an IFA at
least 1 time, and paired blood samples were available for
304 (46%) patients. The median time from acute-phase
sample collection to convalescent-phase sample collection was 14 days (interquartile range 11–17 days). Of the
304 patients, JSF was confirmed for 33 and ST was confirmed for 155. Of the 357 patients whose convalescentphase samples were unavailable, none had probable JSF
and 35 had probable ST. Three patients who did not fulfill
the serologic criteria for having a rickettsial disease but
whose eschar was positive for O. tsutsugamushi DNA
were confirmed as having ST. Two patients fulfilled the
criteria for having both JSF and ST, and 1 patient was
confirmed to have murine typhus. Overall, our analysis
included 31 patients with JSF, 188 patients with ST, and
97 patients with nonrickettsial diseases (Figure 1). The
final diagnoses of the nonrickettsial diseases are shown in
online Technical Appendix Table 1 (https://wwwnc.cdc.
gov/EID/article/24/9/17-1436-Techapp1.pdf).
Seasonal and Geographic Distributions
The seasonal distributions of JSF, ST, and nonrickettsial diseases are shown in Figure 2. All patients with
JSF visited a medical facility during April–October; the
numbers peaked slightly in July. Most (91%) patients
with ST visited a medical facility in either November or
December. No seasonal trend was observed for nonrickettsial diseases.
The geographic distributions are shown in Figure 3.
We identified 1 JSF cluster (p<0.001) and 2 ST clusters
(p = 0.013 and p = 0.041), and these clusters rarely overlapped. Patients with JSF and ST resided in less populated
areas (population densities within a 500-m radius were
255/km2 and 295/km2, respectively) than patients with
nonrickettsial diseases (904/km2; p<0.001). Patients with
JSF and ST more frequently resided in wooded areas (proportions in forested area within a 500-m radius were 51%
and 43%, respectively) than patients with nonrickettsial
diseases (17%; p<0.001).
Demographic and Clinical Features
The baseline characteristics of the patients are summarized
in Table 1. The proportion of female patients did not differ
among the 3 groups. Patients with JSF and ST were older
than patients with nonrickettsial diseases; among patients
in the oldest age group, JSF occurred more frequently
than ST. Patients with JSF and ST were more frequently
exposed to the natural outdoor environment than were patients with nonrickettsial diseases.
Clinical characteristics of the patients are summarized
in Table 2. The triad (i.e., fever, rash, and eschar) was commonly observed by physicians but not necessarily noticed
by the patients. Fever was a primary sign; however, at the
initial physical examination, body temperature was high in
only 74% of patients with JSF and 73% with ST. Among
patients who did not have a high body temperature at their
initial physical examination, fever developed during hospitalization for 5 (71%) of 7 with JSF and 9 (38%) of 24
with ST. Although most patients had a rash, only 60% of
patients with JSF and 44% with ST had noticed their rash.
Moreover, only 45% of patients with JSF and 28% of patients with ST reported their rash. Most patients did not notice the presence of eschar.
During physical examination, patients with JSF had
hypotension more frequently than patients with ST (OR
5.1, 95% CI 1.9–13.8), but no significant difference was
observed in the frequency of tachycardia and tachypnea.
Considerably higher proportions of patients with JSF and
ST than with nonrickettsial diseases had a rash and eschar;
the mean ± SD size of the eschar was smaller in patients
with JSF (5.8 ± 2.1 mm) than in patients with ST (9.7 ± 5.6
mm; p = 0.024). Purpura, palmar/plantar rash, and lung involvement were more frequently observed in patients with
JSF than in those with ST. Prevalence of lymphadenopathy
did not differ among the groups.
Patients with JSF and ST were less likely than patients
with nonrickettsial diseases to have leukocytosis and anemia but more likely to have elevated aspartate aminotransferase and lactate dehydrogenase levels, hyponatremia,
Figure 1. Numbers of patients with rickettsial or nonrickettsial diseases, Japan, 2004–2015. Of 43 patients tested by
immunofluorescence and immunoperoxidase assays, 4 fulfilled the criteria for having confirmed JSF, 7 for confirmed ST, and 7 for
probable ST. Gray shading indicates the cases included in the main analysis. JSF, Japanese spotted fever; MT, murine typhus; non-R,
nonrickettsial diseases; ST, scrub typhus.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1635
SYNOPSIS
Figure 2. Number of patients
with Japanese spotted fever,
scrub typhus, and nonrickettsial
diseases, central Japan, by
month, 2004–2015.
and urine occult blood (Table 3). Patients with JSF were
more likely than patients with ST to have low platelet
counts; elevated bilirubin, creatinine kinase, blood urea
nitrogen, and creatinine levels; hyponatremia; and high Creactive protein.
Patients with JSF required hospitalization more frequently than did patients with ST; these associations did
not change after we adjusted for age. Patients with JSF
tended to visit a medical facility earlier than did patients
in the other groups. JSF and ST were successfully treated
in patients who received tetracycline; a 51-year-old patient
receiving psychiatric care died of ST, but no patient died of
JSF. The time to defervescence after treatment was longer
for patients with JSF than for patients with ST.
Discussion
By using standardized laboratory definitions for diagnosis,
we determined that the clinical and epidemiologic characteristics of JSF and ST in Japan differed by seasonality,
geographic distribution, physical signs, and severity. JSF
and ST showed distinct seasonal patterns. JSF occurred
during April–October and peaked slightly in July, whereas
most ST occurred during November–December. JSF and
ST were distributed in less populated and more wooded areas, although their geographic clusters rarely overlapped.
Patients with JSF were more likely than patients with ST to
have purpura, palmar/plantar rash, and organ damage and
to be hospitalized.
The different seasonal distribution of JSF and ST observed in our study can be explained by the ecology of the
vectors (3,22) as follows: 1) Haemaphysalis flava and H.
longicornis ticks, which transmit R. japonica, are active
from spring until autumn in Chiba (23); 2) Leptotorombidium scutellare mites, which transmit the Irie/Kawasaki
(and Hirano/Kuroki) serotypes of O. tsutsugamushi, are
active in autumn and early winter (24) and unable to survive the winter; and 3) L. pallidum mites, which transmit
the Karp and Gilliam serotypes of O. tsutsugamushi, are
1636
active from October through May (24). The difference in
geographic distributions of JSF and ST may also be explained by the different distribution of the reservoirs in our
study settings. Sika deer are wild hosts of ticks, and their
distribution overlaps with that of ticks (25). The cluster of
JSF identified in our study overlapped with the distribution of sika deer and Reeves’s muntjacs, which are related
to sika deer (26,27). In contrast, the field rat, which is the
primary host of the Leptotrombidium mite, is spreading
throughout this area, which may explain the wide distribution of ST. Although our data are limited, similar patterns
(i.e., the clustering of JSF and relatively wide distribution
of ST) were also observed in other prefectures (28,29).
Further studies are needed to establish the temporal and
geographic associations among the vectors, reservoirs, and
rickettsial pathogens.
Although the clinical features of patients in this study
with JSF and ST were similar, some clinical findings were
characteristic of JSF. Patients with JSF more frequently
had rashes on the palms/soles, purpura, and small eschars.
Moreover, the following severe conditions occurred more
frequently among patients with JSF than among those with
ST: hypotension, low platelet counts, and increased creatinine levels. Rickettsiae invade and proliferate within vascular endothelial cells and cause a vasculitis-like systemic
disease (30). In a study by Tai et al., cytokine and chemokine levels were higher in patients with JSF than in patients
with ST, but no significant association was observed between cytokine levels and the clinical severity of disease
(17). Although previous human and animal model studies
have revealed the pathogenic mechanisms of severe rickettsial infections (31–32), the mechanisms of severe JSF remain not fully understood. Of note, the clinical severity of
ST may differ according to the Orientia serotype. According to a systematic review, the mortality rate from ST substantially varied according to patients’ age, co-occurring
conditions, and regional Rickettsia strains (33). Our findings of ST in regions where Irie/Kawasaki type and Hirano/
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Japanese Spotted Fever and Scrub Typhus
Figure 3. Geographic distribution and clusters of JSF and ST, Japan, 2004–2015. A) JSF; B) ST; C) geographic clusters of JSF and
ST; D) locations of study facilities. White diamonds (JSF) and circles (ST) represent the locations of each patient’s address. Shaded
circles (red, JSF; blue, ST) represent statistically significant spatial clusters (p<0.05). The geographic distribution of the patients with
nonrickettsial diseases, which were used for the cluster analysis as the reference, is shown in the Technical Appendix Figure (https://
wwwnc.cdc.gov/EID/article/24/9/17-1436-Techapp1.pdf). ARMEC, Awa Regional Medical Center; JSF, Japanese spotted fever; KFCT,
Kameda Family Clinic Tateyama; KMC, Kameda Medical Center; ST, scrub typhus.
Kuroki type are endemic may not be directly applicable to
other settings in which other serotypes are endemic, such as
Akita and Niigata in northern Japan.
Fever has been considered one of the typical signs of
JSF and ST. Most patients in our study had a high body
temperature during the clinical course of their illness; however, fever was not apparent at the time of initial physical examination for 26% of patients with JSF and 27% of
patients with ST. Although rash and eschar were commonly observed by the physicians, more than half of the
patients did not notice these signs. Consequently, 33% of
the patients with JSF and 34% of the patients with ST received incorrect diagnoses during their first medical visit.
Furthermore, fewer clinicians were aware of JSF than of
ST (34). These findings indicate that a substantial number
of rickettsial diseases may be underdiagnosed in Japan.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1637
SYNOPSIS
Table 1. Baseline characteristics of patients with JSF, ST, and nonrickettsial diseases, central Japan, 2004–2015*
JSF,
ST,
Non-R,
JSF vs. non-R†
ST vs. non-R†
JSF vs. ST‡
no. (%), no. (%), no. (%),
Characteristic
n = 31 n = 188 n = 97
OR (95% CI)
p value
OR (95% CI) p value
OR (95% CI) p value
Female sex
16 (52) 85 (45) 35 (36)
1.9 (0.8–4.3)
0.127
1.5 (0.9–2.4)
0.14
1.3 (0.6–2.8)
0.509
Age, y, mean (SD) 73 (10) 65 (15) 57 (20)
Age group, y
<54
1 (3)
29 (15) 43 (44)
Reference
Reference
Reference
55–64
7 (23)
48 (26) 14 (14) 21.5 (2.4–190.3)
0.006
5.1 (2.4–10.9) <0.001
4.2 (0.5–36.1) 0.188
65–74
7 (23)
56 (30) 13 (13) 23.2 (2.6–205.9)
0.005
6.4 (3.0–13.7) <0.001
3.6 (0.4–30.9) 0.239
>75
16 (52) 55 (29) 27 (28) 25.5 (3.2–203.3)
0.002
3.0 (1.6–5.8)
0.001
8.4 (1.1–66.8) 0.043
No exposure
1 (3)
18 (12) 32 (46)
Reference
Reference
Reference
Living in/
12 (40) 58 (38) 16 (23) 24.0 (2.9–201.2)
0.003
6.4 (2.9–14.3) <0.001
3.7 (0.5–30.6) 0.162
stepped into
mountainous
areas
Stepped into a
1 (3)
12 (8)
3 (4)
10.7 (0.5–217.2)
0.124
7.1 (1.8–28.6) 0.006
1.5 (0.1–26.4) 0.162
bush
Farming
16 (53) 65 (42) 14 (20) 36.6 (4.4–303.4)
0.001
8.3 (3.6–18.7) <0.001
4.4 (0.5–35.7) 0.162
*JSF, Japanese spotted fever; non-R, nonrickettsial diseases; OR, odds ratio; ST, scrub typhus.
†Non-R reference.
‡ST reference.
Because of the difficulties associated with locating
patients to collect blood samples during the convalescent phase of illness, previous studies have relied on
laboratory confirmation that uses acute-phase samples
with variable cutoff IgM titers without considering local
endemicity, which may have resulted in misclassification (35). In this study, we used the IFA or immunoperoxidase IgM titer of >80 as a cutoff for the diagnosis of
Table 2. Clinical characteristics of patients with JSF, ST, and nonrickettsial diseases, central Japan, 2004–2015*
JSF,
ST,
Non-R,
JSF vs. non-R†
ST vs. non-R†
JSF vs. ST‡
no. (%), no. (%), no. (%),
Characteristic
n = 31 n = 188 n = 97
OR (95% CI) p value
OR (95% CI)
p value
OR (95% CI) p value
Chief complaint
Fever
26 (84) 135 (72) 78 (80) 1.3 (0.4–3.7)
0.668
0.6 (0.3–1.1)
0.115
2.0 (0.7–5.6)
0.165
Rash
14 (45) 52 (28) 17 (18) 3.9 (1.6–9.3)
0.003
1.8 (1.0–3.3)
0.06
2.2 (1.0–4.7)
0.053
Eschar
0 (0)
5 (3)
1 (1)
Not applicable 1.000§
2.6 (0.3–22.8)
0.382
Not applicable 1.000§
Headache
1 (3)
29 (15)
5 (5)
0.6 (0.1–5.5)
0.661
3.4 (1.3–9.0)
0.016
0.2 (0–1.4)
0.101
Fatigue
3 (10)
35 (19)
6 (6)
1.6 (0.4–6.9)
0.511
3.5 (1.4–8.6)
0.007
0.5 (0.1–1.6)
0.233
At history collection
Fever
27 (87) 148 (82) 81 (84) 1.3 (0.4–4.1)
0.712
0.8 (0.4–1.6)
0.586
1.5 (0.5–4.6)
0.473
Rash
18 (60) 74 (44) 24 (26) 4.3 (1.8–10.1)
0.001
2.2 (1.3–3.8)
0.099
2.0 (0.9–4.3)
0.664
Eschar
1 (4)
20 (12)
5 (6)
0.6 (0.1–5.5)
0.664
2.1 (0.8–5.9)
0.141
0.3 (0–2.2)
0.232
Headache
4 (25)
75 (56) 27 (59) 0.2 (0.1–0.8)
0.026
0.9 (0.5–1.8)
0.748
0.3 (0.1–0.9)
0.026
Fatigue
17 (94) 97 (84) 32 (94) 1.1 (0.1–12.6)
0.962
0.3 (0.1–1.4)
0.138
3.3 (0.4–26.5) 0.256
Physical examination findings
BT >37.5°C
23 (74) 132 (73) 53 (59) 2.0 (0.8–5.0)
0.132
1.9 (1.1–3.2)
0.02
1.1 (0.4–2.5)
0.883
Hypotension¶
8 (26)
12 (6)
5 (5)
6.4 (1.9–21.4)
0.003
1.3 (0.4–3.7)
0.679
5.1 (1.9–13.8) 0.001
Heart rate
2 (7)
13 (8)
6 (7)
0.9 (0.2–4.9)
0.942
1.2 (0.4–3.2)
0.777
0.8 (0.2–3.8)
0.793
>120 bpm
Respiratory rate
13 (54) 40 (39) 23 (45) 1.4 (0.5–3.8)
0.464
0.8 (0.4–1.5)
0.457
1.9 (0.8–4.6)
0.174
>20/min
Altered mental
5 (16)
14 (7)
15 (15) 1.1 (0.3–3.2)
0.929
0.4 (0.2–1.0)
0.038
2.4 (0.8–7.2)
0.121
status
Rash
30 (100) 181 (96) 52 (57) Not applicable <0.001§
19.4 (8.2–45.9) <0.001
Not applicable 0.597§
Localized
0
3 (2)
6 (12) Not applicable 0.079§
0.1 (0–0.5)
0.004
Not applicable 1.000§
Purpura
11 (44)
4 (2)
7 (8)
8.9 (2.9– 26.8) <0.001
0.2 (0.1–0.9)
0.028
36.1
<0.001
(10.1–128.3)
Palms/soles
21 (84)
13 (7)
4 (5)
101.1
0.001
1.4 (0.5–4.6)
0.537
70.3
<0.001
(23.3– 438.4)
(21.0–235.3)
Eschar
24 (89) 163 (87) 18 (22)
28.0
<0.001
23.8
<0.001
1.2 (0.3–4.2)
0.801
(7.6– 103.7)
(12.1–46.8)
Lung involv#
8 (26)
21 (11)
9 (9)
3.4 (1.2–9.8)
0.023
1.2 (0.5–2.8)
0.622
2.8 (1.1–7.0)
0.031
*BT, body temperature; involve, involvement; JSF, Japanese spotted fever; non-R, nonrickettsial diseases; OR, odds ratio; ST, scrub typhus.
†Non-R = reference.
‡ST = reference.
§Fisher exact tests.
¶Systolic blood pressure <90 mm Hg or vasopressor usage.
#Lung rales with pulmonary infiltrative shadow.
1638
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Japanese Spotted Fever and Scrub Typhus
Table 3. Laboratory and treatment data for patients with JSF, ST, and nonrickettsial diseases, central Japan, 2004–2015*
JSF,
ST,
Non-R,
JSF vs. non-R†
ST vs. non-R†
JSF vs. ST‡
no. (%), no. (%), no. (%),
Characteristic
n = 31 n = 188 n = 97
OR (95% CI) p value
OR (95% CI) p value
OR (95% CI) p value
Laboratory data
Leukocytes
5 (16)
23 (12) 42 (45)
0.2 (0.1–0.7)
0.006
0.2 (0.1–0.3)
<0.001
1.4 (0.5–3.9)
0.556
>9,800/L
Hb <11 g/dL (F)
5 (16)
29 (16) 46 (49)
0.2 (0.1–0.6)
0.002
0.2 (0.1–0.3)
<0.001
1.0 (0.4–2.9)
0.939
or <13.5 g/dL
(M)
Platelets
22 (71) 59 (32) 28 (30) 5.7 (2.3–13.9) <0.001
1.1 (0.6–1.8)
0.806
5.3 (2.3–12.2) <0.001
<130,000/L
Albumin
14 (61) 37 (29) 31 (55)
1.3 (0.5–3.4)
0.653
0.3 (0.2–0.6)
0.001
3.8 (1.5–9.6)
0.004
<3.4 g/dL
AST >33 IU/L
29 (94) 154 (83) 46 (50)
14.5
<0.001
4.8 (2.8–8.4)
<0.001
3.0 (0.7–13.3) 0.145
(3.3–64.3)
ALT >42 IU/L
16 (52) 100 (54) 42 (46)
1.3 (0.6–2.9)
0.566
1.4 (0.8–2.3)
0.204
0.9 (0.4–2.0)
0.824
LDH >229 IU/L
30 (97) 179 (97) 70 (78) 8.6 (1.1–66.8)
0.040
8.5 (3.3–22.1) <0.001
1.0 (0.1–8.7)
0.996
Total bilirubin
9 (29)
13 (7)
15 (17)
2.0 (0.8–5.1)
0.166
0.4 (0.2–0.8)
0.016
5.2 (2.0–13.6) 0.001
>1.0 mg/dL
Direct bilirubin
4 (22)
7 (5)
16 (28)
0.8 (0.2–2.6)
0.652
0.1 (0.1–0.4)
<0.001
5.2 (1.3–19.9) 0.017
>0.4 mg/dL
Creatine kinase
19 (66) 46 (29) 21 (28) 4.9 (2.0–12.2)
0.001
1.2 (0.6–1.9)
0.861
4.6 (2.0–10.7) <0.001
>150 IU/L
BUN >22 mg/dL
15 (48) 35 (19) 20 (22)
3.4 (1.4–8.0)
0.006
0.8 (0.5–1.6)
0.58
4.0 (1.8–8.9)
0.001
Creatinine
11 (35) 22 (12)
7 (8)
6.7 (2.3–19.4) <0.001
1.6 (0.7–4.0)
0.277
4.1 (1.7–9.6)
0.001
>1.2 mg/dL
Sodium
24 (77) 71 (39) 16 (17)
16.3
<0.001
3.0 (1.6–5.6)
<0.001
5.4 (2.2–13.2) <0.001
<135 mEq/L
(6.0–44.3)
Chloride
17 (55) 37 (22) 15 (16) 6.2 (2.5–15.3) <0.001
1.4 (0.7–2.7)
0.302
4.4 (2.0–9.7) <0.001
<98 mEq/L
CRP >10 mg/dL
16 (52) 32 (18) 34 (40)
1.6 (0.7–3.7)
0.266
0.3 (0.2–0.6)
<0.001
5.0 (2.2–11.1) <0.001
Urine protein
27 (87) 116 (75) 34 (62) 4.2 (1.3–13.6)
0.018
1.8 (1.0–3.5)
0.068
2.3 (0.7–6.9)
0.148
Urine blood
29 (94) 122 (79) 31 (56) 11.2 (2.4–51.8) 0.002
2.9 (1.5–5.5)
0.002
3.9 (0.9–17.3) 0.071
Treatment and prognosis
Duration of
16 (59) 74 (39) 24 (27)
4.0 (1.6–9.8)
0.002
1.8 (1.0–3.1)
0.039
2.2 (1.0–5.1)
0.054
illness§ <5 d
Treatment:
31 (100) 180 (99) 42 (91) Not applicable 0.144¶
17.1 (1.9–
0.012
Not applicable 1.000¶
MINO/DOXY
157.4)
Delayed
11 (37) 17 (13) 30 (67)
0.3 (0.1–0.8)
0.012
0.1 (0–0.2)
<0.001
3.8 (1.5–9.3)
0.004
defervescence#
Hospitalization
28 (90) 104 (55) 80 (82)
2.0 (0.5–7.3)
0.302
0.3 (0.1–0.5)
<0.001
7.5 (2.2–25.7) 0.001
30-d mortality
0
1 (1)
2 (2)
Not applicable 1.000§
0.3 (0–3.0)
0.287
Not applicable 1.000¶
*ALT, alanine aminotransferase; AST, aspartate aminotransferase; BT, body temperature; BUN, blood urea nitrogen; CRP, C-reactive protein; DOXY,
doxycycline; F, female patients; Hb, hemoglobin; JSF, Japanese spotted fever; LDH, lactate dehydrogenase; M, male patients; MINO, minocycline; non-R,
nonrickettsial diseases; OR, odds ratio; ST, scrub typhus.
†Non-R = reference.
‡ST = reference.
§Duration from the onset of symptoms to the first diagnostic test.
¶Fisher exact tests.
#>3 d to decline of fever <37.3°C.
JSF and ST for patients for whom convalescent-phase
samples were unavailable. To determine the optimum
cutoff titer in our setting, we collected blood samples
from patients with nonrickettsial diseases and confirmed
that the highest IgM titer for R. japonica was <20 and
that for O. tsutsugamushi was 10 (online Technical Appendix Table 2). Therefore, our diagnostic criteria must
be very specific.
During the acute phase of the disease, sensitivity of the
IFA is quite low; in our study, an elevated IgM titer by IFA
was observed in the acute-phase samples of only 2 (6.5%)
of 31 patients with JSF and 73 (38.8%) of 188 patients with
ST. Hence, physicians may overlook these diseases if their
diagnosis relies on IgM titer by IFA during the early phase.
Furthermore, the ST serotypes affect the sensitivity of the
IFA. In our study, of the 22 patients for whom serotype
was identified, 16 serotypes were Irie/Kawasaki and 6 serotypes were Hirano/Kuroki. In Japan, health insurance covers IFAs for the standard serotypes Kato, Karp, and Gilliam only but not for serotypes Irie/Kawasaki and Hirano/
Kuroki, which may not be cross-reactive to the standard
serotypes (22). In our study population, use of IFAs to test
for the standard serotypes could have led to underdiagnosis
of ST for ≈5% of the patients because 2 patients with the
Irie/Kawasaki and Hirano/Kuroki serotypes did not react to
any of the standard serotypes.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1639
SYNOPSIS
Our study has limitations because we did not include the other 2 hospitals in the southern Boso Peninsula. However, our study sites are the only medical
facilities in the district that have infectious disease specialists. Most patients with acute disease and fever in
this district are expected to visit our clinic and hospitals.
Thus, we believe that the effect of selection bias was
minimal. Because our study is a combined prospective
and retrospective case-series, the quality of the information may have differed between the prospectively and
the retrospectively identified patients. However, we used
an identical case definition throughout the study, and
further analyses indicated that the clinical and epidemiologic characteristics did not differ between 2 groups
(online Technical Appendix Table 3).
In conclusion, although JSF and ST share similar
clinical features, in Japan the 2 diseases differ in seasonality, geographic distribution, physical signs, and
severity. Patients with rickettsial diseases often do not
notice their rash and eschar, and the sensitivity of the
serologic test can be low during the acute phase of illness. A substantial number of rickettsial diseases may be
underdiagnosed.
Acknowledgments
We thank the clinical laboratory staff at Kameda Medical Center
and Takeshi Kimura and Yasuhisa Matsushita for collecting the
data at the Awa Regional Medical Center.
This study was funded by the Kameda Medical Center; grants
from the Japan Ministry of Health, Labour and Welfare
(H21-Shinkou-Ippan-006 and H24-Shinkou-Ippan-008); and
Grants-in-Aid for Scientific Research (Japan Society for the
Promotion of Science).
About the Author
Dr. Sando is a general physician at Kameda Medical Center,
Kamogawa, Japan, and a postgraduate at Nagasaki University
Graduate School of Biomedical Sciences, Nagasaki, Japan. His
primary research interests include rickettsial diseases such as ST
and JSF.
References
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
1.
Blake FG, Maxcy KF, Sadusk JF Jr, Kohls GM, Bell EJ.
Studies on tsutsugamushi disease (scrub typhus, mite-borne
typhus) in New Guinea and adjacent islands: epidemiology,
clinical observations, and etiology in the Dobadura Area. Am J
Hyg. 1945;41:245–6.
2. Nagino T, Kawakami S. Review: a disease caused by poisonous
insect [in Japanese]. Tokyo Medical Journal. 1878;20:3–7.
3. National Institute of Infectious Diseases–Japan. Scrub typhus
and Japanese spotted fever in Japan 2007–2016. Infectious Agent
Surveillance Report. Tokyo: The Institute; 2017. p. 109–12.
4. Maina AN, Farris CM, Odhiambo A, Jiang J, Laktabai J,
Armstrong J, et al. Q fever, scrub typhus, and rickettsial diseases
1640
18.
19.
in children, Kenya, 2011–2012. Emerg Infect Dis. 2016;22:883–6.
http://dx.doi.org/10.3201/eid2205.150953
Weitzel T, Dittrich S, López J, Phuklia W, Martinez-Valdebenito C,
Velásquez K, et al. Endemic scrub typhus in South America.
N Engl J Med. 2016;375:954–61. http://dx.doi.org/10.1056/
NEJMoa1603657
Mahara F, Koga K, Sawada S, Taniguchi T, Shigemi F, Suto T,
et al. The first report of the rickettsial infections of spotted fever
group in Japan: three clinical cases [in Japanese]. Kansenshogaku
Zasshi. 1985;59:1165–71. http://dx.doi.org/10.11150/
kansenshogakuzasshi1970.59.1165
Takada N, Fujita H, Yano Y, Oikawa Y, Mahara F. Vectors
of Japanese spotted fever [in Japanese]. Kansenshogaku
Zasshi. 1992;66:1218–25. http://dx.doi.org/10.11150/
kansenshogakuzasshi1970.66.1218
Chung MH, Lee SH, Kim MJ, Lee JH, Kim ES, Kim MK,
et al. Japanese spotted fever, South Korea. Emerg Infect Dis.
2006;12:1122–4. http://dx.doi.org/10.3201/eid1207.051372
Hamaguchi S, Cuong NC, Tra DT, Doan YH, Shimizu K,
Tuan NQ, et al. Clinical and epidemiological characteristics
of scrub typhus and murine typhus among hospitalized patients
with acute undifferentiated fever in Northern Vietnam.
Am J Trop Med Hyg. 2015;92:972–8. http://dx.doi.org/10.4269/
ajtmh.14-0806
Su TH, Liu CJ, Chen DS, Kao JH. Milder clinical manifestation
of scrub typhus in Kinmen, Taiwan. J Formos Med Assoc.
2013;112:201–7. http://dx.doi.org/10.1016/j.jfma.2012.02.002
Sharma N, Biswal M, Kumar A, Zaman K, Jain S, Bhalla A.
Scrub typhus in a tertiary care hospital in north India. Am J
Trop Med Hyg. 2016;95:447–51. http://dx.doi.org/10.4269/
ajtmh.16-0086
Park JH, Kim SJ, Youn SK, Park K, Gwack J. Epidemiology of
scrub typhus and the eschars patterns in South Korea from 2008 to
2012. Jpn J Infect Dis. 2014;67:458–63. http://dx.doi.org/10.7883/
yoken.67.458
Ogawa M, Hagiwara T, Kishimoto T, Shiga S, Yoshida Y, Furuya Y,
et al. Scrub typhus in Japan: epidemiology and clinical features
of cases reported in 1998. Am J Trop Med Hyg. 2002;67:162–5.
http://dx.doi.org/10.4269/ajtmh.2002.67.162
Kodama K, Senba T, Yamauchi H, Nomura T, Chikahira Y.
Clinical study of Japanese spotted fever and its aggravating
factors. J Infect Chemother. 2003;9:83–7. http://dx.doi.
org/10.1007/s10156-002-0223-5
Yasunaga H, Horiguchi H, Kuwabara K, Hashimoto H, Matsuda S.
Delay in tetracycline treatment increases the risk of complications
in tsutsugamushi disease: data from the Japanese Diagnosis
Procedure Combination database. Intern Med. 2011;50:37–42.
http://dx.doi.org/10.2169/internalmedicine.50.4220
Nakamura T, Takagaki K, Matsubara Y, Kikuchi K. Predictive
values of clinical parameters for severe Japanese spotted fever.
J Infect Chemother. 2011;17:246–53. http://dx.doi.org/10.1007/
s10156-010-0113-1
Tai K, Iwasaki H, Ikegaya S, Takada N, Tamaki Y, Tabara K, et al.
Significantly higher cytokine and chemokine levels in patients with
Japanese spotted fever than in those with tsutsugamushi disease.
J Clin Microbiol. 2014;52:1938–46. http://dx.doi.org/10.1128/
JCM.03238-13
Fujita H. Development and optimization of antibody detection
assays. In: Ando S, editor. Diagnostics and Therapeutics for
Tick-Borne Bacterial Diseases. MHLW Grant Research Report
201225058A [in Japanese]. Tokyo (Japan): Ministry of Health,
Labour and Welfare; 2012. p. 95–100.
Furuya Y, Yoshida Y, Katayama T, Yamamoto S, Kawamura A Jr.
Serotype-specific amplification of Rickettsia tsutsugamushi
DNA by nested polymerase chain reaction. J Clin Microbiol. 1993;
31:1637–40.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Japanese Spotted Fever and Scrub Typhus
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
Furuya Y, Katayama T, Yoshida Y, Kaiho I. Specific amplification
of Rickettsia japonica DNA from clinical specimens by PCR.
J Clin Microbiol. 1995;33:487–9.
Kulldorff M. A spatial scan statistic. Commun Stat Theory Methods.
2007;26:1481–96. http://dx.doi.org/10.1080/03610929708831995
National Institute of Infectious Diseases–Japan. The topic of this
month. Infectious Agent Surveillance Report (IASR). Tokyo:
The Institute; 2001. p. 211–2.
Mori K, Fujimagari M. Distribution and seasonal fluctuation of
ticks in Chiba. Chiba Prefectural Institute of Public Health
Research Report. Chiba (Japan): Chiba Prefectural Institute of
Public Health; 1994. p. 53–8
Suzuki T, Nanayama Y, Sasa M, Tanaka H, Hayashi S, Suzuki T,
et al. Studies on scrub typhus in Chiba Prefecture. V: seasonal
occurrence of the trombiculid mites in southern part of Boso
Peninsula. Medical Entomology and Zoology. 1955;6:69–75.
http://dx.doi.org/10.7601/mez.6.69
Tsukada H, Nakamura Y, Kamio T, Inokuma H, Hanafusa Y,
Matsuda N, et al. Higher sika deer density is associated with higher
local abundance of Haemaphysalis longicornis nymphs and adults
but not larvae in central Japan. Bull Entomol Res. 2014;104:19–28.
http://dx.doi.org/10.1017/S0007485313000308
Asada M. Distribution and population estimation for Sika deer in
2010 in Chiba Prefecture, Japan. Chiba (Japan); Chiba Biodiversity
Center; 2011. p. 16–7.
Asada M. Distribution and population estimation for Reeves’s
muntjac in 2010 in Chiba Prefecture, Japan. Chiba (Japan); Chiba
Biodiversity Center; 2011. p. 36–43.
Gokuden M, Ishitani K, Yoshikuni K, Ueno N, Shinkawa N,
Kuramoto T, et al. Epidemiology of tsutsugamushi disease and
Japanese spotted fever in Kagoshima Prefecture, Japan. Jpn J Infect
Dis. 2006;59:273.
Tabara K, Hoshina K, Itagaki A, Katayama T, Fujita H,
Kadosaka T, et al. Epidemiological study of Japanese spotted fever
and tsutsugamushi disease in Shimane Prefecture, Japan. Jpn J
Infect Dis. 2006;59:204–5.
Paris DH, Day NP. Tropical rickettsial infections. In: Farrer J,
Hotez PJ, Kang G, Lalloo D, White NJ, editors. Manson’s Tropical
Diseases. 23rd ed. New York: Elsevier; 2014. p. 273–91.
Walker DH. Rickettsiae and rickettsial infections: the current state
of knowledge. Clin Infect Dis. 2007;45(Suppl 1):S39–44.
http://dx.doi.org/10.1086/518145
Paris DH, Stephan F, Bulder I, Wouters D, van der Poll T,
Newton PN, et al. Increased nucleosomes and neutrophil activation
link to disease progression in patients with scrub typhus but not
murine typhus in Laos. PLoS Negl Trop Dis. 2015;9:e0003990.
http://dx.doi.org/10.1371/journal.pntd.0003990
Taylor AJ, Paris DH, Newton PN. A systematic review of mortality
from untreated scrub typhus (Orientia tsutsugamushi). PLoS Negl
Trop Dis. 2015;9:e0003971. http://dx.doi.org/10.1371/
journal.pntd.0003971
Matsui T, Kobayashi J, Satoh H, Fujimoto T, Okabe N, Ando S,
et al. Surveillance, recognition, and reporting of tsutsugamushi
disease (scrub typhus) and Japanese spotted fever by general
practice clinics in Miyazaki Prefecture, determined by
questionnaire survey in 2007. J Infect Chemother. 2009;15:269–72.
http://dx.doi.org/10.1007/s10156-009-0696-6
Blacksell SD, Bryant NJ, Paris DH, Doust JA, Sakoda Y,
Day NP. Scrub typhus serologic testing with the indirect
immunofluorescence method as a diagnostic gold standard: a
lack of consensus leads to a lot of confusion. Clin Infect Dis.
2007;44:391–401. http://dx.doi.org/10.1086/510585
May 2016:
V e ct or bor n e D ise a se s
• An Operational Framework
for Insecticide Resistance
Management Planning
• Rickettsia parkeri Rickettsiosis,
Arizona, USA
• Plasmodium falciparum K76T pfcrt Gene Mutations
and Parasite Population Structure, Haiti, 2006–2009
• Outbreak of Middle East Respiratory Syndrome at
Tertiary Care Hospital, Jeddah, Saudi Arabia, 2014
• Expansion of Shiga Toxin–Producing Escherichia coli
by Use of Bovine Antibiotic Growth Promoters
• Acute Human Inkoo and Chatanga Virus Infections,
Finland
• Differences in Genotype, Clinical Features, and
Inflammatory Potential of Borrelia burgdorferi sensu
stricto Strains from Europe and the United States
• Projecting Month of Birth for At-Risk Infants after Zika
Virus Disease Outbreaks
• Genetic Characterization of
Archived Bunyaviruses and
Their Potential for Emergence
in Australia
• Plasmodium falciparum
In Vitro Resistance to
Monodesethylamodiaquine, Dakar, Senegal, 2014
• Astrovirus MLB2, a New Gastroenteric Virus
Associated with Meningitis and Disseminated Infection
• Spectrum of Viral Pathogens in Blood of Malaria-Free
Ill Travelers Returning to Canada
• Expanded Geographic Distribution and Clinical
Characteristics of Ehrlichia ewingii Infections,
United States
• Molecular Characterization of Canine Rabies Virus,
Mali, 2006–2013
• Fatal Monocytic Ehrlichiosis in Woman, Mexico, 2013
• Rickettsia sibirica mongolitimonae Infection, France,
2010–2014
https://wwwnc.cdc.gov/eid/articles/
issue/22/5/table-of-contents
Address for correspondence: Motoi Suzuki, Nagasaki University,
Department of Clinical Medicine, Institute of Tropical Medicine, Sakamoto
1-12-4, Nagasaki, 852-8523, Japan; email: mosuzuki@nagasaki-u.ac.jp
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1641
SYNOPSIS
Syst e m a t ic Re vie w a n d
M e t a - a n a lysis of Post e x posu r e
Pr oph yla x is for Cr im e a n - Con go
H e m or r h a gic Fe ve r Vir u s
a m on g H e a lt h ca r e W or k e r s
Önder Ergönül, Şiran Keske, Melis Gökçe Çeldir, İlayda Arjen Kara,
Natalia Pshenichnaya, Gulzhan Abuova, Lucille Blumberg, Mehmet Gönen
We performed a systematic review and meta-analysis on
the effectiveness of ribavirin use for the prevention of infection and death of healthcare workers exposed to patients
with Crimean-Congo hemorrhagic fever virus (CCHFV) infection. Splashes with blood or bodily fluids (odds ratio [OR]
4.2), being a nurse or physician (OR 2.1), and treating patients who died from CCHFV infection (OR 3.8) were associated with healthcare workers acquiring CCHFV infection;
7% of the workers who received postexposure prophylaxis
(PEP) with ribavirin and 89% of those who did not became
infected. PEP with ribavirin reduced the odds of infection
(OR 0.01, 95% CI 0–0.03), and ribavirin use <48 hours after symptom onset reduced the odds of death (OR 0.03,
95% CI 0–0.58). The odds of death increased 2.4-fold every
day without ribavirin treatment. Ribavirin should be recommended as PEP and early treatment for workers at mediumto-high risk for CCHFV infection.
C
rimean-Congo hemorrhagic fever (CCHF) virus
(CCHFV) is listed as a highly infectious pathogen that
could cause a public health emergency (http://www.who.
int/medicines/ebola-treatment/WHO-list-of-top-emergingdiseases/en/). CCHFV infection has been reported from
>30 countries in Africa, Asia, Europe, and the Middle East
(1,2). CCHFV is a member of the genus Orthonairovirus
in the family Nairoviridae that causes severe disease in humans; the reported case fatality rate is 3%–30% (1). Humans can become infected through the bites of ticks, by
Author affiliations: Koç University, Istanbul, Turkey (Ö. Ergönül,
M.G. Çeldir, İ.A. Kara, M. Gönen); American Hospital, Istanbul
(Ş. Keske); Rostov State Medical University, Rostov-on-Don,
Russia (N. Pshenichnaya); South-Kazakhstan State
Pharmaceutical Academy, Shymkent, Kazakhstan (G. Abuova);
National Institute for Communicable Diseases, Johannesburg,
South Africa (L. Blumberg)
DOI: DOI: https://doi.org/10.3201/eid2409.171709
1642
contact with patient blood or bodily fluids, or by contact
with blood or tissues from viremic livestock. The risk for
human-to-human transmission of CCHFV increases in parallel with the lack of preparedness (3).
Healthcare workers need to be well prepared against
the emerging threat of CCHF outbreaks. The efficacy of
postexposure prophylaxis (PEP) with ribavirin for high-risk
exposures to CCHFV needs clear evidence. The relatively
low secondary attack rates of CCHFV and ethics constraints
make controlled, prospective efficacy trials for ribavirin PEP
unlikely. In the absence of efficacy studies, a thorough examination and logical extrapolation of the existing data can
be useful for developing recommendations. The efficacy of
PEP for healthcare workers exposed to CCHF patients might
be similar to that for healthcare workers with high-risk exposures to Lassa fever patients (4). A series of cases of healthcare workers infected with CCHFV has been reported (5–10).
Integration of the details on the exposures and the outcomes
of the infections from these published reports could provide
the opportunity to generate powerful conclusions about the
risk for infection and death among healthcare workers. We
described the efficacy of PEP with ribavirin for CCHFV infection and early ribavirin use in CCHF treatment.
Methods
Search Strategy
We performed a systematic review of individual participant
data (IPD) and reported data by using PRISMA-IPD (Preferred Reporting Items for Systematic Reviews and MetaAnalyses for IPD) guidelines (11). We searched PubMed,
Google, ProMED, and conference proceedings by using
the keywords “Crimea-Congo hemorrhagic fever,” “health
care worker,” “nosocomial,” “CCHF,” and “health professional.” We included all published reports in peer-reviewed
journals through September 3, 2017.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Postexposure Prophylaxis for CCHFV
Definitions and Outcome of Interest
We defined CCHFV exposure as visible contact or imperceptible contact (i.e., contact with patient aerosols) with
a CCHF patient. Primary outcomes were infection with
no symptoms, infection with symptoms, and death. The
primary study objective was to assess the protective role
of PEP and early ribavirin treatment. Early treatment was
defined as treatment occurring <48 hours after the onset
of symptoms.
Exposure Risk Groups
Healthcare workers were grouped into 3 categories with
respect to their risks for CCHFV infection. The high-risk
group consisted of healthcare workers who were directly
exposed to blood or bodily fluids of a CCHFV-infected patient, such as through a needle stick or splash. Healthcare
workers in this group were categorized as being without
personal protective equipment (PPE) of any sort by default
because a PPE breach had occurred. The moderate-risk
group comprised healthcare workers without a known direct exposure to blood or bodily fluids of a CCHFV-infected patient but either handled patients who bleed or visibly
produced other body fluids or were involved in aerosolproducing procedures (e.g., intubation, bronchoscopy, and
resuscitation) without wearing an N95 mask. The low- or
unknown-risk group consisted of healthcare workers who
cared for CCHFV-infected patients who did not actively
bleed or produce bodily fluids and did not participate in
aerosol-producing procedures.
Inclusion and Exclusion Criteria
In this study, we included healthcare workers who were
exposed to CCHFV through a defined transmission event
who did and did not receive PEP, healthcare workers with
laboratory-confirmed CCHFV infections who had a detailed exposure history and were closely followed by laboratory tests for their clinical outcomes, and symptomatic
healthcare workers who did and did not receive ribavirin
<48 hours after the onset of symptoms. In the reports from
Albania (12,13), Pakistan (14,15), South Africa (9,16,17),
and India (18,19), some of the cases were duplicates (included in >1 article). In these instances, we avoided duplicated data and selected the case information from the
earlier publication for inclusion. We did not include seroprevalence studies, gray literature, or screening reports for
tracing cases that did not have defined exposures; if the information was incomplete or lacking, we requested the information directly from the authors, and we did not include
the articles if the data we needed were unavailable.
Data Collection
We entered IPD obtained from reports into a structured data
sheet. We performed analyses using an integrated dataset
in Stata version 11 (https://www.stata.com/). In our dataset, we included information on demographics, transmission, PEP, the course of infection, the number of days from
onset of disease, and treatment. The dataset also included
information on the predictors of infection and death. Study
authors (Ö.E., Ş.K., M.G.Ç., and İ.A.K.) resolved discrepancies during discussions with local physicians.
Statistical Analysis
We followed the PRISMA-IPD statement guidelines (11)
using R studio (https://www.rstudio.com/). We used a
2-stage approach for analyses. First, we analyzed the studies that were suitable for calculating an effect estimate
(odds ratio [OR]). Then, we pooled all the participant studies, including single case reports, and calculated a common effect estimate (OR) and 95% CI. We used random
effects models.
Bias Assessment
We performed an analysis for confounders with the integrated dataset. We used the χ2 test for categorical data and
t-test for continuous data and performed logistic regression
to detect potential confounding predictors of infection and
death. To predict infection, we included in our model the
covariates PEP with ribavirin, being in the high-risk group,
being a nurse or physician, and providing care for a CCHF
patient who died. To predict death, we included in our model the covariates days from onset of symptoms to ribavirin
treatment, being in the high-risk group, and being a nurse
or physician. These were the most critical variables for predicting death. In statistical analyses, we used Stata version
11, and we considered p values <0.05 statistically significant. For meta-analysis, we used meta: General Package
for Meta-Analysis version 4.9-1 (https://cran.r-project.org/
web/packages/meta/index.html).
Results
We reviewed 1,224 published reports on CCHF, and 33
studies met our inclusion criteria (Figure 1). In the included studies, 175 healthcare workers from Turkey
(5,7,20–25), Pakistan (15,26–32), Germany (6), Iran
(33–36), India (18,19), South Africa (9), Russia (8), Tajikistan (37), United Arab Emirates (38), Mauritania (39),
Kazakhstan (40), Sudan (41,42), Albania (12), and Spain
(2) were exposed to patients infected with CCHFV (Table). We included all of the healthcare workers who were
infected, but because of the lack of detailed exposure histories among those who were not infected, we excluded
47 healthcare workers from Tajikistan (37), 75 from Turkey (5,10), 40 from Germany (6), and 33 from Pakistan
(15,30). The diagnoses were based on reverse transcription PCR results for 58 (57%) healthcare workers, ELISA
for 47 (46%), both ELISA and reverse transcription PCR
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1643
SYNOPSIS
Figure 1. Identification and selection of studies included in a
meta-analysis of the effectiveness of postexposure prophylaxis
with ribavirin and early treatment with ribavirin among
healthcare workers exposed to patients infected with CrimeanCongo hemorrhagic fever virus, 1976–2017. IPD, individual
participant data.
for 26 (25%), immunofluorescence assay for 13 (12%),
and complement fixation for 10 (10%).
The population of healthcare workers included in our
study was 53% male and 47% female. The percentages of
infected male and female healthcare workers did not differ (p = 0.828), and the percentage of symptomatic male
(38%) and female (29%) healthcare workers who died was
not significantly different (p = 0.413). Among symptomatic healthcare workers, the mean age was 33 (SD 8.5,
range 20–61) years, and the case-fatality rate was 34%.
The percentage of symptomatic cases did not differ from
the percentage of asymptomatic cases (p = 0.545), and the
case-fatality rate was not higher in symptomatic than asymptomatic healthcare workers (p = 0.674). Being a nurse
or physician (p = 0.01) and caring for a CCHF patient who
died (94% of infected healthcare workers vs. 80% of noninfected healthcare workers; p = 0.006) were factors more
common among healthcare workers who were infected
than those who were not.
We performed 2 meta-analyses: 1 on the effectiveness
of PEP with ribavirin to prevent CCHFV infection (Figure 2, panel A) and 1 on the effectiveness of early ribavirin treatment after CCHF symptom onset to prevent death
(Figure 2, panel B). In the first stage of the meta-analysis
on PEP, the OR could be calculated for only 4 studies (OR
0.05, 95% CI 0.01–0.26); at the second stage, after pooling
all healthcare worker study data, the OR was 0.01 (95%
CI 0–0.03; Figure 2, panel A). The heterogeneity of these
studies was not significant (I2 = 3%, Γ2 = 0.1157; p = 0.38).
During the first stage of the meta-analysis on early ribavirin
use, the OR could be calculated for only 2 studies (OR 0.04,
95% CI 0–1.33); at the second stage of the analysis, after
pooling all healthcare worker study data, the OR was 0.03
(95% CI 0–0.58; Figure 2, panel B). No heterogeneity was
detected among these studies (I2 = 0%, Γ2 = 0; p = 0.92).
In univariate analyses of healthcare workers exposed
to CCHF patients, splashes with blood or bodily fluids (OR
4.2, 95% CI 2.04–9.7; p<0.001), being a nurse or physician (OR 2.1, 95% CI 1.13–4.1; p = 0.019), and caring for
a patient who died (OR 3.8, 95% CI 1.38–10.46; p = 0.01)
significantly increased the odds of a healthcare worker
acquiring an infection. However, PEP with ribavirin significantly reduced the risk for CCHFV infection (OR 0.01,
95% CI 0.003–0.03; p<0.001). To control for confounders,
we performed a multivariate analysis of the dataset. In multivariate analyses of exposed healthcare workers, PEP with
ribavirin was found to significantly protect against CCHFV
infection (OR 0.009, 95% CI 0.001–0.039; p<0.001). In a
sensitivity analysis, the area under the receiver operating
curve was 94%. In a multivariate analysis of symptomatic
healthcare workers adjusted by risk group (high risk vs.
others) and worker type (nurse or physician vs. others), the
Table. Characteristics and outcomes for healthcare workers exposed to patients with Crimean-Congo hemorrhagic fever virus
infection, 1976–2017
No. (%)
Exposed,
High risk,
Moderate risk, Low or no known
Infected,
N = 175
n = 107
n = 65
risk, n = 3
n = 102
Country (references)
Died, n = 34
Turkey (5,7,20–25)
49 (28)
23 (22)
26 (40)
0
19 (19)
3 (9)
Pakistan (15,26–32)
45 (26)
21 (20)
24 (36)
0
18 (18)
6 (18)
Germany (6)
18 (10)
18 (17)
0
0
2 (2)
0
Iran (33–36)
12 (7)
10 (9)
1 (2)
1 (33)
12 (12)
3 (9)
India (18,19)
8 (5)
5 (5)
3 (5)
0
8 (8)
6 (18)
Russia (8)
8 (5)
6 (6)
0
2 (67)
8 (8)
0
South Africa (9)
8 (5)
3 (3)
5 (8)
0
8 (8)
2 (6)
Tajikistan (37)
7 (4)
7 (7)
0
0
7 (7)
2 (6)
United Arab Emirates (38)
5 (3)
1 (1)
4 (6)
0
5 (5)
2 (6)
Kazakhstan (40)
5 (3)
3 (3)
2 (3)
0
5 (5)
3 (9)
Mauritania (39)
5 (3)
5 (5)
0
0
5 (5)
5 (15)
Sudan (41,42)
3 (2)
2 (2)
1 (2)
0
3 (3)
2 (6)
Albania (12)
1 (1)
1 (1)
0
0
1 (1)
0
Spain (2)
1 (1)
(1)
0
0
1 (1)
0
1644
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Postexposure Prophylaxis for CCHFV
risk for death increased 2.4-fold for every day of delay in
the start of ribavirin treatment (OR 2.4, 95% CI 1.27–4.56;
p = 0.005). Appropriate use of PPE and PEP with ribavirin
predicted death completely; therefore, both of these factors were not included in the model. The sensitivity of this
model, calculated by the area under the receiver operating
curve, was 95%.
Of 175 healthcare workers exposed to CCHF patients,
55 (31%) received and 110 (63%) did not receive PEP
with ribavirin (Figure 3). In the PEP arm, 7% acquired
infection, and in the no PEP arm, 89% acquired infection
(p<0.001; Figure 3). In the no PEP arm, 97 (99%) of 98
infected healthcare workers became symptomatic. None of
the symptomatic healthcare workers who received ribavirin
within 48 hours after the onset of symptoms died, whereas
42% of the symptomatic healthcare workers who did not
receive ribavirin within 48 hours died (p<0.001; Figure
3). Among symptomatic healthcare workers who received
ribavirin, the median time from onset of symptoms to ribavirin treatment was 5 days for those who died and 1.25 days
for those who survived (p<0.001).
For 104 (59.4%) of 175 healthcare workers, the appropriateness of the PPE was assessed by the authors of the
original report. The percentage who became infected was
lower for those who used PPE appropriately (55%) than
those who did not (70%), although this difference was not
significant (p = 0.301). No fatal cases were reported among
those who used PPE appropriately. In all reports, the PPE
used included a mask, gloves, and a gown; in 1 study in
Germany (6), the additional use of goggles was reported.
Discussion
We analyzed all published reports on healthcare workers
who were exposed to CCHF patients and had a moderateto-high risk of acquiring a CCHFV infection. These cases
represent the case density in the 14 countries included, in
parallel with previous reports (43,44). Most cases were from
Turkey, Pakistan, and Iran. However, healthcare workers
could acquire the infection from persons from other countries (6), and in 2017, a nurse in Spain acquired (2) a CCHFV infection from a patient with an autochthonous case.
We determined that PEP with ribavirin reduced CCHFV infection among healthcare workers and early ribavirin use reduced death among CCHFV-infected healthcare
workers (Figure 2). In most case series and case reports, no
healthcare workers died who received PEP with ribavirin
(5–8,10), including those who received PEP soon after a
high-risk incident (Figure 3).
Early use of ribavirin in the treatment of CCHFV infection has been reported as beneficial (45,46) and is considered to be beneficial, despite a controversial report (47).
In the report in which authors disagreed with ribavirin
use being beneficial, the authors did not account for the
starting time of ribavirin treatment after symptom onset,
Figure 2. Effectiveness of PEP and early treatment with ribavirin among healthcare workers exposed to patients infected with CrimeanCongo hemorrhagic fever virus, 1976–2017. A) Two-step meta-analysis of the effectiveness of PEP with ribavirin for preventing
Crimean-Congo hemorrhagic fever virus infection. We could determine the effect estimates for only 4 individual studies, and we included
33 reports in the final pooled estimate. B) Two-step meta-analysis on the effectiveness of early ribavirin use for preventing death caused
by Crimean-Congo hemorrhagic fever virus infection. We could determine the effect estimate for only 2 individual studies, and we
included 33 reports in the final pooled estimate. OR, odds ratio; PEP, postexposure prophylaxis.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1645
SYNOPSIS
Figure 3. Flowchart of
healthcare workers exposed
to patients infected with
Crimean-Congo hemorrhagic
fever virus who did and
did not receive PEP with
ribavirin or early ribavirin
treatment <48 hours after
symptom onset, 1976–2017.
*Healthcare workers for
which PEP information
was not included in the
original report. PEP,
postexposure prophylaxis.
even though this factor can significantly alter its efficacy.
Close follow-up of infected healthcare workers provides
an opportunity to determine the efficacy of early ribavirin
use; assessing the quality of treatments given to exposed
healthcare workers is much more feasible than assessing
that of patients with suspected CCHF transferred from rural areas. In this study, we showed that every day of treatment delay increases the risk for death by 2.4-fold. Of note,
none of the symptomatic healthcare workers who received
ribavirin within 48 hours after the onset of symptoms died,
whereas 42% of those who did not receive treatment in
that time frame died (p<0.001; Figure 3). Late diagnosis of
the source case can result in delayed PEP and treatment of
healthcare workers with ribavirin (21,30).
Some centers have reported aerosol CCHFV transmission
(5–8,33,48). A number of procedures (e.g., bronchoscopy, nasal
tamponade, intubation, cardiopulmonary resuscitation) as well
as patient bleeding can lead to the aerosolization of CCHFV.
Persons near CCHFV patients during these activities should
be considered at moderate risk for acquiring the infection.
Awareness of transmission after percutaneous injuries is high,
but healthcare workers with imperceptible exposures to aerosolized pathogens should also be considered for close followup. Our study findings indicate that PEP with ribavirin should
be recommended for those with CCHFV exposures, similar
to the recommendations for healthcare workers with Lassa
virus exposures (4).
In this study, we included all published reports of detailed, laboratory-confirmed cases; we avoided duplicated
cases and excluded screenings of healthcare workers with
nonspecified risk (5,6,15,28,49,50). One limitation of this
study is reporting bias; we did not include unreported cases. Because of medical and legal issues, some fatal cases
1646
involving healthcare workers who were not using PPE
appropriately or who did not receive PEP might not have
been reported. For example, 2 fatal cases involving healthcare workers who were not given ribavirin, 1 from Turkey
(http://www.hurriyet.com.tr/gundem/kan-alirken-elineigne-batan-kubra-kkka-dan-oldu-11861967) and 1 from
Pakistan (https://www.samaa.tv/uncategorized/2016/07/
congo-fever-cases-emerge-in-bahawalpur/), were not published in the literature, but their stories appeared in the media. Even though we received detailed information about
these cases, we did not include them in our study because
they were not published in peer-reviewed journals. These
unreported fatal cases support the use of ribavirin for PEP
and early treatment, as we recommend in this report.
Another limitation of this study was regarding the reporting of the appropriateness of the PPE used, which was
reported for only ≈60% of the healthcare workers included.
PPE use is not standardized; appropriate use varies substantially from country to country. For instance, in a study in
Germany, the use of surgical masks instead of N95 masks
during aerosol-generating procedures is considered inappropriate (6); however, this practice was considered appropriate
in many other studies. Implementing standard use of PPE
in healthcare settings is urgently needed. Our study shows
that N95 masks should be used in high- and moderate-risk
events, including those involving contact with patients who
are bleeding or visibly generating bodily fluids or aerosols.
Our analyses were performed by using an integrated
dataset that included all necessary detailed information
about the demographics, transmission, PEP, course of the
infection, days from onset of disease, and treatment. This
dataset could be supplied to researchers in the field and
used as a tool for future investigations.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Postexposure Prophylaxis for CCHFV
In conclusion, our results indicate a significant beneficial effect of PEP with ribavirin after CCHFV exposure.
This beneficial effect extended to early use of ribavirin for
treatment of infected healthcare workers. Imperceptible
contact with infectious particles and splashes of blood or
bodily fluids from infected patients should all be considered and prevented. A universal standard of care that includes PPE and PEP and treatment with ribavirin should
be implemented for healthcare workers at risk for CCHF.
M.G. was supported by the Turkish Academy of Sciences
(TÜBA-GEBİP, the Young Scientist Award Program) and the
Science Academy of Turkey (BAGEP, the Young Scientist
Award Program).
About the Author
Dr. Ergönül is professor of infectious disease and clinical
microbiology at Koç University School of Medicine in Istanbul,
Turkey. His primary research interests include emerging infections.
11.
12.
13.
14.
15.
16.
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
Ergönül O. Crimean-Congo haemorrhagic fever. Lancet Infect Dis.
2006;6:203–14. http://dx.doi.org/10.1016/S1473-3099(06)70435-2
Negredo A, de la Calle-Prieto F, Palencia-Herrejón E, Mora-Rillo M,
Astray-Mochales J, Sánchez-Seco MP, et al.; Crimean Congo
Hemorrhagic Fever@Madrid Working Group. Autochthonous
Crimean-Congo hemorrhagic fever in Spain. N Engl J Med.
2017;377:154–61. http://dx.doi.org/10.1056/NEJMoa1615162
Tarantola A, Ergonul O, Tattevin P. Estimates and prevention of
Crimean-Congo hemorrhagic fever risks for health-care workers.
In: Ergonul O, Whitehouse CA, editors. Crimean-Congo
hemorrhagic fever: a global perspective. Dordrecht (the
Netherlands): Springer; 2007. p. 281–94.
Bausch DG, Hadi CM, Khan SH, Lertora JJ. Review of the
literature and proposed guidelines for the use of oral ribavirin
as postexposure prophylaxis for Lassa fever. Clin Infect Dis.
2010;51:1435–41. http://dx.doi.org/10.1086/657315
Celikbas AK, Dokuzoğuz B, Baykam N, Gok SE, Eroğlu MN,
Midilli K, et al. Crimean-Congo hemorrhagic fever among health
care workers, Turkey. Emerg Infect Dis. 2014;20:477–9.
http://dx.doi.org/10.3201/eid2003.131353
Conger NG, Paolino KM, Osborn EC, Rusnak JM, Günther S,
Pool J, et al. Health care response to CCHF in US soldier and
nosocomial transmission to health care providers, Germany, 2009.
Emerg Infect Dis. 2015;21:23–31. http://dx.doi.org/10.3201/
eid2101.141413
Guner R, Hasanoglu I, Tasyaran MA, Yapar D, Keske S, Guven T,
et al. Is ribavirin prophylaxis effective for nosocomial transmission
of Crimean-Congo hemorrhagic fever? Vector Borne Zoonotic Dis.
2014;14:601–5. http://dx.doi.org/10.1089/vbz.2013.1546
Pshenichnaya NY, Nenadskaya SA. Probable Crimean-Congo
hemorrhagic fever virus transmission occurred after aerosolgenerating medical procedures in Russia: nosocomial cluster.
Int J Infect Dis. 2015;33:120–2. http://dx.doi.org/10.1016/
j.ijid.2014.12.047
Richards GA. Nososcomial transmission of viral haemorrhagic
fever in South Africa. S Afr Med J. 2015;105:709–12.
http://dx.doi.org/10.7196/SAMJnew.8168
Leblebicioglu H, Sunbul M, Guner R, Bodur H, Bulut C, Duygu F,
et al. Healthcare-associated Crimean-Congo haemorrhagic fever
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
in Turkey, 2002–2014: a multicentre retrospective cross-sectional
study. Clin Microbiol Infect. 2016;22:387.e1–4. http://dx.doi.org/
10.1016/j.cmi.2015.11.024
Papa A, Bino S, Llagami A, Brahimaj B, Papadimitriou E,
Pavlidou V, et al. Crimean-Congo hemorrhagic fever in Albania,
2001. Eur J Clin Microbiol Infect Dis. 2002;21:603–6.
http://dx.doi.org/10.1007/s10096-002-0770-9
Harxhi A, Pilaca A, Delia Z, Pano K, Rezza G. Crimean-Congo
hemorrhagic fever: a case of nosocomial transmission. Infection.
2005;33:295–6. http://dx.doi.org/10.1007/s15010-005-4129-x
Khan JA, Rehman S, Fisher-Hoch SP, Mirza S, Khurshid M,
McCormick JB. Crimean Congo-haemorrhagic fever treated with
oral ribavirin. Lancet. 1995;346:472–5. http://dx.doi.org/10.1016/
S0140-6736(95)91323-8
Altaf A, Luby S, Ahmed AJ, Zaidi N, Khan AJ, Mirza S, et al.
Outbreak of Crimean-Congo haemorrhagic fever in Quetta,
Pakistan: contact tracing and risk assessment. Trop
Med Int Health. 1998;3:878–82. http://dx.doi.org/10.1046/
j.1365-3156.1998.00318.x
Swanepoel R, Shepherd AJ, Leman PA, Shepherd SP,
McGillivray GM, Erasmus MJ, et al. Epidemiologic and clinical
features of Crimean-Congo hemorrhagic fever in southern Africa.
Am J Trop Med Hyg. 1987;36:120–32. http://dx.doi.org/10.4269/
ajtmh.1987.36.120
van de Wal BW, Joubert JR, van Eeden PJ, King JB. A nosocomial
outbreak of Crimean-Congo haemorrhagic fever at Tygerberg
Hospital. Part IV. Preventive and prophylactic measures. S Afr Med
J. 1985;68:729–32.
Mishra AC, Mehta M, Mourya DT, Gandhi S. Crimean-Congo
haemorrhagic fever in India. Lancet. 2011;378:372.
http://dx.doi.org/10.1016/S0140-6736(11)60680-6
Patel AK, Patel KK, Mehta M, Parikh TM, Toshniwal H, Patel K.
First Crimean-Congo hemorrhagic fever outbreak in India. J Assoc
Physicians India. 2011;59:585–9.
Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M,
Stewart G, et al.; PRISMA-IPD Development Group. Preferred
reporting items for systematic review and meta-analyses of
individual participant data. The PRISMA-IPD statement. JAMA.
2015;313:1657–65. http://dx.doi.org/10.1001/jama.2015.3656
Bulut C, Yilmaz GR, Karakoc E, Önde U, Kocak Tufan Z,
Demiröz AP. Risk of Crimean-Congo haemorrhagic fever among
healthcare workers. Presented at: 19th European Congress of
Clinical Microbiology and Infectious Diseases; May 16–19, 2009;
Helsinki, Finland.
Guven G, Talan L, Altintas ND, Memikoglu KO, Yoruk F,
Azap A. An unexpected fatal CCHF case and management of
exposed health care workers. Int J Infect Dis. 2017;55:118–21.
http://dx.doi.org/10.1016/j.ijid.2016.12.026
Parlak E, Ertürk A, Koşan Z, Parlak M, Özkurt Z. A nosocomial
outbreak of Crimean-Congo hemorrhagic fever. J Microbiol
Infect Dis. 2015;5:5–9. http://dx.doi.org/10.5799/
ahinjs.02.2015.01.0166
Yildirmak T, Tulek N, Bulut C. Crimean-Congo haemorrhagic
fever: transmission to visitors and healthcare workers. Infection.
2016;44:687–9. http://dx.doi.org/10.1007/s15010-016-0923-x
Tütüncü EE, Gurbuz Y, Ozturk B, Kuscu F, Sencan I. Crimean
Congo haemorrhagic fever, precautions and ribavirin
prophylaxis: a case report. Scand J Infect Dis. 2009;41:378–80.
http://dx.doi.org/10.1080/00365540902882434
Sunbul M, Esen S, Fletcher TE, Dilek A, Guler N, Beeching NJ, et al.
A fatal case of healthcare associated Crimean-Congo haemorrhagic
fever with severe disease and multi-organ failure. J Infect. 2016;
72:253–5. http://dx.doi.org/10.1016/j.jinf.2015.10.005
Burney MI, Ghafoor A, Saleen M, Webb PA, Casals J.
Nosocomial outbreak of viral hemorrhagic fever caused by
Crimean Hemorrhagic fever-Congo virus in Pakistan, January
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1647
SYNOPSIS
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
1648
1976. Am J Trop Med Hyg. 1980;29:941–7. http://dx.doi.org/
10.4269/ajtmh.1980.29.941
Bangash SA, Khan EA. Treatment and prophylaxis with ribavirin
for Crimean-Congo hemorrhagic fever-is it effective? J Pak Med
Assoc. 2003;53:39–41.
Athar MN, Baqai HZ, Ahmad M, Khalid MA, Bashir N,
Ahmad AM, et al. Short report: Crimean-Congo hemorrhagic fever
outbreak in Rawalpindi, Pakistan, February 2002. Am J Trop Med
Hyg. 2003;69:284–7.
Hasan Z, Mahmood F, Jamil B, Atkinson B, Mohammed M,
Samreen A, et al. Crimean-Congo hemorrhagic fever nosocomial
infection in a immunosuppressed patient, Pakistan: case report and
virological investigation. J Med Virol. 2013;85:501–4.
http://dx.doi.org/10.1002/jmv.23473
Yadav PD, Patil DY, Shete AM, Kokate P, Goyal P, Jadhav S,
et al. Nosocomial infection of CCHF among health care workers in
Rajasthan, India. BMC Infect Dis. 2016;16:624. http://dx.doi.org/
10.1186/s12879-016-1971-7
Yadav PD, Raut CG, Mourya DT. Re-occurrence of CrimeanCongo haemorrhagic fever in Ahmedabad, Gujarat, India (2012): a
fatal case report. Indian J Med Res. 2013;138:1027–8.
Jamil B, Hasan RS, Sarwari AR, Burton J, Hewson R,
Clegg C. Crimean-Congo hemorrhagic fever: experience at a
tertiary care hospital in Karachi, Pakistan. Trans R Soc
Trop Med Hyg. 2005;99:577–84. http://dx.doi.org/10.1016/
j.trstmh.2005.03.002
Naderi HR, Sarvghad MR, Bojdy A, Hadizadeh MR, Sadeghi R,
Sheybani F. Nosocomial outbreak of Crimean-Congo haemorrhagic
fever. Epidemiol Infect. 2011;139:862–6. http://dx.doi.org/10.1017/
S0950268810002001
Naderi HR, Sheybani F, Bojdi A, Khosravi N, Mostafavi I. Fatal
nosocomial spread of Crimean-Congo hemorrhagic fever with very
short incubation period. Am J Trop Med Hyg. 2013;88:469–71.
http://dx.doi.org/10.4269/ajtmh.2012.12-0337
Mardani M, Keshtkar-Jahromi M, Ataie B, Adibi P. CrimeanCongo hemorrhagic fever virus as a nosocomial pathogen in Iran.
Am J Trop Med Hyg. 2009;81:675–8. http://dx.doi.org/10.4269/
ajtmh.2009.09-0051
Chinikar S, Shayesteh M, Khakifirouz S, Jalali T, Rasi Varaie FS,
Rafigh M, et al. Nosocomial infection of Crimean-Congo
haemorrhagic fever in eastern Iran: case report. Travel Med Infect
Dis. 2013;11:252–5. http://dx.doi.org/10.1016/j.tmaid.2012.11.009
Tishkova FH, Belobrova EA, Valikhodzhaeva M, Atkinson B,
Hewson R, Mullojonova M. Crimean-Congo hemorrhagic fever in
Tajikistan. Vector Borne Zoonotic Dis. 2012;12:722–6.
http://dx.doi.org/10.1089/vbz.2011.0769
Suleiman MNEH, Muscat-Baron JM, Harries JR, Satti AGO,
Platt GS, Bowen ETW, et al. Congo/Crimean haemorrhagic fever in
Dubai: an outbreak at the Rashid Hospital. Lancet. 1980;316:939–
41. http://dx.doi.org/10.1016/S0140-6736(80)92103-0
Nabeth P, Cheikh DO, Lo B, Faye O, Vall IO, Niang M, et al.
Crimean-Congo hemorrhagic fever, Mauritania. Emerg Infect Dis.
2004;10:2143–9. http://dx.doi.org/10.3201/eid1012.040535
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
ProMED-RUS. Crimean-Congo hemorrhagic fever-Kazakhstan
(South Kazakhstan). ProMed. 2009 Jul 15 [cited 2016 Feb 21].
http://www.promedmail.org/, archive no. 20090715.2529.
Aradaib IE, Erickson BR, Mustafa ME, Khristova ML,
Saeed NS, Elageb RM, et al. Nosocomial outbreak of CrimeanCongo hemorrhagic fever, Sudan. Emerg Infect Dis. 2010;16:837–
9. http://dx.doi.org/10.3201/eid1605.091815
Elata AT, Karsany MS, Elageb RM, Hussain MA, Eltom KH,
Elbashir MI, et al. A nosocomial transmission of Crimean-Congo
hemorrhagic fever to an attending physician in North Kordufan,
Sudan. Virol J. 2011;8:303. http://dx.doi.org/10.1186/
1743-422X-8-303
Bente DA, Forrester NL, Watts DM, McAuley AJ, Whitehouse CA,
Bray M. Crimean-Congo hemorrhagic fever: history,
epidemiology, pathogenesis, clinical syndrome and genetic
diversity. Antiviral Res. 2013;100:159–89. http://dx.doi.org/10.1016/
j.antiviral.2013.07.006
Ince Y, Yasa C, Metin M, Sonmez M, Meram E, Benkli B, et al.
Crimean-Congo hemorrhagic fever infections reported by ProMED.
Int J Infect Dis. 2014;26:44–6. http://dx.doi.org/10.1016/
j.ijid.2014.04.005
Dokuzoguz B, Celikbas AK, Gök SE, Baykam N, Eroglu MN,
Ergönül Ö. Severity scoring index for Crimean-Congo hemorrhagic
fever and the impact of ribavirin and corticosteroids on fatality.
Clin Infect Dis. 2013;57:1270–4. http://dx.doi.org/10.1093/cid/
cit527
Ergonul O. Treatment of Crimean-Congo hemorrhagic fever.
Antiviral Res. 2008;78:125–31. http://dx.doi.org/10.1016/
j.antiviral.2007.11.002
Ergonul O. DEBATE (see Elaldi N et al, Efficacy of oral
ribavirin treatment in Crimean-Congo haemorrhagic fever: a
quasi-experimental study from Turkey. Journal of Infection 2009;
58: 238–244): biases and misinterpretation in the assessment of the
efficacy of oral ribavirin in the treatment of Crimean–Congo
hemorrhagic fever. J Infect. 2009;59:284–6. http://dx.doi.org/
10.1016/j.jinf.2009.08.006
Pourahmad M, Raoofi R, Chinikar S, Ghiasi SM,
Ghalyanchi-Langeroudi A. Nosocomial transmission of CrimeanCongo hemorrhagic fever in a health care worker, Fars Province,
Iran. Iran J Clin Infect Dis. 2011;6:47–50.
Ergonul O, Zeller H, Celikbas A, Dokuzoguz B. The lack of
Crimean-Congo hemorrhagic fever virus antibodies in healthcare
workers in an endemic region. Int J Infect Dis. 2007;11:48–51.
http://dx.doi.org/10.1016/j.ijid.2005.10.009
Mardani M, Rahnavardi M, Rajaeinejad M, Naini KH,
Chinikar S, Pourmalek F, et al. Crimean-Congo hemorrhagic fever
among health care workers in Iran: a seroprevalence study in two
endemic regions. Am J Trop Med Hyg. 2007;76:443–5.
Address for correspondence: Önder Ergönül, Koç University, School of
Medicine, Infectious Diseases Department, Davutpaşa Caddesi, No. 4,
34010 Topkapi, Istanbul, Turkey; email: oergonul@ku.edu.tr
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Eve n t - Ba se d Su r ve illa n ce
a t Com m u n it y a n d H e a lt h ca r e
Fa cilit ie s, Vie t n a m , 2 0 1 6 – 2 0 1 7
Alexey Clara,1 Trang T. Do,1 Anh T.P. Dao, Phu D. Tran, Tan Q. Dang, Quang D. Tran,
Nghia D. Ngu, Tu H. Ngo, Hung C. Phan, Thuy T.P. Nguyen, Anh T. Lai, Dung T. Nguyen,
My K. Nguyen, Hieu T.M. Nguyen, Steven Becknell, Christina Bernadotte,
Huyen T. Nguyen, Quoc C. Nguyen, Anthony W. Mounts, S. Arunmozhi Balajee
Surveillance and outbreak reporting systems in Vietnam required improvements to function effectively as early warning
and response systems. Accordingly, the Ministry of Health
of Vietnam, in collaboration with the US Centers for Disease
Control and Prevention, launched a pilot project in 2016
focusing on community and hospital event–based surveillance. The pilot was implemented in 4 of Vietnam’s 63 provinces. The pilot demonstrated that event-based surveillance
resulted in early detection and reporting of outbreaks, improved collaboration between the healthcare facilities and
preventive sectors of the ministry, and increased community
participation in surveillance and reporting.
A
fter several international outbreaks of infectious
diseases, including severe acute respiratory syndrome
in 2003, all World Health Organization (WHO) Member
States, including Vietnam, agreed to comply with the
revised International Health Regulations 2005 (IHR 2005)
to ensure global health security (1). The IHR 2005 requires
countries to develop early warning and response functions
that can rapidly detect, report, and respond to—and thereby
control—public health events. WHO defines early warning
and response as “the organized mechanism to detect as
Author affiliations: Centers for Disease Control and Prevention,
Atlanta, Georgia, USA (A. Clara, T.T. Do, A.T.P. Dao, S. Becknell,
A.W. Mounts, S.A. Balajee); General Department of Preventive
Medicine, Hanoi, Vietnam (P.D. Tran, T.Q. Dang, Q.D. Tran);
National Institute of Hygiene and Epidemiology, Hanoi (N.D. Ngu,
T.H. Ngo); Pasteur Institute, Ho Chi Minh City, Vietnam
(H.C. Phan, T.T.P. Nguyen); Preventive Medicine Center, Nam
Dinh, Vietnam (A.T. Lai); Preventive Medicine Center, Quang
Ninh, Vietnam (D.T. Nguyen); Preventive Medicine Center,
An Giang, Vietnam (M.K. Nguyen); Preventive Medicine
Center, Ba Ria-Vung Tau, Vietnam (H.T.M. Nguyen); Program for
Appropriate Technology in Health, Seattle, Washington, USA
(C. Bernadotte, H.T. Nguyen, Q.C. Nguyen)
DOI: https://doi.org/10.3201/eid2409.171851
early as possible any abnormal occurrence or any
divergence from the usual or normally observed
frequency of phenomena” (2). Two complementary types
of surveillance form the foundation of a functional early
warning and response: indicator-based surveillance (IBS)
and event-based surveillance (EBS) (2,3).
In Vietnam, IBS is mandated by Circular 54, a Ministry of Health regulation, disseminated in 2015 (4,5). Circular 54 focuses primarily on reporting of case-based hospital admissions through an electronic system, the eCDS
(electronic Communicable Disease Surveillance software).
Several disease- or syndrome-specific sentinel surveillance programs complement eCDS, focusing on conditions
such as dengue; hand, foot, and mouth disease; Japanese
encephalitis virus; influenza-like illness; and severe acute
respiratory infections.
WHO defines EBS as the organized collection, monitoring, assessment, and interpretation of mostly unstructured information from diverse ad hoc sources, including
communities, schools, and media. Signals may represent
unusual disease patterns that signify early signs of an
outbreak or event (2,6). Both IBS and EBS generate signals, which might consist of reports of cases or deaths
(individual or aggregated); potential human exposure
to biological, chemical, or radiologic hazards; or occurrence of natural or human-made disasters. These signals,
which are unfiltered reports, are first triaged and verified
to confirm the occurrence of a true event that needs further investigation. Decision 134/QD-DP, issued in 2014
by Vietnam’s Ministry of Health’s General Department
of Preventive Medicine (GDPM), describes national EBS
procedures but is largely focused on signal identification
through media scanning and omits collection of information from other sources, such as pharmacies, animal and
agricultural sectors, community, workplaces, the private
sector, and schools (7).
1
These authors contributed equally to this article.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1649
SYNOPSIS
Regional Institutes in each of Vietnam’s 4 administrative health regions are responsible for implementing and overseeing surveillance and response. Within
each region, Provincial Preventive Medicine Centers
(PPMCs) lead these activities within their jurisdictions,
involving the Regional Institutes for larger events. The
PPMCs are supported by 2 lower administrative levels,
the District Health Center (DHC) and Commune Health
Station (CHS). The CHS is generally staffed by a medical professional and village health workers (VHWs), who
are largely volunteers. The VHWs promote prenatal visits
and vaccinations and in theory are responsible for reporting outbreaks from their communities. In addition, several
community members called health collaborators assist
VHWs in these tasks.
A 2014 assessment of Vietnam’s surveillance and
reporting structures by a joint Ministry of Health and US
Centers for Disease Control and Prevention (CDC) team
found that the existing surveillance was largely IBS with
reliance on healthcare facility (HCF) reporting that was
case-based. HCFs were not required to report unusual patterns of unknown diseases, resulting in delays in detection
of outbreaks and events caused by emerging pathogens (5).
In addition, the team found that VHWs were underutilized
and not actively engaged with detection and reporting of
suspected outbreaks from their communities. Finally, the
team found no alert thresholds established for routinely reported HCF data for many endemic seasonal diseases, such
as dengue or hand, foot, and mouth disease.
To complement and reinforce the surveillance system,
the GDPM in collaboration with CDC launched an EBS
pilot project in 2016 focusing on communities and HCFs,
including hospitals. Community EBS entailed reporting
symptoms and unusual patterns that do not require specialized healthcare training from the communities by VHWs,
health collaborators, and key informants. HCF EBS required healthcare workers to recognize and report unusual
occurrences or disease patterns, such as a surge in admissions or healthcare worker sickness after patient exposure
with similar illness.
For phase 1 implementation, GDPM selected the National Institute of Hygiene and Epidemiology and the Pasteur Institute of Ho Chi Minh City, the 2 larger Regional
Institutes, and worked with them to select 2 pilot provinces per region. Criteria used to select provinces included
support from the local government; availability of personnel for response; and previous occurrence of diseases of
high concern, such as avian influenza. For phase 2, the
intention was to pilot in 2 remaining Regional Institutes,
including 2 provinces within their jurisdictions. Phase 1
of the pilot was implemented in 4 of Vietnam’s 63 provinces. We describe the steps of phase 1 implementation
and its preliminary assessment results.
1650
Methods
Establishing a Technical Working Group for EBS
The GDPM formed an EBS Technical Working Group
(TWG) consisting of stakeholders from the Ministry of
Health, including the 2 Regional Institutes, PATH (an international organization), CDC, WHO, and technical staff
from the pilot province PPMC. In addition to guiding the
EBS planning and preparations, the TWG served as the
advisory group for implementation throughout the project. TWG members also served on an assessment team
and later assisted in disseminating the assessment results
to stakeholders.
EBS signals do not need to be disease specific.
However, to reduce the background noise and to provide
a framework for reporting, the TWG listed priority diseases and conditions that were important for early detection in Vietnam. Criteria for inclusion included diseases
that 1) have large public health impact in the country, 2)
are outbreak prone and pose a major public health threat,
3) have previously been prevalent and might reemerge,
and 4) are slated for eradication or elimination. Highpriority diseases identified were rabies, avian influenza,
vaccine-preventable diseases, cholera, and emerging
new diseases.
The TWG then drafted a list of signals that could serve
as an early indication of the appearance of these priority
diseases in the community. Community signals represented
constellations of symptoms and patterns that do not require
specialized healthcare training; signals aimed at HCF were
based on unusual occurrences and/or disease patterns, such
as surge in admissions.
The TWG drafted an Interim Technical Implementation Guideline and training materials (8). Other materials
included posters and flyers to increase community awareness of the signals and need to report, notebooks for VHWs
with printed signals and pages for notes, logbooks for recording signals, and a monitoring checklist for supervisory
visits at each administrative level.
Training the Public Health Workforce in EBS
A training of trainers workshop was conducted for the Regional Institutes and pilot provinces. These participants
became master trainers and led cascade trainings in each
province down to the commune level. At each level, a trainer from a higher administrative level provided mentorship
and support.
Resources for Implementation Support
In addition to external funding for training, each province received a one-time start-up grant for infrastructural
improvements, including purchase of a limited number of
computers for reporting, a one-time allowance for VHW
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Event-Based Surveillance, Vietnam
Figure 1. Existing surveillance
and reporting system improved
for event-based surveillance,
Vietnam, September 2016–May
2017. Enhancements are shown
in dashed boxes; the reporting
tools at each level are shown in
gray dashed boxes.
cellular phone minutes, and the printing and distribution of
logbooks and communication materials. During the pilot
phase, EBS district and provincial focal points received a
small monthly honorarium for EBS oversight and support.
to immediately report events by phone call, in-person
meeting, or email; and 6) training of healthcare providers to detect and immediately report signals to the correct public health unit.
Enhancing Existing Information Flow and
EBS Reporting
Assessing the EBS Pilot
For EBS, the existing organizational structure and information flow from CHS to DHC to PPMC and to Regional Institutes was maintained with some enhancements (Figure 1), including 1) inclusion of VHWs at
the CHS to identify and report signals; 2) addition of a
triage step (the CHS decided which signals were “true”
signals [rather than a spurious situation or nonthreatening rumor] before reporting these as events to DHCs); 3)
training of DHCs and PPMCs in event verification and
risk assessment; 4) distribution of logbooks for recording signals and events; 5) establishment of a requirement
Approximately 9 months after launch, the TWG assessed
the EBS pilot, with qualitative and quantitative methods,
for timeliness of detection and reporting of events, as well
as EBS acceptability and sustainability at all levels. This
assessment included 1) a retrospective data collection table
sent electronically to all districts to collect logbook time
stamps for event notification and response, 2) questionnaires sent electronically to all levels with acceptability
and sustainability related questions, and 3) key informant
interviews and focus group discussions through field visits.
We used 3 criteria to select field visit sites. First, we
assessed districts that were performing optimally and
Table 1. General characteristics of selected provinces in the pilot of event-based surveillance, Vietnam, September 2016–May 2017
Province
North
South
Demographic and administrative profile
Quang Ninh
Nam Dinh
Ba-Ria Vung Tau
An Giang
Demographics
Population
1,211,300
1,850,600
1,072,600
2,158,300
Population density, persons/km 2
198
1119
539
610
Urban population rate, %
62.5
18
50.1
31.1
No. households
316,732
555,605
256,336
524,759
Administrative division no.
Cities under provinces
4
1
2
2
District-level towns
2
0
0
1
Rural districts
8
9
6
8
Wards
67
20
24
21
Commune-level towns (townlets)
8
15
7
16
Commune Health Station
111
194
51
119
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1651
SYNOPSIS
suboptimally as defined by the metric signal incidence rate.
Signal incidence rates were the number of signals detected
from each district, adjusted by the district’s population and
the number of days engaged in signal reporting. We defined
optimal performance as districts with a signal incidence
rate higher than the 50th percentile and suboptimal performance districts as districts with a signal incidence rate of
the 50th percentile or lower. Second, we selected districts
that investigated public health events reported through EBS
that could be useful case studies. Third, we selected sites
that were willing to receive assessors.
We sent the time stamp data extraction form to all 43
pilot districts. Approximately 7,000 participants encompassing EBS focal points and volunteers at all levels of the
workforce in all 4 provinces received the acceptability/sustainability survey. In each province, 2 districts and 2 CHSs
per district were selected for site visits and key informant
interviews/focus group discussions deployment.
Results
The EBS pilot covered 7% of the total population of Vietnam (9). The provinces represented both rural and urban
areas (Table 1; Figure 2).
Resources and EBS Workforce
Figure 2. Provinces participating in event-based surveillance pilot
project (stars), Vietnam, September 2016–May 2017.
Twenty-four master trainers were trained in August 2016: two from each province and 16 GDPM and
Regional Institute staff. A cascade training to lower
administrative levels followed the master training. By October 2016, >7,000 persons in 4 provinces were trained
to detect, record, and report signals and events, and 52
DHC staff were trained in basic risk assessment. Staff
from every district, CHS, and public hospital within each
province were trained, achieving 100% training coverage
(Table 2).
At least 15,000 posters with community signals and
reporting information were provided to CHSs (Figure 3).
These posters were prominently displayed at public meeting places, CHS, village meetings, and other highly visible
locations. In addition, 1,300 logbooks and 703,000 leaflets
for the community were distributed (Table 3).
Table 2. Number of persons trained in the pilot provinces, Vietnam, September 2016–May 2017*
North
Province
National level,
RI,
PI-HCMC
Type of training
GDPM
RI, NIHE
Quang Ninh
Nam Dinh
Training of trainers
4
6
2
2
6
Cascade
Hospital
NA
NA
17
13
NA
District
NA
NA
42
30
NA
CHS
NA
NA
186
229
NA
VHWs/HCs
NA
NA
1,768
3,801
NA
Total
4
6
2,015
4,075
6
South
Province
BRVT
An Giang
2
2
8
24
82
710
826
14
33
156
888
1,093
Total
24
52
129
653
7167
8,025
*BRVT, Ba Ria-Vung Tau; CHS, Commune Health Station; GDPM, General Department of Preventive Medicine, Vietnam Ministry of Health; NIHE,
National Institute of Hygiene and Epidemiology, Hanoi, Vietnam; PI-HCMC, Pasteur Institute, Ho Chi Minh City, Vietnam; RI, Regional Institute;
VHWs/HCs, village health workers/health collaborators; NA, not applicable.
1652
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Event-Based Surveillance, Vietnam
Figure 3. Poster displaying community-level signals for pilot of
event-based surveillance, Vietnam, September 2016–May 2017.
EBS Pilot Assessment
As of July 1, 2017, we received 2,105 acceptability/
sustainability surveys from 5 PPMC staff, 39 DHCs,
428 CHS, and 1,633 VHWs. Twenty-four (56%) of 43
districts returned the timeliness data extraction forms.
We conducted 34 key informant interviews, and 32
focus group discussions, both totaling 160 participants
(Figure 4).
During September 2016–May 2017, CHSs reported
2,520 signals to the districts (Figure 5). Quang Ninh province reported the largest number of signals. Of all 2,520
signals, 176 (7%) were verified as events by the districts
and were responded to by the DHC or PPMC.
Although no preexisting timeline data were available
for comparison, the pilot demonstrated that the mean times
from detection to notification and detection to response
were within 24 hours and 48 hours, respectively (Table 4)
(10). We identified a case study illustrating the value of
early event detection resulting in timely response (Figure
6). A trained VHW learned that diarrhea and vomiting developed in 2 persons who had attended a wedding party
meal on September 25, 2016, at ≈13:00 hrs. The VHW
called the CHS and reported the signal 30 minutes after
learning of the episode. The CHSs EBS focal point visited
the village and, after confirming the signal, immediately
reported to the DHC EBS focal point, who joined the CHS
team. The investigation found 93 other affected persons, 38
of whom were hospitalized. The DHC reported the event to
the PPMC, which conducted a risk assessment classifying
the event as high risk and launched a response the same
day. The time to notification to the DHC was within 30
minutes, and the time to response was within 3 hours.
At the community level, signals were being recognized
and reported from multiple sources. The most frequent EBS
reporters were VHWs, teachers, community members, traditional healers, veterinarians, and representatives from industrial complexes (Figure 7). Reported events included multiple suspected avian influenza poultry die-offs and human
outbreaks of chickenpox, mumps, and foodborne disease.
During the key informant interviews and focus group
discussions, interviewees reported that the signal language
should be further simplified, including alternatives for medical terms such “severe,” “dehydration,” and “complications.”
Table 3. Resources provided to implement event-based surveillance in pilot provinces, Vietnam, September 2016–May 2017*
Province
North
South
Resource
Quang Ninh, no. Nam Dinh, no.
BRVT, no.
An Giang, no.
Total
Computer + printer
15
11
9
12
47
Logbook
For provincial level
2
2
2
2
8
For district level
26
22
16
22
86
For commune level
372
458
164
312
1,306
Communication materials
Poster
For community, displayed in public places
3,720
5,255
3,029
2,997
15,001
For HCFs at provincial level
60
40
100
60
260
For HCFs at district level
195
352
256
143
946
Other
Leaflet for community
186,000
147,400
214,500
155,800
703,700
Plastic flyer holder
726
1,016
1,981
1,246
4,969
Handbook for VHWs/HCs
1,800
3,572
713
900
6,985
*BRVT, Ba Ria-Vung Tau; HCF, healthcare facility; VHW/HC, village health worker/health collaborator.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1653
SYNOPSIS
Figure 4. Assessment
tools deployed at each
site for assessment of an
EBS pilot project, Vietnam,
September 2016–May
2017. Acceptability survey
and time stamp events tool
were sent to all districts in
the pilot provinces, not only
to the sites selected for
the FGD and KII site visits.
CHS, commune health
station; EBS, event-based
surveillance; FGD, focus
group discussion; FP, focal
point; KII, key informant
interview; POC, point of
contact; PPMC, Provincial
Preventive Medicine
Center; VHW, village
health worker.
Furthermore, some of the guideline language was deemed
overly academic and needed to reflect everyday language.
Most interviewees appreciated the illustrations in the posters
and leaflets and noted their usefulness in areas that included
ethnic minority populations that did not read Vietnamese.
A total of 82%–88% of VHW, CHS, and district respondents reported that EBS is very important in detecting public health events and helps to detect public health
events earlier than before (Table 5). In addition, ≈85% of
VHW and CHS respondents and 77% of district respondents said they were willing to continue participating in
EBS. Data collected during field visits substantiated these
results (data not shown).
Key motivating factors for participation expressed by
the VHWs were a sense of service to the community, opportunities to increase community ties, and improvement
in community trust. Some VHWs also said that the EBS
project better defined their responsibilities. Staff reported
that the EBS project increased communications between
different levels of the public health system, which aided in
early detection of events and outbreaks.
Discussion
The EBS pilot project builds on and expands the existing surveillance system in Vietnam to include community and HCF
event-based surveillance. The pilot EBS implementation
Figure 5. Number of signals
reported to districts in the 4 eventbased surveillance pilot provinces,
Vietnam. Data were collected
from the district monthly summary
report during September 2016–
May 2017.
1654
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Event-Based Surveillance, Vietnam
Table 4. Time to notification and response during event-based surveillance pilot project, Vietnam, September 2016–May 2017
Mean time to notification, h*
Mean time to response, h†
Type of event
No. events
(median [range])
(median [range])
Suspected chickenpox
28
11 (12 [<1–24])
15.3 (12 [<1–48])
Hand, foot, and mouth disease
27
15 (12 [<1–171])
18 (12 [<1–171])
Suspected dengue
22
36 (12 [5–318])
6.6 (2.5 [<1 27])
Avian influenza‡
14
3.4 (<1 [<1–12])
4.5 (1 [<1–15])
Foodborne disease
11
6.7 (<1 [<1–24])
5 (<1 [<1 24])
Acute respiratory infection
10
9 (12 [1–12])
10 (12 [6–12])
Suspected mumps
9
9 (12 [<1–18])
18 (12 [<1–48])
Other
15
Not calculated
Not calculated
Total
136§
Not calculated
Not calculated
*Time from first detection to notification to the district level.
†Time from first detection to response.
‡Avian influenza in poultry, not human cases.
§From 176 events reported, 40 were excluded for timeliness analysis (incomplete, missing, incoherent or nonverified data).
Figure 6. Case study of a
cluster of food poisoning
illustrating the value of EBS in
early detection leading to rapid
response, Dai Thang commune,
Vu ban District, Nam Dinh
Province, Vietnam, September
2016. CHS, Commune Health
Station; DHC, District Health
Center; DPMC, District
Preventive Medicine Center;
EBS, event-based surveillance;
PPMC, Provincial Preventive
Medicine Center; VHW, village
health worker.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1655
SYNOPSIS
Figure 7. Sources contributing
to signal detection and reporting
through EBS at the community
level in pilot provinces, Vietnam,
September 2016–May 2017.
Data were extracted from
428 acceptability survey
questionnaires completed by
Commune Health Station EBS
focal points in July 2017. Each
bar represents the number
of survey respondents who
identified the information source
as contributing to EBS within
the last 4 weeks. EBS, eventbased surveillance.
in Vietnam demonstrated earlier detection and reporting of
outbreaks, improved collaboration among HCFs, the preventive health and animal health sectors of the government,
and increased participation of communities in surveillance
and reporting. Thus, EBS implementation contributes to
Vietnam’s compliance with IHR 2005, thereby enhancing
global health security.
The pilot initiative trained an existing network of VHWs
and health collaborators to increase their awareness to look
for and report signals as they appear in the community and
to improve their understanding of patterns of disease that
could signal the start of an outbreak. In most communes, the
CHSs also recruited and trained additional community members as health collaborators through the current project. Most
were persons with strong community ties, including money
lenders, insurance agents, veterinary health staff, landlords,
factory managers, community leaders, and others in a good
position to directly observe community events. This wide
participation broadened the sources of reporting and resulted
in the reporting of numerous signals that otherwise would
have been missed, such as school absenteeism reported by
teachers and the resulting multiple detections of vaccine-preventable diseases (e.g., mumps and chickenpox). In contrast
to reporting by clinicians from HCFs, VHWs recognized
connections between cases in the community that doctors
can miss, such as clusters among neighbors, co-workers, or
persons with social connections.
The system did not rely on data reporting, aggregation, and analysis but rather used direct reporting methods
to existing district and provincial authorities responsible
for outbreak response. Based on the pilot implementation of EBS, it is plausible that focusing on patterns of
occurrence in the community enabled outbreaks to be detected before they were large enough for HCFs to notice.
Although all district and provincial public hospitals reported, no private hospitals and clinics participated in the
EBS, making community-level participation critical to the
detection process.
In the pilot districts, all events were detected and reported within 48 hours, and response was timely. Before
EBS, such a rapid response by DHCs would not have been
possible because ill persons would have to have been hospitalized to alert the system and, for certain diseases, traditional reporting often bypassed the CHSs. For example,
foodborne illness events would first have to be reported to
the Department of Food Safety and Hygiene, rather than
the CHS, and ultimately to the DHC, resulting in delays.
Similarly, animal events such as poultry die-offs or rabid
dogs previously would have been reported to the Animal
Health Department, and human health officials would not
necessarily be alerted. During field visits, the DHC staff
stated that because of the EBS pilot, multisectoral communication, such as between food safety and public health and
human and animal health sectors, improved substantially.
Table 5. Acceptability and sustainability of survey results, EBS pilot project, Vietnam, June–July 2017*
Indicator
VHW, %, n = 1,633 CHS, %, n = 428
Agree that EBS is very important in the detection of public health events
87.2
87.6
Agree that EBS helps detect public health events earlier than before
87.1
88
Willing to continue taking part in EBS
85.2
84.1
Agree that EBS should be continued
85.4
82.2
DHC, %, n = 39
82.1
84.7
77
79.5
*The 5 provincial-level staff who received the survey responded. All agreed that EBS is important and should be continued. CHS, commune health
station, community level; DHC, district health center, district level; EBS, event-based surveillance; VHW, village health workers.
1656
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Event-Based Surveillance, Vietnam
Table 6. Revised signals for community and healthcare facilities in provinces participating in event-based surveillance pilot project,
Vietnam, June 2017
Facility type
Signal
Community
1 child <15 y of age with
Sudden weakness of limbs
Fever, rash, respiratory infection, and possibly red eyes
A single case severe enough to require hospital admission or causing death of any of the following:
>3 rice watery stools in 24 h in any person >5 y of age with dehydration
A new respiratory infection with fever in a person who has traveled abroad in the past 14 d
A new respiratory infection with fever after contact with live poultry
Illness within 14 d after vaccination
Illness never seen before or rare symptoms in the community
>2 hospitalized persons and/or death with similar type of symptoms occurring in the same community, school, or
workplace in the same 7-d period
Unexpected large numbers of
Children absent from school because of the same illness in the same 7-d period
Sales at pharmacies of many people buying medicines for the same kind of illness
People sick with the similar type of symptoms at the same time
Deaths of poultry or other domestic animals
A dog that is suspected to be rabid or
A sick dog that has bitten someone
Any dog that has bitten >2 persons in the past 7 d
Healthcare facility
Severe illness requiring hospital admission in healthcare workers after they cared for patients with similar
symptoms
>2 cases of severe acute respiratory infections within 7 d in the same community or household
Large unexpected, sudden increases in admissions for any illness of the same type, including patients in
intensive care units
Severe, unusual, unexplainable illness, including failure to respond to standard treatment
The greatest challenge in quantifying EBS impact was
lack of baseline outbreak data. Although Circular 54 requires outbreak reporting through eCDS, outbreak reports
are not recorded even if detected, and therefore baseline
data were not available. However, the absence of preexisting data demonstrates another important EBS contribution:
the availability of data on outbreaks and events for planning public health interventions.
The assessment was an important part of the pilot
and highlighted several problems that had to be rectified. Specifically, for some signals, wording needed to be
simplified for VHWs, and the signal list itself needed to
be more concise. In addition, for some diseases, such as
hand, foot, and mouth disease, ongoing surveillance requires reporting of every case rather than clusters, creating some confusion. In some jurisdictions, leadership decided unilaterally to broaden signals to include single case
reports, whereas the signal had been defined as a cluster,
increasing the system’s sensitivity, but with a very low
specificity. This change resulted in only 7% of all signals
becoming public health events. In the future, adherence to
accepted signal definitions by the workforce can be maintained with continuous training and experience. Based
on the assessment, the guidelines and training materials
were revised and will undergo pilot testing before scaleup (Table 6).
Another challenge was the number of respondents
to the online survey. The online acceptability survey
was sent to the entire EBS workforce in the pilot provinces, but GDPM closed the survey after only 3 weeks.
Thus, only a relatively small proportion (25%) of VHWs
respondents were able to complete the survey, which
might have limited the representativeness of some of the
survey findings.
Despite the above limitations, experience gained
through the pilot project in Vietnam might be useful for
other countries looking to launch EBS. To that end, we recommend the following:
1. Early in the implementation process, form a TWG
led and coordinated by the Ministry of Health and
with participation from all stakeholders. A TWG
facilitates coordination of technical and financial resources and a better understanding of the
existing landscape of systems and actors, thereby
reducing redundancies and improving buy-in
from implementers.
2. Position EBS to fit within the existing legal framework for surveillance and reporting. The EBS TWG
for this project researched the existing regulations
around reporting and demonstrated how the program complemented the existing systems rather than
something additional. The TWG also avoided introduction of new technologies and regulations whenever possible to minimize disruption.
3. Include focused training on risk assessment to help
staff to prioritize events for investigation.
4. Provide repeated follow-up refresher training.
5. Build in resources for supportive monitoring visits
and mentoring of district-level staff and below and
include an evaluation process.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1657
SYNOPSIS
6. Engage community leaders early in the process to
ensure uptake of the program.
7. Design pilot projects that can be scaled up.
Based on the experience gained by the initial EBS
pilot project, the Vietnam Ministry of Health expanded
the pilot to 2 new provinces in the central and highlands areas. The TWG revised training materials based
on the findings of a final assessment and drafted with
GDPM a decision letter to formally integrate EBS into
the national surveillance system. The vice minister of
health issued a mandate in March 2018 that directed all
provinces to integrate event-based surveillance into the
national surveillance strategy, ensuring sustainability
of the CEBS program. The formalization of EBS as a
Ministry of Health regulation will enable the provinces
to seek funds in the provincial budget to support EBS.
With the Ministry of Health mandate, revised EBS materials, and experience gained by launching an EBS pilot,
Vietnam’s surveillance system will soon function as an
effective early warning and response system.
Acknowledgments
We are grateful to the following staff for their ongoing
support of the EBS project: Vanessa Shaw-Dore, Dinh
Phuong Thao, Tran Minh Quy, and Cuc Tran. We are
grateful to all the collaboration and leadership of surveillance
staff from GDPM, National Institute of Hygiene and
Epidemiology, and Pasteur Institute in Ho Chi Minh City, as
well as from local agencies and organizations of the 4 pilot
provinces. We also humbly acknowledge the enthusiastic
participation of healthcare workers and collaborators who
have participated in this pilot.
Funding for this EBS project was provided by the Global
Health Security Agenda through CDC cooperative agreements
with GDPM (GH001249), National Institute of Hygiene and
Epidemiology (GH001989 and GH000116), Pasteur Institute,
Ho Chi Minh City (GH001992 and GH001628), and
PATH (GH001812).
1658
About the Author
Dr. Balajee is the Associate Director for Global Health
Sciences, Division of Viral Diseases, National Center for
Immunization and Respiratory Diseases, CDC. Her primary
research interests include strengthening capacities in resourcelimited settings for early detection of events, rapid reporting,
and appropriate response, in order to prevent the spread of
infectious disease outbreaks.
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
World Health Organization. International Health Regulations 2005,
2nd ed. Geneva: The Organization; 2008.
World Health Organization. Early detection, assessment and
response to acute public health events: implementation of early
warning and response with a focus on event-based surveillance.
Interim version. Geneva: The Organization; 2014.
World Health Organization Regional Office for the Western Pacific.
A guide to establishing event-based surveillance. Geneva: The
Organization; 2008.
Vietnam Ministry of Health. Circular: Guidance on notification,
reporting and declaration of communicable diseases, number:
54/2015/TT-BYT, Hanoi (Vietnam): The Ministry: 2015.
World Health Organization. Joint external evaluation of IHR core
capacities of Viet Nam. Geneva: The Organization; 2017.
Balajee SA, Arthur R, Mounts AW. Global health security:
building capacities for early event detection, epidemiologic
workforce, and laboratory response. Health Secur. 2016;14:424–32.
http://dx.doi.org/10.1089/hs.2015.0062
General Department of Preventive Medicine, Ministry of
Health, The Socialist Republic of Viet Nam. Decision: approving
“event-based surveillance (EBS) procedures.” No. 134/QD-DP.
Hanoi (Vietnam): Vietnam Ministry of Health; 2014..
General Department of Preventive Medicine, Ministry of Health
of Vietnam. Technical guideline for event-based surveillance pilot.
Interim version. Hanoi (Vietnam): Vietnam Ministry of Health; 2016.
General Statistics Office of Vietnam. Statistical handbook of
Vietnam 2016 [cited 2016 Aug 15]. http://www.gso.gov.vn/
default_en.aspx?tabid=515&idmid=5&ItemID=18513
World Health Organization. Communicable disease surveillance
and response systems. Guide to monitoring and evaluating.
Geneva: The Organization; 2006.
Address for correspondence: S. Arunmozhi Balajee, Centers for Disease
Control and Prevention, 1600 Clifton Rd NE, Mailstop A27, Atlanta, GA
30329-4027, USA; email fir3@cdc.gov
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Ca se Re por t a n d Ge n e t ic Se qu e n ce
An a lysis of Ca n dida t u s Bor r e lia
k a la h a r ica , Sou t h e r n Afr ica
Katarina Stete,1 Siegbert Rieg,1 Gabriele Margos, Georg Häcker,
Dirk Wagner, Winfried V. Kern, Volker Fingerle
Tickborne relapsing fever caused by Borrelia species is
rarely reported in travelers returning from Africa. We report
a case of a 71-year-old woman who sought treatment at
University Medical Center in Freiburg, Germany, in 2015
with recurrent fever after traveling to southern Africa. We
detected spirochetes in Giemsa-stained blood smears.
Treatment with doxycycline for suspected tickborne relapsing fever was successful. Sequence analyses of several loci
(16S rRNA, flagellin, uvrA) showed high similarity to the recently described Candidatus Borrelia kalaharica, which was
found in a traveler returning from the same region earlier
that year. We provide additional information regarding the
genetic relationship of Candidatus B. kalaharica. Sequence
information for an additional 6 housekeeping genes enables
improved comparability to other borrelial species that cause
relapsing fever. Our report underlines the importance and
possible emergence of the only recently delineated pathogen in southern Africa.
A
n infection with Borrelia species bacteria causes relapsing fever (RF). It is transmitted by several arthropods, and dependent on the transmitting vector; louseborne
relapsing fever (LBRF) is different from tickborne relapsing fever (TBRF) (1,2). The clinical picture of RF includes
recurrent fever episodes accompanied by headache, hepatomegaly, splenomegaly, vomiting, conjunctivitis, myalgia,
and arthralgia. It may be difficult to differentiate RF from
other febrile illnesses, especially malaria. RF can be diagnosed by detection of spirochetes in blood smears or by
PCR of EDTA-blood, and treatment is typically with penicillins or tetracyclines (1,3).
Whereas B. recurrentis is the cause of LBRF, which
occurs mainly in the Horn of Africa, several Borrelia
species may cause TBRF, which is found in many areas
of the world. The endemic Borrelia species differ across
Author affiliations: Medical Center—University of Freiburg Faculty
of Medicine, Freiburg, Germany (K. Stete, S. Rieg, G. Häcker,
D. Wagner, W.V. Kern); National Reference Center for Borrelia,
Oberschleißheim, Germany (G. Margos, V. Fingerle)
DOI: https://doi.org/10.3201/eid2409.171381
geographic regions, and they have traditionally been divided into Old World and New World Borrelia. So far, ≈15
Borrelia species have been described to cause TBRF in humans worldwide (1). In Africa, TBRF has been traditionally
attributed to B. crocidurae in western Africa, B. hispanica
in northern Africa, and B. duttonii in eastern Africa (1,4).
Because microscopy is currently the standard method
for diagnosis of TBRF in most countries in Africa, diagnosis does not usually include differentiation of species. With
the advent of molecular diagnostic methods, scientists can
identify species by sequencing different loci of Borrelia
DNA from blood, such as the 16S rRNA gene, the flagellin gene (flaB), or the glpQ gene (5,6). Sequence analysis
has challenged the assumption of strict division of species
across Africa not only by the detection of geographic overlap of several Borrelia species, but also by detection of
previously unknown species (6). Moreover, a Borrelia species found in ticks and in human blood in Tanzania showed
more homology to New World Borrelia species than to the
species known to be present in Africa (7–9). These findings were based on 16S rRNA and flaB partial sequences,
which were deposited in GenBank as B. duttonii (accession nos. AB113315, AB105169, AB105132, AB057547,
and AB105118). In 2015, a case of RF was described in a
German tourist after traveling to the Kalahari Desert. The
strain also showed greater genetic homology to New World
Borrelia spp. and was proposed as a new species Candidatus B. kalaharica on the basis of the analysis of 16S rRNA,
flaB, and uvrA genes (10).
Although RF is believed to be endemic to many areas in Africa, it is rarely diagnosed in travelers returning
from these regions (11). In previous years, several cases of
LBRF have been reported from several countries in Europe
in migrants from eastern Africa (2,3,12–16). Reports on
TBRF in travelers returning from Africa to Europe are limited to case reports. Most of these infections were acquired
in West Africa (17–23), with single reports from other areas, such as Ethiopia and Morocco (21,24).
1
These authors contributed equally to this article.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1659
SYNOPSIS
We present a case of TBRF in a tourist from Germany
returning from southern Africa and describe the results of
a comprehensive molecular diagnostic analysis that underlines that Candidatus B. kalaharica represents a new species that is genetically distant from other RF group species
and that it appears to be an emerging pathogen for humans
that should be considered in the differential diagnosis of febrile patients. We obtained written informed consent from
the patient for publication.
Materials and Methods
We performed slide microscopy after standard Giemsa
staining of a thick and a thin blood smear. We obtained
photographs from a 100× magnification objective using a Nikon Eclipse Ni microscope (Nikon Corporation,
Tokyo, Japan).
We initiated in vitro cultures of infected blood using
medium and conditions as previously described for RF species (25,26). We performed DNA extraction from EDTA
blood using the Maxwell 16 FFS Nucleic Acid Extraction
System Custom Kit (Promega, Mannheim, Germany) according to the manufacturer’s instructions. We amplified
fragments of the 16S rRNA, glpQ and flaB using primers
and PCR conditions as described previously (25,27,28).
We performed multilocus sequence analysis (MLSA) on
housekeeping genes (clpA, clpX, nifS, pepX, pyrG, rplB,
recG, and uvrA) as described (29; online Technical Appendix Table 1, https://wwwnc.cdc.gov/EID/article/24/9/171381-Techapp1.pdf). For PCR we ran HotStarTaq Mastermix (QIAGEN, Hilden, Germany) as touch-down protocol
for the first 9 cycles with annealing temperatures of 55°C–
48°C, decreasing 1°C each cycle, followed by 32 cycles at
48°C annealing temperature. The temperature profile was
95°C for 15 min for activation of Taq polymerase, 94°C for
30 s for denaturation, 30 s for annealing at the temperatures
given previously, and 72°C for 60 s for elongation. A final
step of elongation was at 72°C for 5 min, and then we held
the samples at 12°C.
We used GATC Biotech AG (Konstanz, Germany) for
sequencing, and performed sequence alignment, genetic
distance analyses, and construction of phylogenetic trees
in MEGA5 (30,31). We used BLAST (32) to compare
the sequences we obtained (GenBank accession nos.
KY560340–8) to sequences in GenBank (accession
numbers in online Technical Appendix Tables 2–4) using
standard settings. We conducted genetic distance analyses
in MEGA5 (31) using the Kimura 2-parameter model (30).
We inferred the evolutionary history by using the maximum
likelihood method based on the general time-reversible
model (33). We generated the initial trees for the heuristic
search automatically by applying neighbor-joining
and BioNJ algorithms to a matrix of pairwise distances
estimated using the maximum composite likelihood
1660
approach, and then selecting the topology with superior
log likelihood value. We calculated node support values
with 1,000 bootstrap repeats. We used discrete gamma
distribution to model evolutionary rate differences
among sites [+G]. The rate variation model allowed for
some sites to be evolutionarily invariable [+I]. The trees
are drawn to scale, with branch lengths measured in the
number of substitutions per site. Codon positions included
were 1st + 2nd + 3rd + Noncoding for flaB sequences and
housekeeping gene sequences. We eliminated all positions
containing gaps and missing data.
Results
Case Report
A 71-year old woman sought treatment for fever after a
4-week camping trip to South Africa, Namibia, Botswana,
and Zimbabwe. The patient reported no malaria chemoprophylaxis, fresh water contact, or tick bites. Other than
horseback riding, she could recall no direct contact with
animals. Preexisting conditions were nonmetastatic breast
cancer under treatment with exemestan and a history of
penicillin allergy.
The patient reported fever episodes starting 3 days before returning to Germany. Malaria was ruled out at a local health unit in South Africa by thick smear microscopy.
Three days after arriving in Germany, the patient came to
our clinic with a history of fever but no other abnormal
signs or symptoms. Leukocyte counts were normal; levels of C-reactive protein and procalcitonin were slightly
elevated (Figure 1). A malaria thick blood smear, blood
cultures, and a dengue nonstructural protein 1 antigen test
showed negative results. The fever resolved spontaneously,
and the patient was discharged and asked to return in case
of recurrence of symptoms.
Seventeen days later, the patient returned with RF
(temperature >39°C). She reported 2 episodes of fever
lasting 2–3 days flanked by symptom-free intervals of ≈4
days (Figure 1). Leukocyte counts again were normal, and
levels of C-reactive protein and procalcitonin were elevated. We detected no malaria parasites in a thick smear;
however, we found multiple spirochetes compatible with
Borrelia species (Figure 2). We made a presumptive diagnosis of TBRF on the basis of the travel route and with no
evidence of body lice infestation. We started antimicrobial therapy with doxycycline (2 × 100) mg/d and close
monitoring. We observed no signs of a Herxheimer reaction. PCR diagnostics of 16S rRNA confirmed the diagnosis of Borrelia infection. For further species differentiation, we sent a blood sample to the German National
Reference Center for sequence analysis for Borrelia. An
11-day course of doxycycline led to an uneventful recovery with no recurrence of fever.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Candidatus Borrelia kalaharica, Southern Africa
Figure 1. Timeline of the course of symptoms and treatment, including laboratory test results, for a patient with recurrent fever after
traveling to southern Africa, 2015. Temp, temperature; CRP, C-reactive protein; PCT, procalcitonin.
Sequence Analysis and Phylogeny
To investigate the Borrelia species designation, we conducted BLAST searches using the 16S rRNA PCR fragment. Top hits included Candidatus B. kalaharica, B. duttonii strain VS4, B. turicatae, and B. parkeri. Genetic distance
analyses using the 16S rRNA fragments in MEGA5 (31) revealed strains Candidatus B. kalaharica (10) and VS4 from
Tanzania, an atypical RF strain present in the Old World
(8), as closest matches (online Technical Appendix Table
2). Although designated B. duttonii in GenBank, VS4 was
closely related to some strains found in the Mvumi region
of Tanzania (7) which were shown to be more closely related to New World RF species than to B. duttonii. Genetic
distance values obtained for the 16S rRNA fragment were
0.2% for Candidatus B. kalaharica and slightly higher for
B. parkeri, B. crocidurae, and B. turicatae (0.4%) (online
Technical Appendix Table 2).
When the sequence of a flagellin gene (flaB) fragment
(252 bp) was used for genetic distance analysis, Candidatus B. kalaharica was again the most closely related strain,
with genetic distance value = 0.000 (online Technical
Appendix Table 3). Strains representing atypical B. duttonii (7,8) showed higher genetic distance values (strain TnB,
0.8%; strain EM14, 1.2%), whereas for other Borrelia species such as B. anserina BA2 (5.8%), B. turicatae (6.2%),
and B. parkeri (6.2%) the values were even higher, indicating a close genetic relationship of the strain investigated
here to Ca. B. kalaharica. This was also reflected in phylogenies (online Technical Appendix Figures 1, 2). In the
16S rRNA phylogeny, the DNA isolate investigated here
formed a clade together with Candidatus B. kalaharica and
VS4 from Mvumi, Tanzania (8,10). In the flaB phylogeny,
our DNA isolate and Candidatus B. kalaharica formed a
sister clade to strains from the Mvumi region in Tanzania
(7,8), notably outside the clade containing Old World RF
species such as B. duttonii, suggesting that they are divergent from B. duttonii.
We obtained similar results using 7 housekeeping
loci (Figure 3; online Technical Appendix Tables 4, 5)
and, in particular locus uvrA. For this locus, sequences of
Candidatus B. kalaharica were available (Figure 3, panel
A). Genetic distance analysis (online Technical Appendix
Figure 2. Microscopy of blood
from a patient with recurrent
fever episodes after traveling
to southern Africa, 2015.
Arrows indicate spirochetes.
A) Thick smear specimen;
B) thin smear specimen.
Original magnification ×100.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1661
SYNOPSIS
Figure 3. Molecular phylogenetic
analysis by maximum-likelihood
method of isolates from a patient
in Germany with recurrent fever
episodes after traveling to southern
Africa, 2015. A) Phylogeny of uvrA
sequence fragments. The tree with the
highest log likelihood (–2566.8936) is
shown. A discrete gamma distribution
was used to model evolutionary rate
differences among sites (4 categories
[+G, parameter = 0.9541]). The rate
variation model allowed for some sites
to be evolutionarily invariable ([+I],
43.5691% sites). The tree is drawn to
scale, with branch lengths measured
in the number of substitutions per
site. The analysis involved 19 nt
sequences. There were a total of 570
positions in the final dataset. Bootstrap
values >50 are shown. Black dot
indicates the sample analyzed in
this study. Black triangle represents
the clade containing B. burgdorferi
s.l. isolates, collapsed for simplicity.
Scale bar indicates substitutions per
site. B) Phylogeny of concatenated
sequences of 7 MLST housekeeping
loci (clpX, nifS, pepX, pyrG, recG,
rplB, uvrA). The tree with the highest
log likelihood (–31066.7852) is shown.
The percentage of trees in which the
associated taxa clustered together
is shown next to the branches. A
discrete gamma distribution was
used to model evolutionary rate
differences among sites (4 categories
[+G, parameter = 0.7881]). The rate
variation model allowed for some sites
to be evolutionarily invariable ([+I], 36.6955% sites). The analysis involved 33 nt sequences. There were a total of 4,203 positions in the
final dataset. The subtree containing the LB group of spirochetes was collapsed. Bootstrap values >50 are shown. Black dot indicates the
sample analyzed in this study. Scale bar indicates substitutions per site.
Tables 4, 5) and phylogenetic inferences (Figure 3, panel
B) further support the close genetic relationship of the
specimen investigated here with Ca. B. kalaharica and both
clusters next to B. anserina. For MLST analysis, only 7
genes could be included as clpA PCR did not yield a PCR
product. The PCR for the glpQ locus also proved negative
in spite of several amplification attempts suggesting that
perhaps base differences in the primer regions prevented
amplification. Despite our efforts, we were unable to
cultivate the causative pathogen from blood.
Discussion
The case described here is the second report within a few
months of TBRF in a tourist from Germany traveling to
countries in southern Africa, such as South Africa, Namibia,
and Botswana (10). In the previous case, a presumed soft
1662
tick bite in the Kalahari Desert was described, whereas our
patient did not report any arthropod bite. However, contact
with arthropods was likely as the patient was camping.
Soft tick Ornithodoros species only need short blood
meals and do not attach tightly to the host (34), making
it conceivable that a feeding tick was not noticed. These
cases underscore that, in returning travelers with RF, TBRF
should be considered in the differential diagnosis, even if
no tick bite is reported. Thick smears are the diagnostic
procedure of choice and should be carefully evaluated for
corkscrew-shaped spirochetes (1). However, the sensitivity
of this method may change depending on febrile versus
afebrile periods with different pathogen loads circulating
in the blood. Thus, as we saw in this patient, thick smears
may turn negative during infection and should therefore be
repeated preferentially during febrile episodes.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Candidatus Borrelia kalaharica, Southern Africa
Death as a result of TBRF is considered to be rare;
however, higher mortality rates have been suspected as a
result of Herxheimer reactions, even though there is a lack
of data for TBRF in Africa (1,35). Clinicians need to be
aware that the initiation of antimicrobial treatment might
be associated with a severe Herxheimer reaction, necessitating aggressive supportive care.
Borrelia species can be identified and differentiated
by means of DNA sequence analysis, although it may be
hard to distinguish closely related Borrelia species, such
as B. duttonii, B. recurrentis, and B. crocidurae (36,37).
16S rRNA sequences are available for many of the Borrelia
species and strains that have been found in Africa and thus,
although the locus may have low resolution, it can give a
first indication of relationships. Other loci that have been
used in previous reports were also used in the current study,
including flaB and housekeeping loci (37). Because there
is so little information about which RF-causing species do
occur in southern Africa (6), a more thorough characterization of the DNA isolate would be beneficial to epidemiologists and other researchers in the field.
The traditional concept of strict division of geographic
areas into Old World and New World Borrelia and division of species across Africa has been challenged by the description of new Borrelia species. This is the second report
of a species that has not been described previously. Genetically, Candidatus B. kalaharica is most closely related to
TBRF Borrelia described from the Mvumi region in Tanzania (8,38). In previous publications it was suggested that
these Borrelia strains from Mvumi may belong to the new
species (8,38). Unfortunately, the only available sequences
were for 16S rRNA and flaB, but more sequence data will
be needed to reveal the taxonomic position of these strains.
Of interest, both the strains from Mvumi and Candidatus
B. kalaharica show more genetic similarity to New World
RF species than to the expected Old World species.
We report the second case of a human infection with
the proposed new species Candidatus B. kalaharica. Our
findings support the definition of Candidatus B. kalaharica
as a new species that is genetically distant from other RF
group species and more closely related to New World RF
Borreliae. It appears to be an emerging pathogen for humans that should be considered in the differential diagnosis
of febrile patients.
Acknowledgment
We thank the patient for providing consent to publish this case.
About the Author
Dr. Stete is a resident in internal medicine and infectious diseases
at the Division of Infectious Diseases, University Medical Center,
Freiburg, Germany. Her primary research interests are in the field
of parasitic diseases, travel medicine, and migration health.
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
Cutler SJ, Abdissa A, Trape J-F. New concepts for the old
challenge of African relapsing fever borreliosis. Clin
Microbiol Infect. 2009;15:400–6. http://dx.doi.org/10.1111/
j.1469-0691.2009.02819.x
Seilmaier M, Guggemos W, Wieser A, Fingerle V, Balzer L,
Fenzl T, et al. Louse-borne-relapsing-fever in refugees from the
Horn of Africa; a case series of 25 patients [in German]. Dtsch Med
Wochenschr. 2016;141:e133–42.
Hoch M, Wieser A, Löscher T, Margos G, Pürner F, Zühl J, et al.
Louse-borne relapsing fever (Borrelia recurrentis) diagnosed in
15 refugees from northeast Africa: epidemiology and preventive
control measures, Bavaria, Germany, July to October 2015. Euro
Surveill. 2015;20:30046. http://dx.doi.org/10.2807/1560-7917.
ES.2015.20.42.30046
Elbir H, Henry M, Diatta G, Mediannikov O, Sokhna C, Tall A,
et al. Multiplex real-time PCR diagnostic of relapsing fevers in
Africa. PLoS Negl Trop Dis. 2013;7:e2042. http://dx.doi.org/
10.1371/journal.pntd.0002042
Fukunaga M, Okada K, Nakao M, Konishi T, Sato Y. Phylogenetic
analysis of Borrelia species based on flagellin gene sequences
and its application for molecular typing of Lyme disease
borreliae. Int J Syst Bacteriol. 1996;46:898–905. http://dx.doi.org/
10.1099/00207713-46-4-898
Elbir H, Raoult D, Drancourt M. Relapsing fever borreliae in
Africa. Am J Trop Med Hyg. 2013;89:288–92. http://dx.doi.org/
10.4269/ajtmh.12-0691
Kisinza WN, McCall PJ, Mitani H, Talbert A, Fukunaga M.
A newly identified tick-borne Borrelia species and relapsing fever
in Tanzania. Lancet. 2003;362:1283–4. http://dx.doi.org/10.1016/
S0140-6736(03)14609-0
Mitani H, Talbert A, Fukunaga M. New World relapsing fever
Borrelia found in Ornithodoros porcinus ticks in central Tanzania.
Microbiol Immunol. 2004;48:501–5. http://dx.doi.org/10.1111/
j.1348-0421.2004.tb03545.x
Scott JC, Wright DJM, Cutler SJ. Typing African relapsing fever
spirochetes. Emerg Infect Dis. 2005;11:1722–9. http://dx.doi.org/
10.3201/eid1111.050483
Fingerle V, Pritsch M, Wächtler M, Margos G, Ruske S, Jung J,
et al. “Candidatus Borrelia kalaharica” detected from a febrile
traveller returning to Germany from vacation in southern Africa.
PLoS Negl Trop Dis. 2016;10:e0004559. http://dx.doi.org/10.1371/
journal.pntd.0004559
Rebaudet S, Parola P. Epidemiology of relapsing fever borreliosis
in Europe. FEMS Immunol Med Microbiol. 2006;48:11–5.
http://dx.doi.org/10.1111/j.1574-695X.2006.00104.x
Antinori S, Mediannikov O, Corbellino M, Raoult D. Louse-borne
relapsing fever among East African refugees in Europe. Travel Med
Infect Dis. 2016;14:110–4. http://dx.doi.org/10.1016/j.tmaid.2016.01.004
Wilting KR, Stienstra Y, Sinha B, Braks M, Cornish D,
Grundmann H. Louse-borne relapsing fever (Borrelia recurrentis)
in asylum seekers from Eritrea, the Netherlands, July 2015. Euro
Surveill. 2015;20:21196. http://dx.doi.org/10.2807/1560-7917.
ES2015.20.30.21196
Osthoff M, Schibli A, Fadini D, Lardelli P, Goldenberger D.
Louse-borne relapsing fever - report of four cases in Switzerland,
June–December 2015. BMC Infect Dis. 2016;16:210.
http://dx.doi.org/10.1186/s12879-016-1541-z
Ciervo A, Mancini F, di Bernardo F, Giammanco A, Vitale G,
Dones P, et al. Louseborne relapsing fever in young migrants,
Sicily, Italy, July–September 2015. Emerg Infect Dis. 2016;22:152–
3. http://dx.doi.org/10.3201/eid2201.151580
Lucchini A, Lipani F, Costa C, Scarvaglieri M, Balbiano R,
Carosella S, et al. Louseborne relapsing fever among East
African refugees, Italy, 2015. Emerg Infect Dis. 2016;22:298–301.
http://dx.doi.org/10.3201/eid2202.151768
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1663
SYNOPSIS
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
1664
Colebunders R, De Serrano P, Van Gompel A, Wynants H,
Blot K, Van den Enden E, et al. Imported relapsing fever in
European tourists. Scand J Infect Dis. 1993;25:533–6.
http://dx.doi.org/10.3109/00365549309008539
Chatel G, Gulletta M, Matteelli A, Marangoni A, Signorini L,
Oladeji O, et al. Short report: diagnosis of tick-borne
relapsing fever by the quantitative buffy coat fluorescence method.
Am J Trop Med Hyg. 1999;60:738–9. http://dx.doi.org/10.4269/
ajtmh.1999.60.738
Gallien S, Sarfati C, Haas L, Lagrange-Xelot M, Molina JM.
Borreliosis: a rare and alternative diagnosis in travellers’ febrile
illness. Travel Med Infect Dis. 2007;5:247–50. http://dx.doi.org/
10.1016/j.tmaid.2007.01.002
Million M, Cazorla C, Doudier B, La Scola B, Parola P,
Drancourt M, et al. Molecular identification of Borrelia crocidurae
in a patient returning from Senegal. BMJ Case Rep. 2009;2009:
pii:bcr06.2008.0298.. http://casereports.bmj.com/content/2009/
bcr.06.2008.0298
Wyplosz B, Mihaila-Amrouche L, Baixench M-T, Bigel M-L,
Berardi-Grassias L, Fontaine C, et al. Imported tickborne relapsing
fever, France. Emerg Infect Dis. 2005;11:1801–3. http://dx.doi.org/
10.3201/eid1111.050616
Tordini G, Giaccherini R, Corbisiero R, Zanelli G. Relapsing fever
in a traveller from Senegal: determination of Borrelia species using
molecular methods. Trans R Soc Trop Med Hyg. 2006;100:992–4.
http://dx.doi.org/10.1016/j.trstmh.2005.11.002
van Dam AP, van Gool T, Wetsteyn JC, Dankert J. Tick-borne
relapsing fever imported from West Africa: diagnosis by
quantitative buffy coat analysis and in vitro culture of Borrelia
crocidurae. J Clin Microbiol. 1999;37:2027–30.
Socolovschi C, Honnorat E, Consigny PH, Dougados J,
Passeron A, Parola P, et al. Tick-borne relapsing fever with
cutaneous eschar and radiculopathy, Ethiopia. J Travel Med. 2012;
19:261–3. http://dx.doi.org/10.1111/j.1708-8305.2012.00625.x
Margos G, Stockmeier S, Hizo-Teufel C, Hepner S, Fish D,
Dautel H, et al. Long-term in vitro cultivation of Borrelia
miyamotoi. Ticks Tick Borne Dis. 2015;6:181–4. http://dx.doi.org/
10.1016/j.ttbdis.2014.12.001
Marosevic D, Margos G, Wallich R, Wieser A, Sing A,
Fingerle V. First insights in the variability of Borrelia recurrentis
genomes. PLoS Negl Trop Dis. 2017;11:e0005865.
http://dx.doi.org/10.1371/journal.pntd.0005865
Assous MV, Wilamowski A, Bercovier H, Marva E. Molecular
characterization of tickborne relapsing fever Borrelia, Israel.
Emerg Infect Dis. 2006;12:1740–3. http://dx.doi.org/10.3201/
eid1211.060715
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
Venczel R, Knoke L, Pavlovic M, Dzaferovic E, Vaculova T,
Silaghi C, et al. A novel duplex real-time PCR permits
simultaneous detection and differentiation of Borrelia miyamotoi
and Borrelia burgdorferi sensu lato. Infection. 2016;44:47–55.
http://dx.doi.org/10.1007/s15010-015-0820-8
Jolley KA, Maiden MCJ. BIGSdb: Scalable analysis of bacterial
genome variation at the population level. BMC Bioinformatics.
2010;11:595. http://dx.doi.org/10.1186/1471-2105-11-595
Kimura M. A simple method for estimating evolutionary rates
of base substitutions through comparative studies of nucleotide
sequences. J Mol Evol. 1980;16:111–20. http://dx.doi.org/10.1007/
BF01731581
Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S.
MEGA5: molecular evolutionary genetics analysis using maximum
likelihood, evolutionary distance, and maximum parsimony
methods. Mol Biol Evol. 2011;28:2731–9. http://dx.doi.org/
10.1093/molbev/msr121
Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ.
Basic local alignment search tool. J Mol Biol. 1990;215:403–10.
http://dx.doi.org/10.1016/S0022-2836(05)80360-2
Nei M, Kumar S. Molecular evolution and phylogenetics. New
York: Oxford University Press, Inc; 2000.
Boyle WK, Wilder HK, Lawrence AM, Lopez JE. Transmission
dynamics of Borrelia turicatae from the arthropod vector. PLoS
Negl Trop Dis. 2014;8:e2767. http://dx.doi.org/10.1371/journal.
pntd.0002767
Dworkin MS, Anderson DE Jr, Schwan TG, Shoemaker PC,
Banerjee SN, Kassen BO, et al. Tick-borne relapsing fever in the
northwestern United States and southwestern Canada. Clin Infect
Dis. 1998;26:122–31. http://dx.doi.org/10.1086/516273
Elbir H, Gimenez G, Sokhna C, Bilcha KD, Ali J, Barker SC, et al.
Multispacer sequence typing relapsing fever Borreliae in Africa.
PLoS Negl Trop Dis. 2012;6:e1652. http://dx.doi.org/10.1371/
journal.pntd.0001652
Fotso Fotso A, Drancourt M. Laboratory diagnosis of tick-borne
African relapsing fevers: latest developments. Front Public Health.
2015;3:254. http://dx.doi.org/10.3389/fpubh.2015.00254
Cutler SJ, Ruzic-Sabljic E, Potkonjak A. Emerging borreliae—
expanding beyond Lyme borreliosis. Mol Cell Probes. 2017;
31:22–7. http://dx.doi.org/10.1016/j.mcp.2016.08.003
Address for correspondence: Katarina Stete, University of Freiburg
Division of Infectious Diseases, Department of Medicine II, Medical
Center, Faculty of Medicine, Hugstetterstr 55, 79106 Freiburg, Germany;
email: katarina.stete@uniklinik-freiburg.de
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
RESEARCH
N ove l Or t h opox vir u s a n d
Le t h a l D ise a se in Ca t , I t a ly
Gianvito Lanave, Giulia Dowgier, Nicola Decaro, Francesco Albanese, Elisa Brogi, Antonio Parisi,
Michele Losurdo, Antonio Lavazza, Vito Martella, Canio Buonavoglia, Gabriella Elia
We report detection and full-genome characterization of a
novel orthopoxvirus (OPXV) responsible for a fatal infection
in a cat. The virus induced skin lesions histologically
characterized by leukocyte infiltration and eosinophilic
cytoplasmic inclusions. Different PCR approaches were
unable to assign the virus to a defined OPXV species. Large
amounts of typical brick-shaped virions, morphologically
related to OPXV, were observed by electron microscopy.
This OPXV strain (Italy_09/17) was isolated on cell
cultures and embryonated eggs. Phylogenetic analysis
of 9 concatenated genes showed that this virus was
distantly related to cowpox virus, more closely related to
to ectromelia virus, and belonged to the same cluster of
an OPXV recently isolated from captive macaques in Italy.
Extensive epidemiologic surveillance in cats and rodents
will assess whether cats are incidental hosts and rodents
are the main reservoir of the virus. The zoonotic potential of
this novel virus also deserves further investigation.
O
rthopoxviruses
(OPXVs;
family
Poxviridae,
subfamily Chordopoxvirinae, genus Orthopoxvirus)
are complex, double-stranded DNA viruses with ongoing
interest because of their potential use as bioterrorism agents
and in gene therapy. Variola virus (VARV), the causative
agent of smallpox, has been eradicated in nature; however,
there is still the possibility of accidental or intentional
release, and it is currently classified as a category A biologic
agent (1). Another concern is the zoonotic potential of
some OPXVs, such as monkeypox virus, camelpox virus,
buffalopox virus, and cowpox virus (CPXV) (2,3).
CPXV, which has a wide host range and a distribution
restricted to the Eurasian continent, causes localized dermatitis in humans, although severe disease might develop
in immuneocompromised persons, occasionally with a fatal
Author affiliations: University of Bari, Valenzano, Italy (G. Lanave,
G. Dowgier, N. Decaro, M. Losurdo, V. Martella, C. Buonavoglia,
G. Elia); La Vallonea Veterinary Laboratory, Milan, Italy
(F. Albanese); Centro Veterinario Montarioso, Siena, Italy
(E. Brogi); Istituto Zooprofilattico Sperimentale di Puglia e Basilicata,
Putignano, Italy (A. Parisi); Istituto Zooprofilattico Sperimentale di
Lombardia ed Emilia Romagna, Brescia, Italy (A. Lavazza)
DOI: https://doi.org/10.3201/eid2409.171283
outcome. Natural hosts for CPXV are wild rodents (4), but
the infection is acquired mainly through direct contact with
cats, which are natural hosts, and rarely by exotic animals
and wild species (5). Ectromelia virus (ECTV) is the causative agent of mousepox, a severe exanthematous disease
of mice in laboratory colonies and has been reported worldwide in several outbreaks and causes high economic losses
in biomedical research (6). ECTV has never been reported
in humans, and little is known regarding its natural distribution and hosts (7).
Reports of OPXV infections in animals and humans
have largely increased during recent decades, which has
enhanced their zoonotic potential and led to the perception
of an increasing risk for humans (8). For cats, there are several reports of poxvirus infections, but the causative agent
has been characterized as CPXV (9–14) or has not been
characterized (15–18).
We report a case of fatal infection with an OXPV
in a household cat. This virus was more closely related
to ECTV than to CPXV, putatively representing a novel
OPXV species.
Materials and Methods
Case Study
A domestic, short-haired, male, 6-month-old cat was
brought to a veterinarian because of multicentric, nodular, ulcerative dermatitis (Figure 1). The cat was regularly
vaccinated for common feline diseases (feline panleukopenia, rhinhotracheitis, calicivirosis, and chlamydiosis) and
showed negative test results for retroviral infections. An
antiparasitic product had been applied monthly (Frontline
Combo Spot On; Merial, Ingelheim, Germany). The cat
was fed a balanced commercial diet and lived indoors, but
it had access to outdoors and had a hunting behavior.
The cat had multiple nodular, plaque-like, ulcerative
lesions on its body, particularly on the feet and face. Results of diagnostic testing, including a wood lamp examination, skin scrapings, trichogram, and fungal culture,
were negative. Cytological examination showed a mixed
inflammatory population of cells with a relevant amount of
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1665
RESEARCH
Figure 1. Cat with orthopoxvirus
infection, Italy. Ulcerated
nodules and plaques were
observed on the lips (A), thorax
(B), and forelimb (C). Skin
punch biopsy specimen (D)
showing leukocyte infiltration
and cytoplasmic inclusion
bodies (arrows) (hematoxylin
and eosin stain, original
magnification × 60).
eosinophils. A blood test showed only a mild leukocytosis
with an increase in numbers of lymphocytes, neutrophils,
and eosinophils. Because of rapid worsening of its clinical
conditions, the cat was euthanized.
Histopathologic Analysis
We collected multiple skin biopsy specimens for histopathologic analysis by using an 8-mm biopsy punch and fixed
these specimens in 10% buffered formalin. Samples were
embedded in paraffin, sectioned, and stained with hematoxylin and eosin, according to standard protocols.
DNA Extraction and PCR Amplification
An OPXV infection was suspected on the basis of clinical
presentation and histopathologic analysis. Therefore, we
processed histologic preparations for molecular investigations to confirm the presumptive diagnosis. We purified total DNA from a thin section of ≈20 mg of formalin-fixed,
paraffin-embedded tissue by using the DNeasy Blood and
Tissue Kit (QIAGEN, Hilden, Germany) according to the
manufacturer’s instructions.
We tested the DNA extract by using 2 panchordopoxvirus PCRs specific for the variable GC content of the genera included in the subfamily Chordopoxvirinae and other
unclassified chordopoxviruses (19). For the low GC content PCR, we used DNA from a laboratory vaccinia virus
Western Reserve strain (VACV-WR) as a positive control.
For the high GC content PCR, we used an Orf virus isolated during an outbreak of contagious ecthyma as a positive control. We initially conducted subsequent identification of OPXV by using a PCR specific for the gene coding
A-type inclusion protein (20), followed by a second PCR
specific for the hemagglutinin (HA) gene (21). In addition,
we performed 2 species-specific PCRs, 1 for ECTV and 1
for CPXV, to further characterize the virus (22).
1666
We conducted all PCR amplifications by using an LA
PCR Kit (version r.2.1) (Takara Bio, Tokyo, Japan) in a
50-µL reaction containing 1 mmol/L of primers, LA PCR
Buffer (Mg2+), 8 µL of dNTP mixture (corresponding to
400 mmol/L of each dNTP), 2.5 units of TaKaRa LA Taq
polymerase, and 1 µL of template DNA. The cycling protocol used for each assay was programmed as described (19).
PCR products were subjected to electrophoresis on a 1.5%
agarose gel containing a fluorescent nucleic acid marker
(GelRed; Bio-Rad Laboratories, Hercules, CA, USA) at 80
V for 45 min and visualized under fluorescent light on the
Gel Doc EZ Imaging System with Image Laboratory Software (Bio-Rad Laboratories). PCR products were directly
sequenced by Eurofins Genomics GmbH (Ebersberg, Germany). We manually edited and analyzed sequences by using the Geneious platform version 10.1.3 (Biomatters Ltd.,
Auckland, New Zealand).
Virus Isolation
After diagnosis of OPXV infection, we collected additional biopsy specimens from skin lesions of the diseased
cat intravitam and then used for subsequent virologic investigations. For virus isolation, we used African green
monkey kidney fibroblast CV-1 cells and African green
monkey kidney epithelial Vero cells. Cells were grown in
Dulbecco’s modified minimum essential medium (DMEM)
supplemented with 10% fetal bovine serum. Tissues were
homogenized in DMEM (10%, wt/vol) and centrifuged at
8,000 × g for 10 min. Supernatants were treated with antimicrobial drugs (penicillin 5,000 IU/mL, streptomycin
2,500 µg/mL, and amphotericin B 10 µg/mL) for 30 min,
inoculated on partially confluent CV-1 and Vero cell cultures, and incubated at 37°C in a 5% CO2 incubator. After
an adsorption period of 45 min, DMEM was added. Cells
were observed daily for cytopathic effects.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Orthopoxvirus and Lethal Disease in Cat, Italy
For hematoxylin and eosin staining and indirect immunofluorescence (IIF) assay, we grew cells on coverslips
placed in 12-well plates. Cells were mock- or virus-infected
and coverslips were harvested at 48 hours postinfection. For
detection of inclusion bodies, we fixed cells in Bouin solution for 2 h and stained them with hematoxylin and eosin.
For the IIF assay, cells were fixed with 80% acetone for 30
min. Coverslips were rinsed twice with phosphate-buffered
saline and incubated 30 min in a humidified chamber at 37°C
with a serum sample (diluted 1:50) collected from the ill cat.
Coverslips were washed twice with phosphate-buffered saline and incubated with goat anti-cat IgG conjugated with
fluorescein isothiocyanate (Sigma-Aldrich, Milan, Italy).
The homogenate of skin biopsy specimens was inoculated onto the chorioallantoic membrane of 12-day-old
chick embryos. After 2 days of incubation at 37°C, membranes were collected from the eggs and pock morphology
was observed.
Electron Microscopy
We performed negative staining and electron microscopic
analysis of homogenates of skin punch biopsy specimens and
supernatants of infected Vero cells that showed an evident
cytopathic effect. Samples were frozen and thawed twice
and centrifuged at 4,000 × g for 20 min and at 9,300 × g
for 10 min to clarify the supernatant. The second supernatant
(82 µL) was then ultracentrifuged in an Airfuge centrifuge
(Beckman Coulter, Brea, CA, USA) for 15 min at 21 lbs/
in2 (82,000 × g). The Airfuge was fitted with an A 100 rotor
that held six 175-µL test tubes containing specific adapters
for 3-mm grids, which enables direct pelleting of virus particles on carbon-coated, formvar copper grids. These grids
were stained with 2% sodium phosphotungstate, pH 6.8, for
1.5 min, and observed with a Tecnai G2 Biotwin Transmission Electron Microscope (Field Electron and Ion Company,
Hillsboro, OR, USA) operating at 85 kV. We identified poxvirus particles, observed at magnifications of 11,000×–26,500×,
on the basis of their typical morphologic characteristics.
Serologic Analysis
We tested the serum sample collected intravitam from the
diseased cat for OPXV antibodies by virus neutralization
and IIF assays. We used strains Italy_09/17 isolated from
the same cat and VACV-WR in these tests.
For the virus neutralization test, we mixed 2-fold dilutions of heat-inactivated serum (starting at a dilution of
1:2) with 100 50% tissue culture infective doses of virus
in 96-well microtiter plates. After incubation at room temperature for 60 min, 2 × 104 CV-1 cells were added to each
well. Plates were read after 4 days of incubation at 37°C in
a humidified atmosphere of 5% CO2.
For the IIF assay, we fixed confluent monolayers of
CV-1 cells grown on coverslips and infected with strain
Italy_09/17 or VACV-WR with 80% acetone. We tested
2-fold dilutions of heat-inactivated serum (diluted 1:20 to
1:5,120) by using 1 coverslip/dilution. Goat anti-cat IgG
conjugated with fluorescein isothiocyanate was used as a
secondary antibody (Sigma-Aldrich).
Next-Generation Sequencing
For DNA extraction, we obtained virus stocks from semipurified virus particles. In brief, we infected CV-1 cells
with strain Italy_09/17. At 48 hours postinfection, the cell
medium was collected and nuclei and cell debris were
discarded by centrifugation at 1,000 × g for 10 min at
4°C. We extracted virus DNA by using a QIAamp Cador
Pathogen Mini Kit (QIAGEN) according to the manufacturer’s instructions.
We quantified DNA by using the Fluorometric Qubit
dsDNA High Sensitivity Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA). We prepared a genomic DNA
library by using the Nextera DNA Sample Prep Kit (Illumina, San Diego, CA, USA) according to the manufacturer’s
protocol and performed a size-selection step manually by
using Ampure XP magnetic beads (Beckman Coulter). We
performed quality control analysis of the sample library by
using the QIAxcel Advanced System with QIAxcel ScreenGel Software 1.4.0 (QIAGEN). We normalized library
samples as suggested by QIAGEN and performed sequencing by using a MiSeq instrument, version 2, and a MiSeq
Reagent Kit (Illumina).
Genome Annotation and Comparison
We obtained 1,497,762 paired reads in next-generation
sequencing (NGS) experiments (Illumina); these reads
had an average length of 155.4 bp. We performed quality
control of reads by using FastQC (23) and sequence trimming by using the plugin Trim Ends in Geneious software
version 10.1.3 (https://www.geneious.com/). We filtered
NGS sequences by using the genome of African green
monkey (Chlorocebus sabeus), which yielded 217,236
unmapped reads. We used these unmapped reads for de
novo assembling of the feline OPXV genome by using the
Geneious Assembler.
We annotated the nearly full-length genome sequence
of the Italy_09/17 isolate by using ECTV strain Naval as
reference (GenBank accession no. KJ563295). We performed genome annotation by using FindORFs software
in Geneious version 10.1.3 and a set of reference sequences, including ECTV Naval (accession no. KJ563295),
ECTV Mos (accession no. AF012825), CPXV BR (accession no. AF482758), and VACV COP (accession no.
35027) for comparison. We further analyzed open reading
frames that remained unassigned or with a lower similarity to the reference sequences by using MyOrfeome
(http://myorfeome.sourceforge.net).
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1667
RESEARCH
Phylogenetic Analysis
For characterization of the OPXV strain, we used the strategy proposed by Emerson et al. (24). We selected 9 coding sequences from the genome of the feline OPXV strain
Italy_09/17: A7L, early transcription factor/VETF large
subunit; A10L, major core protein; A24R, RNA polymerase
132; D1R, messenger RNA capping enzyme, large subunit;
D5R, DNA-independent NTPase (DNA replication); E6R,
hypothetical protein; E9L, DNA polymerase; H4L, RNA
polymerase-associated protein; and J6R, RNA polymerase
147. Gene designations refer to the VACV COP genome.
We aligned concatenated genome sequences of OPXVs representative of North American and Old World (African and
Eurasian) viruses by using Geneious version 10.1.3 and the
MAFFT algorithm (25). After searching the GenBank database, we retrieved complete HA gene sequences of 2 felinederived human OPXV strains (accession nos. EF612709 and
FJ445747) and of an OPXV isolated from captive macaques
(accession no. KY100116) and aligned them with cognate
OPXV sequences.
We performed phylogenetic analysis for concatenated
DNA alignments with Bayesian inference by using 4 chains
run for >1 million generations (26,27). We used ModelTest software (http://evomics.org/resources/software/
molecular-evolution-software/modeltest/) to identify the
most appropriate model of evolution for the entire dataset
and for each gene individually. The identified program settings for all partitions, under the Akaike Information Criteria, included 6 character states (general time reversible
model), a proportion of invariable sites, and a gamma distribution of rate variation across sites. We deposited nucleotide sequences of strain Italy_09/17 used for phylogeny in
GenBank (accession nos. MF578930–9).
wall. Many roundish to oval brightly eosinophilic inclusion bodies were clearly evident in the cytoplasm of both
epidermal and follicular keratinocytes, including in a few
sebocytes. The morphology of cells suggested a possible
OPXV infection (Figure 2, panel A). Nodular to diffuse
dermatitis caused by mixed inflammatory cells was also
present in dermis and hypodermis; those cells were mainly
represented by eosinophils, histiocytes, and lymphocytes,
together with few plasma cells and neutrophils.
Molecular Investigations
Molecular analysis of formalin-fixed, paraffin-embedded
tissues showed positive results for the low GC panchordopoxvirus PCR and negative results for the high GC panchordopoxvirus PCR (19). This pattern of amplification
was consistent with an OPXV infection. Amplification of
the gene coding for the A-type inclusion protein generated
an amplicon of ≈1,237 bp, and amplification of the HA
gene (20,21) generated an amplicon of 846 bp, which are
expected sizes for these genes in ECTV. All samples collected from the cat were negative for other pathogens by
the molecular assays used.
Sequence analysis of the HA gene of strain Italy_09/17
showed high nucleotide identity (98%) with that of CPXV
strain Germany (GenBank accession no. HQ420897)
and to feline-derived human poxvirus IT1 (accession no.
EF612709). In addition, strain Italy_09/17 was also highly
related to most of the ECTV strains in GenBank; the highest (97%) nucleotide identity was with ECTV strain Naval
(accession no. KJ563295). Strain Italy_09/17 showed positive results in the ECTV-specific PCR and negative results
in the CPXV-specific PCR (22) (Table 1).
Virus Isolation
Detection of Other Pathogens
We subjected nucleic acids extracted from freshly collected
skin biopsy specimens and serum of the affected cat to a TaqMan assay for detection of canine parvovirus 2/feline panleukopenia virus (28) and to a minor groove binder probe
assay for rapid discrimination between true feline panleukopenia virus strains and antigenic variants of canine parvovirus 2 (29). We also used DNA extracts to detect proviral
DNA of feline immunodeficiency virus (30) and feline leukemia virus (31) and DNA of feline hemoplasmas (32) and
feline herpesvirus (33). We screened RNA extracts by realtime PCR or conventional reverse transcription PCR specific
for carnivore coronaviruses (34) and caliciviruses (33,35).
Results
Histopathologic Analysis
Histopathologic analysis of multiple skin specimens
showed mild hyperplasia of the epidermis and the follicular
1668
Virus isolation from freshly collected skin biopsy specimens was successful with Vero and CV-1 cells. We observed a cytopathic effect at 48 hours postinfection that
showed rounding of cells, increased granularity, and detachment from the monolayer. In Vero cells, a cytopathic
effect was less evident than in CV-1 cells. Cells stained
with hematoxylin and eosin contained large eosinophilic
cytoplasmic inclusion bodies that were compatible with
infection by poxviruses, including CPXV (36) and ECTV
(37) (Figure 2, panel B).
The IIF assay showed granular fluorescence areas that
displayed the morphology of the inclusion bodies in cell
cytoplasms (Figure 2, panel C). Both CV-1 and Vero cells
showed positive IIF assay results, but there was no fluorescence staining in the negative control.
At 48 hours postinoculation on embryonated eggs,
virus produced superficial pocks on the chorioallantoic
membrane. Most of these pocks were small (diameter 1.0
mm), gray, and had central hemorrhages. Few (3%–5%)
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Orthopoxvirus and Lethal Disease in Cat, Italy
Figure 2. Analysis of an
orthopoxvirus isolated from an
infected cat, Italy. A) Cytoplasmic
fluorescence in infected Vero cells
using serum from the diseased
cat (original magnification ×400).
B) Cytoplasmic inclusion bodies
(arrows) in infected Vero cells
(hematoxylin and eosin stain,
original magnification ×400). C)
Pocks (arrows) in the inoculated
chorioallantoic membrane of
a 12-day-old chick embryo.
D) Electron micrograph of
orthopoxvirus-like particle from
infected Vero cells. The virus
preparation was negative-stained
with sodium phosphotungstate
(original magnification ×25,000).
pocks were larger (1.8 mm in diameter), white, and without hemorrhages.
Electron Microscopy
Many typical brick-shaped virions (≈320 × 240 nm) morphologically related to the genus Orthopoxvirus were observed by negative staining and electron microscopy. We
observed these results for skin punch biopsy specimens and
cell culture supernatants.
As in a previous study (15), few particles showed the
characteristic ribbon structure of the M form of vaccinia
virus (38) (Figure 2, panel D), which is usually prevalent in
fresh preparations collected during acute-phase infections.
Most virions were slightly larger, showed a uniform electron density, and had a thick capsule outlined by a ragged
edge (i.e., the morphologic aspect known as the C form),
which are less infective and prevalent during evolution of
a chronic infection.
Serologic Analysis
The infected cat was negative by virus neutralization for
strain Italy_09/17 and reference VACV isolates. However,
Table 1. PCR approach for identification of viruses of the subfamily Chordopoxvirinae*
Amplicon,
Specificity
Target gene
Reference Result
bp
Panchordopoxvirus, low GC
Insulin
(19)
+
220
metalloproteinase-like
protein gene/IMV
membrane protein
gene
Panchordopoxvirus, high GC
Insulin
(19)
ND
ND
metalloproteinase-like
protein gene/IMV
membrane protein
gene
Eurasian/African OPXVs
A-type inclusion
(20)
+
1, 237‡
protein gene
Eurasian/African OPXVs
Hemagglutinin gene
(21)
+
864§
First match by
Nucleotide
Sequence BLAST analysis† identity, %
+
ECTV Naval
100
KJ563295
ND
ND
ND
+
CPXV Germany
91–3 DQ437593
Feline poxvirus
ITA2 FJ445747
ECTV Naval
KJ563295
ND
98
+
ECTV
Hemagglutinin gene
(22)
+
150
+
CPXV
Hemagglutinin gene
(22)
ND
629–677
ND
96
99
ND
*CPXV, cowpox virus: ECTV, ectromelia virus; IMV, intracellular mature virus; ND, not determined; OPXV, orthopoxvirus; +, sequence obtained.
†https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch. GenBank accession numbers are provided.
‡Expected size for CPXV: 1,601 or 1,673 bp; expected size for ECTV: 1,220 bp.
§Expected size for CPXV: 942 bp; expected size for ECTV: 846 bp.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1669
RESEARCH
the IIF assay detected antibody titers of 1:1,280 for virus
Italy_09/17 and 1:640 for VACV-WR.
Identification of a Novel OPXV by NGS
We used 217,236 paired reads for de novo assembling and
obtained 3 contigs (contig one, 195,015 bp; contig two,
21,014 bp; and contig three, 1,596 bp) and a quality score
>99%. The mean coverage of the assembled contigs was 61×.
The 9 open reading frames (A7L, A10L, A24R, D1R, D5R,
E6R, E9L, H4L, and J6R) used for OPXV characterization
were mapped in contig 1, and their sequences (total 27,228
nt) were concatenated and aligned with concatenated cognate sequences of selected OPXVs. In addition, because the
HA gene of 2 feline-derived human virus isolates was available in the sequence databases, we performed an alignment
based on the HA gene. We conducted phylogenetic analysis
on the basis of the 9 concatenated sequences by using Bayesian inference. Posterior probabilities percentages were consistently high (>90%) for all clades on phylograms, which
supported inferred phylogenetic relationships.
Figure 3. Phylogenetic relationship of extant orthopoxviruses with a feline poxvirus isolated from a cat, Italy. Phylogenetic tree
shows 27,228 nt concatenated alignment of 9 coding gene (A7L, A10L, A24R, D1R, D5R, E6R, E9L, H4L, and J6R) sequences of
orthopoxvirus. Gene designations refer to the VACV-COP genome (GenBank accession no. M35027). Posterior output of the tree
was derived from Bayesian inference using 4 chains run for >1 million generations, a general time-reversible model, a proportion of
invariable sites, a gamma distribution of rate variation across sites, and a subsampling frequency of 1,000. Posterior probability values
>0.95 are indicated on the tree nodes. The black arrow indicates the feline poxvirus Italy_09/17 isolated in this study. Raccoonpox virus
strain MD85A was used as an outgroup. Strain name, host and year of detection, location of origin, and GenBank accession numbers for
orthopoxviruses used for phylogeny are shown in Table 2 (https://wwwnc.cdc.gov/EID/article/24/9/17-1283-T2.htm). Scale bar indicates
nucleotide substitutions per site. CMLV, camelpox virus; CPXV, cowpox virus; ECTV, ectromelia virus; MPXV, monkeypox virus; RPXV,
raccoonpox virus; SPXV, skunkpox virus; TATV, taterapox virus; VACV, vaccinia virus; VARV, variola virus; VPXV, volepox virus.
1670
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Orthopoxvirus and Lethal Disease in Cat, Italy
In the consensus phylogenetic tree (Figure 3), we
found that strain Italy_09/17 was distantly related to other
OPXVs, including all 10 CPXV lineages (39) and other
recently identified, deep-branching OPXVs (40,41) and
displayed a closer relatedness with ECTV prototypes, albeit forming a separate cluster. This cluster also included
strain Abatino, which was recently isolated from a poxvirus outbreak in a captive colony of Tonkean macaques in
Italy (42). Nucleotide identity of strain Italy_09/17 with
strain Abatino was 99.66% and identity with reference
ECTVs was 98.11%–98.13%. Higher nucleotide identities
were found among ECTVs (99.97%–99.99%) and between
VARV-Garcia1966 (variola minor) and VARV-India1967
(variola major) (99.68%). Thus, on the basis of current
OPXV criteria of species demarcation, the cat and macaque
isolates should be considered prototypes of a novel OPXV.
Also, for the HA gene, strain Italy_09/17 appeared more
closely related to strain Abatino (99.79% nt identity) than
to feline-derived human OPXV strains (95.83%–95.99% nt
identity) that were identified in Italy in 2009, for which a
full-length genome and concatenated genes used for species demarcation using phylogeny are not available (43).
Discussion
OPXV infection in cats is frequently observed, and OPXV
transmission from cats to humans has been demonstrated
or at least suspected on several occasions (8,11,14,43–
47). Cats are susceptible to CPXV infection, for which
they represent only incidental hosts, as are humans, cattle,
horses, and dogs. The virus is usually transmitted to cats
by hunted rodents; cat-to-cat transmission is apparently
rare (47). In contrast, ECTV has a host range restricted
to laboratory mice, and cat or human infections have not
been reported (6).
Additional OPXVs, such as raccoonpox virus and
skunkpox virus, have been reported in wildlife and infect
carnivores (48). Conversely, cats have been found to be
susceptible to members of the genus Parapoxvirus, raccoonpox virus, and uncharacterized poxviruses (49). There
are >400 reports of OPXV infection in domestic cats, but
the total number of feline cases is considered to be much
greater (5). Despite this large number of reports, genetic
characterization of the detected poxvirus has been achieved
in only a few instances. Thus, circulation in cats of other
OPXVs cannot be ruled out.
We report detection of an OPXV strain that caused a
fatal infection in a cat. The virus was not a classical CPXV,
which is common in felids. Analysis of 9 concatenated
genes showed that the poxvirus detected was only distantly
related to all CPXV lineages currently known and formed
a separate cluster with respect to ECTV, with which it was
strictly related and grouped with an OPXV strain recently
isolated from captive macaques in Italy (42). These 2
viruses had lower genetic identity with ECTV than that
observed with reference ECTVs and between variola minor
virus and variola major virus. Therefore, these ECTVlike poxviruses likely represent a novel OPXV species.
However, the true animal reservoir of this novel OPXV
needs to be assessed, and the idea that wild rodents can act
as carriers for the new virus cannot be ruled out.
If one considers the close relatedness between strain
Italy_09/17 and ECTV, which has been detected only in
laboratory animals, it could be speculated that an ECTV-like virus circulating in wild rodents has resulted in
ECTV strains adapted to laboratory mice. Alternatively,
an ECTV strain might have escaped from laboratory mice
and adapted to wild conditions. In addition, the zoonotic
potential of the feline ECTV-like OPXV deserves an indepth investigation. Feline poxvirus was also related to
an unclassified OPXV, which was detected in a human
in Italy almost 10 years ago and for which only partial
HA gene has been identified (43). Consequently, this feline poxvirus could represent a threat to human health.
Thus, veterinarians and cat breeders and owners should
be aware of this additional risk associated with handling
of cats with skin lesions.
Acknowledgments
We thank Costantina Desario and Carlo Armenise for providing
excellent technical assistance and G. Tekes for providing the
VACV-WR strain and CV-1 cells.
This study was supported by grants from the University of Bari.
About the Author
Dr. Lanave is a postdoctoral fellow in the Department of
Veterinary Medicine, University of Bari, Bari, Italy. His primary
research interest is emerging viruses of animals.
References
1.
Centers for Disease Control and Prevention. Bioterrorism agents/
diseases, 2015 [cited 2015 Nov 18] http://www.bt.cdc.gov/agent/
agentlist-category.asp
2. Reynolds MG, Carroll DS, Karem KL. Factors affecting the
likelihood of monkeypox’s emergence and spread in the
post-smallpox era. Curr Opin Virol. 2012;2:335–43.
http://dx.doi.org/ 10.1016/j.coviro.2012.02.004
3. Hendrickson RC, Wang C, Hatcher EL, Lefkowitz EJ.
Orthopoxvirus genome evolution: the role of gene loss. Viruses.
2010;2:1933–67. http://dx.doi.org/10.3390/v2091933
4. Kinnunen PM, Henttonen H, Hoffmann B, Kallio ER, Korthase C,
Laakkonen J, et al. Orthopox virus infections in Eurasian
wild rodents. Vector Borne Zoonotic Dis. 2011;11:1133–40.
http://dx.doi.org/10.1089/vbz.2010.0170
5. Essbauer S, Pfeffer M, Meyer H. Zoonotic poxviruses.
Vet Microbiol. 2010;140:229–36. http://dx.doi.org/10.1016/
j.vetmic.2009.08.026
6. Esteban DJ, Buller RM. Ectromelia virus: the causative agent
of mousepox. J Gen Virol. 2005;86:2645–59. http://dx.doi.org/
10.1099/vir.0.81090-0
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1671
RESEARCH
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
1672
Osterhaus AD, Teppema JS, Wirahadiredja RM, van Steenis G.
Mousepox in the Netherlands. Lab Anim Sci. 1981;31:704–6.
Vorou RM, Papavassiliou VG, Pierroutsakos IN. Cowpox virus
infection: an emerging health threat. Curr Opin Infect Dis.
2008;21:153–6. http://dx.doi.org/10.1097/QCO.0b013e3282f44c74
Schaudien D, Meyer H, Grunwald D, Janssen H, Wohlsein P.
Concurrent infection of a cat with cowpox virus and feline
parvovirus. J Comp Pathol. 2007;137:151–4. http://dx.doi.org/
10.1016/j.jcpa.2007.05.007
Schöniger S, Chan DL, Hollinshead M, Humm K, Smith GL,
Beard PM. Cowpox virus pneumonia in a domestic cat in Great
Britain. Vet Rec. 2007;160:522–3. http://dx.doi.org/10.1136/
vr.160.15.522
Schulze C, Alex M, Schirrmeier H, Hlinak A, Engelhardt A,
Koschinski B, et al. Generalized fatal Cowpox virus infection
in a cat with transmission to a human contact case. Zoonoses
Public Health. 2007;54:31–7. http://dx.doi.org/10.1111/
j.1863-2378.2007.00995.x
Johnson MS, Martin M, Stone B, Hetzel U, Kipar A. Survival of
a cat with pneumonia due to cowpox virus and feline herpesvirus
infection. J Small Anim Pract. 2009;50:498–502. http://dx.doi.org/
10.1111/j.1748-5827.2009.00784.x
Kaysser P, von Bomhard W, Dobrzykowski L, Meyer H.
Genetic diversity of feline cowpox virus, Germany 2000-2008.
Vet Microbiol. 2010;141:282–8. http://dx.doi.org/10.1016/
j.vetmic.2009.09.029
Herder V, Wohlsein P, Grunwald D, Janssen H, Meyer H,
Kaysser P, et al. Poxvirus infection in a cat with presumptive
human transmission. Vet Dermatol. 2011;22:220–4.
http://dx.doi.org/10.1111/j.1365-3164.2010.00947.x
Canese MG, Lavazza A, Massone A, Galeano F, Boldini M.
Feline poxvirus infection. A case report. Schweiz Arch Tierheilkd.
1997;139:454–7.
Haenssle HA, Kiessling J, Kempf VA, Fuchs T, Neumann C,
Emmert S. Orthopoxvirus infection transmitted by a domestic cat.
J Am Acad Dermatol. 2006;54(Suppl):S1–4. http://dx.doi.org/
10.1016/j.jaad.2005.09.040
Schiavi S, Vercelli A, Abtamo FU. A case of viral poxvirus
dermatitis in a cat [in Italian]. Presented at the Congress of
the Italian Society of Veterinary Dermatology; March 11, 2007;
Cremona, Italy.
Appl C, von Bomhard W, Hanczaruk M, Meyer H, Bettenay S,
Mueller R. Feline cowpoxvirus infections in Germany: clinical
and epidemiological aspects. Berl Munch Tierarztl Wochenschr.
2013;126:55–61.
Li Y, Meyer H, Zhao H, Damon IK. GC content-based pan-pox
universal PCR assays for poxvirus detection. J Clin Microbiol.
2010;48:268–76. http://dx.doi.org/10.1128/JCM.01697-09
Meyer H, Ropp SL, Esposito JJ. Gene for A-type inclusion body
protein is useful for a polymerase chain reaction assay to
differentiate orthopoxviruses. J Virol Methods. 1997;64:217–21.
http://dx.doi.org/10.1016/S0166-0934(96)02155-6
Ropp SL, Jin Q, Knight JC, Massung RF, Esposito JJ.
Polymerase chain reaction strategy for identification and
differentiation of smallpox and other orthopoxviruses.
J Clin Microbiol. 1995;33:2069–76.
Meyer H, Damon IK, Esposito JJ. Orthopoxvirus diagnostics.
Methods Mol Biol. 2004;269:119–34.
Andrews S. FastQC: a quality control tool for high
throughput sequence data, 2010 [cited 2018 May 15].
http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/
Emerson GL, Li Y, Frace MA, Olsen-Rasmussen MA,
Khristova ML, Govil D, et al. The phylogenetics and ecology
of the orthopoxviruses endemic to North America. PLoS One.
2009;4:e7666. http://dx.doi.org/10.1371/journal.pone.0007666
Katoh K, Misawa K, Kuma K, Miyata T. MAFFT: a novel
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
method for rapid multiple sequence alignment based on
fast Fourier transform. Nucleic Acids Res. 2002;30:3059–66.
http://dx.doi.org/10.1093/nar/gkf436
Huelsenbeck JP, Ronquist F. MRBAYES: Bayesian
inference of phylogenetic trees. Bioinformatics. 2001;17:754–5.
http://dx.doi.org/10.1093/bioinformatics/17.8.754
Ronquist F, Huelsenbeck JP. MrBayes 3: Bayesian phylogenetic
inference under mixed models. Bioinformatics. 2003;19:1572–4.
http://dx.doi.org/10.1093/bioinformatics/btg180
Decaro N, Elia G, Martella V, Desario C, Campolo M,
Trani LD, et al. A real-time PCR assay for rapid detection and
quantitation of canine parvovirus type 2 in the feces of dogs.
Vet Microbiol. 2005;105:19–28. http://dx.doi.org/10.1016/
j.vetmic.2004.09.018
Decaro N, Desario C, Lucente MS, Amorisco F, Campolo M,
Elia G, et al. Specific identification of feline panleukopenia virus
and its rapid differentiation from canine parvoviruses using minor
groove binder probes. J Virol Methods. 2008;147:67–71.
http://dx.doi.org/10.1016/j.jviromet.2007.08.006
Stiles J, Bienzle D, Render JA, Buyukmihci NC, Johnson EC.
Use of nested polymerase chain reaction (PCR) for detection
of retroviruses from formalin-fixed, paraffin-embedded uveal
melanomas in cats. Vet Ophthalmol. 1999;2:113–6.
http://dx.doi.org/10.1046/j.1463-5224.1999.00066.x
Quackenbush SL, Dean GA, Mullins JI, Hoover EA. Analysis
of FeLV-FAIDS provirus burden and productive infection
in lymphocyte subsets in vivo. Virology. 1996;223:1–9.
http://dx.doi.org/10.1006/viro.1996.0449
Tasker S, Binns SH, Day MJ, Gruffydd-Jones TJ, Harbour DA,
Helps CR, et al. Use of a PCR assay to assess the prevalence and
risk factors for Mycoplasma haemofelis and ‘Candidatus
Mycoplasma haemominutum’ in cats in the United Kingdom.
Vet Rec. 2003;152:193–8. http://dx.doi.org/10.1136/vr.152.7.193
Di Martino B, Di Francesco CE, Meridiani I, Marsilio F.
Etiological investigation of multiple respiratory infections in cats.
New Microbiol. 2007;30:455–61.
Gut M, Leutenegger CM, Huder JB, Pedersen NC, Lutz H.
One-tube fluorogenic reverse transcription-polymerase chain
reaction for the quantitation of feline coronaviruses. J Virol
Methods. 1999;77:37–46. http://dx.doi.org/10.1016/
S0166-0934(98)00129-3
Jiang X, Huang PW, Zhong WM, Farkas T, Cubitt DW, Matson DO.
Design and evaluation of a primer pair that detects both Norwalkand Sapporo-like caliciviruses by RT-PCR. J Virol Methods.
1999;83:145–54. http://dx.doi.org/10.1016/S0166-0934(99)00114-7
Downie AW. A study of the lesions produced experimentally
by cowpox virus. J Pathol Bacteriol. 1939;48:361–79.
http://dx.doi.org/10.1002/path.1700480212
Barnard JE, Elford WJ. The causative organism in infectious
ectromelia. Proceedings of the Royal Society, Series B.
1931;109:360–80. http://dx.doi.org/10.1098/rspb.1931.0088
Westwood JC, Harris WJ, Zwartouw HT, Titmuss DH,
Appleyard G. Studies on the structure of vaccinia virus.
J Gen Microbiol. 1964;34:67–78. http://dx.doi.org/10.1099/
00221287-34-1-67
Mauldin MR, Antwerpen M, Emerson GL, Li Y, Zoeller G,
Carroll DS, et al. Cowpox virus: what’s in a name? Viruses.
2017;9:E101. http://dx.doi.org/10.3390/v9050101
Springer YP, Hsu CH, Werle ZR, Olson LE, Cooper MP,
Castrodale LJ, et al. Novel orthopoxvirus infection in an Alaska
resident. Clin Infect Dis. 2017;64:1737–41. http://dx.doi.org/
10.1093/cid/cix219
Vora NM, Li Y, Geleishvili M, Emerson GL, Khmaladze E,
Maghlakelidze G, et al. Human infection with a zoonotic
orthopoxvirus in the country of Georgia. N Engl J Med.
2015;372:1223–30. http://dx.doi.org/10.1056/NEJMoa1407647
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Orthopoxvirus and Lethal Disease in Cat, Italy
42.
Cardeti G, Gruber CEM, Eleni C, Carletti F, Castilletti C,
Manna G, et al. Fatal outbreak in Tonkean macaques
caused by possibly novel orthopoxvirus, Italy, January 2015.
Emerg Infect Dis. 2017;23:1941–9. http://dx.doi.org/10.3201/
eid2312.162098
43. Carletti F, Bordi L, Castilletti C, Di Caro A, Falasca L, Gioia C,
et al. Cat-to-human orthopoxvirus transmission, northeastern Italy.
Emerg Infect Dis. 2009;15:499–500. http://dx.doi.org/10.3201/
eid1503.080813
44. Eis-Hübinger AM, Gerritzen A, Schneweis KE, Pfeiff B,
Pullmann H, Mayr A, et al. Fatal cowpox-like virus infection
transmitted by cat. Lancet. 1990;336:880. http://dx.doi.org/
10.1016/0140-6736(90)92387-W
45. Schupp P, Pfeffer M, Meyer H, Burck G, Kölmel K,
Neumann C. Cowpox virus in a 12-year-old boy: rapid
identification by an orthopoxvirus-specific polymerase chain
reaction. Br J Dermatol. 2001;145:146–50. http://dx.doi.org/
10.1046/j.1365-2133.2001.04300.x
EID
journal
46.
47.
48.
49.
Hawranek T, Tritscher M, Muss WH, Jecel J, Nowotny N,
Kolodziejek J, et al. Feline orthopoxvirus infection transmitted
from cat to human. J Am Acad Dermatol. 2003;49:513–8.
http://dx.doi.org/10.1067/S0190-9622(03)00762-X
Świtaj K, Kajfasz P, Kurth A, Nitsche A. Cowpox after a cat
scratch: case report from Poland. Ann Agric Environ Med.
2015;22:456–8. http://dx.doi.org/10.5604/12321966.1167713
International Committee on Taxonomy of Viruses. Virus taxonomy:
2016 release, 2017 [cited 2018 May 15]. https://talk.ictvonline.org/
taxonomy/
Greene CE. Poxvirus infections. In: Greene CE, editor. Infectious
diseases of the dog and cat. 4th ed. St. Louis: Saunders Elsevier;
2006. p. 166–9.
Address for correspondence: Nicola Decaro, Department of Veterinary
Medicine, University of Bari, Strada Provinciale per Casamassima Km 3,
70010 Valenzano, Bari, Italy; email: nicola.decaro@uniba.it.
@CDC_ EIDj our nal
Follow the EID journal on Twitter and
get the most current information
from Emerging Infectious Diseases.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1673
RESEARCH
Em e r ge n ce of Ca r ba pe n e m a se Pr odu cin g Enterobacteriaceae,
Sou t h - Ce n t r a l On t a r io, Ca n a da 1
Philipp P. Kohler,2 Roberto G. Melano, Samir N. Patel, Shumona Shafinaz, Amna Faheem,
Brenda L. Coleman, Karen Green, Irene Armstrong, Huda Almohri, Sergio Borgia,
Emily Borgundvaag, Jennie Johnstone, Kevin Katz, Freda Lam, Matthew P. Muller, Jeff Powis,
Susan M. Poutanen, David Richardson, Anu Rebbapragada, Alicia Sarabia, Andrew Simor,
Allison McGeer, for the Toronto Invasive Bacterial Diseases Network (TIBDN)3
We analyzed population-based surveillance data from the
Toronto Invasive Bacterial Diseases Network to describe
carbapenemase-producing Enterobacteriaceae (CPE) infections during 2007–2015 in south-central Ontario, Canada. We reviewed patients’ medical records and travel histories, analyzed microbiologic and clinical characteristics of
CPE infections, and calculated incidence. Among 291 cases
identified, New Delhi metallo-β-lactamase was the predominant carbapenemase (51%). The proportion of CPE-positive patients with prior admission to a hospital in Canada
who had not received healthcare abroad or traveled to highrisk areas was 13% for patients with oxacillinase-48, 24%
for patients with New Delhi metallo-β-lactamase, 55% for
patients with Klebsiella pneumoniae carbapenemase, and
67% for patients with Verona integron-encoded metallo-βlactamase. Incidence of CPE infection increased, reaching
0.33 cases/100,000 population in 2015. For a substantial
proportion of patients, no healthcare abroad or high-risk
Author affiliations: Sinai Health System, Toronto, Ontario, Canada
(P.P. Kohler, S. Shafinaz, A. Faheem, B.L. Coleman, K. Green,
E. Borgundvaag, S.M. Poutanen, A. McGeer); Public Health
Ontario Laboratories, Toronto (R.G. Melano, S.N. Patel);
University of Toronto, Toronto (R.G. Melano, S.N. Patel,
B.L. Coleman, I. Armstrong, J. Johnstone, K. Katz, M.P. Muller,
J. Powis, S.M. Poutanen, A. Sarabia, A. Simor, A. McGeer);
Toronto Public Health, Toronto (I. Armstrong); LifeLabs, Toronto
(H. Almohri); McMaster University, Hamilton, Ontario, Canada
(S. Borgia); William Osler Health System, Brampton, Ontario,
Canada (S. Borgia, D. Richardson); St. Joseph’s Health Centre,
Toronto (J. Johnstone); Public Health Ontario, Toronto
(J. Johnstone, K. Katz, F. Lam); North York General Hospital,
Toronto (K. Katz); St. Michael’s Hospital, Toronto (M.P. Muller);
Toronto East Health Network, Toronto (J. Powis); University
Health Network, Toronto (S.M. Poutanen); Dynacare, Brampton
(A. Rebbapragada); Trillium Health Partners, Toronto and
Mississauga, Ontario, Canada (A. Sarabia); Sunnybrook Health
Sciences Centre, Toronto (A. Simor)
DOI: https://doi.org/10.3201/eid2409.180164
1674
travel could be established, suggesting CPE acquisition in
Canada. Policy and practice changes are needed to mitigate nosocomial CPE transmission in hospitals in Canada.
T
he global emergence of carbapenemase-producing
Enterobacteriaceae (CPE) poses a threat to the
achievements of modern medicine. The Centers for Disease Control and Prevention and the World Health Organization have recently classified CPE as one of the most
urgent antimicrobial-resistance threats (1,2). CPE rarely
arise de novo; rather, colonization and infection occur as
a result of transmission of organisms, plasmids, or transposons from person to person, with such transmission
occurring predominantly in healthcare institutions. An
understanding of the epidemiology of the emergence of
CPE and the changing burden over time is critical to the
implementation of control programs and the management
of individual patients.
In Canada, CPE were first reported in 2008 and
have until recently been limited to individual cases and
small outbreaks (3–8). Laboratory surveillance suggests
substantial geographic variability, with Klebsiella pneumoniae carbapenemase (KPC) predominating in Quebec,
whereas New Delhi metallo-β-lactamase (NDM) is most
frequent in British Columbia (9,10). Nationally, time
trends for CPE are discrepant; data from Canada’s Nosocomial Infection Surveillance Program suggest stable
CPE numbers in recent years, but data from voluntary
laboratory reporting indicate a clear increase (11–13). To
avoid the limitations of these surveillance systems and to
better assess changes in disease burden and epidemiology
in Ontario, we analyzed data from population-based surveillance for CPE.
Preliminary results from this study were presented at IDWeek,
October 26–30, 2016, New Orleans, Louisiana, USA.
1
2
Current affiliation: Cantonal Hospital, St. Gallen, Switzerland.
3
Additional members are listed at the end of this article.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Emergence of CPE, South-Central Ontario, Canada
Methods
Setting
Metropolitan Toronto (Toronto) and the Regional Municipality of Peel (Peel) are adjacent municipalities in southcentral Ontario, Canada; the 2016 populations were 2.7
million for Toronto and 1.4 million for Peel (14,15). The
Toronto Invasive Bacterial Diseases Network (TIBDN)
is a collaborative network of microbiology laboratories,
infection-control practitioners, and public health departments that performs population-based surveillance for infectious diseases in Toronto and Peel. TIBDN laboratories
provide service to all hospitals and >87% of long-term
care homes and physician offices serving area residents.
Among TIBDN hospitals, 13% (3/23) perform admission
screening for CPE colonization for all previously hospitalized patients, and an additional 65% (15/23) screen
only if patients have been hospitalized outside of Canada
(A. Jamal, Sinai Health System, unpub. data, 2018).
Data Sources
In Ontario, cases and clusters of CPE were first reported in
2008 (16). In 2011, guidelines for laboratory identification
of CPE were published, and voluntary reporting to Public
Health Ontario was initiated. In July 2014, TIBDN started
active, population-based surveillance for laboratory-confirmed episodes of colonization or infection attributable to
CPE. To identify CPE-colonized or -infected patients before
July 2014, TIBDN laboratories and infection prevention and
control programs accessed data from voluntary surveillance,
searched microbiology laboratory databases for meropenemnonsusceptible Enterobacteriaceae, reviewed hospital infection control department line lists and databases, and analyzed data from annual antimicrobial resistance reports from
the Ontario Institute for Quality Management in Healthcare
(IQMH). In addition, all isolates submitted for confirmatory
testing to the Public Health Ontario Laboratory (PHOL),
Canada’s National Microbiology Laboratory (NML), and
the Canadian Nosocomial Infection Surveillance Program
were identified. During active surveillance, each newly identified case in TIBDN laboratories was reported to the central
study office, with annual audits of participating and reference
laboratories conducted to ensure complete case identification
(17). Patient information was reviewed for each isolate to
ensure that patients were counted only once.
Laboratory Identification of CPE
All 18 TIBDN laboratories are accredited by IQMH and
follow IQMH recommendations for CPE identification, which
include screening of all clinical isolates with an ertapenem MIC
>1 mg/L or a meropenem disc diffusion diameter <25 mm.
Before 2010, laboratories (including PHOL) used the modified
Hodge test for screening; during 2010–2015, laboratories
either sent all such isolates to PHOL for confirmation (n
= 7) or screened with the modified Hodge test (n = 1), the
ROSCO KPC + MBL confirm ID KIT (Rosco Diagnostica,
Taastrup, Denmark) (n = 9), or by direct in-house PCR (n =
1) (18). All isolates with a positive screen in all years were
tested by PCR for the presence of blaKPC, blaOXA-48–like,
blaVIM, blaNDM, blaIMP, and blaSME genes at either PHOL (16
laboratories) (19) or NML (2 laboratories) (20).
For laboratory specimens yielding CPE, we recorded
date of collection, body site, bacterial species, carbapenemase gene (or genes), reason for collection (i.e., screening
versus clinical), and results of susceptibility testing. We used
the first isolate from each patient to describe the distribution of bacterial species and carbapenemases. We reviewed
charts associated with all isolates to identify CPE infections.
Data Collection and Definitions
We collected data by performing chart review for all patients. We approached patients first identified on or after
January 1, 2013, to obtain consent, and we collected additional data by conducting interviews with patients or
with next of kin if the patient was deceased or otherwise
not able to provide information. We used a standard case
report form to extract data from hospital or office charts
from the admission or outpatient visit during which CPE
was first identified and for any TIBDN hospital admissions
in the prior year. We recorded demographic information,
postal code of residence, co-occuring conditions (including
Charlson index score) (21), antimicrobial drug use, protonpump and immunosuppressive therapies, surgeries, intensive care unit admissions, and medical interventions.
We collected dates, hospital names, country, and reason for consultation for healthcare contacts within and
outside of Canada in the year before the culture that identified each patient as being CPE colonized or infected. We
obtained travel history within 1 year before CPE detection
from patient interviews conducted by study staff or infection control practitioners. We defined high-risk travel as
travel to the Indian subcontinent (India, Sri Lanka, Bangladesh, Pakistan, and Afghanistan) (22,23).
For bacteremia, a positive blood culture result sufficed
for the diagnosis of infection. For all other culture sites,
we defined infection as the presence of a positive clinical
culture, a chart-documented physician diagnosis, and the
initiation of targeted antimicrobial therapy. We calculated
the 30-day mortality rate starting from the date the relevant
clinical culture was obtained.
Statistical Analysis
We used
NC) for
variables
variables
SAS University Edition (SAS Institute, Cary,
statistical analyses. We reported categorical
as frequencies and proportions and continuous
as median with interquartile range. We used
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1675
RESEARCH
χ2 or Fisher exact test, as appropriate, for comparison of
dichotomous variables. For continuous variables, we
used the Mann-Whitney U or Kruskal-Wallis test. We
used the Benjamini and Hochberg procedure, with a false
discovery rate of <0.05, to correct for multiple comparisons (24). We calculated incidence of CPE infection and
bacteremia by using the first CPE infection or bacteremia from each resident of Toronto and Peel, on the basis
of population estimates from Statistics Canada (25). We
performed Poisson regression to assess time trends for all
CPE infections, bloodstream infections, and sterile sites
or urine isolates (26). We considered p values <0.05 statistically significant.
Results
Incidence and Outcome of CPE Infections
We identified 291 residents of Toronto or Peel who
were colonized or infected with CPE during October
2007–December 2015. Charts were not available for 21
patients, and 12 patients declined consent. Among the
remaining 258 patients, median age was 70 years (range
3 months–95 years), and 65% were male. Overall, 149
(58%) patients had >1 clinical isolate, and 92 (36%) had
an infection caused by CPE. Urinary tract infections (n
= 75 [82%]) were most common, followed by pneumonia and primary bacteremia (n = 13 [14%] each) (Table
1). Thirty-day mortality was 16% (15/92) for all infected
patients and 31% (9/29) for patients with primary (5/13)
or secondary (4/16) bacteremia.
The incidence of all CPE infections increased
from 0 before 2007 to 0.33 cases/100,000 population
in 2015 (p<0.0001); incidence of CPE bloodstream infections (primary and secondary) increased from zero
before 2007 to 0.19 cases/100,000 population in 2015
(p = 0.045) (Figure 1). For patients with >1 sterile
site (i.e., blood, pleural or peritoneal space, or bone)
or urine isolate, the incidence in 2015 was 0.52 cases/
100,000 population.
Patient Factors Associated with CPE Acquisition
In the year before CPE identification, 67% of patients
had received antimicrobial drugs, 35% had undergone >1
surgical procedure, and 30% had had an intensive care
unit admission. Overall, 71% (183/258) of CPE infections
were categorized as hospital acquired (27). Risk profiles
differed somewhat between patients with different carbapenemases (Table 2).
Travel history was available for 238 patients (92%
of patients for whom clinical data were available);
information was collected through patient interviews
by study staff for 93 patients (39%) and from infection
prevention and control staff for 145 patients (61%).
A total of 142 patients (60%) had received healthcare
abroad (n = 111) or reported travel to high-risk countries
without a healthcare encounter (n = 31). Among these
Table 1. Isolate source and infection type among patients colonized or infected with carbapenemase-producing Enterobacteriaceae,
Metropolitan Toronto and the Regional Municipality of Peel, south-central Ontario, Canada, 2007–2015*
No. (%)
All patients,
Escherichia
Klebsiella
Enterobacter
n = 258
coli, n = 86
pneumoniae, n = 122
spp., n = 30
Characteristic
Other,† n = 20
Isolate source‡
Only screening
115 (45)
58 (67)
47 (39)
6 (20)
4 (20)
>1 clinical
149 (58)
30 (35)
79 (65)
24 (80)
16 (80)
Positive specimen types at first identification§
Rectal or colostomy
138 (54)
61 (71)
64 (53)
9 (30)
4 (20)
Urine
89 (35)
19 (22)
52 (43)
11 (37)
7 (35)
Blood
21 (8)
4 (5)
9 (7)
3 (10)
5 (25)
Wound
15 (6)
2 (2)
10 (8)
1 (3.3)
2 (10)
Sputum or broncoalveolar lavage
12 (5)
1 (1)
6 (5)
3 (10)
2 (10)
Other
17 (7)
4 (5)
5 (4)
6 (20)
2 (10)
Infection‡
Any
92 (36)
21¶ (24)
46 (38)
13 (43)
12 (60)
Urinary tract
75 (29)
19 (22)
46 (38)
6 (20)
4 (20)
Pneumonia
13 (5)
4 (5)
3 (3)
4 (13)
2 (10)
Other#
13 (5)
3 (4)
5 (4)
3 (10)
2 (15)
Primary bacteremia**
13 (5)
2 (2)
4 (3)
2 (7)
1 (5)
*Among first patient isolates; sums of specimen types exceed the number of patients because >1 specimen type may have yielded carbapenemaseproducing Enterobacteriaceae.
†Citrobacter spp. (n = 7), Morganella morganii (n = 4), Serratia marcescens (n = 4), Klebsiella oxytoca (n = 3), Providencia rettgeri (n = 1), Proteus
mirabilis (n = 1).
‡Including all follow-up isolates available and all infections during the patients' hospitalization.
§Including isolates from all specimens obtained within 2 days of the first positive specimen.
¶One patient originally colonized with a carbapenemase-producing E. coli subsequently experienced an infection with a carbapenemase-producing
Enterobacter cloacae.
#Includes 7 skin or soft tissue infections, 5 bone or joint infections, and 1 abdominal infection.
**Patients with secondary bacteremia were classified according to their primary source of infection (urinary tract [n = 12] and pneumonia [n = 6]). Two
bacteremic patients had both urinary tract infection and pneumonia diagnosed.
1676
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Emergence of CPE, South-Central Ontario, Canada
Microbiology
Overall, NDM was the most common carbapenemase
(148/291 isolates [51%]), followed by KPC (72/291 isolates [25%]). NDM was most commonly found in Escherichia coli (69/148 isolates [47%]) and K. pneumoniae
(60/148 isolates [41%]), whereas KPC was found predominantly in K. pneumoniae (44/72 isolates [61%]). The type
of carbapenemases varied considerably over time and between Toronto and Peel (Figure 3).
Fourteen percent (12/86) of tested isolates were susceptible to nitrofurantoin, 14% (18/131) to ciprofloxacin, 25%
(36/142) to trimethoprim/sulfamethoxazole, 30% (43/142)
to gentamicin, 52% (15/29) to tigecycline, and 88% (15/17)
to colistin. Isolates containing NDM genes were less susceptible to all antimicrobial drugs than isolates with other
carbapenemase genes (online Technical Appendix, https://
wwwnc.cdc.gov/EID/article/24/9/18-0164-Techapp1.pdf).
Figure 1. Incidence of all carbapenemase-producing
enterobacterial infections per 100,000 inhabitants, 2007–2015 (A),
and bloodstream infections per 100,000 inhabitants, 2010–2015
(B), calculated by using a Poisson regression model, Metropolitan
Toronto and the Regional Municipality of Peel, south-central
Ontario, Canada, 2007–2015. Shading indicates 95% CI.
patients, 95/97 (97%) with NDM-producing isolates and
14/19 (74%) with oxacillinase 48 (OXA-48)–producing
isolates reported travel to the Indian subcontinent with
or without a healthcare encounter. In contrast, 15 (68%)
of 22 patients with KPC-producing isolates had received
healthcare in the United States or southern Europe, and
2 of 3 patients with Verona integron-encoded metallo-βlactamase (VIM)–producing isolates had been admitted to
hospitals in Croatia (n = 1) and Portugal (n = 1).
The proportion of CPE-positive patients with prior
admission to a hospital in Canada who had not received
healthcare abroad or traveled to high-risk areas was 13%
for patients with OXA-48, 24% for patients with NDM,
55% for patients with KPC, and 67% for patients with
VIM (p = 0.001). Of the 17 patients without healthcare
encounters in Ontario or elsewhere (i.e., patients with
presumptive community-acquired CPE), 9 (8 with NDM
and 1 with OXA-48) reported high-risk travel in the year
before CPE identification. Of an additional 8 patients
(4 with OXA-48 and 1 each with NDM, KPC, Serratia
marcescens enzyme, and VIM), 4 had detailed interviews
conducted by study staff and reported neither healthcare
exposure nor high-risk travel (Figure 2).
Discussion
Since the first detection of CPE in Ontario in 2007, the incidence of CPE infections has been increasing steadily. Most
patients with CPE had a recent history of healthcare abroad
or travel to high-risk countries; NDM and OXA-48 producers were associated with travel in the Indian subcontinent
and KPC producers with healthcare encounters in the United States and Mediterranean countries (22,23). However, a
notable proportion of CPE patients had received healthcare
in Canada but had no history of healthcare or travel abroad,
suggesting that CPE transmission is occurring in Canada.
The small number of patients without a history of healthcare abroad or high-risk travel might represent community
acquisition in Canada but might also have resulted from
travel or healthcare encounters that occurred >1 year before
CPE detection.
Measuring population-based incidence is key to understanding the burden of disease and prioritizing public
health interventions; however, population-based surveillance for CPE is complex and has rarely been performed.
A non–population-based US study using 2012–2013 data
estimated that the population incidence of CPE from urine
or sterile sites combined was 1.4 cases/100,000 population
(26). In our study, the incidence of urine or sterile site CPE
isolates was 0.5 cases/100,000 population for 2015, which
is ≈40% of the overall US CPE incidence and higher than
the incidence in Oregon or New Mexico. Comparing this
incidence in Canada with incidence elsewhere in the world
is difficult because of the lack of published data; nevertheless, our data emphasize the steady increase and the geographic variability in CPE occurrence.
In immediately adjacent urban areas in south-central
Ontario, substantial differences exist in the incidence and
epidemiology of CPE infection. The higher incidence of
NDM producers in Peel is probably associated with the
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1677
RESEARCH
Table 2. Characteristics of patients with carbapenemase-producing Enterobacteriaceae infections, by type of carbapenemase,
Metropolitan Toronto and the Regional Municipality of Peel, south-central Ontario, Canada, 2007–2015*
All patients,
NDM,
KPC,
OXA-48,
VIM,
n = 258†
n = 145
n = 64
n = 32
n = 12
Patient characteristics and risk profile
p value‡
Sex
M
168 (65)
94 (65)
37 (58)
25 (78)
8 (67)
0.32
F
90 (35)
51 (35)
27 (42)
7 (22)
4 (33)
Age, y, median (IQR‡)
70 (57–79) 70 (59–79) 70 (50–79) 70 (52–77) 77 (65–88)
0.37
Charlson index score >2§
88 (34)
47 (32)
25 (39)
7 (22)
7 (58)
0.15
Inpatient at time of diagnosis
233 (90)
129 (89)
58 (91)
29 (91)
12 (100)
0.85
0.03
Days from admission to diagnosis, median (IQR)¶
2.5 (0–21)
0 (0–11)
14 (0–41)
0 (0–11)
19 (5–67)
CPE acquisition according to SHEA definitions#
Hospital acquired, hospital onset
113 (44)
55 (38)
35 (55)
12 (38)
8 (67)
0.10
Hospital acquired, community onset
70 (27)
41 (28)
21 (33)
4 (13)
3 (25)
0.24
0.024
Undetermined
58 (23)
40 (28)
7 (11)
11 (34)
0
Community acquired
17 (7)
9 (6)
1 (2)
5 (16)
1 (8)
0.12
0.018
Residing in long-term care facility
9 (4)
2 (2)
4 (7)
0
3 (25)
0.0012
Healthcare abroad or high-risk travel**
142/238 (60) 98/135 (73) 22/59 (37)
19/27 (70) 3/12 (25)
Exposures and medical interventions††
Intensive care stay
78 (30)
39 (27)
26 (41)
6 (19)
5 (42)
0.13
Mechanical ventilation
52 (20)
24 (17)
20 (31)
3 (9)
3 (25)
0.11
0.0012
Previous surgery
91 (35)
29 (20)
41 (64)
13 (41)
4 (33)
0.03
Central venous catheter
86 (33)
41 (28)
32 (50)
9 (28)
2 (17)
0.03
Antibiotic exposure, any
173 (67)
92 (64)
51 (80)
16 (50)
10 (83)
3rd- and 4th-generation cephalosporins
74 (29)
40 (28)
18 (28)
7 (22)
7 (58)
0.16
Carbapenems
33 (13)
14 (10)
12 (19)
3 (9)
3 (25)
0.17
Quinolones
81 (31)
41 (28)
26 (41)
6 (19)
7 (58)
0.05
*Values are no. (%) except as indicated. All characteristics and risk profile descriptors apply to the 1-year period preceding CPE detection. CPE,
carbapenemase-producing Enterobacteriaceae; IQR, interquartile range; KPC, Klebsiella pneumoniae carbapenemase; NDM, New Delhi metalloβ-lactamase; OXA-48, oxacillinase 48; SHEA, Society for Healthcare Epidemiology of America; VIM, Verona integron-encoded metallo-β-lactamase.
†Three patients with Serratia marcescens enzyme and 2 with non–metallo-carbapenemase are not listed separately.
‡p values corrected for multiple testing with the Hochberg and Benjamini procedure. Bold type indicates statistical significance (p<0.05).
§No significant differences observed for any comorbid conditions.
¶Only patients included where first isolate is a clinical sample (n = 126).
#Defined as hospital acquired if hospital admission occurred within 90 days before CPE detection.
**High-risk countries and the Indian subcontinent. Denominators indicate no. patients with travel information available.
††Not listed because of nonsignificance: bronchoscopy, cystoscopy, dialysis, Foley catheter, urostomy, colostomy, tracheostomy, blood transfusion,
proton-pump inhibitors, steroids, chemotherapy, immunosuppression, previously identified antibiotic-resistant pathogens (e.g., methicillin-resistant
Staphylococcus aureus and extended-spectrum β-lactamase).
fact that ≈28% of the local population is of South Asian
descent compared with ≈12% in Toronto (14,15). Our
finding that 51% of NDM carriers had healthcare encounters and an additional 21% reported travel to the Indian
subcontinent supports the hypothesis that NDM is often
introduced from these highly endemic countries. In contrast, patients with KPC and VIM producers more often
do not have a history of high-risk travel or healthcare
abroad, suggesting that CPE was acquired in hospitals in
Canada. The facts that 1) KPC and VIM most commonly
occurred in species associated with hospital-acquired infections (K. pneumoniae and Enterobacter spp.) whereas
E. coli, the main cause of community-acquired enterobacterial infections, almost exclusively harbored NDM and
OXA-48; 2) clinical isolates producing KPC or VIM were
detected later in the course of hospitalization; and 3) most
patients with KPC producers had had previous surgery or
a central venous catheter, are consistent with other studies
and with these isolates having been acquired during hospital admission (28,29). Similarly, in a Germany study, a
higher proportion of patients with OXA-48 had traveled
before CPE detection compared with patients with VIM,
suggesting nosocomial acquisition of VIM producers
1678
(30). In a multicenter study conducted in 34 hospitals in
Spain, VIM producers were also more likely to be hospital acquired than OXA-48 producers (31).
The fact that most CPE in our study population appear to be acquired in healthcare settings strongly suggests
that intensification of control programs in this population
is needed if we wish to protect patients from the impacts
of CPE (32,33). Although the cost of control programs is a
concern, the relatively low incidence of CPE in our population should be an incentive to implement such programs;
control programs have been shown to be cost-effective in
low-prevalence areas (34,35), and success in transmission
control programs is more likely when they are implemented
while prevalence of colonization is low (33). Our data are
consistent with a recent assessment of CPE transmission in
England; although we might perceive that large problems
in India pose the greatest risk, the much larger number of
our patients exposed to a smaller problem in Ontario likely
poses the greater risk to our patient population (36).
Relative to isolates from other countries, CPE isolates in Toronto and Peel are more susceptible to commonly used antimicrobial drugs (37). Nonetheless, most
isolates are resistant to all commonly used orally available
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Emergence of CPE, South-Central Ontario, Canada
Figure 2. Healthcare visits abroad and travel history in patients with carbapenemase-producing Enterobacteriaceae infection in the 1 year
before detection, stratified by type of carbapenemase, Metropolitan Toronto and the Regional Municipality of Peel, south-central Ontario,
Canada, 2007–2015. Patients who traveled to any location other than the Indian subcontinent were classified as low-risk travel and
indicated as no high-risk travel in the graph. n values indicate number of patients. KPC, Klebsiella pneumoniae carbapenemase; NDM,
New Delhi metallo-β-lactamase; OXA-48, oxacillinase 48; VIM, Verona integron-encoded metallo-β-lactamase.
antimicrobial drugs, and choices for parenteral therapy
are limited. These concerns emphasize the need for the
continued development of new antimicrobial drugs active
against these resistant organisms.
Our study has several limitations. Although laboratory
testing in Ontario is standardized, the modified Hodge test,
the only screening test available before 2011, might have
missed a small number of CPE during this period. However, PCR screening of all meropenem-nonsusceptible
Enterobacteriaceae isolates from 4 TIBDN teaching hospitals during 2009–2011 at NML identified only a single
additional CPE. Further, the increase in CPE infection incidence during 2010–2015 remains statistically significant.
Because most TIBDN hospitals screen only patients who
have accessed healthcare outside of Canada, our data on
colonization will be biased toward the identification of
CPE in these populations. This bias will underestimate the
number of patients with colonization acquired in Canada.
Similarly, our surveillance system detects only laboratoryconfirmed infections, and infections for which cultures are
not obtained will have been missed. This misclassification
error might be lower for CPE than other organisms because
resistance by CPE means that they might fail empiric therapy. We used a definition of high-risk countries for travel
and healthcare currently used in Ontario hospitals (A. Jamal, Sinai Health System, unpub. data, 2018), but surveillance data are not available for many countries to validate
this definition. In addition, we asked only about travel in
the preceding year, and some infection control departments
might only have asked about high-risk travel. We do not
have molecular typing data for all isolates, which limits our
ability to detect transmission within Canada. Similarly, we
do not have data regarding the investigation of transmission or environmental reservoirs at individual hospitals.
Although we have corrected for multiple comparisons, particular caution should be used in interpreting the statistical
significance of comparisons with p values close to 0.05. We
did not identify endoscopy as a risk factor for acquisition of
CPE; however, our power to do so might have been limited,
and exposure to outpatient endoscopy might not have been
captured in patients with data from chart review only.
In conclusion, the incidence of CPE infection is increasing in south-central Ontario. Our data suggest that,
even early on in the emergence of CPE, a substantial
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1679
RESEARCH
Figure 3. Distribution of
carbapenemases in 291 first
isolates of carbapenemaseproducing Enterobacteriaceae,
by enterobacterial species (A)
and region (B), Metropolitan
Toronto and the Regional
Municipality of Peel, south-central
Ontario, Canada, 2007–2015.
Other enterobacterial species
were Serratia marcescens (n
= 4), Klebsiella oxytoca (n =
3), Providencia rettgeri (n = 1),
and Proteus mirabilis (n =1).
Other carbapenemases or coproductions were NDM–OXA48 (n = 2) and S. marcescens
enzyme (n = 1). KPC, Klebsiella
pneumoniae carbapenemase;
NDM, New Delhi metallo-βlactamase; OXA-48, oxacillinase
48; VIM, Verona integronencoded metallo-β-lactamase.
proportion of CPE infections are autochthonous cases,
including most of those with KPC- and VIM-producing
isolates. Policy and practice changes are needed to better protect patients from CPE exposure and acquisition in
southern Ontario.
Acknowledgments
The other members of TIBDN are Mahin Baqi, William Osler
Health System, Toronto; Abdelbaset Belhaj and Ian Kitai, Rouge
Valley Health System, Toronto; Danny Chen, Mackenzie Health,
Richmond Hill; Eileen de Villa, Region of Peel Public Health,
Brampton; Hani Dick, Vita-Tech Canada Inc., Markham; James
Downey, Michael Garron Hospital, Toronto; Nataly Farshait
and King S. Lee, Humber River Regional Hospital, Toronto;
Wayne Gold and Sharon Walmsley, University Health Network,
Toronto; Frances Jamieson, Ontario Agency for Health
Protection and Promotion, Toronto; Sigmund Krajden, St.
Joseph’s Health Centre, Toronto; Michael Lingley, Southlake
Regional Health Centre, Newmarket; Reena Lovinsky and David
1680
Rose, The Scarborough Hospital, Toronto; Larissa Matukas,
St. Michael’s Hospital, Toronto; Sharon O’Grady, Sinai
Health System, Toronto; Anne Opavsky, Joseph Brant
Memorial Hospital, Burlington; Krystyna Ostrowska, Trillium
Health Partners, Mississauga; Astrid Petrich and Susan
Richardson, The Hospital for Sick Children, Toronto; Agron
Plevneshi, Wallis Rudnick, and Barbara Willey, Sinai Health
System, Toronto; Neil Rau, Halton Healthcare, Oakville; Daniel
Ricciuto, Lakeridge Health, Oshawa; Valerie Sales, Markham
Stouffville Hospital, Markham; Mary Vearncombe, Sunnybrook
Health Sciences Centre, Toronto; Barbara Yaffe, City of Toronto
Public Health, Toronto; Deborah Yamamura, Hamilton Health
Sciences Centre, Hamilton.
This work was supported by the Canadian Institutes for Health
Research (grant no. 313039 to A.M.) and Switzerland’s
National Science Foundation (grant no. 158728 to P.P.K.).
This study was approved the by institutional review boards of all
participating TIBDN hospitals and PHO.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Emergence of CPE, South-Central Ontario, Canada
About the Author
Dr. Kohler is an infectious disease specialist currently
working at the Cantonal Hospital in St. Gallen, Switzerland.
His research interests include epidemiologic aspects of antibiotic
resistance with a focus on gram-negative pathogens and
nosocomial outbreaks.
14.
15.
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
Centers for Disease Control and Prevention. Antibiotic resistance
threats in the United States, 2013 [cited 2018 Mar 19].
http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf
World Health Organization. Factsheet on antimicrobial resistance
[cited 2018 Mar 19]. http://www.who.int/mediacentre/
factsheets/fs194
Goldfarb D, Harvey SB, Jessamine K, Jessamine P, Toye B,
Desjardins M. Detection of plasmid-mediated KPC-producing
Klebsiella pneumoniae in Ottawa, Canada: evidence of
intrahospital transmission. J Clin Microbiol. 2009;47:1920–2.
http://dx.doi.org/10.1128/JCM.00098-09
Pillai DR, Melano R, Rawte P, Lo S, Tijet N, Fuksa M, et al.
Klebsiella pneumoniae carbapenemase, Canada. Emerg
Infect Dis. 2009;15:827–9. http://dx.doi.org/10.3201/
eid1505.081536
Mataseje LF, Boyd DA, Willey BM, Prayitno N, Kreiswirth N,
Gelosia A, et al. Plasmid comparison and molecular analysis of
Klebsiella pneumoniae harbouring blaKPC from New York City
and Toronto. J Antimicrob Chemother. 2011;66:1273–7.
http://dx.doi.org/10.1093/jac/dkr092
Kus JV, Tadros M, Simor A, Low DE, McGeer AJ, Willey BM,
et al. New Delhi metallo-β-lactamase-1: local acquisition in
Ontario, Canada, and challenges in detection. CMAJ.
2011;183:1257–61. http://dx.doi.org/10.1503/cmaj.110477
Borgia S, Lastovetska O, Richardson D, Eshaghi A, Xiong J,
Chung C, et al. Outbreak of carbapenem-resistant
Enterobacteriaceae containing blaNDM-1, Ontario, Canada.
Clin Infect Dis. 2012;55:e109–17. http://dx.doi.org/10.1093/
cid/cis737
Tijet N, Macmullin G, Lastovetska O, Vermeiren C, Wenzel P,
Stacey-Works T, et al. Verona integron-encoded metallo-βlactamase 1 in Enterobacteria, Ontario, Canada. Emerg Infect Dis.
2013;19:1156–8. http://dx.doi.org/10.3201/eid1907.121294
Lefebvre B, Lévesque S, Bourgault AM, Mulvey MR, Mataseje L,
Boyd D, et al. Carbapenem non-susceptible Enterobacteriaceae
in Quebec, Canada: results of a laboratory surveillance program
(2010–2012). PLoS One. 2015;10:e0125076. http://dx.doi.org/
10.1371/journal.pone.0125076
Sekirov I, Croxen MA, Ng C, Azana R, Chang Y, Mataseje L, et al.
Epidemiologic and genotypic review of carbapenemase-producing
organisms in British Columbia, Canada, between 2008 and 2014.
J Clin Microbiol. 2016;54:317–27. http://dx.doi.org/10.1128/
JCM.02289-15
Public Health Agency of Canada. Canadian Antimicrobial
Resistance Surveillance System—report 2016 [cited 2018 Mar 19].
https://www.canada.ca/content/dam/phac-aspc/documents/services/
publications/drugs-health-products/antibiotic-resistanceantibiotique/antibiotic-resistance-antibiotique-2016-eng.pdf
Public Health Agency of Canada. Canadian Antimicrobial
Resistance Surveillance System 2017 report [cited 2018 Mar 19].
https://www.canada.ca/en/public-health/services/publications/
drugs-health-products/canadian-antimicrobial-resistancesurveillance-system-2017-report-executive-summary.html
Mataseje LF, Abdesselam K, Vachon J, Mitchel R, Bryce E,
Roscoe D, et al. Results from the Canadian Nosocomial
Infection Surveillance Program, 2010–2014. Antimicrob Agents
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
Chemother. 2016;60:6787–94. http://dx.doi.org/10.1128/
AAC.01359-16
Statistics Canada. Census Program, National Household
Survey 2016. Results for Toronto [cited 2018 Mar 19].
http://www12.statcan.gc.ca/census-recensement/2016/dp-pd/prof/
details/page.cfm?Lang=E&Geo1=CD&Code1=3520&Geo2=PR&
Code2=35&Data=Count&SearchText=toronto&SearchType=Begin
s&SearchPR=01&B1=All&TABID=1
Statistics Canada. Census Program, National Household Survey
2016. Results for Peel [cited 2018 Mar 19]. http://www12.statcan.
gc.ca/census-recensement/2016/dp-pd/prof/details/page.cfm?
Lang=E&Geo1=CD&Code1=3521&Geo2=PR&Code2=35&Data=
Count&SearchText=peel&SearchType=Begins&SearchPR=01&B
1=All&TABID=1
Tijet N, Sheth PM, Lastovetska O, Chung C, Patel SN,
Melano RG. Molecular characterization of Klebsiella pneumoniae
carbapenemase (KPC)–producing Enterobacteriaceae in Ontario,
Canada, 2008–2011. PLoS One. 2014;9:e116421. http://dx.doi.org/
10.1371/journal.pone.0116421
Shigayeva A, Rudnick W, Green K, Tyrrell G, Demczuk WH,
Gold WL, et al.; Toronto Invasive Bacterial Diseases Network.
Association of serotype with respiratory presentations of
pneumococcal infection, Ontario, Canada, 2003-2011.
Vaccine. 2016;34:846–53. http://dx.doi.org/10.1016/
j.vaccine.2015.11.021
Cabrera A, Armstrong I, Coleman B, Faheem A, Green K,
Johnstone J, et al. Detection of Carbapenemase-producing
Enterobacteriaceae in TIBDN laboratories, 2014. Abstract F02.
Meeting of the Association of Medical Microbiology and
Infectious Disease Canada; March 30–April 2, 2016;
Vancouver, British Columbia, Canada [cited 2018 Mar 19].
https://www.ammi.ca/Annual-Conference/2016/Abstracts/
2016 JAMMI Abstracts.pdf
Fattouh R, Tijet N, McGeer A, Poutanen SM, Melano RG,
Patel SN. What is the appropriate meropenem MIC for screening
of carbapenemase-producing Enterobacteriaceae in lowprevalence settings? Antimicrob Agents Chemother. 2015;60:
1556–9. http://dx.doi.org/10.1128/AAC.02304-15
Mataseje LF, Bryce E, Roscoe D, Boyd DA, Embree J,
Gravel D, et al.; Canadian Nosocomial Infection Surveillance
Program. Carbapenem-resistant Gram-negative bacilli in Canada
2009–10: results from the Canadian Nosocomial Infection
Surveillance Program (CNISP). J Antimicrob Chemother. 2012;
67:1359–67. http://dx.doi.org/10.1093/jac/dks046
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method
of classifying prognostic comorbidity in longitudinal studies:
development and validation. J Chronic Dis. 1987;40:373–83.
http://dx.doi.org/10.1016/0021-9681(87)90171-8
van Duin D, Doi Y. The global epidemiology of carbapenemaseproducing Enterobacteriaceae. Virulence. 2017;8:460–9.
http://dx.doi.org/10.1080/21505594.2016.1222343
van der Bij AK, Pitout JD. The role of international travel
in the worldwide spread of multiresistant Enterobacteriaceae.
J Antimicrob Chemother. 2012;67:2090–100. http://dx.doi.org/
10.1093/jac/dks214
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a
practical and powerful approach to multiple testing. J R Stat
Soc B. 1995;57:289–300.
Statistics Canada. Census program [cited 2018 Mar 19].
http://www12.statcan.gc.ca/census-recensement/index-eng.cfm
Guh AY, Bulens SN, Mu Y, Jacob JT, Reno J, Scott J, et al.
Epidemiology of carbapenem-resistant Enterobacteriaceae in
7 US communities, 2012–2013. JAMA. 2015;314:1479–87.
http://dx.doi.org/10.1001/jama.2015.12480
Cohen AL, Calfee D, Fridkin SK, Huang SS, Jernigan JA,
Lautenbach E, et al.; Society for Healthcare Epidemiology
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1681
RESEARCH
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
of America and the Healthcare Infection Control Practices
Advisory Committee. Recommendations for metrics for multidrugresistant organisms in healthcare settings: SHEA/HICPAC
position paper. Infect Control Hosp Epidemiol. 2008;29:901–13.
http://dx.doi.org/10.1086/591741
da Silva KE, Maciel WG, Sacchi FPC, Carvalhaes CG,
Rodrigues-Costa F, da Silva ACR, et al. Risk factors for
KPC-producing Klebsiella pneumoniae: watch out for surgery.
J Med Microbiol. 2016;65:547–53. http://dx.doi.org/10.1099/
jmm.0.000254
Tumbarello M, Trecarichi EM, Tumietto F, Del Bono V,
De Rosa FG, Bassetti M, et al. Predictive models for identification
of hospitalized patients harboring KPC-producing Klebsiella
pneumoniae. Antimicrob Agents Chemother. 2014;58:3514–20.
http://dx.doi.org/10.1128/AAC.02373-13
Kaase M, Pfennigwerth N, Lange F, Anders A, Gatermann SG.
Molecular epidemiology of VIM-1 producing Escherichia coli
from Germany referred to the National Reference Laboratory.
Int J Med Microbiol. 2015;305:784–9. http://dx.doi.org/10.1016/
j.ijmm.2015.08.032
Palacios-Baena ZR, Oteo J, Conejo C, Larrosa MN, Bou G,
Fernández-Martínez M, et al.; GEIH-GEMARA (SEIMC) and
REIPI Group for CPE. Comprehensive clinical and epidemiological
assessment of colonisation and infection due to carbapenemaseproducing Enterobacteriaceae in Spain. J Infect. 2016;72:152–60.
http://dx.doi.org/10.1016/j.jinf.2015.10.008
Schwaber MJ, Carmeli Y. An ongoing national intervention
to contain the spread of carbapenem-resistant Enterobacteriaceae.
Clin Infect Dis. 2014;58:697–703. http://dx.doi.org/10.1093/cid/
cit795
European Centre for Disease Prevention and Control. Systematic
review of the effectiveness of infection control measures to
prevent the transmission of carbapenemase-producing
Enterobacteriaceae through cross-border transfer of patients
[cited 2018 Mar 19]. http://ecdc.europa.eu/en/publications/
Publications/CPE-systematic-review-effectiveness-infectioncontrol-measures-to-prevent-transmission-2014.pdf
Ho KW, Ng WT, Ip M, You JH. Active surveillance of
carbapenem-resistant Enterobacteriaceae in intensive
care units: is it cost-effective in a nonendemic region?
Am J Infect Control. 2016;44:394–9. http://dx.doi.org/10.1016/
j.ajic.2015.10.026
Lapointe-Shaw L, Voruganti T, Kohler P, Thein HH,
Sander B, McGeer A. Cost-effectiveness analysis of
universal screening for carbapenemase-producing
Enterobacteriaceae in hospital inpatients. Eur J Clin
Microbiol Infect Dis. 2017;36:1047–55. http://dx.doi.org/10.1007/
s10096-016-2890-7
Donker T, Henderson KL, Hopkins KL, Dodgson AR,
Thomas S, Crook DW, et al. The relative importance of
large problems far away versus small problems closer to home:
insights into limiting the spread of antimicrobial resistance in
England. BMC Med. 2017;15:86. http://dx.doi.org/10.1186/
s12916-017-0844-2
Rimoldi SG, Gentile B, Pagani C, Di Gregorio A, Anselmo A,
Palozzi AM, et al. Whole genome sequencing for the
molecular characterization of carbapenem-resistant
Klebsiella pneumoniae strains isolated at the Italian ASST
Fatebenefratelli Sacco Hospital, 2012-2014. BMC Infect Dis.
2017;17:666. http://dx.doi.org/10.1186/s12879-017-2760-7
EI D Podca st :
Deat hs At t ribut able t o
Carbapenem - Resist ant
Ent erobact eriaceae
I nfect ions
Carbapenem-resistant strains have emerged among
species belonging to the family Enterobacteriaceae.
Several outbreaks caused by carbapenemresistant Enterobacteriaceae (CRE) have been
recorded in healthcare facilities around the world,
and in some places, CRE have become endemic.
Serious concurrent conditions and prior use of
fluoroquinolones, carbapenems, or broad-spectrum
cephalosporins have been independently associated
with acquisition of infections caused by CRE.
Visit ou r w e bsit e t o list e n :
h t t p:/ / w w w 2 c.cdc.gov/ podca st s/
pla ye r .a sp?f= 8 6 3 3 5 7 4
Address for correspondence: Philipp P. Kohler, Cantonal Hospital St.
Gallen, Clinic for Infectious Diseases and Hospital Epidemiology,
Rorschacher Strasse 95, 9007 St. Gallen, Switzerland; email:
philipp.kohler@kssg.ch
1682
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Fr om Cu lt u r om ics t o Clin ica l
M icr obiology a n d For w a r d
Grégory Dubourg, Sophie Baron, Frédéric Cadoret, Carine Couderc,
Pierre-Edouard Fournier, Jean-Christophe Lagier, Didier Raoult
Culturomics has permitted discovery of hundreds of new
bacterial species isolated from the human microbiome.
Profiles generated by using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry have been added to the mass spectrometer database
used in clinical microbiology laboratories. We retrospectively collected raw data from MALDI-TOF mass spectrometry used routinely in our laboratory in Marseille, France,
during January 2012–March 2018 and analyzed 16S rDNA
sequencing results from misidentified strains. During the
study period, 744 species were identified from clinical
specimens, of which 21 were species first isolated from
culturomics. This collection involved 105 clinical specimens, accounting for 98 patients. In 64 cases, isolation
of the bacteria was considered clinically relevant. MALDITOF mass spectrometry was able to identify the species
in 95.2% of the 105 specimens. While contributing to the
extension of the bacterial repertoire associated with humans, culturomics studies also enlarge the spectrum of
prokaryotes involved in infectious diseases.
T
he diagnosis of bacterial diseases in clinical microbiology has relied on phenotypic identification, based
on the bacterial repertoire known to be associated with humans. This mode of identification, which is, in fact, recognition of previously described microorganisms, does not
allow for the identification of new bacteria. Recently, the
systematic use of universal 16S rDNA gene sequencing of
cultivated bacteria that presented an atypical phenotypical profile paved the way for identifying rare, fastidious,
and new microorganisms (1,2). However, this method
implies redefining specific phenotypical characteristics,
Author affiliations: Aix Marseille University, Institut de Recherche
pour le Développement (IRD), Assistance Publique des Hôpitaux
de Marseille (APHM), Microbes, Evolution, Phylogeny and
Infections (MEPHI), Institut Hospitalo-Universitaire (IHU)
Méditerranée Infection, Marseille, France (G. Dubourg, S. Baron,
J.-C. Lagier, D. Raoult); APHM, IHU Méditerranée Infection,
Marseille (F. Cadoret, C. Couderc); Aix Marseille University, IRD,
APHM, Vecteurs–Infections Tropicales et Méditerranéennes, IHU
Méditerranée Infection, Marseille (P.-E. Fournier)
DOI: https://doi.org/10.3201/eid2409.170995
which sometimes cannot be done because of the limited
number of available biochemical tests. More recently, the
revolution provided by matrix-assisted laser desorption/
ionization time-of-flight (MALDI-TOF) mass spectrometry identification permits comparison of a protein spectrum obtained from a colony with a database, which can
be permanently incremented with newly identified bacteria (3,4). The use of a cutoff identification score, with
values in the range of 1.7–2, enables correct identification
of the isolate. However, when MALDI-TOF mass spectrometry recognizes bacteria never previously associated
with humans, it is reasonable to carry out confirmation by
sequencing the 16S rDNA gene. The main advantage of
MALDI-TOF mass spectrometry compared with sequencing methods is that it is extremely fast and cost-effective
(3,4). Indeed, the cost involves mainly the cost of the machine; the individual cost per test is insignificant. Thus,
the ease in testing bacterial colonies led us to establish
the repertoire of commensal bacteria of the human microbiota in the laboratory at IHU Méditerranée Infection
in Marseille, France, by using a high-throughput culture
and MALDI-TOF mass spectrometry identification. Sequencing of the 16S rDNA gene enables identification of
atypical bacteria with definition of new bacterial species,
whose genomes are then sequenced. This approach, called
culturomics (5,6), has made possible the addition of 672
bacteria to the known repertoire of the bacteria already
isolated from the human mucosa. Other teams, in parallel,
have used similar approaches (7,8).
The usefulness of culturomics in increasing knowledge of the repertoire of cultivable bacteria from human
mucous membranes appears clear for microbiota studies.
However, the benefit of this process in clinical microbiology is prone to controversy. We speculated that commensal bacteria found in humans may be involved in opportunistic infections. In our experience, the creation of
new spectra enabled us to increment our MALDI-TOF
mass spectrometry database used for clinical microbiology, thus enabling recognition of bacterial species first
isolated as a part of culturomics studies and improving
the accuracy of diagnosis of infectious diseases involving bacteria.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1683
RESEARCH
Figure. Annual ratio of
unidentified bacteria and
evolution of the number of
spectral references available
in the matrix-assisted laser
desorption/ionization timeof-flight mass spectrometry
database in a clinical laboratory
in Marseille, France.
Materials and Methods
(BioMérieux) for third-generation, cephalosporin-resistant, gram-negative bacteria.
Settings
All data included in this study were obtained from the
routine microbiology laboratory at IHU Méditerranée Infection, which receives a mean annual number of 350,400
samples from the 4 Marseille university hospitals (Timone, Conception, North, and Sainte-Marguerite hospitals),
which contain a total of 3,700 beds. Retrospective data
were collected for January 2012–March 2018.
Routine Bacteriological Practices
We analyzed samples according to standard microbiological procedures, as previously described, depending
on the specimen (9–12). This process included systematic inoculation onto Columbia agar with 5% sheep
blood (BioMérieux, Craponne, France), chocolate agar
(BioMérieux) (excluding urine and fecal samples), and
specific media such as colistin-nalidixic agar or MacConkey agar (both BioMérieux) for specimens potentially contaminated by resident flora. Blood cultures
were incubated into a Bactec device (Becton Dickinson,
Le Pont de Claix, France) and analyzed as previously
described (9).
Specific Cultures
We plated fecal specimens taken following a regional
outbreak of Clostridioides (formerly Clostridium) difficile 027 during May 2013–March 2018 (13), in which
toxin detection was positive using GeneXpert C. difficile PCR (Cepheid, Paris, France) after ethanol treatment (14), to obtain C. difficile isolates. We also investigated possible multidrug-resistant bacteria carriage by
plating on chromID MRSA agar for methicillin-resistant
Staphylococcus aureus, chromID CARBA SMART medium (BioMérieux) for carbapenemase-producing Enterobacteriaceae (CPE), and Drigalski/MacConkey agar
1684
Identification of Colonies
We performed bacterial identification on colonies using
MALDI-TOF mass spectrometry, as previously described
(3,4). We considered identification to be correct when the
identification score was >1.9 and when the same single species was recognized. When identification did not meet these
criteria, we performed proteic extraction using formic acid
and acetonitrile (15). If identification was still incorrect following the proteic extraction protocol, we performed 16S
rDNA sequencing systematically, as previously described
(16), in 3 situations: when the identification score was <1.9
despite proteic extraction, when multiple different species
were recognized with a correct identification score, and
when a bacterium was isolated for the first time in the clinical microbiology laboratory.
Culturomics Studies
In brief, culturomics consists of the multiplication of culture
conditions applied to human specimens to increase the repertoire of the human microbiome. The pioneering study used
212 conditions (5); this number was reduced to 70 in 2012
(17,18) and then to 18 in 2014 (6). In addition, several specific conditions were designed for archaea, microcolonies,
proteobacteria, and microaerophilic and halophilic bacteria.
Most specimens used were fecal samples. However, respiratory, vaginal, and urine samples have been analyzed recently
in the context of culturomics studies. Identification has also
been performed using MALDI-TOF mass spectrometry.
Colonies were considered correctly identified when 2 colonies exhibited an identification score >1.9. If identification
scores were not correct after 3 attempts, sequencing of the
16S rDNA gene was performed (16). If there was <98.7%
similarity with the closest neighbor, the bacterial isolate was
considered to be a new species (19).
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Culturomics and Clinical Microbiology
Updating the MALDI-TOF Mass Spectrometry Database
The database used for routine bacterial identification is updated through 3 sources: updates from the MALDI-TOF
mass spectrometry manufacturer, updates from culturomics
studies, and routine laboratory results. Updates from culturomics studies and routine laboratory results are based on
16S rDNA sequencing results.
Analysis of Data from MALDI-TOF Mass Spectrometry
Used in the Clinical Microbiology Laboratory
We retrospectively collected raw data from MALDI-TOF
mass spectrometry used in the microbiology laboratory
involving identifications performed during January 2012–
March 2018, which are saved monthly. Data were deduced
from the samples. These data do not consider the clinical
relevance of the identified microorganism, the final result,
or multiple attempts to identify the colony using MALDITOF mass spectrometry.
Results
Bacterial Identification in Clinical
Microbiology Laboratory
During January 2012–March 2018, the clinical microbiology laboratory performed 351,937 nondereplicated bacterial identifications using MALDI-TOF mass spectrometry.
Of these, 28,391 (8.1%) were unidentified or misidentified.
When we looked at the yearly ratio of unidentified bacteria,
we noticed that it fell from 17.7% in 2012 to 3.6% in 2018
(Figure). Overall, we identified 744 unique bacterial species correctly using MALDI-TOF mass spectrometry.
Contribution to MALDI-TOF Mass Spectrometry
Database Updates
During the study period, we added 4,539 references to our
database. Updates from the manufacturer comprised 3,255
references, whereas 983 references came from routine
Table 1. Main features of the bacteria discovered as part of culturomics studies identified in a clinical microbiology laboratory*
GenBank
Date of spectrum
No.
Species
Culturomics study CSUR no.
Strain
accession no. implementation
cases
References
Actinomyces
Gut microbiota
P2825
MarseilleLT576385
2017 Apr
3
Unpub. data
(storied samples)
bouchesdurhonensis
P2825T
Actinomyces ihuae
Gut microbiota
P2006
SD1
LN866997
2015 Jul
17
(6,20)
(HIV)
Actinomyces marseillensis
Respiratory
P2818
MarseilleLT576400
Not added
1
(21)
microbiota
P2818T
Alistipes jeddahensis
Gut microbiota
P1209
AL1
LK021116
2015 Oct
4
(6,22)
Anaerosalibacter
Gut microbiota
P762
ND1
HG315673
2013 Apr
1
(6,23)
massiliensis
(Polynesia)
Bacteroides timonensis
Gut microbiota
P194
AP1
JX041639
2016 Apr
2
(6,24)
(anorexia nervosa)
Butyricimonas phocaeensis
Gut microbiota
P2478
AT9
LN881597
2015 Nov
1
(6,25)
(obese)
Clostridium
Gut microbiota
P1184
CL6
LK021117
2014 Sep
1
(6,26)
culturomicsense
(Saudian obese)
Clostridium
Gut microbiota
P1230
CL2
LK021118
2014 Aug
7
(6)
jeddahtimonense
(obese)
Clostridium
Gut microbiota
P1360
ND2
HG315672
2013 May
1
(6)
massilioamazoniense
(Polynesia)
Clostridium saudii
Gut microbiota
P697
JCC
HG726039
2014 Aug
11
(6,27)
(Saudian obese)
Corynebacterium ihuae
Gut microbiota
P892
GD6
JX424768
2013 May
3
(6,28)
(antimicrobials)
Corynebacterium
Urinary microbiota
P2174
MC3
LN881612
2013 Sep
6
(6)
lascolaense
Corynebacterium
Urinary microbiota
P1905
MC1
LN849777
2015 May
12
(6,29)
phoceense
Gabonia massiliensis
Gut microbiota
P1910
GM3
LN849789
2017 Apr
1
(6,30)
Nosocomicoccus
Gut microbiota
P246
NP2
JX424771
2012 Feb
1
(6,31)
massiliensis
(HIV)
Peptoniphilus grossensis
Gut microbiota
P184
ph5
JN837491
2015 Nov
18
(6,32)
(obese)
Polynesia massiliensis
Gut microbiota
P1280
MS3
HF952920
2013 Mar
1
(6)
(Polynesia)
Prevotella ihuae
Gut microbiota
P3385
MarseilleLT631517
Not added
1
(33)
(fresh feces)
P3385T
Pseudomonas massiliensis
Gut microbiota
P1334
CB1
LK985396
2015 Apr
5
(6,34)
(Polynesia)
Varibaculum timonense
Gut microbiota
P3369
MarseilleLT797538
Not added
1
(33)
(fresh feces)
P3369T
*Accession numbers indicate nucleotide sequences. CSUR, Collection de Souches de l’Unité des Rickettsies (an international strain collection).
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1685
RESEARCH
Table 2. Identification of bacterial pathogens by MALDI-TOF mass spectrometry, Marseille, France*
Species
MALDI-TOF identification (score)
Specimen
Actinomyces bouchesdurhonensis
Actinomyces bouchesdurhonensis (1.85)
Pharynx swab
A. bouchesdurhonensis
A. bouchesdurhonensis (1.9)
Abscess
Actinomyces ihuae
Actinomyces ihuae (1.97)
Abscess
A. ihuae
A. ihuae (1.9)
Abscess
A. ihuae
A. ihuae (2.5)
Abscess
A. ihuae
A. ihuae (1.92)
Abscess
A. ihuae
A. ihuae (2.5)
Abscess
A. ihuae
A. ihuae (1.73)
Abscess
A. ihuae
A. ihuae (2.23)
Abscess
A. ihuae
A. ihuae (2.2)
Abscess
A. ihuae
A. ihuae (2.1)
Abscess
A. ihuae
A. ihuae (2.1)
Bone
A. ihuae
A. ihuae (2.52)
Puncture fluid
A. ihuae‡
A. ihuae (2.47)
Puncture fluid
A. ihuae‡
Actinomyces spp. (1.65)
Biopsy
A. ihuae‡
A. ihuae (2.32)
Abscess
A. ihuae‡
A. ihuae (2.33)
Abscess
A. ihuae‡
A. ihuae (1.95)
Puncture fluid
A. ihuae‡
A. ihuae (2.07)
Abscess
Actinomyces marseillensis
Actinomyces marseillensis (NA)
Blood culture
Alistipes jeddahensis
Alistipes jeddahensis (1.97)
Abscess
Bacteroides timonensis
Bacteroides timonensis (1.95)
Blood culture
B. timonensis
B. timonensis (1.88)
Blood culture
B. timonensis
B. timonensis (1.96)
Blood culture
Corynebacterium ihuae‡
Corynebacterium ihuae (2)
Blood culture
C. ihuae
C. ihuae (2.2)
Wound
C. ihuae
C. ihuae (1.8)
Blood culture
Corynebacterium lascolaense
Corynebacterium lascolaense (2.2)
Urine
C. lascolaense
C. lascolaense (2.3)
Pacemaker
C. lascolaense
C. lascolaense (2.1)
Urine
C. lascolaense
C. lascolaense (2.14)
Urine
C. lascolaense‡
C. lascolaensis (2.2)
Urine
Corynebacterium phoceense
Corynebacterium phoceense (1.91)
Urine
C. phoceense
Corynebacterium spp. (2.3)
Unknown
C. phoceense
C. phoceense (2.6)
Blood culture
C. phoceense‡
No reliable identification
Blood culture
Nosocomicoccus massiliensis‡
Nosocomicoccus massiliensis (2.3)
Blood culture
Peptinophilus grossensis
Peptinophilus grossensis (2.1)
Abscess
P. grossensis
P. grossensis (2.18)
Biopsy
P. grossensis
P. grossensis (1.9)
Abscess
P. grossensis
P. grossensis (2.3)
Biopsy
P. grossensis
P. grossensis (1.9)
Biopsy
P. grossensis
P. grossensis (2.2)
Biopsy
P. grossensis
P. grossensis (2.18)
Biopsy
P. grossensis
P. grossensis (2)
Material
P. grossensis
P. grossensis (1.78)
Abscess
P. grossensis
P. grossensis (2.1)
Abscess
P. grossensis
P. grossensis (2.15)
Abscess
P. grossensis
P. grossensis (1.9)
Puncture fluid
P. grossensis
P. grossensis (2.1)
Puncture fluid
P. grossensis
P. grossensis (2.3)
Puncture fluid
P. grossensis
P. grossensis (2.2)
Puncture fluid
P. grossensis
P. grossensis (2.1)
Abscess
P. grossensis
P. grossensis (2.1)
Abscess
P. grossensis
P. grossensis (1.9)
Puncture fluid
P. grossensis
P. grossensis (2.3)
Biopsy
P. grossensis
P. grossensis (2.31)
Biopsy
P. grossensis
P. grossensis (1.86)
Abscess
Polynesia massiliensis
Polynesia massiliensis (2.21)
Peritoneal fluid
Prevotella ihuae
No reliable identification
Abscess
Pseudomonas massiliensis
Pseudomonas massiliensis (2.5)
Blood culture
Pseudomonas massiliensis
Pseudomonas massiliensis (2)
Blood culture
Pseudomonas massiliensis‡
Pseudomonas massiliensis (1.9)
Blood culture
Varibaculum timonense
No reliable identification
Abscess
*MALDI-TOF, matrix-assisted laser desorption/ionization time-of-flight; NA, not available.
†Replicated isolates in different specimens from the same patient.
‡Strains for which 16S rDNA sequencing was performed.
1686
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Duplicates per patient?†
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
Yes
Yes
No
No
No
No
No
No
Yes
Yes
No
No
No
No
No
No
No
No
No
No
Yes
Yes
No
No
No
No
No
No
Yes
Yes
No
Yes
Yes
No
No
No
No
No
No
No
No
No
No
Culturomics and Clinical Microbiology
Table 3. Identification of bacteria discovered as a part of culturomics studies in the clinical microbiology laboratory as commensals,
Marseille, France*
MALDI-TOF mass spectrometry
Duplicates
Species
identification (score)
Specimen
per patient?†
Additional information
Actinomyces bouchesdurhonensis
A. bouchesdurhonensis (2)
Larynx biopsy
No
Polymicrobial
Alistipes jeddahensis
Alistipes jeddahensis (2.38)
Liquid feces
No
Seeking Salmonella spp.
A. jeddahensis
A. jeddahensis (2.45)
Liquid feces
No
Seeking Salmonella spp.
A. jeddahensis
A. jeddahensis (2.5)
Liquid feces
No
Seeking Salmonella spp.
Anaerosalibacter massiliensis
Anaerosalibacter massiliensis (1.78)
Rectal swab
No
Seeking MDR bacteria
Butyricimonas phocaeensis
Butyricimonas phoaceensis (2.36)
Liquid feces
No
Seeking toxigenic CD
Clostridium culturomicsense
Clostridium culturomicsense (2)
Liquid feces
No
Seeking toxigenic CD
Clostridium jeddahtimonense
Clostridium jeddahtimonense (2.1)
Liquid feces
No
Seeking toxigenic CD
C. jeddahtimonense
C. jeddahtimonense (2.3)
Liquid feces
No
Seeking toxigenic CD
C. jeddahtimonense
C. jeddahtimonense (2.4)
Liquid feces
No
Seeking toxigenic CD
C. jeddahtimonense
C. jeddahtimonense (2.1)
Liquid feces
No
Seeking toxigenic CD
C. jeddahtimonense
C. jeddahtimonense (2.2)
Liquid feces
Yes
Seeking toxigenic CD
C. jeddahtimonense
C. jeddahtimonense (1.72)
Liquid feces
Yes
Seeking toxigenic CD
C. jeddahtimonense
C. jeddahtimonense (2.3)
Liquid feces
No
Seeking toxigenic CD
C. jeddahtimonense
C. jeddahtimonense (2.1)
Liquid feces
No
Seeking toxigenic CD
Clostridium massilioamazoniense
Clostridium massilioamazoniense (1.7) Liquid feces
No
Seeking toxigenic CD
Clostridium saudii
Clostridium saudii (2.5)
Liquid feces
No
Seeking toxigenic CD
C. saudii
C. saudii (1.74)
Liquid feces
No
Seeking toxigenic CD
C. saudii
C. saudii (2.5)
Liquid feces
No
Seeking toxigenic CD
C. saudii
C. saudii (1.94)
Liquid feces
No
Seeking toxigenic CD
C. saudii
C. saudii (2.18)
Liquid feces
No
Seeking toxigenic CD
C. saudii
C. saudii (1.77)
Liquid feces
No
Seeking toxigenic CD
C. saudii
C. saudii (1.93)
Liquid feces
No
Seeking toxigenic CD
C. saudii
C. saudii (2.1)
Liquid feces
No
Seeking toxigenic CD
C. saudii
C. saudii (1.9)
Liquid feces
No
Seeking toxigenic CD
C. saudii
C. saudii (2.47)
Liquid feces
No
Seeking toxigenic CD
C. saudii
C. saudii (1.83)
Liquid feces
No
Seeking toxigenic CD
Corynebacterium lascolaense
Corynebacterium lascolaense (1.85)
Intrauterine
No
Not considered
device
C. lascolaense
C. lascolaense (2.1)
Urine
No
Growth not significant
Corynebacterium phoceense
Corynebacterium phoceense (2.1)
Vagina
No
Not considered
C. phoceense
C. phoceense (1.9)
Vagina
No
Not considered
C. phoceense
C. phoceense (2.1)
Vagina
No
Not considered
C. phoceense
C. phoceense (2)
Vagina
No
Not considered
C. phoceense
C. phoceense (2.2)
Vagina
No
Not considered
C. phoceense
C. phoceense (2)
Vagina
No
Polymicrobial
C. phoceense
C. phoceense (2.2)
Vagina
No
Not considered
C. phoceense
C. phoceense (1.97)
Urine
No
Polymicrobial
Gabonia massiliensis
Gabonia massiliensis (2.3)
Liquid feces
No
Seeking MDR bacteria
Pseudomonas massiliensis
Pseudomonas massiliensis (2)
Skin swab
Yes
Seeking S. aureus
carriage
P. massiliensis
P. massiliensis (2.5)
Skin swab
Yes
Seeking S. aureus
carriage
*MALDI-TOF, matrix-assisted laser desorption/ionization time-of-flight.
†Replicated isolates in different specimens from the same patient.
laboratory results. In addition, 306 (23.4%) updates were
from new bacterial species discovered as a part of culturomics studies. Overall, references from the manufacturer represented 87% of the total database, routine laboratory results represented 8%, and new culturomics species
represented 5% (Figure).
Routine Identification of Species Isolated as Part of
Culturomics Studies
Among the 351,937 bacterial identifications performed
routinely during the study period, we identified species
first isolated from culturomics studies in 105 clinical
specimens, accounting for 98 patients. This collection
represents a total of 21 species, accounting for 2.8%
(21/744) of the overall microbiology laboratory bacterial
diversity (Table 1).
Among the 105 colonies identified as new species isolated as a part of culturomics studies, identification was
correct for 100 (95.2%) using MALDI-TOF mass spectrometry. Thus, 16S rDNA gene sequencing was required
for 5 strains to achieve final identification. MALDI-TOF
mass spectrometry was not able to provide a reliable identification for Varibaculum timonense, Prevotella ihuae,
Actinomyces ihuae, and 2 Corynebacterium phoceense
isolates. We confirmed identification of 9 supplementary
strains, representing 5 species (Corynebacterium lascolaense, Actinomyces ihuae, Corynebacterium ihuae, Nosocomiicoccus massiliensis, and Pseudomonas massiliensis),
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1687
RESEARCH
Table 4. Characteristics of 17 persons with A. ihuae infection, Marseille, France, April 2015–March 2018*
Patient
Patient age,
Incubation
MALDI-TOF mass
no.
y/sex
time, h
spectrometry score
Sampling site
Culture result
1
24/F
Periareolar right breast
48
Polymicrobial
2.54
2
26/F
Umbilical collection
48
Pure
2.5
3
37/M
Periareolar left breast
72
Polymicrobial
1.97
4
33/F
Breast
72
Polymicrobial
2.1
5
77/F
Bone
72
Polymicrobial
2.1
6
22/M
Testicular collection
96
Pure
1.95
7
56/M
Back
48
Pure
2.32
8
55/F
Labia majora
72
Polymicrobial
2.07
9
30/F
Labia majora
72
Pure
2.47
10
26/F
Labia majora
72
Polymicrobial
2.33
11
44/M
Leg ulcer
48
Polymicrobial
NA
12
66/M
Cervical collection
72
Polymicrobial
2.23
13
49/M
Superinfected sebaceous
48
Polymicrobial
1.9
cyst
14
18/F
Sacrococcygeal cyst
96
Pure
2.45
15
26/F
Labia majora
72
Polymicrobial
2.2
16
45/F
Breast abcess
72
Polymicrobial
1.73
17
44/M
Axillar abcess
96
Polymicrobial
1.92
16S rRNA result
NA
NA
NA
NA
NA
A. ihuae 99.70%
A. ihuae 99.70%
A. ihuae 99.70%
A. ihuae 99.70%
A. ihuae 99.60%
A. ihuae 99.50%
NA
NA
NA
NA
NA
NA
* MALDI-TOF, matrix-assisted laser desorption/ionization time-of-flight; NA, not available.
using 16S rDNA gene sequencing (Tables 2, 3). Overall,
we sequenced 14 isolates, accounting for 8 species, for the
16S rDNA gene.
Species Potentially Relevant as Human Pathogens
Among the 105 isolates included in this work, 64 were isolated as potential pathogens, accounting for 14 different species. Most were anaerobes that were cultured from abscesses
or punctures, often involved in cases of polymicrobial infections. Peptoniphilus grossensis (18 cases) and Actinomyces
ihuae (17 cases) were the most commonly isolated bacteria
(Table 1). These species were initially cultured from the human gut. Special attention was given to A. ihuae infections
(Table 4), which were strongly associated with breast abscess
or genital area infections. Also, 10 bacteremia-involved species were isolated as a part of culturomics studies. Bacteroides timonensis was thus isolated in 3 blood cultures from
2 patients, whereas Pseudomonas massiliensis was found
in 3 bacteremia episodes. Corynebacterium phoceense and
Corynebacterium ihuae were recovered from 2 bloodstream
infection episodes, whereas Actinomyces marseillensis and
Nosocomicoccus massiliensis were each isolated from 1
blood sample (from 2 different patients). B. timonensis, P.
massiliensis, N. massiliensis, and C. ihuae were first cultured
from the human gut, whereas A. marseillensis was first isolated from respiratory microbiota and C. phoceense was first
isolated from urinary microbiota. Overall, species cultured
as part of culturomics studies were found to be potential
pathogens in 59 different patients (Table 2). The significance
of the presence of P. massiliensis in a lens from a patient
with keratitis was ultimately not interpreted.
Species Isolated as Human Commensal Members
In this work, 40 isolates corresponding to 12 species discovered as a part of culturomics studies were isolated as
1688
belonging to the human flora. Of these, 22 were recovered
when evaluating for toxigenic C. difficile, following a positive result with the GeneXpert C. difficile test. C. saudii
was isolated in this context 11 times, followed by C. jeddahtimonense (8 times), C. culturomicsense, Butyricimonas phocaeensis, and Anaerosalibacter massiliensis (1
time each) (Table 3). These 5 species were first cultured
from fecal specimens (Table 1).
In addition, Corynebacterium lascolaense was identified in 1 urine specimen, but in an insufficient quantity to be
considered clinically relevant. Similarly, C. phoceense was
recovered from 1 urine sample and from 7 vaginal swabs
but was never reported to a physician in this context. These
species were first cultured from urinary microbiota. Finally, Pseudomonas massiliensis, which was cultured from
the human gut, was also recovered twice from skin swabs
collected from the same physician after an epidemiologic
investigation. Overall, species cultured for the first time as
a part of culturomics studies were found as commensals in
38 different patients.
Discussion
This work constitutes the proof of concept that exploration
of the repertoire of commensal bacteria enables identification of microorganisms involved in clinical microbiology.
Indeed, the strategy of combining high-throughput culture
techniques, MALDI-TOF mass spectrometry identification, and 16S rDNA gene sequencing of misidentified isolates enabled us to add 306 spectral references for 292 different new bacterial species to our laboratory’s database.
Thus, with culturomics, 21 new species were identified 105
times, in 98 patients. The results are robust; identification
scores were all >1.9 with exclusion of multiple identifications. In addition, identification of 9 strains using 16S
rDNA sequencing, accounting for 5 species, confirmed
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Culturomics and Clinical Microbiology
the initial recognition by MALDI-TOF mass spectrometry
(Table 2). These results strengthen our belief that identifying commensal microbes provides a valuable contribution
to clinical microbiology, as revealed by the decrease in the
number of unidentified colonies by MALDI-TOF mass
spectrometry over time (Figure).
As exemplified for A. ihuae infections (Table 4),
these microorganisms, which were isolated mainly from
the human gut, can probably be found frequently in
polymicrobial cultures. Thus, the microbiologist may be
tempted to abandon the final identification of a microorganism found in such a situation, concluding that the
infection is polymicrobial.
The extension of the bacterial repertoire associated
with humans will considerably increase the number of bacteria associated with human diseases. In this study alone,
over a 5-year period, 2.8% (21/744) of the overall identified
bacteria would not have been identified without incrementing the MALDI-TOF mass spectrometry database with
spectra obtained from culturomics studies.
On the whole, pathogenic microbes are also often
found as commensals, as is currently well known for C. difficile, S. aureus, and S. pneumoniae (35–37). In our study,
for example, Corynebacterium phoceense, Pseudomonas
massiliensis, and C. lascolaense were found as both commensals and pathogens. This finding highlights the need
for establishment of a repertoire of human microbes (38),
which was recently estimated at 2,776 species, of which
more than 10% were recovered by culturomics studies.
Such a repertoire of prokaryotes associated with humans
not only benefits microbiota studies, through notation of
unknown sequences with new species genome sequencing,
but also enables studying the role of these species in human
infections (39). We estimate that, among the cases included
here, the presence of species cultured as part of culturomics
studies was potentially clinically relevant for 60 of them
(61.2%). The online availability of the MALDI-TOF mass
spectrometry spectra obtained from these species discovered by culturomics (http://www.mediterranee-infection.
com/article.php?laref = 256&titre = urms-database) ensures their further identification by other laboratories.
Culturomics was initially designed to exhaustively
identify commensals inhabiting human surfaces and thus
can potentially lead in the future to personal medical interventions as a part of microbiome studies. However, the
thinnest barrier between commensalism and pathogenicity,
which should lead researchers to rethink Koch’s postulate
(40), has rendered culturomics studies useful in the field
of clinical microbiology despite a potential skepticism. We
show herein that, while contributing to the extension of the
bacterial repertoire associated with humans, culturomics
studies also enlarge the spectrum of prokaryotes involved
in infectious diseases.
This work has benefited from French state support, managed by
the Agence Nationale pour la Recherche, including the
Programme d’Investissement d’Avenir under the reference
Méditerranée Infection 10-IAHU-03. This work was also
supported by Région Provence Alpes Côte d’Azur and Fonds
Européen de Développement Regional—Plateformes de
Recherche et d’Innovation Mutualisées Méditerranée Infection
(FEDER PRIMI).
About the Author
Dr. Dubourg is an assistant professor of bacteriology at IHU
Méditerranée Infection, Marseille, France. His primary research
interest is human microbiome studies.
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
Drancourt M, Berger P, Raoult D. Systematic 16S rRNA gene
sequencing of atypical clinical isolates identified 27 new bacterial
species associated with humans. J Clin Microbiol. 2004;42:2197–
202. http://dx.doi.org/10.1128/JCM.42.5.2197-2202.2004
Drancourt M, Bollet C, Carlioz A, Martelin R, Gayral JP,
Raoult D. 16S ribosomal DNA sequence analysis of a large
collection of environmental and clinical unidentifiable bacterial
isolates. J Clin Microbiol. 2000;38:3623–30.
Clark AE, Kaleta EJ, Arora A, Wolk DM. Matrix-assisted laser
desorption ionization-time of flight mass spectrometry: a fundamental
shift in the routine practice of clinical microbiology. Clin Microbiol
Rev. 2013;26:547–603. http://dx.doi.org/10.1128/CMR.00072-12
Seng P, Drancourt M, Gouriet F, La Scola B, Fournier PE,
Rolain JM, et al. Ongoing revolution in bacteriology: routine
identification of bacteria by matrix-assisted laser desorption
ionization time-of-flight mass spectrometry. Clin Infect Dis. 2009;
49:543–51. http://dx.doi.org/10.1086/600885
Lagier JC, Armougom F, Million M, Hugon P, Pagnier I,
Robert C, et al. Microbial culturomics: paradigm shift in the human
gut microbiome study. Clin Microbiol Infect. 2012;18:1185–93.
http://dx.doi.org/10.1111/1469-0691.12023
Lagier JC, Kheliaifia S, Tidjani Alou MT, Ndongo S, Dione N,
Hugon P, et al. Culture of previously uncultured members
of the human gut microbiota by culturomics. Nat Microbiol.
2016;1:16203. http://dx.doi.org/10.1038/nmicrobiol.2016.203.
Goodman AL, Kallstrom G, Faith JJ, Reyes A, Moore A,
Dantas G, et al. Extensive personal human gut microbiota culture
collections characterized and manipulated in gnotobiotic mice. Proc
Natl Acad Sci U S A. 2011;108:6252–7. http://dx.doi.org/10.1073/
pnas.1102938108
Browne HP, Forster SC, Anonye BO, Kumar N, Neville BA,
Stares MD, et al. Culturing of ‘unculturable’ human microbiota
reveals novel taxa and extensive sporulation. Nature.
2016;533:543–6. http://dx.doi.org/10.1038/nature17645
Gouriet F, Million M, Henri M, Fournier PE, Raoult D.
Lactobacillus rhamnosus bacteremia: an emerging clinical
entity. Eur J Clin Microbiol Infect Dis. 2012;31:2469–80.
http://dx.doi.org/10.1007/s10096-012-1599-5
Dubourg G, Delord M, Gouriet F, Fournier PE, Drancourt M.
Actinomyces gerencseriae hip prosthesis infection: a case report.
J Med Case Rep. 2015;9:223. http://dx.doi.org/10.1186/
s13256-015-0704-7
Levy PY, Fournier PE, Fenollar F, Raoult D. Systematic PCR
detection in culture-negative osteoarticular infections.
Am J Med. 2013;126:1143.e25–33. http://dx.doi.org/10.1016/
j.amjmed.2013.04.027
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1689
RESEARCH
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
1690
Dubourg G, Abat C, Rolain JM, Raoult D. Correlation between
sputum and bronchoalveolar lavage fluid cultures. J Clin Microbiol.
2015;53:994–6. http://dx.doi.org/10.1128/JCM.02918-14
Cassir N, Delarozière JC, Dubourg G, Delord M, Lagier JC,
Brouqui P, et al. A regional outbreak of Clostridium difficile
PCR-ribotype 027 infections in southeastern France from a
single long-term care facility. Infect Control Hosp Epidemiol.
2016;37:1337–41. http://dx.doi.org/10.1017/ice.2016.164
Marler LM, Siders JA, Wolters LC, Pettigrew Y, Skitt BL,
Allen SD. Comparison of five cultural procedures for isolation of
Clostridium difficile from stools. J Clin Microbiol. 1992;30:514–6.
El Khéchine A, Couderc C, Flaudrops C, Raoult D, Drancourt M.
Matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry identification of mycobacteria in routine clinical
practice. PLoS One. 2011;6:e24720. http://dx.doi.org/10.1371/
journal.pone.0024720
Morel AS, Dubourg G, Prudent E, Edouard S, Gouriet F, Casalta JP,
et al. Complementarity between targeted real-time specific PCR
and conventional broad-range 16S rDNA PCR in the syndromedriven diagnosis of infectious diseases. Eur J Clin Microbiol Infect
Dis. 2015;34:561–70. http://dx.doi.org/10.1007/s10096-014-2263-z
Dubourg G, Lagier JC, Robert C, Armougom F, Hugon P, Metidji S,
et al. Culturomics and pyrosequencing evidence of the reduction
in gut microbiota diversity in patients with broad-spectrum
antibiotics. Int J Antimicrob Agents. 2014;44:117–24.
http://dx.doi.org/10.1016/j.ijantimicag.2014.04.020
Pfleiderer A, Lagier JC, Armougom F, Robert C, Vialettes B,
Raoult D. Culturomics identified 11 new bacterial species from a
single anorexia nervosa stool sample. Eur J Clin Microbiol Infect
Dis. 2013;32:1471–81. http://dx.doi.org/10.1007/s10096-013-1900-2
Rossi-Tamisier M, Benamar S, Raoult D, Fournier P-E. Cautionary
tale of using 16S rRNA gene sequence similarity values in
identification of human-associated bacterial species. Int J Syst Evol
Microbiol. 2015;65:1929–34. http://dx.doi.org/10.1099/ijs.0.000161
Ndongo S, Khelaifia S, Bittar F, Fournier P-E, Raoult D.
“Actinomyces ihumii,” a new bacterial species isolated from the
digestive microbiota of a HIV-infected patient. New Microbes New
Infect. 2016;12:71–2. http://dx.doi.org/10.1016/j.nmni.2016.04.013
Fonkou MDM, Bilen M, Cadoret F, Fournier PE, Dubourg G,
Raoult D. ‘Enterococcus timonensis’ sp. nov., ‘Actinomyces
marseillensis’ sp. nov., ‘Leptotrichia massiliensis’ sp. nov.,
‘Actinomyces pacaensis’ sp. nov., ‘Actinomyces oralis’ sp. nov.,
‘Actinomyces culturomici’ sp. nov. and ‘Gemella massiliensis’
sp. nov., new bacterial species isolated from the human respiratory
microbiome. New Microbes New Infect. 2018;22:37–43.
http://dx.doi.org/10.1016/j.nmni.2017.12.005
Lagier JC, Bibi F, Ramasamy D, Azhar EI, Robert C, Yasir M, et al.
Non contiguous-finished genome sequence and description of
Clostridium jeddahense sp. nov. Stand Genomic Sci. 2014;9:1003–
19. http://dx.doi.org/10.4056/sigs.5571026
Dione N, Sankar SA, Lagier JC, Khelaifia S, Michele C,
Armstrong N, et al. Genome sequence and description of
Anaerosalibacter massiliensis sp. nov. New Microbes New Infect.
2016;10:66–76. http://dx.doi.org/10.1016/j.nmni.2016.01.002
Ramasamy D, Lagier JC, Rossi-Tamisier M, Pfleiderer A,
Michelle C, Couderc C, et al. Genome sequence and description of
Bacteroides timonensis sp. nov. Stand Genomic Sci. 2014;9:1181–
97. http://dx.doi.org/10.4056/sigs.5389564
Togo AH, Diop A, Dubourg G, Nguyen TT, Andrieu C, Caputo A,
et al. Butyricimonas phoceensis sp. nov., a new anaerobic species
isolated from the human gut microbiota of a French morbidly
obese patient. New Microbes New Infect. 2016;14:38–48.
http://dx.doi.org/10.1016/j.nmni.2016.07.010
Pham TP, Cadoret F, Tidjani Alou M, Brah S, Ali Diallo B,
Diallo A, et al. ‘Marasmitruncus massiliensis’ gen. nov., sp. nov.,
‘Clostridium culturomicum’ sp. nov., ‘Blautia provencensis’ sp.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
nov., ‘Bacillus caccae’ sp. nov. and ‘Ornithinibacillus massiliensis’
sp. nov., isolated from stool samples of undernourished African
children. New Microbes New Infect. 2017;19:38–42.
http://dx.doi.org/10.1016/j.nmni.2017.05.005
Angelakis E, Bibi F, Ramasamy D, Azhar EI, Jiman-Fatani AA,
Aboushoushah SM, et al. Non-contiguous finished genome
sequence and description of Clostridium saudii sp. nov. Stand
Genomic Sci. 2014;9:8. http://dx.doi.org/10.1186/1944-3277-9-8
Padmanabhan R, Dubourg G, Lagier JC, Couderc C, Michelle C,
Raoult D, et al. Genome sequence and description of
Corynebacterium ihumii sp. nov. Stand Genomic Sci. 2014;9:1128–
43. http://dx.doi.org/10.4056/sigs.5149006
Cresci M, Ibrahima Lo C, Khelaifia S, Mouelhi D, Delerce J,
Di Pinto F, et al. Corynebacterium phoceense sp. nov., strain
MC1T a new bacterial species isolated from human urine. New
Microbes New Infect. 2016;14:73–82. http://dx.doi.org/10.1016/
j.nmni.2016.09.001
Mourembou G, Rathored J, Ndjoyi-Mbiguino A, Lekana-Douki JB,
Fenollar F, Robert C, et al. Noncontiguous finished genome
sequence and description of Gabonia massiliensis gen. nov., sp.
nov. New Microbes New Infect. 2015;9:35–44. http://dx.doi.org/
10.1016/j.nmni.2015.11.002
Mishra AK, Edouard S, Dangui NP, Lagier JC, Caputo A,
Blanc-Tailleur C, et al. Non-contiguous finished genome sequence and
description of Nosocomiicoccus massiliensis sp. nov. Stand Genomic
Sci. 2013;9:205–19. http://dx.doi.org/10.4056/sigs.4378121
Mishra AK, Hugon P, Robert C, Raoult D, Fournier PE.
Non-contiguous finished genome sequence and description of
Peptoniphilus grossensis sp. nov. Stand Genomic Sci. 2012;7:320–
30. http://dx.doi.org/10.4056/sigs.3076460
Guilhot E, Lagier JC, Raoult D, Khelaifia S. ‘Prevotella ihumii’ sp.
nov. and ‘Varibaculum timonense’ sp. nov., two new bacterial species
isolated from a fresh human stool specimen. New Microbes New
Infect. 2017;18:3–5. http://dx.doi.org/10.1016/j.nmni.2017.03.002
Bardet L, Cimmino T, Buffet C, Michelle C, Rathored J, Tandina F,
et al. Microbial culturomics application for global health:
noncontiguous finished genome sequence and description of
Pseudomonas massiliensis strain CB-1T sp. nov. in Brazil. OMICS.
2018;22:164–75. http://dx.doi.org/10.1089/omi.2017.0027
Zhang L, Dong D, Jiang C, Li Z, Wang X, Peng Y. Insight into
alteration of gut microbiota in Clostridium difficile infection and
asymptomatic C. difficile colonization. Anaerobe. 2015;34:1–7.
http://dx.doi.org/10.1016/j.anaerobe.2015.03.008
Mendy A, Vieira ER, Albatineh AN, Gasana J. Staphylococcus
aureus colonization and long-term risk for death, United States.
Emerg Infect Dis. 2016;22:1966–9. http://dx.doi.org/10.3201/
eid2211.160220
Lewnard JA, Huppert A, Givon-Lavi N, Pettigrew MM,
Regev-Yochay G, Dagan R, et al. Density, serotype diversity, and
fitness of Streptococcus pneumoniae in upper respiratory tract
cocolonization with nontypeable Haemophilus influenzae. J Infect
Dis. 2016;214:1411–20. http://dx.doi.org/10.1093/infdis/jiw381
Bilen M, Dufour JC, Lagier JC, Cadoret F, Daoud Z, Dubourg G,
et al. The contribution of culturomics to the repertoire of isolated
human bacterial and archaeal species. Microbiome. 2018;6:94.
http://dx.doi.org/10.1186/s40168-018-0485-5
Lagier JC, Dubourg G, Million M, Cadoret F, Bilen M, Fenollar F,
et al. Culturing the human microbiota and culturomics. Nat Rev
Microbiol. 2018. http://dx.doi.org/10.1038/s41579-018-0041-0
Lagier JC, Dubourg G, Amrane S, Raoult D. Koch postulate: why
should we grow bacteria? Arch Med Res. 2017;48:774–9.
http://dx.doi.org/10.1016/j.arcmed.2018.02.003
Address for correspondence: Didier Raoult, IHU Méditerranée Infection,
19-21 Boulevard Jean Moulin, 13385 Marseille CEDEX 5, France;
email: didier.raoult@gmail.com
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
D I SPATCH ES
Associa t ion of Ba t a i Vir u s I n fe ct ion a n d
En ce ph a lit is in H a r bor Se a ls, Ge r m a n y, 2 0 1 6
Wendy K. Jo,1 Vanessa M. Pfankuche,1
Annika Lehmbecker, Byron Martina,
Ana Rubio-Garcia, Stefanie Becker,
Jochen Kruppa, Klaus Jung, Daniela Klotz,
Julia Metzger, Martin Ludlow,
Wolfgang Baumgärtner,
Erhard van der Vries,2 Albert Osterhaus
We isolated Batai virus from the brain of a euthanized,
26-year-old, captive harbor seal with meningoencephalomyelitis in Germany. We provide evidence that this orthobunyavirus can naturally infect the central nervous
system of a mammal. The full-genome sequence showed
differences from a previously reported virus isolate from a
mosquito in Germany.
B
atai virus (BATV) is a member of the Bunyamwera
serogroup of orthobunyaviruses of the family Peribunyaviridae. Orthobunyaviruses are single-stranded, negative-sense RNA viruses with a tripartite genome composed
of small, medium, and large segments, which encode nucleocapsid, glycoproteins, and polymerase, respectively
(1). These segments can be interchanged between viruses
of the same genus, resulting in stable reassortant bunyaviruses. For example, the Ngari virus genome consists of segments from BATV and Bunyamwera virus. Ngari virus is
associated with outbreaks of hemorrhagic fever in humans
and shows a clinical spectrum different from that of both
parent viruses (2).
BATV has been documented to cause mild illness in
ruminants and humans (3,4). Other hosts include domestic
pigs and wild birds (3). BATV is transmitted mainly by
Anopheles and Culex spp. mosquitoes and is widely distributed throughout Europe, Asia, and Africa (3).
In Germany, BATV was first detected in Anopheles maculipennis mosquitoes in 2009 (5). Enzootic
Author affiliations: University of Veterinary Medicine Hannover,
Hannover, Germany (W.K. Jo, V.M. Pfankuche, A. Lehmbecker,
S. Becker, J. Kruppa, K. Jung, D. Klotz, J. Metzger, M. Ludlow,
W. Baumgärtner, E. van der Vries, A. Osterhaus); Center for
Systems Neuroscience, Hannover (W.K. Jo, V.M. Pfankuche,
W. Baumgärtner, A. Osterhaus); Artemis One Health, Delft, the
Netherlands (B. Martina, A. Osterhaus); Seal Centre, Pieterburen,
the Netherlands (A. Rubio-Garcia)
DOI: https://doi.org/10.3201/eid2409.171829
transmission cycles involving domestic and wild mammals was reported in a serologic study in which 3 (0.55%)
of 548 cattle had BATV-neutralizing serum antibodies
(6). We report natural BATV infection of 2 captive harbor
seals (Phoca vitulina) in Germany, in which meningoencephalomyelitis developed in 1 of them.
The Study
In September 2016, a 26-year-old male harbor seal (Phoca
vitulina) in a zoo in northern Germany showed peracute
deterioration of its general condition. Because of progression and severity of illness, the seal was euthanized and
the carcass sent to the Department of Pathology, University of Veterinary Medicine Hannover (Hannover, Germany), for necroscopic analysis. Macroscopic examination showed signs of distress but no gross lesions were
detected. Histologic analysis showed a mild to moderate,
multifocal, perivascularly accentuated, lymphohistiocytic
meningoencephalomyelitis, which affected the cerebrum,
cerebellum (Figure 1, panel A), brain stem, medulla oblongata, and cervical spinal cord. Histologic analysis indicated a virus etiology.
Routine immunohistochemical tests of the seal brain
for morbilliviruses, Borna disease virus, and tick-borne
encephalitis virus (7,8) and immunofluorescence analysis
for rabies virus were performed by the Department of Consumer and Food Safety of Lower Saxony (Hannover, Germany). All tests showed negative results.
We attempted virus isolation from homogenized brain
in Vero cells. Cytopathic changes were observed within 3
days and continued to emerge in subsequent passages. To
identify the pathogen, we investigated supernatant from
the initial Vero cell isolation by using deep sequencing
and a modified sequence-independent, single-primer amplification protocol as described (9,10). Analysis of raw
reads with Bowtie 2 version 2.2.9 (https://sourceforge.net/
projects/bowtie-bio/files/bowtie2/2.2.9/) for DNA mapping and Pauda version 1.0.1 (https://bioconda.github.io/
recipes/pauda/README.html) for amino acid mapping
identified BATV.
We created a reference assembly for all 3 genome
segments (GenBank accession nos. S, MH299972; M,
MH299973; and L, MH299974) by using CLC Genomics
1
These authors contributed equally to this article.
2
Current affiliation: Utrecht University, Utrecht, the Netherlands.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1691
DISPATCHES
Figure 1. Histologic analysis and fluorescent in situ hybridization (FISH) of a Batai virus BATV)–infected harbor seal, Germany,
2016. A) Cerebellum showing mild to moderate, perivascularly accentuated, lymphohistiocytic inflammation (hematoxylin and eosin
stain; scale bar indicates 200 µm). B) Purkinje cells and neurons of granular cell layer showing intracytoplasmic BATV–specific pink,
positive result detected by FISH (fast red stain; scale bar indicates 200 µm). Inset: Higher magnification view of analysis using the
QuantiGene ViewRNA ISH Tissue 1-Plex Assay Kit and the QuantiGene ViewRNA Chromogenic Signal Amplification Kit (AffymetrixPanomics, Santa Clara, CA, USA) (fast red stain; scale bar indicates 20 µm). C) Scattered neurons of spinal cord showing a strong,
pink, intracytoplasmic BATV-specific result detected by FISH (fast red stain; scale bar indicates 100 µm). D) Cortical and medullary
lymphocytes of pulmonary lymph node showing a mild, pink, intracytoplasmic BATV-specific result detected by FISH (fast red stain;
scale bar indicates 20 µm). E). Negative control (incubation without probe) of spinal cord showing no BATV-specific result (fast red
stain; scale bar indicates 100 µm).
Workbench version 9.0 (QIAGEN, Hilden, Germany). The
isolated virus was closely related to previously identified
BATV strains from Europe (Figure 2) but had the highest
sequence homology with strains from Russia (nucleotide
pairwise identity S, 99%; M, 98.6%; and L, 98.5%).
We tested seal tissues (Table) for BATV by
using real-time PCR and fluorescent in situ hybridization (FISH) as described (5,12). We used
BATV-specific probe 5′-FAM-AACAGTCCAGTTCCAGACGATGGTC-BHQ-1-3′ and primers Fwd-5′GCTGGAAGGTTACTGTATTTAATAC-3′ and Rv-5′CAAGGAATCCACTGAGTCTGTG-3′ specific for the
S segment (5). A BATV-specific probe for nucleotides 28–
899 of the S segment was designed for FISH experiments
(QuantiGene ViewRNA Kits; Affymetrix-Panomics, Santa
Clara, CA, USA), which were performed according to the
manufacturer’s protocol with minor modifications (12).
The highest virus load (by real-time PCR) was found
in the central nervous system, and lesion-associated Purkinje cells and neurons of the granular cell layer of the
cerebellum showed positive FISH results (Figure 1, panel B). A positive cytoplasmic result was also obtained
for single spinal cord neurons (Figure 1, panel C). More
1692
limited BATV infection was found in peripheral organs,
and the lowest cycle threshold was for the intestine. We
also found BATV in single cells of the tunica mucosa of
the small intestine and in cortical and medullary lymphocytes of the pulmonary lymph node by FISH (Figure 1, panel D). Other organs showed negative results in
both assays.
We also performed histopathologic analysis of archived formalin-fixed paraffin-embedded (FFPE) organ
samples of a seal that had shared the enclosure with the
BATV-infected seal and had died 2 months before the euthanized seal showed the first clinical signs. Glomerular and
tubular epithelial kidney cells (online Technical Appendix
Figure, https://wwwnc.cdc.gov/EID/article/24/9/17-1829Techapp1.pdf), cells of the tunica mucosa of the small intestine, and cortical and medullary lymphocytes of the pulmonary lymph node showed positive results for BATV by
FISH. These FFPE samples did not show positive results
by real-time PCR, probably because of low sensitivity of
the assay for FFPE samples (13).
Retrospective analysis of FFPE brain samples of seals
(n = 7) that had histopathologic changes suggestive of an
unknown virus etiology and were isolated from harbor
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Batai Virus and Encephalitis in Harbor Seals
Figure 2. Bayesian phylogeny trees based on full-genome coding region sequences of small, medium, and large RNA segments of
Batai virus and comparison viruses. A) Small RNA segments (69–770 bp). Bunyamwera virus (GenBank accession no. D00353) was
used as the outgroup. B) Medium RNA segments (42–4,346 bp). Bunyamwera virus (GenBank accession no. M11852) was used as
the outgroup. C) Large RNA segments (49–6,762 bp). Bunyamwera virus (GenBank accession no. X14383) was used as the outgroup.
Bold indicates virus isolated in this study. Analysis was performed for 1 million generations and sampled every 100 steps. The first 25%
of samples were discarded as burn-in according to MrBayes (11). Hasegawa-Kishino-Yano nucleotide substitution model was selected
as best-fit model according to Bayesian information criteria. Numbers at the nodes indicate posterior probabilities percentage. GenBank
accession numbers are provided for comparison isolates; accession nos. of the isolated Batai virus strain PV424/DE-2016 are small,
MH299972; medium, MH299973; large, MH299974. Scale bars indicate nucleotide substitutions per site.
seals in coastal waters of Germany in the past decade all
had negative results for BATV by FISH. Therefore, we
screened 100 serum samples from harbor seals and 100
serum samples from gray seals (Halichoerus grypus) collected in 2016 and 2017 after admission to a seal rehabilitation center in the Netherlands that covers seal populations
partially overlapping those of coastal waters of Germany.
We neutralized isolated seal BATV (100 50% tissue culture infective doses) with diluted serum samples before
application to reporter cells and examined for cytopathic
effects after 3 days. However, no BATV antibodies (titer
>1:20) were detected.
Table. Analysis of a Batai virus–infected harbor seal with meningoencephalomyelitis, Germany, 2016*
Sample material
Brain
Lung
Spleen
Kidney
Pulmonary lymph node
Mesenteric lymph node
Liver
Small intestine
Large intestine
Nose
Heart
Stomach
Histopathologic finding
Cerebrum, cerebellum, brain stem, medulla oblongata, and cervical
spinal cord: mild to moderate, multifocal, and lymphohistiocytic
meningoencephalomyelitis, perivascularly accentuated; parietal lobe:
multiple glial nodules; thoracic spinal cord: mild to moderate and
multifocal meningitis, perivascularly accentuated, lymphohistiocytic with
few eosinophilic granulocytes; cauda equina: mild to moderate,
multifocal, and lymphohistiocytic perineuritis
Mild and multifocal anthracosis; acute, diffuse, and severe hyperemia;
acute, diffuse, and moderate edema
Moderate to severe and diffuse hyperemia
Mild, interstitial, and lymphohistiocytic nephritis with single, intratubular
concrements
Mild follicular hyperplasia
Mild to moderate follicular hyperplasia and hemosiderosis
Mild, multifocal, lymphohistiocytichepatitis, mild to moderate
hepatocellular storage of iron
Mild, diffuse, lymphoplasmacytic, and partially eosinophilic enteritis
NSML
NSML
NSML
NSML
Real-time PCR
(cycle threshold)†
+ (15)
FISH
+
– (>35)
–
– (35)
– (>35)
–
–
NI
NI
– (>35)
+
–
–
+ (28)
NI
NI
NI
NI
+
–
–
–
–
*FISH, fluorescent in situ hybridization; NI, not investigated; NSML, no major microscopic lesions; –, negative; +, positive.
†Negative result >35; positive result <35.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1693
DISPATCHES
Conclusions
We isolated and characterized BATV from the brain of a captive harbor seal in Germany. This seal had lymphohistiocytic
meningoencephalomyelitis and evidence of virus replication
in Purkinje cells, neurons, enterocytes, and lymphocytes in
peripheral tissues. Evidence of BATV infection by FISH
was also obtained for a second harbor seal that had died 2
months before in the same enclosure. No additional evidence
was found for seals as natural hosts for BATV infection by
investigating brains from seals with encephalitis in coastal
waters of Germany and by conducting a serosurvey among
free-living harbor and gray seals. Results obtained from the
2 BATV-infected animals indicated BATV circulation in
the area during the mosquito season and that captive seals
were possible dead-end hosts. Because seals in their natural environment are most likely less exposed to mosquitoes
than seals in captivity, the observed seal BATV infections
might be unnatural captivity-associated events. Phylogenetic
analysis indicated that BATV isolated from the seal brain
differed from BATV isolated from a mosquito in Germany
and is more closely related to strains identified in Russia.
This study provides evidence of BATV associated
with central nervous system disease in a naturally infected
mammal. Other orthobunyaviruses have also been shown
to cross the blood–brain barrier and show neurotropic properties (14). For example, a virus from the same serogroup,
Bunyamwera virus, was recently associated with neurologic disease and abortion in horses (15). Moreover, possible human BATV infection in disease-endemic regions
requires further investigation because BATV infection of
mammals, including humans, has been reported in Europe
(3) and Sudan (4).
Furthermore, BATV is the donor of the M segment of
Ngari virus, which causes hemorrhagic fever in humans
(2). The 2 BATV-infected seals could have been exceptionally sensitive to BATV infection because of predisposing factors, such as advanced age, concurrent conditions,
genetic predisposition, or immunologic deficiencies. This
possibility raises the question whether immunocompromised humans or other mammals might be at increased
risk for development of neurologic BATV infection. Collectively, our data indicate the need for increased surveillance of BATV infection in mosquitoes, mammals, and
birds in Europe.
Acknowledgments
We thank M. Tieke, M. Schubert, H. Heidtmann, B. Buck, and
P. Grünig for technical assistance; the Department of Consumer
and Food Safety of Lower-Saxony, Hannover, for investigative
work in searching for the causative agent; the Genomics
Laboratory at the Institute of Animal Breeding and Genetics,
Hannover, for performing analysis using the MiSeq system; and
Joachim Schöne for collaborating in the study.
1694
This study was supported by the Niedersachsen-Research
Network on Neuroinfectiology (grant N-RENNT) from the
Ministry of Science and Culture of Lower Saxony, Germany;
and the European Union Horizon 2020 research and innovation
program COMPARE (grant agreement no. 643476).
About the Author
Ms. Jo is a doctoral candidate at the University of Veterinary
Medicine Hannover Research Center for Emerging Infections
and Zoonoses, Hannover, Germany. Her research interests are
virus discovery, emerging and reemerging infectious diseases,
cross-species transmission of viruses, virus evolution, and
host adaptation.
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
Elliott RM. Orthobunyaviruses: recent genetic and structural
insights. Nat Rev Microbiol. 2014;12:673–85. http://dx.doi.org/
10.1038/nrmicro3332
Yanase T, Kato T, Yamakawa M, Takayoshi K, Nakamura K,
Kokuba T, et al. Genetic characterization of Batai virus indicates a
genomic reassortment between orthobunyaviruses in nature.
Arch Virol. 2006;151:2253–60. http://dx.doi.org/10.1007/
s00705-006-0808-x
Hubálek Z. Mosquito-borne viruses in Europe. Parasitol Res. 2008;
103(Suppl 1):S29–43. http://dx.doi.org/10.1007/s00436-008-1064-7
Nashed NW, Olson JG, el-Tigani A. Isolation of Batai virus
(Bunyaviridae:Bunyavirus) from the blood of suspected malaria
patients in Sudan. Am J Trop Med Hyg. 1993;48:676–81.
http://dx.doi.org/10.4269/ajtmh.1993.48.676
Jöst H, Bialonski A, Schmetz C, Günther S, Becker N,
Schmidt-Chanasit J. Isolation and phylogenetic analysis of
Batai virus, Germany. Am J Trop Med Hyg. 2011;84:241–3.
http://dx.doi.org/10.4269/ajtmh.2011.10-0483
Hofmann M, Wiethölter A, Blaha I, Jöst H, Heinemann P,
Lehmann M, et al. Surveillance of Batai virus in bovines from
Germany. Clin Vaccine Immunol. 2015;22:672–3. http://dx.doi.org/
10.1128/CVI.00082-15
Lempp C, Jungwirth N, Grilo ML, Reckendorf A, Ulrich A,
van Neer A, et al. Pathological findings in the red fox (Vulpes
vulpes), stone marten (Martes foina) and raccoon dog (Nyctereutes
procyonoides), with special emphasis on infectious and zoonotic
agents in Northern Germany. PLoS One. 2017;12:e0175469.
http://dx.doi.org/10.1371/journal.pone.0175469
Uhde AK, Lehmbecker A, Baumgärtner W, Spitzbarth I. Evaluation
of a panel of antibodies for the immunohistochemical identification
of immune cells in paraffin-embedded lymphoid tissues of
new- and old-world camelids. Vet Immunol Immunopathol.
2017;184:42–53. http://dx.doi.org/10.1016/j.vetimm.2017.01.001
Allander T, Emerson SU, Engle RE, Purcell RH, Bukh J. A virus
discovery method incorporating DNase treatment and its
application to the identification of two bovine parvovirus species.
Proc Natl Acad Sci U S A. 2001;98:11609–14. http://dx.doi.org/
10.1073/pnas.211424698
Endoh D, Mizutani T, Kirisawa R, Maki Y, Saito H, Kon Y, et al.
Species-independent detection of RNA virus by representational
difference analysis using non-ribosomal hexanucleotides for
reverse transcription. Nucleic Acids Res. 2005;33:e65.
http://dx.doi.org/10.1093/nar/gni064
Huelsenbeck JP, Ronquist F. MRBAYES: Bayesian inference
of phylogenetic trees. Bioinformatics. 2001;17:754–5.
http://dx.doi.org/10.1093/bioinformatics/17.8.754
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Batai Virus and Encephalitis in Harbor Seals
12.
Pfankuche VM, Bodewes R, Hahn K, Puff C, Beineke A,
Habierski A, et al. Porcine bocavirus infection associated
with encephalomyelitis in a Pig, Germany. Emerg Infect Dis.
2016;22:1310–2. http://dx.doi.org/10.3201/eid2207.152049
13. Bodewes R, Zohari S, Krog JS, Hall MD, Harder TC,
Bestebroer TM, et al. Spatiotemporal analysis of the genetic
diversity of seal influenza A(H10N7) virus, northwestern
Europe. J Virol. 2016;90:4269–77. http://dx.doi.org/10.1128/
JVI.03046-15
14. Ludlow M, Kortekaas J, Herden C, Hoffmann B, Tappe D,
Trebst C, et al. Neurotropic virus infections as the cause
of immediate and delayed neuropathology. Acta
Neuropathol. 2016;131:159–84. http://dx.doi.org/10.1007/
s00401-015-1511-3
15. Tauro LB, Rivarola ME, Lucca E, Mariño B, Mazzini R, Cardoso JF,
et al. First isolation of Bunyamwera virus (Bunyaviridae family)
from horses with neurological disease and an abortion in Argentina.
Vet J. 2015;206:111–4. http://dx.doi.org/10.1016/j.tvjl.2015.06.013
Address for correspondence: Albert Osterhaus, Research Center
for Emerging Infections and Zoonoses, University of Veterinary
Medicine, Bünteweg 17, Hannover D-30559, Germany; email:
albert.osterhaus@tiho-hannover.de
T he Public H e a lt h I m a ge Libr a r y (PH I L)
The Public Healt h
I m age Library ( PHI L) ,
Cent ers for Disease
Cont rol and Prevent ion,
cont ains t housands of
public healt h- relat ed
im ages, including
high- resolut ion ( print
qualit y) phot ographs,
illust rat ions, and videos.
PHI L collect ions illust rat e
current event s and
art icles, supply visual
cont ent for healt h
prom ot ion brochures,
document the effects of
disease, and enhance
inst ruct ional m edia.
PHI L im ages, accessible t o
PC and Macint osh users, are
in t he public dom ain and
available wit hout charge.
Visit PH I L a t :
h t t p:/ / ph il.cdc.gov/ ph il
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1695
DI SPATCHES
Use of Fa vipir a vir t o Tr e a t La ssa Vir u s
I n fe ct ion in M a ca qu e s
Kyle Rosenke, Heinz Feldmann,
Jonna B. Westover, Patrick William Hanley,
Cynthia Martellaro, Friederike Feldmann,
Greg Saturday, Jamie Lovaglio, Dana P. Scott,
Yousuke Furuta, Takashi Komeno,
Brian B. Gowen, David Safronetz
Lassa virus, the cause of Lassa fever in humans, is endemic to West Africa. Treatment of Lassa fever is primarily
supportive, although ribavirin has shown limited efficacy if
administered early during infection. We tested favipiravir in
Lassa virus–viremic macaques and found that 300 mg/kg
daily for 2 weeks successfully treated infection.
L
assa virus (LASV; family Arenaviridae, genus Mammarenavirus) is the etiologic agent of the severe
hemorrhagic disease Lassa fever. Annually, ≈300,000
persons become infected with LASV, 20% of which experience life-threatening clinical manifestations including edema, hemorrhage, and multiorgan failure, resulting
in an estimated 5,000 deaths (1). Most human infections
are acquired from the natural rodent reservoir, the multimammate rat (Mastomys natalensis). Human-to-human
transmission, mostly nosocomial, occurs (1). LASV has a
relatively well-defined region of endemicity exclusive to
West Africa. Incidence of LASV infections is highest in
Nigeria, Sierra Leone, Liberia, and Guinea, although sporadic cases and moderate outbreaks of Lassa fever have
been documented in many other West Africa nations (online Technical Appendix Figure 1, https://wwwnc.cdc.gov/
EID/article/24/9/18-0233-Techapp1.pdf) (2). Over several
decades, importation of Lassa fever into Europe, Asia, and
the Americas has increased (2).
Treatment of Lassa fever is largely supportive, although
ribavirin is used off label, despite side effects and limited
Author affiliations: National Institutes of Health, Hamilton,
Montana, USA (K. Rosenke, H. Feldmann, P.W. Hanley,
C. Martellaro, F. Feldmann, G. Saturday, J. Lovaglio, D.P. Scott);
University of Manitoba, Winnipeg, Manitoba, Canada
(H. Feldmann, D. Safronetz); Utah State University, Logan, Utah,
USA (J.B. Westover, B.B. Gowen); Toyama Chemical Co., Ltd.,
Toyama, Japan (Y. Furuta, T. Komeno); Public Health Agency of
Canada, Winnipeg (D. Safronetz)
DOI: https://doi.org/10.3201/eid2409.180233
1696
efficacy data (3). Recently, the antiviral favipiravir (T-705;
6-fluoro-3-hydroxy-2-pyrazinecarboxamide) has gained attention as a broad-spectrum antiviral drug against RNA viruses (4) including LASV; initial studies using small animal
models have been conducted (5,6). We assessed the antiviral
efficacy of favipiravir in LASV-infected cynomolgus macaques; this animal model reliably recapitulates several hallmarks of Lassa fever infection in humans (7).
The Study
We randomly divided 8 female cynomolgus macaques
(Macaca fascicularis) into 2 groups of 4 each (treatment
and control) and injected each animal intramuscularly with
a lethal dose of LASV, strain Josiah (1 × 104 50% tissue
culture infective dose [TCID50]) (Table). Treatment began
at 4 days postinfection (dpi), 1 day after the onset of viremia (7). The initial treatment (300 mg/kg favipiravir) was
administered intravenously; subsequent treatments (300
mg/kg favipiravir every 24 h for 13 d) were administered
subcutaneously. The dosage was based on the successful treatment of Lassa fever in guinea pigs (5). To avoid
the confounding effects of ribavirin, we did not give it in
combination. LASV-infected control animals received an
equivalent volume of vehicle by the same route and schedule. Animals were assessed twice daily; physical examinations, including hematologic, blood chemistry, and virologic assessments, were conducted regularly.
Reduced activity and appetite, probably resulting from
being anesthetized daily, was noted early in animals in both
groups (Figure 1, panel A). At 6 dpi (2 d after treatment
began), clinical scores for 3 of 4 animals in the treatment
group plateaued and remained consistent for the remainder
of the study. Although the score for the remaining animal
was higher, all favipiravir-treated animals survived LASV
challenge (p<0.01; Figure 1, panel B). In contrast, clinical
scores for the control group increased dramatically after 8
dpi; all control animals displayed anorexia, hunched posture, piloerection, and lethargy (Figure 1, panel A). The
control animals reached the humane endpoint and were euthanized on 10, 11, and 12 dpi (Figure 1, panel B).
Although we detected viral RNA by quantitative PCR as
early as 3 dpi (online Technical Appendix Figure 2, panel A),
at no time was infectious LASV isolated from blood (Figure
1, panel C) or postmortem tissue samples (data not shown)
from animals in the favipiravir group. However, in the
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Favipiravir to Treat Lassa Virus, Macaques
Table. Study design for treatment of Lassa virus infection in cynomolgus macaques*
Study, no.
animals
Treatment
Frequency†
Dose, mg/kg
Loading dose, mg/kg Total daily dose, mg/kg
First
4
Placebo
Every 24 h
Volume equivalent
Volume equivalent
Volume equivalent
4
Favipiravir
Every 24 h
300
300
300
Second
4
Placebo
Every 8 h
Volume equivalent.
Volume equivalent
Volume equivalent
4
Favipiravir
Every 8 h
50
300
150
Survived/total,
no.
0/4
4/4
0/4
0/4
*All animals were challenged with a previously determined lethal dose of 104 50% tissue culture infective dose of Lassa virus (strain Josiah) via
intramuscular injection. At day 4 after infection, a time coinciding with the earliest onset of detectable viremia, treatment with placebo or drug was initiated
by intravenous injection of the loading dose followed by daily (days 5–17) subcutaneous dosing. Animals were examined daily for clinical signs of disease,
and samples were taken for hematologic, blood chemistry, and virologic analyses at 12 times throughout the study, beginning on the day of virus
challenge and ending on day 56 after infection.
†For 14 d.
control animals, increased liver enzyme levels were detected
at 6 dpi, coinciding with infectious LASV (Figure 1, panels D, E). One animal in the favipiravir group demonstrated
moderately increased levels of alanine aminotransferase and
aspartate aminotransferase at 6–12 dpi, which resolved after treatment cessation. In the control animals, albumin and
Figure 1. Effect of daily
favipiravir treatments on
morbidity and mortality rates,
viral loads, and selected blood
chemistry and hematology
values during the course of the
efficacy study in cynomolgus
macaques challenged with
104 TCID50 of Lassa virus.
Groups of 4 animals each
were given 300 mg/kg/d of
favipiravir or placebo for 14
consecutive days, beginning
on day 4 postinfection. A)
Daily clinical scores (dotted
line indicates euthanasia
score of 35). B) Survival
curve (*p<0.01 compared
with placebo-treated animals
by the Mantel-Cox log-rank
test). C) Viremia as assessed
by TCID50 assay. D) Alanine
aminotransferase levels. E)
Aspartate aminotransferase
levels. F) Albumin levels. G)
Total protein levels. H) Platelet
levels. TCID50, 50% tissue
culture infective dose.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1697
DISPATCHES
Figure 2. Histologic and in situ
hybridization analyses of livers
from cynomolgus macaques
infected with Lassa virus (LASV) (1
× 104 50% tissue culture infective
dose [TCID50]) and treated 1 time
daily with favipiravir (treated)
or vehicle only (control). A–B)
Histologic analyses. A) Control,
showing multifocal neutrophilic
infiltrates with hepatocyte
necrosis and degeneration
(original magnification ×40).
Inset shows hepatocyte necrosis
(original magnification ×400).
B) Treated, showing essentially
healthy hepatic tissue (original
magnification ×40). Inset shows
healthy hepatic tissue (original
magnification ×400). C–D) In situ
hybridization analyses. C) Control,
showing multifocal and coalescing
viral RNA detected within
hepatocytes (original magnification
×100). D) Treated, showing no
viral RNA detected (original
magnification ×100).
total protein levels decreased dramatically throughout LASV
infection; in the favipiravir-treated animals, these levels displayed a more moderate decrease before returning toward
reference levels (Figure 1, panels F, G).
Hematologic profiles were less uniform between the
2 groups, although we observed several abnormalities previously associated with LASV infection (online Technical Appendix Figure 3). After an initial increase, platelet
counts in the control animals consistently decreased until
euthanasia. In 2 of the favipiravir-treated animals, a similar
increase was noted initially; however, a marked decrease
occurred at 6 dpi (Figure 1, panel H). Platelet levels rebounded by 9 dpi and continued to increase. In addition,
all 4 favipiravir-treated animals had lipemia (>301 mg/dL)
during the treatment phase of the study (4–18 dpi).
Histopathologic examination of livers from control
animals demonstrated hepatitis with neutrophil invasion
and substantial steatosis, consistent with Lassa fever in
this model (Figure 2, panel A) (7). In contrast, livers from
favipiravir-treated animals showed no abnormalities (Figure 2, panel B). In situ hybridization detected LASV RNA
within hepatocytes of control animals but not treated animals (Figure 2, panels C, D).
Conclusions
Over the past 3 years, total numbers of Lassa fever cases
and case-fatality rates among humans have increased (8).
The current Lassa fever outbreak in Nigeria and Benin continues to show large numbers of Lassa fever cases and case1698
fatality rates >30% (8), again highlighting the lack of available treatments. Furthermore, the recent person-to-person
transmission of LASV in Germany (9) serves as a reminder
that Lassa fever is of global health concern.
Lassa fever patients are largely managed by supportive
care in combination with ribavirin (3). Experimental efficacy of ribavirin was initially tested in a Lassa fever rhesus
macaque model in which intramuscular injections 3 times
daily for 14 days improved survival rates (10). In clinical
trials in Sierra Leone, both oral and intravenous ribavirin
increased survival rates of Lassa fever patients (11). Oral
dosing of ribavirin has since remained the standard of
treatment for Lassa fever, despite unproven efficacy from
clinical studies (3,12). Moreover, side effects of ribavirin
therapy have resulted in noncompliance (12).
The successful daily administration of favipiravir to macaques at an elevated dosing regimen of 300 mg/kg/d may
partially explain the transient thrombocytopenia, elevated
liver enzyme levels, and lipemia found in this study. Experimentally, favipiravir is a well-known broad-spectrum antiviral drug with in vitro inhibitory activity against a multitude
of RNA viruses (4). In Japan, favipiravir is approved for influenza treatment; in the United States, phase 3 clinical trials
for the same indication have been completed (4). During the
West Africa Ebola outbreak, favipiravir was administered to
humans on an emergency basis under a different dosing regimen, but effectiveness was limited (13). We therefore designed a second study that more closely followed the dosing
in the Ebola trial (50 mg/kg every 8 h) (13). However, this
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Favipiravir to Treat Lassa Virus, Macaques
multiple dose per day format failed to protect cynomolgus
macaques from Lassa fever and did not alter disease progression (Table; online Technical Appendix Figure 1, panel B,
and Figure 4, panels A–D). Of note, the high-dose favipiravir therapy in macaques successfully abated the pathophysiologic parameters associated with LASV infection, resulting
in survival. These results suggest that low doses of favipiravir have limited therapeutic effect, whereas higher doses are
therapeutic and will improve clinical outcomes.
Favipiravir was recently administered in combination
with ribavirin to successfully treat Lassa fever in 2 human
patients. Although it is not possible to determine how effective favipiravir was in controlling these 2 cases, administration reduced viremia in both patients (9). Combination
therapy with favipiravir and ribavirin in immunocompromised mice with LASV infection showed efficacy with
suboptimal doses of each drug (6). The synergistic effect
of the 2 compounds is also supported by several other studies in rodents (14). Recently, human monoclonal antibody
therapy protected cynomolgus macaques from LASV infection (15). Combination therapy with favipiravir may be
a future therapeutic strategy (15). On the basis of our findings, improved favipiravir tolerability in humans (4), availability of an oral formulation, and its advanced preclinical
status (according to the US Food and Drug Administration), we recommend that favipiravir enter clinical trials as
a treatment for Lassa fever.
Acknowledgments
We thank the Rocky Mountain Veterinary Branch of the
National Institute of Allergy and Infectious Diseases (NIAID),
National Institutes of Health (NIH), for animal care and
veterinary clinical support.
The study was supported in part by the Intramural Research
Program, NIAID, NIH, and the Rocky Mountain Regional
Center of Excellence for Biodefense and Emerging Infectious
Disease Research, NIAID, NIH (subaward to B.B.G. as part of
NIH grant U54 AI-065357). The funders of the study were not
involved in the analysis, interpretation, or discussions associated
with publication of these data.
Y.F. and T.K. are employees of Toyama Chemical Co., the
manufacturers of favipiravir. All other authors declare no
conflict of interest.
About the Author
Dr. Rosenke is a microbiologist in the Laboratory of Virology,
NIAID, NIH. His research interests are the epidemiology,
ecology, pathogenesis, and treatment of emerging viral diseases.
References
1.
Yun NE, Walker DH. Pathogenesis of Lassa fever. Viruses.
2012;4:2031–48. http://dx.doi.org/10.3390/v4102031
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
Sogoba N, Feldmann H, Safronetz D. Lassa fever in West Africa:
evidence for an expanded region of endemicity. Zoonoses Public
Health. 2012;59(Suppl 2):43–7. http://dx.doi.org/10.1111/
j.1863-2378.2012.01469.x
Bausch DG, Hadi CM, Khan SH, Lertora JJ. Review of the
literature and proposed guidelines for the use of oral ribavirin
as postexposure prophylaxis for Lassa fever. Clin Infect Dis.
2010;51:1435–41. http://dx.doi.org/10.1086/657315
Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF,
Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase
inhibitor. Antiviral Res. 2013;100:446–54. http://dx.doi.org/
10.1016/j.antiviral.2013.09.015
Safronetz D, Rosenke K, Westover JB, Martellaro C, Okumura A,
Furuta Y, et al. The broad-spectrum antiviral favipiravir protects
guinea pigs from lethal Lassa virus infection post-disease onset. Sci
Rep. 2015;5:14775. http://dx.doi.org/10.1038/srep14775
Oestereich L, Rieger T, Lüdtke A, Ruibal P, Wurr S, Pallasch E,
et al. Efficacy of favipiravir alone and in combination with ribavirin
in a lethal, immunocompetent mouse model of Lassa fever. J Infect
Dis. 2016;213:934–8. http://dx.doi.org/10.1093/infdis/jiv522
Hensley LE, Smith MA, Geisbert JB, Fritz EA,
Daddario-DiCaprio KM, Larsen T, et al. Pathogenesis of Lassa
fever in cynomolgus macaques. Virol J. 2011;8:205.
http://dx.doi.org/10.1186/1743-422X-8-205
World Health Organization. Weekly bulletin on outbreaks and other
emergencies [cited 2018 Feb 5]. http://apps.who.int/iris/bitstream/
handle/10665/260122/OEW5-2701222018.pdf;jsessionid=D19D5C
05BE101587B3AC601D56544764?sequence=1
Raabe VN, Kann G, Ribner BS, Morales A, Varkey JB, Mehta AK,
et al.; Emory Serious Communicable Diseases Unit. Favipiravir
and ribavirin treatment of epidemiologically linked cases of Lassa
fever. Clin Infect Dis. 2017;65:855–9. http://dx.doi.org/10.1093/
cid/cix406
Jahrling PB, Hesse RA, Eddy GA, Johnson KM, Callis RT,
Stephen EL. Lassa virus infection of rhesus monkeys: pathogenesis
and treatment with ribavirin. J Infect Dis. 1980;141:580–9.
http://dx.doi.org/10.1093/infdis/141.5.580
McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB,
Johnson KM, et al. Lassa fever. Effective therapy with
ribavirin. N Engl J Med. 1986;314:20–6. http://dx.doi.org/10.1056/
NEJM198601023140104
Hadi CM, Goba A, Khan SH, Bangura J, Sankoh M, Koroma S,
et al. Ribavirin for Lassa fever postexposure prophylaxis. Emerg Infect
Dis. 2010;16:2009–11. http://dx.doi.org/10.3201/eid1612.100994
Sissoko D, Laouenan C, Folkesson E, M’Lebing AB, Beavogui AH,
Baize S, et al.; JIKI Study Group. Experimental treatment with
favipiravir for Ebola virus disease (the JIKI Trial): a historically
controlled, single-arm proof-of-concept trial in Guinea. PLoS
Med. 2016;13:e1001967. http://dx.doi.org/10.1371/journal.
pmed.1001967
Westover JB, Sefing EJ, Bailey KW, Van Wettere AJ, Jung KH,
Dagley A, et al. Low-dose ribavirin potentiates the antiviral activity
of favipiravir against hemorrhagic fever viruses. Antiviral Res.
2016;126:62–8. http://dx.doi.org/10.1016/j.antiviral.2015.12.006
Mire CE, Cross RW, Geisbert JB, Borisevich V, Agans KN,
Deer DJ, et al. Human-monoclonal-antibody therapy protects
nonhuman primates against advanced Lassa fever. Nat Med.
2017;23:1146–9. http://dx.doi.org/10.1038/nm.4396
Address for correspondence: Heinz Feldmann, National Institutes of
Health, Laboratory of Virology, Rocky Mountain Laboratories, 903
S 4th St, Hamilton, MT 59840, USA; email: feldmannh@niaid.nih.gov;
David Safronetz, National Microbiology Laboratory, PHAC, Viral
Zoonoses, 1015 Arlington St, Winnipeg, MB R3E 3R2, Canada;
email: david.safronetz@phac-aspc.gc.ca
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1699
DI SPATCHES
Aor t ic En dogr a ft I n fe ct ion w it h
M ycoba ct e r iu m ch im a e r a a n d
Gr a n u lica t e lla a dia ce n s, Sw it ze r la n d, 2 0 1 4
Andreas Plate, Thomas A. Kohl,
Peter M. Keller, Sabine Majer,
Rosamaria Fulchini, Carol Strahm,
Cristoforo Medugno, Zoran Rancic,
Lars Husmann, Hugo Sax,
Stefan Niemann, Barbara Hasse
We describe an aortic endograft infection caused by Mycobacterium chimaera and Granulicatella adiacens, successfully treated with prolonged antimicrobial drug therapy after
complete explantation of the infected endoprosthesis and
extra-anatomical reconstruction. Whole-genome sequencing analysis did not indicate a close relationship to bacterial
strains known to cause infections after cardiac surgery.
A
ortic endograft infection (AGI) is a serious complication of aortic repair, and treatment involves prolonged
antimicrobial drug therapy and complete or partial graft
explantation with subsequent in situ or extra-anatomic arterial reconstruction. AGI attributable to nontuberculous
mycobacteria (NTM) is a rare condition, and sporadic cases
have been described (1). Mycobacterium chimaera is a slowgrowing NTM and a member of the M. avium complex. Recent publications show the emergence of disseminated M.
chimaera infections occurring after open heart surgery (2).
A field investigation identified contaminated heater–cooler
units (HCUs) as the source of infection (3,4). In addition to
valve reconstructions, these cases also involved thoracic aortic grafts. We describe an abdominal AGI caused by M. chimaera and Granulicatella adiacens. Our aim was to find the
Author affiliations: University Hospital Zurich, Zurich, Switzerland
(A. Plate, Z. Rancic, L. Husmann, H. Sax, B. Hasse); Research
Center Borstel–Leibniz-Center for Medicine and Biosciences,
Borstel, Germany (T.A. Kohl, S. Niemann); German Center for
Infection Research, Borstel (T.A. Kohl, S. Niemann); National
Center for Mycobacteria, University of Zurich, Zurich (P.M. Keller);
Institute of Medical Microbiology, University of Zurich, Zurich
(P.M. Keller); Cantonal Hospital Münsterlingen, Münsterlingen,
Switzerland (S. Majer); Cantonal Hospital St. Gallen, St. Gallen,
Switzerland (R. Fulchini, C. Strahm); Cantonal Hospital
Frauenfeld, Frauenfeld, Switzerland (C. Medugno)
DOI: https://doi.org/10.3201/eid2409.180247
1700
source of the M. chimaera infection by using whole-genome
sequencing (WGS) to compare the patient’s isolate to strains
implicated in infections known to occur after cardiac surgery.
The Study
In March 2014, a formerly healthy 60-year-old man underwent an elective endovascular aortic repair because of an
infrarenal aortic aneurysm. In May 2015, the patient sought
medical care for low back pain radiating into the left leg.
Laboratory examinations showed elevated C-reactive protein (57 mg/L [reference range <5 mg/L]), leukocytosis (14.8
g/L [reference range <9 g/L]), and acute kidney injury (estimated glomerular filtration rate 44 mL/min [reference range
>80 mL/min]). A 18Fluorodeoxyglucose positron emission
tomography–computed tomography (PET–CT) examination indicated an AGI and showed an abscess formation in
the iliopsoas muscle in close contact with the left common
iliac artery; the intraoperative situs was highly suspicious
for AGI, including erosion of the left common iliac artery
and a visible endograft. The patient was transferred to the
University Hospital Zurich (Zurich, Switzerland) for repeat
surgery. The surgical procedure entailed complete endoprosthesis removal, closure of the aortic stump below the renal
arteries with polypropylene sutures, and omentum coverage.
All tissues were debrided, and treatment included vacuumassisted open-abdomen treatment. Perfusion of the lower
limbs’ arteries was maintained with an axillo-bifemoral reconstruction using a polytetrafluoroethylene graft (Figure 1).
Deep wound cultures obtained during surgical revisions revealed M. chimaera (in 3/3 cultures) and Granulicatella adiacens (in 4/18 cultures). Histopathologic test
results were compatible with mycobacterial infection (online Technical Appendix Tables 1, 2, https://wwwnc.cdc.
gov/EID/article/24/9/18-0247-Techapp1.pdf). Results of
blood cultures and mycobacteriologic blood and sputum
cultures remained negative. The patient received a combination therapy containing clarithromycin, rifabutin, ethambutol, and amikacin in the early postoperative phase. After
6 weeks, amikacin was replaced by moxifloxacin. For coverage of G. adiacens, amoxicillin was added to the regimen. We treated the patient for a total of 12 months after
the extra-anatomic reconstruction. Several PET–CT scans
showed a complete metabolic response.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Aortic Endograft Infection, Switzerland, 2014
Figure 1. Preoperative, intraoperative, and postoperative images in the case of a patient who received an abdominal aortic
endograft and was later diagnosed with Mycobacterium chimaera and Granulicatella adiacens infection, Switzerland, 2014.
A) 18Fluorodeoxyglucose positron emission tomography–computed tomography scan at diagnosis indicating a strong, metabolically
active (maximum standard uptake value 9.7) aortic endograft infection and an adjacent abscess formation in the iliopsoas in close
contact with the left common iliac artery. B) Intraoperative extra-anatomic position of a polytetrafluoroethylene graft through noninfected
subcutaneous operative field. C) Satisfactory postoperative result of the axillo-bifemoral bypass on volume-rendered reconstructions of
a contrast-enhanced computed tomography.
The diagnostic workup in May 2015 revealed an incidental 5-mm small pulmonary nodulus in the right upper lobe, which was observed to be metabolically active in
PET–CT. After recovery from the abdominal intervention,
the patient underwent wedge resection, and a localized squamous-cell carcinoma of the lung was confirmed. In April
2016, a relapse of his neoplasia occurred. Despite intensified
chemotherapy, the patient died in August 2017 because of
progressive pulmonary cancer; no autopsy was performed.
We cultured mycobacteriologic samples in BD MGIT
tubes (BD, Franklin Lakes, NJ, USA) on Middlebrook
7H11 agar plates (BD) according to previously published
methods (3). Air and water mycobacterial cultures were
performed as suggested by the European Centre for Disease Prevention and Control (5).
We analyzed WGS data from the patient’s isolate and
strains from published studies (2,6–10) by using a reference mapping approach with the M. chimaera DSM-44623
genome (GenBank accession no. NZ_CP015278.1), aided
by Burrows-Wheeler Aligner (http://bio-bwa.sourceforge.
net), SAMtools (http://samtools.sourceforge.net/cns0.
shtml), and GATK (https://software.broadinstitute.org/
gatk) software. We combined variant positions to construct
a phylogenetic tree with DnaSP 5.0 (http://www.ub.edu/
dnasp/index_v5.html), FastTree (http://www.microbes
online.org/fasttree), FigTree (http://tree.bio.ed.ac.uk/
software/figtree), and EvolView (http://www.evolgenius.
info/evolview) software (online Technical Appendix).
The HCU-related outbreak of disseminated M. chimaera infections led us to investigate the hybrid operating
Table. Microbiologic test results of air and water samples from the operating room where an abdominal aortic endograft was
performed on a patient later diagnosed with Mycobacterium chimaera and Granulicatella adiacens infection, Switzerland, 2014
Sample no.
Type
Place of sampling
Result
1
Water
NaCl heater machine
Negative
2
Water
Respirator 1, suction water tank ID 3393
Negative
3
Water
Respirator 1, breathing hose
Negative
4
Water
Respirator 2, suction water tank
Negative
5
Water
Respirator 2, breathing hose
Negative
6
Water
Operating pre-theater, wash basin, siphon
M. intracellulare*
7
Water
Operating pre-theater, wash basin, cold water
Negative
8
Water
Operating pre-theater, wash basin, hot water
Negative
9
Water
Operating pre-theater, sink, siphon
Negative
10
Water
Operating pre-theater, sink, cistern
Negative
11
Water
Operating pre-theater, sink, cold water
M. paragordonae
12
Water
Scrub room 2, right side, wash basins 1–3, siphon water
Negative
13
Water
Scrub room 2, right side, wash basins 1–3, after flushing
Negative
14
Water
Scrub room 2, left side, wash basins 4–6, siphon water
Negative
15
Water
Scrub room 2, left side, wash basins 4–6, after flushing
Negative
16
Water
Operating pre-theater, sink, warm water
Negative
17
Air
Air sample 1
Negative
18
Air
Air sample 2
Negative
19
Air
Air sample 3
Negative
20
Air
Air sample 4
Negative
21
Air
Air sample 5
Negative
*Misidentification of M. chimaera excluded by partial 16S rDNA sequencing.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1701
DISPATCHES
Figure 2. Phylogeny of isolate
from case-patient who received
an abdominal aortic endograft
and was later diagnosed with
Mycobacterium chimaera and
Granulicatella adiacens infection,
Switzerland, 2014, and comparison
isolates. Maximum-likelihood
tree was built from 14,192 singlenucleotide polymorphism positions
of 437 group 1 Mycobacterium
chimaera isolates mapped to
the DSM-44623 M. chimaera
genome (GenBank accession
no. NZ_CP015278.1). DSM44623 is shown as a rectangular
phylogram with the inferred
subgroups indicated. Inset box
shows subgroups 1.8, 1.11, and
1.Branch1, annotated with isolate
origin and the source publication.
Black arrow indicates position of
the patient isolate. Group 1.11
consisted mainly of samples
collected at the Maquet production
site in Rastatt, Germany (n = 12);
1 isolate came from an in-use
Maquet HCU. Branch 1 contained
primarily strains from patients
with pulmonary M. chimaera
infections (n = 70) and strains
from LivaNova HCUs (n = 4),
Maquet HCUs (n = 3), Maquet
ECMOs (n = 11), a hospital-built
HCU (n = 1), Maquet production
site (n = 1), and a patient infected
after cardiac surgery (n = 1).
ECMO, extracorporeal membrane
oxygenation; HCU, heater–cooler
unit. Scale bars indicate numbers
of substitutions per site.
room where the patient had undergone his initial surgery
(online Technical Appendix Figure). The referring hospital did not use HCUs or extracorporeal membrane oxygenation devices. In summer 2015, we obtained water and
air samples from the operating room (Table); results were
negative for M. chimaera.
According to a signature single-nucleotide polymorphism–based classification, the patient isolate was similar
to the group 1 strains of M. chimaera (2). We therefore
included all group 1 strains with sufficient WGS data from
published studies together with the patient isolate in a combined analysis of a total of 437 strains (Figure 2). The patient isolate did not cluster with subgroup 1.1, which represented all but 1 of the reported cases of disseminated M.
chimaera infections associated with contaminated HCUs.
1702
Instead, the patient strain clustered with strains from subgroup 1.11 and branch 1 of group 1 (2); however, the patient strain had no close relationship to any other strain included in the comparison.
The endoprosthetic graft (Excluder RMT261214/
PXC121200) of our patient was produced by Gore Medical
(Newark, DE, USA). The Swiss Agency for Therapeutic
Products submitted a medical device report for the implicated graft to the manufacturer.
Conclusions
We report an endovascular AGI caused by M. chimaera
and G. adiacens, which was successfully treated with
extra-anatomic bypass and prolonged antimicrobial therapy. Because of the histopathology results showing focal
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Aortic Endograft Infection, Switzerland, 2014
granulomatous necrotizing inflammation and detection
of sparse acid-fast rods in Ziehl Neelsen stain, we outweighed the importance of M. chimaera compared with
G. adiacens.
Patients at risk for NTM infections are elderly patients with preexisting pulmonary conditions or immunocompromised patients. At AGI diagnosis, the localized
pulmonic cancer in this patient was in an early stage, and
the patient was not known to be immunocompromised.
Blood cultures and repeated sputum specimens were
negative for mycobacteria, and PET–CT did not reveal
any distant foci. Therefore, we considered a hematogenous spread of a localized and naturally acquired infection to be unlikely. Water and air samples from the operating room were negative for M. chimaera; thus, local
contamination in the operating room was unlikely. When
we compared the patient’s isolate with other available M.
chimaera strains with available WGS data (2,6–10), we
observed no association with the cardiac surgery cluster or any other closely related strain in the collection.
Because the cardiac surgery cluster originated from M.
chimaera–contaminated water in medical devices, a contamination of the medical prosthesis at the production site
was considered, especially because the poorly soluble
polytetrafluoroethylene polymerization is conducted as
an emulsion in purified water. However, according to the
graft manufacturer, its grafts are produced in a controlled
environment, and ethylene oxide gas (EOG) is used for
sterilization as recommended by the International Organization for Standardization (standard no. 11135-2007).
EOG is widely used because of its good bactericidal activity on many bacterial species and even bacillus spores
(11). However, studies showing the effect of EOG on
mycobacteria are lacking, and cases of NTM infections
caused by inadequate implant sterilization have been reported (12). As the logical next step in the investigation,
testing environmental water samples from the production
site or from fresh implants for NTM contamination was
proposed. However, because of a paperwork assessment,
the company decided not to pursue the case further.
Because our investigation involved a single case of an
abdominal AGI caused by M. chimaera and G. adiacens, it
is too early to draw any conclusions. If further infections
emerge, investigations into the adequacy of EOG sterilization for arterial implants should be conducted. In this case,
the combination of prolonged antimicrobial therapy, graft
explantation, and extra-anatomic reconstruction resulted in
sustained healing.
Acknowledgments
We thank Marisa Kälin, Michael Greiner, and Ivo Fuchs for
excellent patient care. We thank Matthias Schlegel for assistance
in the outbreak investigation.
The patient was a member of the University Hospital
Zurich’s Vascular Graft Cohort Study (VASGRA). VASGRA
is supported, in part, by grants to B.H. from the Swiss
National Science Foundation (grant nos. 32473B_163132/1 and
32473B_163132/2). Parts of the work were funded by the
German Center for Infection Research. Members of the
VASGRA Cohort Study are (in alphabetical order): Alexia
Anagnostopoulos, Barbara Hasse (principal investigator),
Lars Husmann, Peter Keller, Bruno Ledergerber, Mario Lachat,
Dieter Mayer, Zoran Rancic, Alberto Weber, Rainer Weber,
Reinhard Zbinden, and Annelies Zinkernagel.
About the Author
Dr. Plate is an internal medicine specialist working as an
infectious disease fellow in the Division of Infectious Diseases
and Hospital Epidemiology, University Hospital Zurich,
Switzerland. His primary research interests are epidemiology
and foreign body–associated infections.
References
1.
2.
3.
4.
5.
6.
7.
8.
Tsilimparis N, Defreitas D, Debus ES, Reeves JG. Latent
Mycobacterium avium infection causing a mycotic suprarenal
aortic aneurysm in a human immunodeficiency virus-positive
patient. Ann Vasc Surg. 2014;28:1035.e1–4. http://dx.doi.org/
10.1016/j.avsg.2013.06.036
van Ingen J, Kohl TA, Kranzer K, Hasse B, Keller PM,
Katarzyna Szafrańska A, et al. Global outbreak of severe
Mycobacterium chimaera disease after cardiac surgery: a
molecular epidemiological study. Lancet Infect Dis. 2017;
17:1033–41. http://dx.doi.org/10.1016/S1473-3099(17)30324-9
Sax H, Bloemberg G, Hasse B, Sommerstein R, Kohler P,
Achermann Y, et al. Prolonged outbreak of Mycobacterium
chimaera infection after open-chest heart surgery. Clin Infect Dis.
2015;61:67–75. http://dx.doi.org/10.1093/cid/civ198
Marra AR, Diekema DJ, Edmond MB. Mycobacterium chimaera
infections associated with contaminated heater-cooler devices
for cardiac surgery: outbreak management. Clin Infect Dis.
2017;65:669–74. http://dx.doi.org/10.1093/cid/cix368
European Centre for Disease Prevention and Control. EU protocol
for case detection, laboratory diagnosis and environmental testing
of Mycobacterium chimaera infections potentially associated
with heater-cooler units: case definition and environmental testing
methodology. Stockholm: European Centre for Disease Prevention
and Control; 2015 [cited 2018 Jun 27]. https://ecdc.europa.eu/en/
publications-data/eu-protocol-case-detection-laboratory-diagnosisand-environmental-testing
Chand M, Lamagni T, Kranzer K, Hedge J, Moore G, Parks S,
et al. Insidious risk of severe Mycobacterium chimaera infection
in cardiac surgery patients. Clin Infect Dis. 2017;64:335–42.
http://dx.doi.org/10.1093/cid/ciw754
Perkins KM, Lawsin A, Hasan NA, Strong M, Halpin AL,
Rodger RR, et al. Mycobacterium chimaera contamination of
heater-cooler devices used in cardiac surgery—United States.
MMWR Morb Mortal Wkly Rep. 2016;65:1117–8.
http://dx.doi.org/10.15585/mmwr.mm6540a6
Svensson E, Jensen ET, Rasmussen EM, Folkvardsen DB,
Norman A, Lillebaek T. Mycobacterium chimaera in heater-cooler
units in Denmark related to isolates from the United States and
United Kingdom. Emerg Infect Dis. 2017;23:507–9.
http://dx.doi.org/10.3201/eid2303.161941
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1703
DISPATCHES
9.
Williamson D, Howden B, Stinear T. Mycobacterium chimaera
spread from heating and cooling units in heart surgery. N Engl J
Med. 2017;376:600–2. http://dx.doi.org/10.1056/NEJMc1612023
10. Mac Aogáin M, Roycroft E, Raftery P, Mok S, Fitzgibbon M,
Rogers TR. Draft genome sequences of three Mycobacterium
chimaera respiratory isolates. Genome Announc. 2015;3:
e01409-15. http://dx.doi.org/10.1128/genomeA.01409-15
11. Mendes GC, Brandão TR, Silva CL. Ethylene oxide sterilization of
medical devices: a review. Am J Infect Control. 2007;35:574–81.
http://dx.doi.org/10.1016/j.ajic.2006.10.014
12.
Robicsek F, Hoffman PC, Masters TN, Daugherty HK, Cook JW,
Selle JG, et al. Rapidly growing nontuberculous mycobacteria: a
new enemy of the cardiac surgeon. Ann Thorac Surg. 1988;
46:703–10. http://dx.doi.org/10.1016/S0003-4975(10)64742-X
Address for correspondence: Andreas Plate, University Hospital
Zurich, Division of Infectious Diseases and Hospital Epidemiology,
Raemistrasse 100 CH-8091, Zurich, Switzerland; email:
andreas.plate@usz.ch
etymologia
Granulicatella [granʹyoo-lik-ə-telʺə]
Ronnie Henry
I
n 1961, Frenkel and Hirsch described strains of streptococci isolated from cases of bacterial endocarditis that
grew only in the presence of other bacteria, around which
they formed satellite colonies, or in media enriched with
sulfhydryl compounds, such as cysteine. These nutritionally variant streptococci were eventually assigned the species Streptococcus defectivus (Latin for “deficient”) and
S. adjacens (because it grows adjacent to other bacteria).
On the basis of later research, these were placed
in a new genus Abiotrophia (Greek a, “un-,” + bios,
“life,” + trophe, “nutrition”) as A. adiacens and
A. defectiva. In 1998 and 1999, 2 additional species of
Abiotrophia were described, A. elegans (Latin, “fastidious,” referring to fastidious growth requirements) and
Sources
1.
Bouvet A, Grimont F, Grimont PA. Streptococcus
defectivus sp. nov. and Streptococcus adjacens sp. nov.,
nutritionally variant streptococci from human clinical
specimens. Int J Syst Bacteriol. 1989;39:290–4.
http://dx.doi.org/10.1099/00207713-39-3-290
2. Collins MD, Lawson PA. The genus Abiotrophia
(Kawamura et al.) is not monophyletic: proposal of
Granulicatella gen. nov., Granulicatella adiacens
comb. nov., Granulicatella elegans comb. nov. and
Granulicatella balaenopterae comb. nov.
Int J Syst Evol Microbiol. 2000;50:365–9.
http://dx.doi.org/10.1099/00207713-50-1-365
3. Frenkel A, Hirsch W. Spontaneous development
of L forms of streptococci requiring secretions of
other bacteria or sulphydryl compounds for normal
growth. Nature. 1961;191:728–30. http://dx.doi.org/
10.1038/191728a0
Figure. Blood agar
plates with (left) and
without (right) pyridoxal
supplement from a study
of neonatal Granulicatella
elegans bacteremia,
London, UK. Image from
Neonatal Granulicatella
elegans Bacteremia,
London, UK; Emerging
Infectious Diseases Vol.
19, no. 7, July 2013.
A. balaenopterae (isolated from a minke whale [Balaenoptera acutorostrata]). In 2000, these new species,
along with A. adiacens, were reclassified in the new
genus Granulicatella (Latin granulum, “small grain,”
+ catella, “small chain”).
4.
Kawamura Y, Hou XG, Sultana F, Liu S, Yamamoto H,
Ezaki T. Transfer of Streptococcus adjacens and
Streptococcus defectivus to Abiotrophia gen. nov. as
Abiotrophia adiacens comb. nov. and Abiotrophia
defectiva comb. nov., respectively. Int J Syst
Bacteriol. 1995;45:798–803. http://dx.doi.org/10.1099/
00207713-45-4-798
5. Lawson PA, Foster G, Falsen E, Sjödén B, Collins MD.
Abiotrophia balaenopterae sp. nov., isolated from
the minke whale (Balaenoptera acutorostrata). Int
J Syst Bacteriol. 1999;49:503–6. http://dx.doi.org/
10.1099/00207713-49-2-503
6. Roggenkamp A, Abele-Horn M, Trebesius KH,
Tretter U, Autenrieth IB, Heesemann J. Abiotrophia
elegans sp. nov., a possible pathogen in patients
with culture-negative endocarditis. J Clin Microbiol.
1998;36:100–4.
Address for correspondence: Ronnie Henry, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop E03,
Atlanta, GA 30329-4027, USA; email: boq3@cdc.gov
DOI: https://doi.org/10.3201/eid2409.ET2409
1704
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Est im a t in g Fr e qu e n cy of Pr oba ble
Au t och t h on ou s Ca se s of D e n gu e , Ja pa n
Akiyoshi Senda,1 Anavaj Sakuntabhai,
Shinako Inaida, Yoann Teissier,
Fumihiko Matsuda, Richard E. Paul1
Imported dengue into naive areas is a recognized but unquantified threat. Differentiating imported and autochthonous cases remains problematic. A threshold approach
applied to Japan identified several aberrant incidences of
dengue. Despite these alerts, no epidemics occurred other
than 1 in Yoyogi Park in Tokyo, which was probably an unusual event.
D
engue is a major international public health concern,
and the number of dengue outbreaks has escalated
over the past decade (1). International travel will ensure
importation of dengue virus (DENV) from dengue-endemic
regions into nonendemic countries (2). The potential threat
of DENV invasion into naive areas is illustrated by autochthonous dengue cases in France and the United States
(3,4) and unprecedented epidemics in the Madeira Islands
of Portugal and Tokyo, Japan (5,6). Most human DENV
infections are asymptomatic (7), but the virus can still be
transmitted to mosquitoes (8), so repeated “silent” DENV
invasion will probably become increasingly frequent.
In 2012, the World Health Organization released a
global strategy for dengue prevention and control, with
the objective of reducing dengue-attributable deaths by
50% and dengue-attributable illness by 25% by 2020 (9).
These reductions are to be achieved, at least in part, by
implementing improved outbreak prediction and detection through coordinated epidemiologic and entomologic
surveillance. This approach is also important for areas
where dengue is nonenedemic, that have no defined surveillance strategy.
Within this context, we examine the case of Japan,
which had an unprecedented autochthonous DENV type
Author affiliations: Kyoto University Faculty of Medicine, Kyoto,
Japan (A. Senda); Kyoto University Graduate School of Medicine,
Kyoto (S. Inaida, F. Matsuda); Pasteur Kyoto International
Joint Research Unit for Integrative Vaccinomics, Kyoto
(A. Sakuntabhai, F. Matsuda, R.E. Paul); Institut Pasteur, Paris,
France (A. Sakuntabhai, R.E. Paul); Centre National de la
Recherche Scientifique, Paris (A. Sakuntabhai, R.E. Paul); Institut
Louis Malardé, Papeete, French Polynesia (Y. Teissier)
DOI: https://doi.org/10.3201/eid2409.170408
1 epidemic in Yoyogi Park in Tokyo in 2014 and is experiencing an ever-increasing number of dengue cases.
Analyzing dengue case surveillance data from a 6-year
period, we assess whether other incidents occurred when
the number of dengue cases exceeded the expected number
because of importation and whether these incidents represented potential foci of epidemics. We discuss whether
the Tokyo epidemic was a rare event, the probability of
a repeat epidemic, and the value of establishing a dengue
alert threshold.
The Study
Since 1999, dengue has been 1 of the notifiable diseases
under national surveillance across Japan. The case definition of dengue fever includes the presence of suspicious
clinical symptoms and laboratory confirmation. The definition of an imported case is DENV infection in a patient
who had traveled to a dengue-infected area within 2 weeks
before symptom onset; all other cases are defined as autochthonous. All diagnosed dengue cases are registered in
the surveillance system database (10).
We selected as study sites the 2 largest metropolitan
areas, Greater Tokyo (including the prefectures of Tokyo, Saitama, Kanagawa, and Chiba) and Greater Osaka
(including the prefectures of Osaka, Hyogo, and Kyoto),
which encompass the largest number of dengue cases
during the study period and can be considered as work
commuting zones. Incidence rate was the number of cases
divided by the population according to the 2015 national census. To calculate the threshold, we extracted data
from annual reports for 2005 through 2014 (http://survey.
tokyo-eiken.go.jp/epidinfo/csvinfo.do). We used Tukey’s
box plot method to establish the median background
weekly incidence of dengue in each study area based on
the previous 6 years’ data. We defined the weekly threshold as the rounded-up value of the third quartile + 1.5
times the interquartile range of the number of cases from
the same week. We applied the 6 previous years’ weekly
thresholds of cases in each prefecture to the weekly reported cases for 2011–2016. We defined an outlier as a
week when the number of cases was >1 above or equal
to the threshold. We defined the threshold for an autochthonous epidemic alert as >2 consecutive weeks in which
outliers were detected.
1
These authors contributed equally to this article.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1705
DISPATCHES
Figure 1. Annual reported
dengue cases reported
in dengue surveillance
system, Greater Tokyo and
Greater Osaka areas, Japan,
2011–2016. Black indicates
imported cases; white indicates
autochthonous cases detected
during Tokyo epidemic.
The number of imported cases in Japan has been rising steadily over the past decade (Figure 1), concomitant
with the increase in visitors, especially from South Korea,
China, Taiwan, and Thailand (online Technical Appendix
Figures 1, 2, https://wwwnc.cdc.gov/EID/article/24/9/170408-Techapp1.pdf). Until 2015, the number of outbound
travelers from Japan exceeded that of inbound foreign travelers; one third of travelers from Japan went to dengueendemic countries.
In the Greater Tokyo and Greater Osaka areas, the
threshold value of the incidence rate varied by year and
place (Table). Outlying dengue case weeks were detected
in all 7 prefectures of the 2 aggregated greater areas during
the 6-year study period (Table; Figure 2). We noted several
occasions when outliers were reported for 2 consecutive
weeks (7 times in Greater Tokyo and 4 times in Greater
Osaka). In Greater Tokyo, conditions warranting an alert
occurred in 2012 (weeks 10–11 and 36–37), 2013 (weeks
19–20), 2015 (weeks 2–3), and 2016 (weeks 1–2, 12–14,
and 17–19); in Greater Osaka, conditions warranting an
alert occurred in 2012 (weeks 34–36), 2013 (weeks 41–42),
2014 (weeks 12–15), and 2016 (weeks 12–13).
At the prefecture level, an alert condition was detected August 25–September 7, 2014, in Kanagawa Prefecture; this timing coincided with the Tokyo autochthonous
epidemic. In addition, alert conditions were identified in
Tokyo in 2013 (weeks 32–33) and 2016 (weeks 13–14), in
Chiba in 2016 (weeks 33–34), and in Osaka in 2016 (weeks
12–13). The Tokyo and Osaka 2016 alert conditions occurred during the cold season and were probably caused
by an increase in imported cases from Indonesia (11). By
contrast, the alert condition in Chiba was followed by 2 additional cases reported in week 39 and 2 in week 42; both
occurrences are outliers but are not in consecutive weeks
and thus do not warrant an alert. The alert condition in 2013
in Tokyo was the first such occurrence observed in our data
and coincided with a visit by a traveler from Germany who
was allegedly infected with dengue in Japan (12) and had
visited Tokyo.
Conclusions
We have addressed the increasing probability of dengue
invasion into Japan in light of the 2014 Yoyogi Park epidemic. Although the increase in dengue cases in Japan is
concomitant with the increase in human travel between
Japan and dengue-endemic areas, several reports exist of
travelers contracting dengue while visiting Japan, which
suggests that DENV is circulating in the form of subclinical infections; by extrapolation, allegedly imported cases
might be autochthonous (12).
Table. Thresholds and conditions warranting an autochthonous dengue case alert, Greater Tokyo and Greater Osaka areas, Japan,
2011–2016
Area and
Total no.
Incidence rate,
Threshold range,
No. occurrences
Population
prefecture
cases
cases/106 person-years maximum (mean) No. outliers of alert conditions
Greater Tokyo area
36,126,355
609
2.8
17 (4.5)
52
7
Tokyo
13,513,734
358
4.4
11 (3.1)
32
2
Kanagawa
9,127,323
111
2.0
5 (0.77)
16
1
Saitama
7,261,271
45
1.0
3 (0.12)
4
0
Chiba
6,224,027
95
2.5
7 (0.89)
14
1
Greater Osaka area
16,986,037
230
2.3
9 (2.0)
25
4
Osaka
8,838,908
140
2.6
5 (1.4)
12
1
Hyogo
5,536,989
52
1.6
4 (0.29)
6
0
Kyoto
2,610,140
38
2.4
3 (0.24)
1
0
1706
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Frequency of Probable Autochthonous Dengue, Japan
Figure 2. Detection of conditions warranting an autochthonous dengue case alert (red bars) compared with number of reported dengue
cases per week (histogram) and estimated background threshold (black line), by year, Greater Tokyo area, Japan, 2011–2016.
Differentiating imported and autochthonous cases
based on recent travel history might be misleading. A
case-patient in Hyogo Prefecture, ≈400 km from Tokyo,
had stayed in Malaysia during the 12 days before symptom
onset but had recollection of mosquito bites 6 days before
onset, and the virus strain 100% matched the Yoyogi Park
strain (13). Unusual above-threshold incidences of dengue
might provide an additional criterion for differentiation. Although no official epidemic coincided with the occurrence
of dengue in the traveler from Germany (12), our alert
threshold pinpointed this period as being aberrant. Unusual above-threshold dengue incidences were noted during
several periods, but no subsequent epidemic progression
was noted. A substantial stochastic dieout of circulating
DENV is occurring, despite permissive temperatures that
would enable efficient transmission of DENV by the predominant mosquito vector, Aedes albopictus, which occurs
at high densities in urban areas of Japan (14). However,
most infections probably will go unnoticed, and the actual
spread of DENV is greater than estimated from surveillance. DENV seroprevalence results for 207 persons who
frequented Yoyogi Park indicated that 10 persons without
recollection of symptoms were seropositive (15).
In conclusion, although increased human movement
and permissive temperatures pose a threat for DENV invasion, evidence suggests that the Yoyogi Park epidemic was
an exception and that a considerable viral biomass after
repeated introduction might be required for successful viral implantation. The added utility of using a threshold approach to detect aberrant incidence rates for public health
activities remains to be developed but could provide a basis
for performing seroprevalence studies around cases detected during weeks with aberrantly high incidence to establish
the extent of the problem.
About the Author
Dr. Senda is a medical school graduate of Kyoto University,
Kyoto, Japan. His primary research interest is the epidemiology
of vectorborne infectious diseases.
References
1.
2.
3.
4.
5.
6.
7.
World Health Organization. Dengue and dengue hemorrhagic
fever, fact sheet 117 [cited 2016 Oct 18]. http://www.who.int/
mediacentre/factsheets/fs117/en
Chen LH, Wilson ME. The role of the traveler in emerging
infections and magnitude of travel. [xi.]. Med Clin North Am.
2008;92:1409–32, xi. http://dx.doi.org/10.1016/j.mcna.2008.07.005
La Ruche G, Souarès Y, Armengaud A, Peloux-Petiot F,
Delaunay P, Desprès P, et al. First two autochthonous dengue virus
infections in metropolitan France, September 2010. Euro Surveill.
2010;15:19676.
Murray KO, Rodriguez LF, Herrington E, Kharat V, Vasilakis N,
Walker C, et al. Identification of dengue fever cases in Houston,
Texas, with evidence of autochthonous transmission between 2003
and 2005. Vector Borne Zoonotic Dis. 2013;13:835–45.
http://dx.doi.org/10.1089/vbz.2013.1413
Alves MJ, Fernandes PL, Amaro F, Osório H, Luz T, Parreira P,
et al. Clinical presentation and laboratory findings for the first
autochthonous cases of dengue fever in Madeira island, Portugal,
October 2012. Euro Surveill. 2013;18:20398.
Kutsuna S, Kato Y, Moi ML, Kotaki A, Ota M, Shinohara K, et al.
Autochthonous dengue fever, Tokyo, Japan, 2014. Emerg Infect
Dis. 2015;21:517–20. http://dx.doi.org/10.3201/eid2103.141662
Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW,
Moyes CL, et al. The global distribution and burden of dengue.
Nature. 2013;496:504–7. http://dx.doi.org/10.1038/nature12060
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1707
DISPATCHES
8.
Duong V, Lambrechts L, Paul RE, Ly S, Lay RS, Long KC,
et al. Asymptomatic humans transmit dengue virus to mosquitoes.
Proc Natl Acad Sci U S A. 2015;112:14688–93. http://dx.doi.org/
10.1073/pnas.1508114112
9. World Health Organization. Global strategy for dengue
prevention and control 2012–2020 [cited 2016 Oct 25].
http://www.who.int/immunization/sage/meetings/2013/april/
5_Dengue_SAGE_Apr2013_Global_Strategy.pdf
10. National Institute of Infectious Diseases. Annual report of
Infectious Diseases Weekly Report [cited 2016 Oct 18].
http://www.nih.go.jp/niid/ja/survei/2270-idwr/nenpou/
6141-kako2014.html
11. National Institute of Infectious Diseases. Notification trends
among imported dengue cases in Japan [cited 2016 Oct 18].
http://www.nih.go.jp/niid/ja/id/690-disease-based/ta/dengue/
idsc/6663-dengue-imported.html
12. Schmidt-Chanasit J, Emmerich P, Tappe D, Günther S, Schmidt S,
Wolff D, et al. Autochthonous dengue virus infection in Japan
imported into Germany, September 2013. Euro Surveill. 2014;
19:20681. http://dx.doi.org/10.2807/1560-7917.ES2014.19.3.20681
13.
Tajima S, Nakayama E, Kotaki A, Moi ML, Ikeda M, Yagasaki K,
et al. Whole genome sequencing-based molecular epidemiologic
analysis of autochthonous dengue virus type 1 strains circulating
in Japan in 2014. Jpn J Infect Dis. 2017;70:45–9. http://dx.doi.org/
10.7883/yoken.JJID.2016.086
14. Kobayashi M, Komagata O, Yonejima M, Maekawa Y,
Hirabayashi K, Hayashi T, et al. Retrospective search for
dengue vector mosquito Aedes albopictus in areas visited
by a German traveler who contracted dengue in Japan.
Int J Infect Dis. 2014;26:135–7. http://dx.doi.org/10.1016/
j.ijid.2014.06.005
15. National Institute of Infectious Diseases. Report on the results
of active epidemiological investigation of dengue autochthonous
infection cases. Infectious Diseases Weekly Report [cited 2016 Dec
12]. http://www.nih.go.jp/niid/ja/id/693-disease-based/ta/dengue/
idsc/iasr-news/5754-pr4252.html
Address for correspondence: Richard E. Paul, Institut Pasteur, 25 Rue du
Dr. Roux, Paris 75015, France; email: richard.paul@pasteur.fr
May 2015: V e ct or bor n e I n fe ct ion s
• Detecting Spread
of Avian Influenza
A(H7N9) Virus
Beyond China
• Delayed-Onset
Hemolytic Anemia in
Patients with TravelAssociated Severe
Malaria Treated with
Artesunate, France,
2011–2013
• Recent US Case of
Variant CreutzfeldtJakob Disease—
Global Implications
• Novel Thogotovirus
Associated with Febrile
Illness and Death,
United States, 2014
• Transmission of
Hepatitis C Virus
among Prisoners,
Australia, 2005–2012
• Itaya Virus, a Novel
Orthobunyavirus
Associated with
Human Febrile Illness,
Peru
• Isolation of
Onchocerca lupi in
Dogs and Black Flies,
California, USA
• Molecular
Epidemiology
of Plasmodium
falciparum Malaria
Outbreak, Tumbes,
Peru, 2010–2012
• Pathologic Changes
in Wild Birds Infected
with Highly Pathogenic
Avian Influenza
(H5N8) Viruses, South
Korea, 2014
• Malaria Imported
from Ghana by
Returning Gold
Miners, China, 2013
• Antimicrobial Drug
Resistance of Vibrio
cholerae, Democratic
Republic of the Congo
• Protective Antibodies
against Placental
Malaria and Poor
Outcomes during
Pregnancy, Benin
• Canine Distemper
in Endangered
Ethiopian Wolves
• Comparative
Sequence Analyses of
La Crosse Virus Strain
Isolated from Patient
with Fatal Encephalitis,
Tennessee, USA
• Transmission Potential
of Influenza A(H7N9)
Virus, China,
2013–2014
• Rapid Emergence of
Highly Pathogenic
Avian Influenza
Subtypes from a
Subtype H5N1
Hemagglutinin Variant
• Postmortem Stability of
Ebola Virus Influenza
A(H5N8) Virus Similar
to Strain in Korea
Causing Highly
Pathogenic Avian
Influenza in Germany
• Canine Infections
with Onchocerca lupi
Nematodes, United
States, 2011–2014
• Low-level Circulation
of Enterovirus D68–
Associated Acute
Respiratory Infections,
Germany, 2014
https://wwwnc.cdc.gov/eid/content/21/5/contents.htm
1708
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Cor r e la t ion of Se ve r it y of H u m a n
Tick - Bor n e En ce ph a lit is Vir u s D ise a se
a n d Pa t h oge n icit y in M ice
Chaitanya Kurhade,1 Sarah Schreier,1
Yi-Ping Lee,1,3 Loreen Zegenhagen,4
Marika Hjertqvist, Gerhard Dobler,
Andrea Kröger,2 Anna K. Överby2
We compared 2 tick-borne encephalitis virus strains isolated from 2 different foci that cause different symptoms
in tick-borne encephalitis patients, from neurologic to mild
gastrointestinal symptoms. We compared neuroinvasiveness, neurovirulence, and proinflammatory cytokine response in mice and found unique differences that contribute
to our understanding of pathogenesis.
T
ick-borne encephalitis (TBE) is an emerging arthropod-borne viral (arboviral) disease in Europe and Asia
characterized by severe central nervous system (CNS) disease in humans. New areas of endemicity and increased
TBE incidence have been reported (1). In Sweden, TBE
cases have increased dramatically; during 2017, a record
year, 391 cases were reported, compared with 238 cases
during 2016. TBE virus (TBEV) is transmitted by tick bites
and ingestion of contaminated milk (2,3). Infection (TBEV,
European subtype) usually follows a biphasic course in
which, during the primary phase, patients show symptoms
of fatigue, headache, myalgia, and fever, followed by a second phase of neurologic involvement with signs of meningitis, encephalitis, and paralysis and high fever. Neurologic
sequelae develop in 20%–60% of cases (4–7). The ability
of the virus to cause CNS disease (neurovirulence) depends
on its ability to enter the brain (neuroinvasiveness).
Recently, a focus of TBE in southeastern Germany was
identified with 5 patients (2005–2011), who showed only
mild gastrointestinal and constitutional symptoms, without
neurologic symptoms. One strain, MucAr HB171/11, was
isolated from 6 questing adult Ixodes ricinus ticks from this
natural focus (49°17′N, 12°12′E) (8). To investigate this low
Author affiliations: Umeå University, Umeå, Sweden (C. Kurhade,
Y.-P. Lee, A.K. Överby); Helmholtz Centre for Infection Research,
Braunschweig, Germany (S. Schreier, L. Zegenhagen, A. Kröger);
Otto-von-Guericke-University Magdeburg, Magdeburg, Germany
(S. Schreier, A. Kröger); Public Health Agency of Sweden, Solna,
Sweden (M. Hjertqvist); Bundeswehr Institute of Microbiology,
Munich, Germany (G. Dobler); DZIF Partner Site Munich, Munich
(G. Dobler)
DOI: https://doi.org/10.3201/eid2409.171825
pathogenic strain and the absence of neurologic symptoms,
we compared its pathogenesis with another European strain,
Torö-2003. Torö-2003 was rescued from a cDNA infectious
clone (9) generated from RNA extracted from a pool of I.
ricinus ticks (9 adults, 106 nymphs) collected in September
2003 on the island of Torö (58°49′N, 17°50′E) in the Stockholm archipelago of Sweden (10). In the focus on Torö,
32 TBE patients (1986–2016) were reported. Data on 4 of
these TBE case-patients show relatively mild neurologic
disease with a few days of hospitalization for 2 of them. In
the mouse model, Torö-2003 shows similar pathogenicity as
the highly virulent Hypr strain (9). Knowledge of differential clinical courses and severity of disease caused by strains
of TBEV can be an important criterion for diagnosing and
treating the disease.
The Study
All animal experiments were performed in compliance with
the German animal welfare law (TierSchG BGBl. S. 1105;
25.05.1998). Mice were housed and handled in accordance
with good animal practice as defined by the Federation for
Laboratory Animal Science Associations. All animal experiments were approved by the responsible state office
(Lower Saxony State Office of Consumer Protection and
Food Safety) under permit no. AZ 33.9-42502-04-11/0528.
Experiments were performed in the Biosafety Level 3 facility at the Helmholtz Center for Infection Research (Braunschweig, Germany). Mice used for primary cell isolation
were maintained under specific pathogen-free conditions,
and studies were conducted according to the guidelines set
out by the Regional Animal Ethical Committee (Umeå,
Sweden; approval no. A77-14).
To assess the pathogenicity of the Torö-2003 and
HB171/11 strains, we challenged C57BL/6 mice with 104
focus-forming units of Torö-2003 and HB171/11 (second
passage in Vero cells) subcutaneously. Mice were highly
susceptible to Torö-2003 infection and 100% succumbed
to the infection; median survival time was 13 days. Mice
showed paralysis, lethargy, hunchback posture, fur ruffling,
and weight loss 2 days before death. In contrast, only 60%
of the HB171/11-infected mice died (median survival time
1
These first authors contributed equally to this article.
2
These senior authors contributed equally to this article.
Current affiliation: National Cheng Kung University, Tainan, Taiwan.
3
Current affiliation: Charles River Laboratories, Freiburg, Germany.
4
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1709
DISPATCHES
18.5 days) (Figure 1, panel A). Analysis of viral RNA in
peripheral organs after infection showed viral replication of
Torö-2003 6 days postinfection (dpi) in the spleen (Figure
1, panel B). In inguinal lymph nodes (Figure 1, panel C) and
lung (data not shown), we detected Torö-2003 RNA only at
10 dpi. In contrast, viral RNA from HB171/11 could hardly
be detected in peripheral organs. Because gastrointestinal
and constitutional symptoms reported for HB171/11 in humans (8) are hardly detectable in mice, we analyzed viral
RNA in colon, appendix, and small intestine. No viral RNA
was detected in these tissues (data not shown).
To investigate whether infection with the different virus
strains changes immune response, we looked for proinflammatory gene induction in lymphoid tissue. Tumor necrosis
factor–α, interleukin-6, and CXC motif ligand–10 were
highly up-regulated in spleen and lymph nodes on infection with HB171/11, compared with Torö-2003 4 dpi. At
later time points, we detected similar expression levels in
Figure 1. Survival analysis and TBEV burden in peripheral organs of Torö-2003–infected and HB171/11-infected C57BL/6 mice. A)
Survival analysis of ten 6–10-week-old female C57BL/6 mice after subcutaneous inoculation with phosphate-buffered saline (mock,
black) or with 104 focus forming units (FFU) of Torö-2003 (blue) or HB171/11 (red) in 100 µL phosphate-buffered saline. Survival
differences were tested for statistical significance by log-rank test. B, C) Viral burdens in spleen (B) and lymph node (C) after
subcutaneous infection of Torö-2003 or HB171/11 (104 FFU, n = 5) were measured by quantitative PCR and normalized to intracellular
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) levels as previously described (14). Each data point represents an individual
mouse. D–I) Cytokine response in spleen (D–F) and lymph node (G–I). Expression levels of GAPDH, TNF-α (D,G), IL-6 (E,H), and
CXCL-10 (F,I) were determined by validated QuantiTect primer assays (QIAGEN, Hilden, Germany) and quantitative PCR from organs
prepared in B and C. Signals of indicated mRNA were normalized to the GAPDH mRNA signal. Bars indicate mean values. Asterisks
indicate statistical significance calculated by Mann-Whitney test (*p<0.05; **p<0.01). Horizontal black bars indicate mean values. a.u.,
arbitrary units; CXCL, CXC motif ligand; IL, interleukin; TBEV, tick-borne encephalitis virus; TNF, tumor necrosis factor.
1710
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
TBEV Pathogenicity
Torö-2003–infected and HB171/11-infected mice (Figure 1,
panels D–I). Macrophages and monocytes are potential producers of these cytokines and may influence immune response
to control virus replication of HB171/11 in the periphery.
Because HB171/11 caused only mild gastrointestinal
and constitutional symptoms without specific neurologic
symptoms, we hypothesized that HB171/11 might be less
neuroinvasive than Torö-2003. To assess this hypothesis,
we infected mice subcutaneously and isolated different parts
of the CNS (olfactory bulb, cerebrum, cerebellum, brain
stem, and spinal cord) at different times after infection and
analyzed viral load in the CNS. At 6 dpi, we detected Torö-
2003 virus in almost all the CNS regions; replication was
highest in the olfactory bulb. At 10 dpi, Torö-2003 virus
replication further increased in all parts except the olfactory
bulb, where viral burden was maintained. For HB171/11, we
detected no viral RNA at 6 dpi and only low levels of virus in
most CNS parts at 10 dpi (Figure 2, panels A–E), indicating
delayed neuroinvasiveness of HB171/11.
Next, we investigated the neurovirulence of the
different strains. We injected mice with 100 focus-forming
units of virus directly into cerebral cortex through the
intracranial route. Torö-2003 was highly pathogenic,
leading to 100% deaths; median survival was 7 days.
Figure 2. TBEV burden in central nervous system (CNS) of mice. A–E) Five 6–10-week-old
female C57BL/6 mice were infected subcutaneously with 104 FFU of Torö-2003 (blue) or
HB171/11 (red), and viral burden in CNS tissue (olfactory bulb [A], cerebrum [B], cerebellum
[C], brain stem [D], and spinal cord [E]) was measured by quantitative PCR and normalized
to intracellular glyceraldehyde 3-phosphate dehydrogenase levels. Horizontal black bars
indicate mean values. Statistical significance calculated by the Mann-Whitney test (*p<0.05;
**p<0.005). F) Survival analysis of C57BL/6 mice after intracranial inoculation with phosphate
buffered saline (mock, black) or with 100 FFU of Torö-2003 (n = 8) or HB171/11 (n = 10)
in 20 µL phosphate buffered saline. For intracranial infections, mice were anesthetized by
intraperitoneal injection with a mixture of ketamine (100 µg/g body weight) and xylazine (5
µg/g body weight). Survival differences were tested for statistical significance by log-rank
test (****p<0.0005). G) Viral replication kinetics in primary cortical neurons. Primary cortical
neurons were isolated as described previously (11). The neurons were infected with Torö-2003
or HB171/11 strain with 0.001 multiplicity of infection at day 7 postseeding, and viral growth
was determined at indicated time points by focus forming assay, as previously described (15).
Statistical significance was calculated using unpaired t test (*p<0.05). a.u., arbitrary units; FFU,
focus-forming units; TBEV, tick-borne encephalitis virus.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1711
DISPATCHES
We observed lower neurovirulence for HB171/11, and
survival was a median of 10.5 days.
To explore the relationship between mice pathogenicity and viral replication in target cells, we analyzed replication in neurons. We isolated primary cortical neurons from
C57BL/6 mice infected with 0.001 multiplicity of infection
and measured progeny particles by focus-forming assay (11).
Both strains replicated to the same level at early time points;
later in infection (48 and 72 h), Torö-2003 replicated to higher levels compared with HB171/11 (Figure 2, panel G).
Taken together, HB171/11 shows lower neurovirulence in mice, probably because of reduced replication in
neurons. However, we cannot exclude that other cell types
within the CNS (astrocytes and microglia) also could contribute to the lower neurovirulence. The low neurovirulence
in combination with the slower neuroinvasiveness, resulting from low replication in the periphery and high up-regulation of proinflammatory cytokines, make the HB171/11
less pathogenic in the mouse model.
Conclusions
TBEV is spreading into new regions in Europe: Sweden,
Norway, Finland, France, the Netherlands, Italy, and Switzerland (1). The typical symptoms of infection are meningitis, encephalitis, and paralysis. However, recent reports
also indicate gastrointestinal problems (8). Such new strains
that cause these rare symptoms complicate the diagnosis
of TBEV infection and raise the question of the number of
unrecognized TBE cases. We characterized the pathogenesis and immune response of 2 European isolates of TBEV
from infection foci that coincide with human cases displaying completely different disease symptoms. To characterize
these clinical manifestations of disease, we used C57BL/6
mice to study TBEV pathogenesis. These mice are susceptible to infection and develop encephalitis without the need
for adaptation of the virus isolates. The pathogenicity of the 2
virus strains clearly differed. We could not detect gastrointestinal symptoms in the HB171/11-infected mice, but the lowvirulence phenotype of HB171/11 could be mimicked. The
mice showed a strong cytokine response in periphery, low
and delayed neuroinvasiveness, and low neurovirulence that,
when translated into humans, might explain the lack of neurologic symptoms. Because genetic changes in TBEV could
affect pathogenicity (12,13), future molecular studies are
needed to determine the low pathogenicity of and enhanced
immune response against low-virulence strain HB171/11.
This work was supported by the Kempe Foundations (to C.K.
and A.K.Ö.); the Laboratory for Molecular Medicine Sweden;
the Umeå Center for Microbial Research and Linneus Support
and the Swedish Foundation for International Cooperation in
Research and Higher Education; the Jeanssons Foundations (to
A.K.Ö.); and the German Ministry of Education and Research
TBENAGER (to A.K.).
1712
About the Author
Mr. Kurhade is a PhD student at the Department of Clinical
Microbiology, Virology, Umeå University. His research focuses
on TBEV.
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
Erber W, Schmitt H-J, Janković TV. Epidemiology by country—
an overview. In: Dobler G, Erber W, Schmitt HJ, editors. TBE—the
book. Singapore: Global Health Press; 2017. 114–274
Kerbo N, Donchenko I, Kutsar K, Vasilenko V. Tickborne
encephalitis outbreak in Estonia linked to raw goat milk, May–June
2005. Euro Surveill. 2005;10:E050623.2.
Dumpis U, Crook D, Oksi J. Tick-borne encephalitis. Clin Infect
Dis. 1999;28:882–90. http://dx.doi.org/10.1086/515195
Gritsun TS, Lashkevich VA, Gould EA. Tick-borne encephalitis.
Antiviral Res. 2003;57:129–46. http://dx.doi.org/10.1016/
S0166-3542(02)00206-1
Heinz FX, Kunz C. Tick-borne encephalitis and the impact of
vaccination. Arch Virol Suppl. 2004; (18):201–5.
Lindquist L, Vapalahti O. Tick-borne encephalitis. Lancet. 2008;
371:1861–71. http://dx.doi.org/10.1016/S0140-6736(08)60800-4
Mansfield KL, Johnson N, Phipps LP, Stephenson JR, Fooks AR,
Solomon T. Tick-borne encephalitis virus—a review of an
emerging zoonosis. J Gen Virol. 2009;90:1781–94.
http://dx.doi.org/10.1099/vir.0.011437-0
Dobler G, Bestehorn M, Antwerpen M, Överby-Wernstedt A.
Complete genome sequence of a low-virulence tick-borne
encephalitis virus strain. Genome Announc. 2016;4:e01145-16.
http://dx.doi.org/10.1128/genomeA.01145-16
Asghar N, Lee YP, Nilsson E, Lindqvist R, Melik W, Kröger A,
et al. The role of the poly(A) tract in the replication and virulence
of tick-borne encephalitis virus. Sci Rep. 2016;6:39265.
http://dx.doi.org/10.1038/srep39265
Melik W, Nilsson AS, Johansson M. Detection strategies of
tick-borne encephalitis virus in Swedish Ixodes ricinus reveal
evolutionary characteristics of emerging tick-borne flaviviruses.
Arch Virol. 2007;152:1027–34. http://dx.doi.org/10.1007/
s00705-006-0922-9
Lindqvist R, Mundt F, Gilthorpe JD, Wölfel S, Gekara NO, Kröger A,
et al. Fast type I interferon response protects astrocytes from flavivirus
infection and virus-induced cytopathic effects. J Neuroinflammation.
2016;13:277. http://dx.doi.org/10.1186/s12974-016-0748-7
Belikov SI, Kondratov IG, Potapova UV, Leonova GN. The
relationship between the structure of the tick-borne encephalitis
virus strains and their pathogenic properties. PLoS One. 2014;
9:e94946. http://dx.doi.org/10.1371/journal.pone.0094946
Leonova GN, Belikov SI, Kondratov IG, Takashima I.
Comprehensive assessment of the genetics and virulence of tickborne encephalitis virus strains isolated from patients with inapparent
and clinical forms of the infection in the Russian Far East. Virology.
2013;443:89–98. http://dx.doi.org/10.1016/j.virol.2013.04.029
Weber E, Finsterbusch K, Lindquist R, Nair S, Lienenklaus S,
Gekara NO, et al. Type I interferon protects mice from fatal
neurotropic infection with Langat virus by systemic and local
antiviral responses. J Virol. 2014;88:12202–12. http://dx.doi.org/
10.1128/JVI.01215-14
Overby AK, Popov VL, Niedrig M, Weber F. Tick-borne
encephalitis virus delays interferon induction and hides its
double-stranded RNA in intracellular membrane vesicles. J Virol.
2010;84:8470–83. http://dx.doi.org/10.1128/JVI.00176-10
Address for correspondence: Anna K. Överby, Umeå University,
Department of Clinical Microbiology, Virology, S-90185 Umeå,
Sweden; email: anna.overby@umu.se
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
I n cr e a sin g Pr e va le n ce of Bor r e lia bu r gdor fe r i
se n su st r ict o– I n fe ct e d Bla ck le gge d Tick s
in Te n n e sse e Va lle y, Te n n e sse e , USA
Graham J. Hickling, Janetta R. Kelly,
Lisa D. Auckland, Sarah A. Hamer
In 2017, we surveyed forests in the upper Tennessee Valley,
Tennessee, USA. We found Ixodes scapularis ticks established in 23 of 26 counties, 4 of which had Borrelia burgdorferi sensu stricto–infected ticks. Public health officials
should be vigilant for increasing Lyme disease incidence in
this region.
I
n the United States, Lyme disease caused by tickborne
bacterium Borrelia burgdorferi sensu stricto occurs primarily in the Northeast and upper Midwest (1). In eastern
Tennessee, which is considered nonendemic for Lyme disease, most of the human population resides in a low-elevation swath of the Tennessee Valley bordered to the west by
the Cumberland Plateau and the east by the Great Smoky
Mountains. The vector of Lyme disease, the blacklegged
tick Ixodes scapularis, was unreported in this area before
2006; in this year, uninfected adult ticks were collected
from hunter-harvested deer in 8 Tennessee Valley counties (Figure 1, panel A) (2). This finding, plus uninfected
I. scapularis ticks detected in Knox County in 2013, were
later incorporated into the national distribution map for I.
scapularis ticks (3).
During 2000–2014, human Lyme disease cases expanded southward along the eastern foothills of the Appalachian Mountains in nearby Virginia (4). In the winters of
2012 and 2013, B. burgdorferi–infected adult I. scapularis
ticks were detected in Pulaski County, Virginia (5). This
report of abundant infected I. scapularis ticks only 100
km from the Tennessee border motivated us to investigate
whether Borrelia-infected ticks might now be present in
the Tennessee Valley.
The Study
In late 2017, we sampled host-seeking I. scapularis ticks
at 70 forested sites in 26 low-elevation counties in the
upper Tennessee Valley (Figure 1, panel B). To find tick
Author affiliations: University of Tennessee Institute of Agriculture,
Knoxville, Tennessee, USA (G.J. Hickling, J.R. Kelly); Texas A&M
University, College Station, Texas, USA (L.D. Auckland, S.A. Hamer)
DOI: https://doi.org/10.3201/eid2409.180343
habitats (hardwood or conifer forests <800 m in elevation) accessible for sampling (i.e., trails through public
forests or margins of public roads through private forests), we reviewed Google Earth (https://www.google.
com/earth/) satellite imagery. We sampled each site once
during the peak of adult I. scapularis tick activity (late
October–January). We recorded site elevation and geocoordinates and collected host-seeking ticks using a standardized drag-cloth method; in brief, we dragged a 1-m2
white corduroy cloth across leaf litter and checked every
10 paces for attached ticks. We dragged cloths 30–60
minutes per site and described tick tallies as number collected per hour to correct for variations in effort per site.
We did not conduct drag-cloth collections during periods
of rain, strong wind, low air temperatures (<8°C), or low
relative humidity (<40%).
We placed ticks in 70% ethanol, identified species using a morphologic key (6), and tested ticks for Borrelia
spirochete infection by DNA extraction and quantitative
multiplex real-time PCR using differential probes targeting the 16S rDNA of Lyme group Borrelia and relapsing
fever group Borrelia (7). We then subjected a random subset of negative samples and samples positive by the 16S
assay (maximum 6 samples/site) to PCR amplification of
the 16S–23S rDNA intergenic spacer region (8) and Sanger
sequencing for species-level identification.
No previous tick drag-cloth counts existed for the
counties in our survey area, except for a 1,050-m transect
of land in a forest in Anderson County, which we have
drag-cloth sampled annually each December since 2012.
To assess a trend in adult I. scapularis tick abundance, we
applied linear regression modeling to the tick tallies from
that transect of land.
In late 2017, we collected 479 adult I. scapularis ticks
from 49 of 70 sites in the upper Tennessee Valley. Two
adult Amblyomma americanum ticks collected during the
survey were excluded from analysis. We detected I. scapularis ticks in all 26 counties surveyed, 23 of which met the
criterion used by Eisen et al. for established I. scapularis
populations (Figure 1, panel B) (3). Site elevations were
210–730 m; the highest elevation at which I. scapularis
ticks were found was 570 m. The average number of adult
ticks collected per hour during drag-cloth surveys was 8.8
(range 0–48). At the Anderson County site that had been
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1713
DISPATCHES
Figure 1. County-level
distribution of Ixodes scapularis
ticks and Borrelia burgdorferi–
infected I. scapularis ticks in
upper Tennessee Valley, USA,
2006 and 2017. A county
was classified as having
an established I. scapularis
population if >6 I. scapularis
adult ticks or ticks of 2 life
stages were collected in that
county. A county was classified
as having I. scapularis ticks
reported if 1–5 I. scapularis
ticks of a single life stage were
collected in that county. A county
was classified as infected if I.
scapularis ticks infected with
B. burgdorferi were detected
in that county. A) I. scapularis
ticks in 2006 (2), determined
by collecting ticks from hunterharvested deer. B) I. scapularis
ticks in 2017 determined by
drag-cloth surveying during the
peak of adult tick activity (late
October–January).
drag-cloth sampled annually, a highly significant increasing trend in I. scapularis ticks was evident (p = 0.003; Figure 2); the count in 2017 (24.8 ticks/hour) was 3.5× higher
than that in 2012.
We tested all I. scapularis ticks collected (N =
479) for Borrelia spp. infection; 46 ticks (9.6%) from
7 sites in 4 counties (Anderson, Claiborne, Hamilton,
and Union; Figure 1, panel B) tested positive for Lyme
group Borrelia by 16S rDNA PCR screening. We tested
26 samples for the intergenic spacer region by PCR; all
were positive for this sequence and identified as B. burgdorferi sensu stricto by sequencing. Most infected ticks
came from 2 Union County sites, which had prevalences
of 44% (14/32) and 78% (18/23). No ticks were found
to be infected with B. miyamotoi or other relapsing fever
group borreliae.
Conclusions
In eastern Tennessee, public awareness and concern about
ticks focuses primarily on the abundant lone star ticks
1714
(Amblyomma americanum) and American dog ticks (Dermacentor variabilis) encountered during the spring and
summer. Both species can spread pathogens (9), but neither are vectors of B. burgdorferi spirochetes. Immature
I. scapularis ticks are similarly active in the summer, but
in southern states, these ticks typically avoid host-seeking
above leaf litter and are rarely seen on humans or dragcloths (10). For this reason, assessment of I. scapularis
distribution in southern states is best achieved by acquiring adult life-stage ticks during cool season drag-cloth
surveys (as reported here) or by collecting ticks from deer
harvested in the fall. Inspection of hunter-harvested deer
is efficient for the detection of low-density I. scapularis
ticks (11). Thus, our drag-cloth sampling for I. scapularis ticks in 14 counties where none were found on deer
a decade ago (Figure 1, panels A, B) suggests that tick
abundance in these counties has increased. This suggestion is supported by a >3-fold increase in I. scapularis
tick counts at the Anderson County site where we have 6
consecutive years of drag-cloth counts.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Increasing Prevalence of B. burgdorferi, Tennessee
Acknowledgments
We thank the University of Tennessee’s Forest Resources
AgResearch and Education Center staff and land owners and
managers for access to survey sites. Tyler Noll and James
Hickling assisted with field collections.
This work was supported by the US Department of
Agriculture National Institute of Food and Agriculture Hatch
project 1012932 (to G.J.H.).
Figure 2. Six-year trend in adult Ixodes scapularis tick counts
at Forest Resources Research and Education Center (36.00°N,
84.22°W; elevation 298 m), Anderson County, Tennessee, USA,
2012–2017. We collected host-seeking I. scapularis adult ticks by
drag-cloth sampling vegetation on a 1,050-m transect of mixed
hardwood forest once each December.
This study documents emergence of B. burgdorferi
senso stricto in tick populations in eastern Tennessee. Infected ticks were predominantly found in high-prevalence
hot spots in Union County (36.39°N). Relative to Lyme
disease–endemic areas in the north, B. burgdorferi prevalence in the study area was low (10%) and had a patchy
distribution (7/49 sites had positive ticks). This distribution could reflect host barriers of B. burgdorferi transmission in the South (12), or more concerning, the hot spots in
Union County might reflect the beginning of an infection
surge, similar to that seen in southwestern Virginia during
the past decade (4).
In the United States, Lyme disease is primarily a
summertime disease associated with bites from nymphal
I. scapularis ticks. In southern states, detection of B.
burgdorferi bacteria in adult ticks does not necessarily
imply risk to humans; for example, B. burgdorferi cycles
in I. scapularis populations on the Outer Banks of North
Carolina, yet nymphs in that area cannot be collected
on drag-cloths and no locally acquired cases of Lyme
disease have been reported (13). In contrast, infected
nymphs have been found on drag-cloths from surveys
in Virginia, where Lyme disease incidence has spiked
(14). We speculate that Borrelia-infected I. scapularis
populations emerging in southwestern Virginia include
immigrant ticks from the North, with some nymphs in
these populations exhibiting host-seeking behaviors that
lead to contact with humans. A similar invasion process
might be under way in eastern Tennessee; the surveillance data reported here provide a baseline for investigating this possibility. Health officials and practitioners
need to be vigilant for increasing Lyme disease incidence in Tennessee.
About the Author
Dr. Hickling is professor in the Center for Wildlife Health at
the University of Tennessee, Knoxville, Tennessee, USA. His
research focuses on the eco-epidemiology of tickborne diseases
in the southeastern United States.
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
Mead PS. Epidemiology of Lyme disease. Infect Dis Clin
North Am. 2015;29:187–210. http://dx.doi.org/10.1016/
j.idc.2015.02.010
Rosen ME, Hamer SA, Gerhardt RR, Jones CJ, Muller LI,
Scott MC, et al. Borrelia burgdorferi not detected in widespread
Ixodes scapularis (Acari: Ixodidae) collected from white-tailed
deer in Tennessee. J Med Entomol. 2012;49:1473–80.
http://dx.doi.org/10.1603/ME11255
Eisen RJ, Eisen L, Beard CB. County-scale distribution of
Ixodes scapularis and Ixodes pacificus (Acari: Ixodidae) in the
continental United States. J Med Entomol. 2016;53:349–86.
http://dx.doi.org/10.1093/jme/tjv237
Lantos PM, Nigrovic LE, Auwaerter PG, Fowler VG Jr,
Ruffin F, Brinkerhoff RJ, et al. Geographic expansion of Lyme
disease in the southeastern United States, 2000–2014.
Open Forum Infect Dis. 2015;2:ofv143. http://dx.doi.org/10.1093/
ofid/ofv143
Herrin BH, Zajac AM, Little SE. Confirmation of Borrelia
burgdorferi sensu stricto and Anaplasma phagocytophilum in
Ixodes scapularis, southwestern Virginia. Vector Borne
Zoonotic Dis. 2014;14:821–3. http://dx.doi.org/10.1089/
vbz.2014.1661
Keirans JE, Clifford CM. The genus Ixodes in the United States: a
scanning electron microscope study and key to the adults. J Med
Entomol Suppl. 1978;2:1–149.
Tsao JI, Wootton JT, Bunikis J, Luna MG, Fish D, Barbour AG.
An ecological approach to preventing human infection:
vaccinating wild mouse reservoirs intervenes in the Lyme
disease cycle. Proc Natl Acad Sci U S A. 2004;101:18159–64.
http://dx.doi.org/10.1073/pnas.0405763102
Bunikis J, Garpmo U, Tsao J, Berglund J, Fish D, Barbour AG.
Sequence typing reveals extensive strain diversity of the Lyme
borreliosis agents Borrelia burgdorferi in North America and
Borrelia afzelii in Europe. Microbiology. 2004;150:1741–55.
http://dx.doi.org/10.1099/mic.0.26944-0
Stromdahl EY, Hickling GJ. Beyond Lyme: aetiology of
tick-borne human diseases with emphasis on the south-eastern
United States. Zoonoses Public Health. 2012;59(Suppl 2):48–64.
http://dx.doi.org/10.1111/j.1863-2378.2012.01475.x
Arsnoe IM, Hickling GJ, Ginsberg HS, McElreath R, Tsao JI.
Different populations of blacklegged tick nymphs exhibit
differences in questing behavior that have implications for
human Lyme disease risk. PLoS One. 2015;10:e0127450.
http://dx.doi.org/10.1371/journal.pone.0127450
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1715
DISPATCHES
11.
Lockwood BH, Stasiak I, Pfaff MA, Cleveland CA, Yabsley MJ.
Widespread distribution of ticks and selected tick-borne pathogens
in Kentucky (USA). Ticks Tick Borne Dis. 2018;9:738–41.
http://dx.doi.org/10.1016/j.ttbdis.2018.02.016
12. Apperson CS, Levine JF, Evans TL, Braswell A, Heller J. Relative
utilization of reptiles and rodents as hosts by immature Ixodes
scapularis (Acari: Ixodidae) in the coastal plain of North Carolina,
USA. Exp Appl Acarol. 1993;17:719–31.
13. Levine JF, Apperson CS, Levin M, Kelly TR, Kakumanu ML,
Ponnusamy L, et al. Stable transmission of Borrelia burgdorferi
sensu stricto on the Outer Banks of North Carolina. Zoonoses
1716
14.
Public Health. 2017;64:337–54. http://dx.doi.org/10.1111/
zph.12302
Brinkerhoff RJ, Gilliam WF, Gaines D. Lyme disease, Virginia,
USA, 2000–2011. Emerg Infect Dis. 2014;20:1661–8.
http://dx.doi.org/10.3201/eid2010.130782
Address for correspondence: Graham J. Hickling, University of
Tennessee Institute of Agriculture, Center for Wildlife Health, 274
Ellington Bldg, 2431 Joe Johnson Dr, Knoxville, TN 37996, USA;
email: ghicklin@utk.edu
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Su sce pt ibilit y of W h it e - Ta ile d D e e r
t o Rift Va lle y Fe ve r Vir u s
William C. Wilson, In Joong Kim,
Jessie D. Trujillo, Sun Young Sunwoo,
Leela E. Noronha, Kinga Urbaniak,
D. Scott McVey, Barbara S. Drolet, Igor Morozov,
Bonto Faburay, Erin E. Schirtzinger,
Tammy Koopman, Sabarish V. Indran,
Velmurugan Balaraman, Juergen A. Richt
Furthermore, modeling suggests that these deer as reservoir hosts would enhance spillover of RVFV into human
populations because of overlap of mosquitoes, humans,
and wildlife in urban and periurban areas (7). Therefore,
we determined the susceptibility of white-tailed deer to
RVFV infection and described the potential role of whitetailed deer populations in RVFV epidemiology.
Rift Valley fever virus, a zoonotic arbovirus, poses major
health threats to livestock and humans if introduced into
the United States. White-tailed deer, which are abundant
throughout the country, might be sentinel animals for arboviruses. We determined the susceptibility of these deer to
this virus and provide evidence for a potentially major epidemiologic role.
The Study
Wild-type RVFV (Kenya 2006 strain 128B-15, KEN06)
was propagated in C6/36 mosquito cells and prepared as
inoculum (1 × 106 PFU/animal). Five 5-month-old male
white-tailed deer from the US Department of Agriculture,
Agricultural Research Service, National Animal Disease
Center (Ames, IA, USA) captive herd were acclimated to
Biosafety Level 3 conditions and housed in such a facility
with specifically designed paneling.
After sedation and blood collection (0 days postinoculation [dpi]), 4 animals were injected subcutaneously
in the neck with virus inoculum; 1 contact control animal
was sham inoculated with cell culture medium. To minimize stress, 2 animals in the virus-inoculated group were
sedated on alternating days (2–6 dpi) and then at 10 and
14 dpi for blood collection and physical examination. The
control was sedated and sampled at 2, 4, 6, and 7 dpi. Animals were initially monitored 2 times/day, then 3 times/day
after development of fever.
We determined blood levels of albumin, alkaline phosphatase, γ-glutamyl transferase, aspartate aminotransferase,
and blood urea nitrogen by using a VetScan VS2 Analyzer
(Abaxis, Union City, CA, USA). We used a quantitative reverse transcription PCR (qRT-PCR) to detect RVFV RNA
(10). We performed humane euthanasia and necropsy when
deer were moribund or at the end of the study (14 dpi). All
animal work was performed at the Biosecurity Research Institute, Kansas State University (Manhattan, KS, USA), in
compliance with Institutional Animal Care and Use Committee protocol no. 3518.
The 5 deer adapted well to the specifically designed
room. Rectal temperatures were in the standard range
(37.5°C–40.1°C) (11) at 0 dpi (Table). On dpi 2, clinical assessment of 2 infected deer (nos. 43 and 44) and the control
(no. 41) showed that 1 inoculated animal (no. 44; 41.3°C)
and the control (41.2°C) had increased body temperatures.
Also, the control was highly agitated during capture.
R
ift Valley fever virus (RVFV) is a zoonotic, arthropodborne RNA virus (order Bunyavirales, family Phenuiviridae, genus Phlebovirus) (1,2). The virus is
maintained in nature in a mosquito–vertebrate host cycle
and is endemic to sub-Saharan Africa where epidemics
have great consequences for livestock and human health.
There is potential for RVFV incursions into neighboring
regions or introductions into other continents, including
North America, which has mosquito species capable of
harboring and transmitting RVFV (3).
Although domestic cattle, sheep, and goats are susceptible to RVFV and function as amplification hosts during
epidemics, the potential role of wildlife host species, such
as white-tailed deer (Odocoileus virginianus) is unknown.
RVFV is capable of infecting a range of cell lines from
wildlife in North America, including white-tailed deer (4),
suggesting in vivo susceptibility. White-tailed deer might
be good sentinel animals for various arboviruses because
of their abundance and wide geographic distribution in the
United States (5).
A serious concern is that white-tailed deer could
serve as reservoir or amplification hosts for RVFV (6–9).
Author affiliations: US Department of Agriculture, Manhattan,
Kansas, USA (W.C. Wilson, L.E. Noronha, D.S. McVey,
B.S. Drolet, E.E. Schirtzinger); Kansas State University College
of Veterinary Medicine, Manhattan (I.J. Kim, J.D. Trujillo,
S.Y. Sunwoo, K. Urbaniak, I. Morozov, B. Faburay, T. Koopman,
S.V. Indran, V. Balaraman, J.A. Richt)
DOI: https://doi.org/10.3201/eid2409.180265
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1717
DISPATCHES
Table. Assessment of Rift Valley fever virus infection in 5 white-tailed deer at selected days postinfection*
Day postinoculation, real-time qRT-PCR/virus isolation results, temperature, °C
Group,
animal no.
0
2
3
4
6
7
10
Mock
+/+, 39.6 +++/+++, 40.7 +++/+++, 41.2,
41
NC
NA
/41.0
/39.2
euthanized
Ken 06
++/++, 40.2
–/–, 40.6
43
NC
+/+, 39.0
NC
/39.3
/39.1
+++/+++, 41.3 +++/+++, died
44
NA
NA
NA
NA
/39.4
47
NC
+++/+++, died
NA
NA
NA
NA
/39.5
52
NC
NC
+/+, 39.3
–/–, 39.9
NC
/39.2
/39.5
14
NA
/39.0
NA
NA
/39.1
*Bold indicates increased body temperature. NA, not available; NC, not collected; qRT-PCR, quantitative reverse transcription PCR; –, negative; +, cycle
threshold range 31–35, 1 × 101–1 × 103 PFU/mL; ++, cycle threshold range 25–30, 1 × 104–1 × 106 PFU/mL; +++, cycle threshold <25, 1 × 107–1 × 108
PFU/mL.
qRT-PCR analysis of RNA isolated from serum samples obtained 2 dpi showed high concentrations of circulating virus RNA in deer no. 44 (8.15 × 1010 copies/mL)
and high concentrations in deer no. 43 (3.0 × 107 copies/
mL). We did not detect RVFV RNA in serum from the
control at 2 dpi. Later that day, 2 deer (nos. 44 and 47)
were less active, and diffuse bilateral hyperemia of the
ocular sclera developed in deer no. 44. At 3 dpi, bloody
diarrhea developed in these 2 deer, and they died suddenly. qRT-PCR showed high serum levels of RVFV RNA (1
× 1011 copies/mL in deer no. 44 and 1 × 1012 copies/mL
in deer no. 47).
Necropsy findings were similar for both animals and
included severe, multifocal, hemorrhagic hepatic necrosis; moderate to severe segmental to diffuse hemorrhagic
enteritis; moderate pulmonary edema; and moderate to
severe hemorrhagic lymphadenopathy (Figure). Hepatic
necrosis and petechiae have also been found in cattle and
sheep with acute RVFV infections (12,13). Enteric lesions
Figure. Gross pathologic view of liver of white-tailed deer no. 44
after experimental infection with Rift Valley fever virus inoculum.
The animal died at day 3 postinoculation; at necropsy, the
liver showed severe, multifocal, hemorrhagic hepatic necrosis
attributed to acute infection with Rift Valley fever virus.
1718
appeared to be severe and unique to white-tailed deer.
Bloody fecal material covered the perineum, ventral tail,
and hind limbs. Segmental hemorrhage of gastrointestinal
mucosa was most severe in deer no. 44. We found watery
and bloody gastrointestinal contents from the abomasum
to the rectum (deer no. 44) or small intestine to the rectum
(deer no. 47). Mesenteric and gastrohepatic lymph nodes
of both animals were edematous and had multifocal hemorrhagic foci. We observed diffuse thymic hemorrhage in
deer no. 44.
The remaining animals were bright, alert, and responsive at 3 dpi. However, 2 deer (nos. 43 and 52) had transient
diarrhea with loose feces persisting until 6 dpi. qRT-PCR of
serum showed moderate levels of RVFV RNA in deer no.
43 and deer no. 52. We also detected a low concentration
(1 × 103 copies/mL) of RVFV RNA in the control by 4 dpi,
indicative of horizontal transmission. On day 6, the control
and 1 inoculated deer (no. 43) had slightly increased body
temperatures (40.7°C for the control and 40.6° for no. 43).
By day 6, serum RVFV RNA concentration for the control
had increased to ≈1 × 1010 copies/mL, and concentrations
of virus RNA in deer no. 47 and no. 52 had decreased to
1 × 102–1 × 103 copies/mL. By 7 dpi, the control was recumbent and febrile (41.2°C) and marked swelling of the
left hind limb had developed, which warranted euthanasia.
At necropsy for the control, hepatic and gastrointestinal lesions attributed to RVFV infection were similar to those in deer no. 44 and no. 47, albeit much less
severe. Examination of the markedly swollen left hind
limb showed marked expansion of subcutis and fascia
with hemorrhage and emphysema but definite diagnosis is
pending further investigation. RVFV infection of the control was supported by the high serum level of RVFV RNA
at 7 dpi (8.1 × 108 copies/mL). Serum qRT-PCR showed
RVFV RNA in deer no. 43 (1 × 103 copies/mL) but not
in deer no. 52 at 10 dpi. By 14 dpi (end of the study), we
did not detect RVFV RNA in serum of either remaining
animal. We did not observe gross lesions in the remaining
deer (nos. 43 and 52) at the end of the study. However, we
detected RVFV RNA in liver, kidneys, spleen, and lymph
nodes from both animals.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Susceptibility of White-Tailed Deer to RVFV
Conclusions
Clinical signs, gross pathology, and qRT-PCR–determined virus RNA loads demonstrated that white-tailed
deer are highly susceptible to RVFV infection, causing
hepatic necrosis and hemorrhage. Supporting this conclusion, we found that levels of aspartate aminotransferase increased in serum of all animals when blood was
collected at the time of clinical illness (range 91–153
U/L at 0 dpi and 629–3,543 U/L at the time of clinical illness). Similar results were reported for previous
experimental RVFV infections of domestic cattle and
sheep (12,13).
In addition, and unique to this study, RVFV infection
in white-tailed deer resulted in development of hemorrhagic enteritis and bloody diarrhea at the time of peak
viremia in 2 infected deer (nos. 44 and 47), which likely
enabled horizontal transmission of RVFV to the control
animal. Additional laboratory analysis is ongoing. However, our results clearly indicate that white-tailed deer in
North America are susceptible to RVFV infection. Infected white-tailed deer died from the infection (n = 2),
might survive the infection (n = 2), and can transmit the
virus through direct contact (n = 1), presumptively by the
fecal–oral route.
This study indicates that white-tailed deer in
North America are highly susceptible to RVFV and capable of horizontal virus transmission. The potential role
of other wildlife in the epidemiology of RVFV should
be evaluated.
Acknowledgments
We thank Rebecca Cox for providing assistance with whitetailed deer acclimatization before the study and Mallory
Hoover, the Biosecurity Research Institute, and staff of the
Kansas State University Comparative Medicine Group for
providing assistance.
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
International Committee on Taxonomy of Viruses. ICTV 10th
report, 2011 [cited 2017 Aug 6]. https://talk.ictvonline.org/
ictv-reports/ictv_9th_report/
Rima B, Collins P, Easton A, Fouchier R, Kurath G, Lamb RA,
et al.; ICTV Report Consortium. ICTV virus taxonomy profile:
Pneumoviridae. J Gen Virol. 2017;98:2912–3. http://dx.doi.org/
10.1099/jgv.0.000959
Turell MJ, Wilson WC, Bennett KE. Potential for North American
mosquitoes (Diptera: Culicidae) to transmit rift valley fever virus.
J Med Entomol. 2010;47:884–9. http://dx.doi.org/10.1093/
jmedent/47.5.884
Gaudreault NN, Indran SV, Bryant PK, Richt JA, Wilson WC.
Comparison of Rift Valley fever virus replication in North
American livestock and wildlife cell lines. Front Microbiol.
2015;6:664. http://dx.doi.org/10.3389/fmicb.2015.00664
Pedersen K, Wang E, Weaver SC, Wolf PC, Randall AR,
Van Why KR, et al. Serologic evidence of various arboviruses
detected in white-tailed deer (Odocoileus virginianus) in
the United States. Am J Trop Med Hyg. 2017;97:319–23.
http://dx.doi.org/10.4269/ajtmh.17-0180
Hartley DM, Rinderknecht JL, Nipp TL, Clarke NP, Snowder GD,
Nipp TL, et al.; National Center for Foreign Animal and Zoonotic
Disease Defense Advisory Group on Rift Valley Fever. Potential effects
of Rift Valley fever in the United States. Emerg Infect Dis. 2011;17:e1.
Kakani S, LaBeaud AD, King CH. Planning for Rift Valley fever
virus: use of geographical information systems to estimate the
human health threat of white-tailed deer (Odocoileus virginianus)–
related transmission. Geospat Health. 2010;5:33–43.
http://dx.doi.org/10.4081/gh.2010.185
Kasari TR, Carr DA, Lynn TV, Weaver JT, Lynn TV, Lynn TV,
et al. Evaluation of pathways for release of Rift Valley fever virus
into domestic ruminant livestock, ruminant wildlife, and human
populations in the continental United States. J Am Vet Med Assoc.
2008;232:514–29. http://dx.doi.org/10.2460/javma.232.4.514
Golnar AJ, Kading RC, Hamer GL. Quantifying the potential
pathways and locations of Rift Valley fever virus entry into the
United States. Transbound Emerg Dis. 2017;179:1397.
Wilson WC, Romito M, Jasperson DC, Weingartl H, Binepal YS,
Maluleke MR, et al. Development of a Rift Valley fever real-time
RT-PCR assay that can detect all three genome segments.
J Virol Methods. 2013;193:426–31. http://dx.doi.org/10.1016/
j.jviromet.2013.07.006
Rogers LL, Moen AN, Shedd ML. Rectal temperatures of 2
free-ranging white-tailed deer fawns. Journal of Wildlife
Management. 1987;51:59–62. http://dx.doi.org/10.2307/3801631
Faburay B, Gaudreault NN, Liu Q, Davis AS, Shivanna V,
Sunwoo SY, et al. Development of a sheep challenge model for
Rift Valley fever. Virology. 2016;489:128–40. http://dx.doi.org/
10.1016/j.virol.2015.12.003
Wilson WC, Davis AS, Gaudreault NN, Faburay B, Trujillo JD,
Shivanna V, et al. Experimental infection of calves by two
genetically-distinct strains of Rift Valley fever virus. Viruses.
2016;8:145. http://dx.doi.org/10.3390/v8050145
This study was supported by the Department of Homeland
Security Center of Excellence for Emerging and Zoonotic
Animal Diseases (grant no. 2010-ST061-AG0001), the Kansas
National Bio and Agro-Defense Facility Transition Fund, the
Kansas Bioscience Authority, and the US Department of
Agriculture (project no. 59-32000-009-00D).
12.
About the Author
Dr. Wilson is a research microbiologist at the US Department
of Agriculture, Manhattan, KS. His research interests are
understanding virus–vector–host interactions and developing
means to detect and control arboviruses.
Address for correspondence: William C. Wilson, US Department
of Agriculture, Agricultural Research Service, Center for Grain and
Animal Health Research, Arthropod-Borne Animal Diseases
Research Unit, 1515 College Ave, Manhattan, KS 66502, USA;
william.wilson@ars.usda.gov
13.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1719
DI SPATCHES
Ou t br e a k of Pn e u m ococca l M e n in git is,
Pa ou a Su bpr e fe ct u r e ,
Ce n t r a l Afr ica n Re pu blic, 2 0 1 6 – 2 0 1 7
Matthew E. Coldiron, Oumar Touré,
Thierry Frank, Nathalie Bouygues,
Rebecca F. Grais
We report a pneumococcal meningitis outbreak in the Central African Republic (251 suspected cases; 60 confirmed
by latex agglutination test) in 2016–2017. Case-fatality
rates (10% for confirmed case-patients) were low. In areas
where a recent pneumococcal conjugate vaccine campaign
was conducted, a smaller proportion of cases was seen in
youngest children.
I
n early January 2017, an abnormally large number of
pneumococcal meningitis cases was reported at Paoua
Subprefectural Hospital in northwestern Central African
Republic. This region is at the southern edge of the traditional meningitis belt in Africa (1), and the hospital has been
supported by the international medical humanitarian organization Médecins Sans Frontières since 2007. Routine data
collected since 2012 showed a weekly maximum of 3 cases
of pneumococcal meningitis (confirmed by latex agglutination test) and never >29 reported cases in any given 25-week
period. A case-based meningitis surveillance system, including latex agglutination testing, was implemented in Paoua
Subprefectural Hospital. All suspected cases in peripheral
health centers were referred free of charge. We provide an
epidemiologic description of this outbreak.
The Study
The Central African Republic has experienced a series of
crises over the past several decades. The most recent acute
crisis began in 2013, when a series of armed rebellions led
to multiple changes of power at the central level; a newly
elected government took office in 2016, but many areas are
still not secure. Thus, health systems, particularly in the rural periphery, are particularly weak.
Vaccination coverage remains low: nationwide administrative coverage for the first dose of 13-valent pneumococcal conjugate vaccine (PCV13) was 77% in 2016 and
Author affiliations: Epicentre, Paris, France (M.E. Coldiron,
R.F. Grais); Epicentre, Paoua, Central African Republic (O. Touré);
Institut Pasteur, Bangui, Central African Republic (T. Frank);
Médecins Sans Frontières, Paris (N. Bouygues)
DOI: https://doi.org/10.3201/eid2409.171058
1720
52% for the third dose. PCV13 was introduced in the Paoua Subprefecture (population 236,000) in 2012. A series
of multiantigen catch-up vaccination campaigns for children <5 years of age that included PCV13 was conducted
by Médecins Sans Frontières in 2016. Several areas were
inaccessible because of security concerns and were not included in the vaccination campaign.
Outbreaks of pneumococcal meningitis have been reported in Africa before and after introduction of pneumococcal vaccine. There was a recent large outbreak in Ghana
(2) and several other smaller outbreaks in the traditional
meningitis belt (3,4). Pneumococcal meningitis has casefatality rates (CFRs) of 36%–66% depending on age, and
the risk for sequelae is high (5). Outbreaks generally occur during the dry season (typical meningitis season), but
these outbreaks are usually smaller than meningococcal
outbreaks (6). Unlike meningococcal meningitis, there is
no formal epidemic definition for pneumococcal meningitis, although a provisional definition was recently issued:
a district or subdistrict with a weekly incidence of >5 suspected cases/100,000 population with >60% of confirmed
meningitis cases caused by Streptococcus pneumoniae and
>10 confirmed cases of pneumococcal meningitis (7,8).
During October 10, 2016–April 9, 2017 (epidemiologic week 41 in 2016 through epidemiologic week 14 in
2017), 251 suspected cases of meningitis were reported at
Paoua Subprefectural Hospital: 200 cases from Paoua Subprefecture (attack rate 85 cases/100,000 population), 40
cases from outside Paoua Subprefecture, and 11 cases from
villages that could not be identified (Figure). Lumbar puncture and latex agglutination testing were performed for 110
patients, of whom 101 had not received antimicrobial drugs
before lumbar puncture.
Of 110 samples, 60 (55%) were positive for S. pneumoniae by latex agglutination test, 1 for Neisseria meningitidis strain NmW/Y, and 2 for Haemophilus influenzae.
Two other samples showed a positive result, but the causative organism could not be identified. The remaining 45
samples were negative by latex agglutination test. Ten samples positive for S. pneumoniae by latex agglutination test
were sent to the national reference laboratory (Institut Pasteur, Bangui, Central African Republic) where 6 were confirmed as serotype 1 S. pneumoniae by PCR, and 4 showed
weak positive results for S. pneumoniae by PCR. Two
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Pneumococcal Meningitis, Central African Republic
Figure. Cases of meningitis
and weekly attack rate, Paoua
Subprefecture, Central African
Republic, 2016–2017.
samples negative by latex agglutination were also negative
by PCR. S. pneumoniae represented 60 (92%) of 65 of all
samples positive by latex agglutination during this period.
Overall, 9 patients died (CFR 3.6%). For case-patients
with confirmed pneumococcal meningitis, 6 patients died
(CFR 10.0%). For all case-patients, median length of treatment with ceftriaxone was 4 days (interquartile range 3–6
days). For case-patients with pneumococcal meningitis,
median length of treatment was 10 days (interquartile
range 9–12 days). Although information was incomplete,
25 case-patients with pneumococcal meningitis had documented evidence of treatment with dexamethasone.
Attack rates were highest for children <2 years of age
(Table) when we considered all suspected cases and confirmed cases of pneumococcal meningitis. Areas targeted
for the 2016 PCV13 vaccination campaign did not necessarily correspond to established political divisions. Thus,
we were unable to calculate attack rates in vaccinated areas
versus nonvaccinated areas because of lack of precise denominators. Nonetheless, in vaccinated areas, 5 (17%) of
30 confirmed cases were in children <5 years of age. In
unvaccinated areas, 10 (36%) of 28 confirmed cases were
in children <5 years of age. PCV13 vaccination status of
case-patients was not recorded.
At a district level, this outbreak seems to have met
the provisional definition of a pneumococcal meningitis
outbreak, at least during epidemiologic weeks 52 in 2016
and weeks 1 and 3 in 2017, although it is unclear whether
the criterion of >10 confirmed pneumococcal meningitis
cases refers to a single week or overall during the outbreak. At a subdistrict level, only 2 subdistricts (BahBessar, population 33,820; and Mia-Pendé, population
35,261) met the provisional definition at any point during
the outbreak.
Conclusions
We describe a pneumococcal meningitis outbreak in the
Central African Republic in 2016–2017. This outbreak was
not large, but it clearly was an abnormal event. Although
pneumococcal outbreaks have been reported more frequently in recent years, outbreak definitions and guidance
remain provisional and have been based on scanty data. We
have highlighted a potential clarification that could be used
in outbreak definitions in terms of the overall number of
confirmed cases of pneumococcal meningitis.
We report low CFRs for case-patients with confirmed
pneumococcal meningitis, which is in contrast to results
of previous reports (9). These differences might have been
Table. Attack rates for pneumococcal meningitis, Paoua Subprefecture, Central African Republic, 2016–2017
Overall cases of pneumococcal meningitis
Confirmed cases of pneumococcal meningitis
Patient
No. cases
Attack rate, no. cases/100,000 population
No. cases
Attack rate, no. cases/100,000 population
age, y
<2
61
301
12
59
2–4
22
82
4
15
5–14
38
62
24
39
15–29
79
124
11
17
30–44
37
96
7
18
>45
14
54
2
8
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1721
DISPATCHES
caused by an extended duration of antimicrobial drug
therapy and, at least for some case-patients, the addition
of corticosteroids. Our small-scale observational data
should not be overinterpreted, but length of therapy and
utility of adjuvant corticosteroids were both highlighted
as knowledge gaps in the provisional guidance document
of the World Health Organization (8).
One limitation of our work was the level of biologic
confirmation. However, the Pastorex Latex Agglutination Test Kit (Bio-Rad Laboratories, Marne-la-Coquette,
France) we used has shown good performance in detecting
S. pneumoniae (10). These kits were shipped and stored
according to manufacturer’s instructions, and positive and
negative controls were tested regularly according to standard procedures (11). We are reassured that at least a few
samples underwent PCR confirmation and serotyping.
Given that it appears that S. pneumoniae serotype 1 was
the circulating serotype, differences in age distribution of
case-patients seen between areas targeted and not targeted
by the 2016 PCV13 catch-up vaccination campaign were
likely caused by this intervention.
This outbreak highlights some of the difficulties inherent with performing surveillance in complex and insecure settings. The lack of infrastructure and laboratory
capacity remain major obstacles to more precise characterizations of similar events. During this outbreak, it was
not possible to perform cell counts or biochemical testing, which could have been useful. Increasing PCV13
coverage in the routine vaccination programs is the most
efficient way to prevent future outbreaks, but given the
overall context in the Central African Republic and other
areas of the traditional meningitis belt, it would be prudent to consider formally evaluating (either by modeling
or in real-life situations) the potential effects of reactive
vaccination as an outbreak response.
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
This work was supported by Médecins Sans Frontières.
About the Author
Dr. Coldiron is a medical epidemiologist at Epicentre–Médecins
Sans Frontières, Paris, France. His primary research interests
are meningitis and malaria in the Sahel region of Africa and
neglected tropical diseases.
1722
11.
Molesworth AM, Thomson MC, Connor SJ, Cresswell MP,
Morse AP, Shears P, et al. Where is the meningitis belt?
Defining an area at risk of epidemic meningitis in Africa. Trans
R Soc Trop Med Hyg. 2002;96:242–9. http://dx.doi.org/10.1016/
S0035-9203(02)90089-1
Kwambana-Adams BA, Asiedu-Bekoe F, Sarkodie B, Afreh OK,
Kuma GK, Owusu-Okyere G, et al. An outbreak of pneumococcal
meningitis among older children (>5 years) and adults after the
implementation of an infant vaccination programme with the
13-valent pneumococcal conjugate vaccine in Ghana. BMC Infect
Dis. 2016;16:575. http://dx.doi.org/10.1186/s12879-016-1914-3
Yaro S, Lourd M, Traoré Y, Njanpop-Lafourcade B-M,
Sawadogo A, Sangare L, et al. Epidemiological and molecular
characteristics of a highly lethal pneumococcal meningitis
epidemic in Burkina Faso. Clin Infect Dis. 2006;43:693–700.
http://dx.doi.org/10.1086/506940
Leimkugel J, Adams Forgor A, Gagneux S, Pflüger V, Flierl C,
Awine E, et al. An outbreak of serotype 1 Streptococcus
pneumoniae meningitis in northern Ghana with features that are
characteristic of Neisseria meningitidis meningitis epidemics.
J Infect Dis. 2005;192:192–9. http://dx.doi.org/10.1086/431151
Gessner BD, Mueller JE, Yaro S. African meningitis belt
pneumococcal disease epidemiology indicates a need for an
effective serotype 1 containing vaccine, including for older
children and adults. BMC Infect Dis. 2010;10:22.
http://dx.doi.org/10.1186/1471-2334-10-22
Mueller JE, Yaro S, Ouédraogo MS, Levina N,
Njanpop-Lafourcade BM, Tall H, et al. Pneumococci in the
African meningitis belt: meningitis incidence and carriage
prevalence in children and adults. PLoS One. 2012;7:e52464.
http://dx.doi.org/10.1371/journal.pone.0052464
World Health Organization. Meningitis outbreak response in subSaharan Africa: WHO guideline. Geneva: The Organization; 2014.
World Health Organization. Pneumococcal meningitis outbreaks in
sub-Saharan Africa. Wkly Epidemiol Rec. 2016;91:298–302.
Kambiré D, Soeters HM, Ouédraogo-Traoré R, Medah I, Sangare L,
Yaméogo I, et al.; MenAfriNet Consortium. Nationwide trends
in bacterial meningitis before the introduction of 13-valent
pneumococcal conjugate vaccine—Burkina Faso, 2011–2013. PLoS
One. 2016;11:e0166384. http://dx.doi.org/10.1371/
journal.pone.0166384
Ouédraogo SM, Yaméogo TM, Kyelem CG, Poda GEA,
Ouédraogo NF, Millogo A, et al. Acute bacterial meningitis with
soluble antigen detected by latex particle agglutination tests at the
Sourô-Sanou University Hospital of Bobo-Dioulasso (Burkina
Faso) [in French]. Med Sante Trop. 2012;22:412–6.
Médecins Sans Frontières. Meningitis, rapid latex agglutination
tests and trans-isolate [video] [cited 2018 Jun 29].
https://media.msf.org/media/MSF203013.html
Address for correspondence: Matthew E. Coldiron, Epicentre, 8 Rue SaintSabin, 75011 Paris, France; email: matthew.coldiron@epicentre.msf.org
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Molecular Confirmation of
Rock y M ou n t a in Spot t e d Fe ve r
Epide m ic Age n t in M e x ica li, M e x ico
Luis Tinoco-Gracia, Moisés Rodríguez Lomelí,
Sawako Hori-Oshima, Nicole Stephenson,
Janet Foley
Since 2008, a large epidemic of Rocky Mountain spotted fever has been emerging among humans and dogs in
Mexicali, adjacent to the United States in Baja California,
Mexico. We molecularly confirmed the causative agent; this
information can be used to study the origin and dynamics of
the epidemic.
R
ocky Mountain spotted fever (RMSF), caused by
the bacteria Rickettsia rickettsii, is responsible for
more human deaths than any other tickborne disease in
North America (1). During 1999–2007, a total of 80 fatal
cases were reported from Sonora, Mexico, alone (2).
Recent epidemics in Arizona (USA) and Sonora have
been associated with the brown dog tick (Rhipicephalus
sanguineus) (3,4), whereas most cases in the United States
have been transmitted by bites of infected Dermacentor
spp. ticks (5). The risk to humans is heightened by the
epidemiologic cycle of the brown dog tick, a cosmopolitan
tick that prefers the dog as its host and can live its entire
life cycle in a periurban setting, often spending its off-host
time indoors. R. sanguineus ticks, in addition to being
vectors of R. rickettsii, are probable or confirmed vectors
of Leishmania, Coxiella burnetii, and R. conorii (6).
The Study
In 2008, an epidemic of RMSF began in Mexicali, adjacent to the US border in Baja California, Mexico. In 2015,
the Mexican Ministry of Health declared the epidemic an
epidemiologic emergency, which as of 2018 has affected
≈4,000 persons. In 2014, a fatal human case in Imperial
County, CA, USA, was probably associated with the Mexicali epidemic. Overall, since 2000, in the United States,
the incidence of RMSF has reportedly increased ≈4-fold
(7); this dramatic increase may be caused in part by increased transmission via the brown dog tick but also by
Author affiliations: Universidad Autónoma de Baja California,
Mexicali, Mexico (L. Tinoco-Gracia, M. Rodríguez Lomelí,
S. Hori-Oshima); University of California, Davis, California, USA
(N. Stephenson, J. Foley)
DOI: https://doi.org/10.3201/eid2409.171523
changes in reporting and inclusion of false-positive test
results in case diagnoses.
Local response to the ongoing epidemic in Mexicali
has involved the Secretariat of Health and doctors and
researchers at the Universidad Autónoma de Baja California schools of medicine and veterinary medicine. During 2008–2009, in the impoverished neighborhood of Los
Santorales in Mexicali, at least 13 persons died of RMSF.
Under agreement with the Sector Salud de Mexicali, the
Universidad Autónoma de Baja California veterinary
team documented 81% seroprevalence among local dogs
and confirmed active R. rickettsii infection in a human
resident by conducting PCR of kidney tissue (8). Of 120
persons from Mexicali with clinical signs compatible with
RMSF, 30 were positive by PCR for the gene gltA, according to an unpublished method (9). In 2014, the local team partnered with researchers at the University of
California, Davis (Davis, California, USA), to further
molecularly characterize the strains of R. rickettsii and
R. sanguineus ticks from Mexicali. We provide definitive
molecular confirmation of the identity of the disease agent
causing the Mexicali epidemic.
The University of California, Davis, laboratory received DNA extracted by use of QIAGEN Blood and Tissue Kits (Valencia, CA, USA) from 16 cases from Mexico.
Initial R. rickettsia–specific real-time PCR for the citrate
synthase gene (10) was positive for 10 samples. To obtain
products for DNA sequencing, we performed traditional
PCR for the ompA and 17kDa genes as published (11,12).
Sequence-confirmed positive DNA and water-containing
negative control reactions were incorporated in each PCR
run. Results were assessed by electrophoresis and UVtransillumination of 1% agarose gels stained with Gelstar
(Lonza, Rockland, ME, USA). Bands of the expected size
were excised and cleaned with a QIAquick Gel Extraction
Kit (QIAGEN) according to the manufacturer’s instructions. Products were sequenced in the forward and reverse
directions in an ABI Prism 3730 Genetic Analyzer at the
UC
DNA Sequencing Facility at the University of California,
Davis. Sequences were manually trimmed and corrected
if the nucleotide could be unambiguously determined,
then aligned by using CLC Main Workbench 6 (CLC bio,
Waltham, MA, USA).
We successfully obtained ompA and 17kDa products
from 5 samples and compared the sequences with those in
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1723
DISPATCHES
the GenBank database by using BLAST (http://blast.ncbi.
nlm.nih.gov/Blast.cgi). For ompA, the resulting 472-bp
amplicons from the 5 products from Mexicali were 100%
similar. For this gene, numerous accessions in GenBank
also have 100% homology with 100% coverage, including strains Sheila Smith, Hauke, Hilo, Colombia, and Arizona. Sequences of 17kDa spanned 206 bps and were also
completely homologous among them. This gene did not
differentiate to species but was 100% homologous with
R. rickettsii, R. parkeri, and others in the database. Representative sequences from Mexicali were submitted to GenBank (accession nos. KY689935 for ompA and KY824575
for 17kDa).
Among sequence-confirmed samples, data were not
available for 1 sample. The other 4 samples were collected
in June, July, and September 2013 and April 2014. Two
samples were from men (41 and 25 years of age) and 2
from women (18 and 29 years of age); all patients had dogs
with ticks. Signs and symptoms were fever and headache
for all; for 1 patient, a rash and convulsions also developed. The 2 men died and the 2 women survived with treatment. All patients had home addresses in various parts of
Mexicali, including central west, southwest, and southeast
bordering agricultural land. Clinical data were not available for patients for whom samples were considered PCR
positive but not sequence confirmed, although inclusion of
such clinical data and risk factors could bias interpretation
if they were false positive or only weakly positive.
Conclusions
The RMSF epidemic in Mexicali has not been contained
and may be spreading to other parts of Baja California
and into the United States. More data are needed before
we can understand why this epidemic emerged, where the
specific areas of high risk for exposure to infected ticks
are located, and whether the particular R. rickettsii strain
or relationship with this R. sanguineus tick strain is likely
to be particularly invasive or virulent. Pockets of RMSF
have occurred in Mexico since at least 1947, when cases
attributable to the brown dog tick in Sonora, Sinaloa, Coahuila, and Durango were described (13). Given the very
limited phylogeographic resolution available for R. rickettsii in many of the commonly used PCR products (14), it
is not known whether the bacteria in the Mexicali epidemic originated from Sonora or more distantly. Next steps
include obtaining a culture of the bacteria from Mexicali,
studying bacterial virulence in vitro or in animal models,
and assessing vector competence of the Mexicali R. sanguineus tick strain for R. rickettsii. Epidemiologic data
on the spatial distribution and prevalence of infection in
dogs are needed.
Aggressive intervention achieved partial and temporary resolution of the Arizona and Sonora epidemics,
1724
which were localized and relatively small; these interventions included dog spay and neuter programs, treatment of
houses against ticks, and use of a long-acting tick collar
(Seresto; Bayer, Shawnee Mission, KS, USA) directly on
the dogs (15). However, the dog collars were initially donated and are prohibitively expensive and not feasible for
the scope of the Mexicali epidemic. This large epidemic
in a major city will require a far greater and more creative
public health response. Studying this epidemic offers an
opportunity to understand the origin and dynamics of this
epidemic and can inform response to emerging tickborne
diseases in general.
Acknowledgments
We thank Zachary Villareal for laboratory support and Marian
Fierro, Christopher Paddock, William Nicholson, and Michael
Levin for logistical and scientific support.
Financial support was provided by the University of California
Institute for Mexico and the United States.
About the Author
Dr. Tinoco-Gracia is a research professor in the School of
Veterinary Medicine at Universidad Autonoma de Baja
California and director of the Laboratory of Veterinary Public
Health Sciences. He studies zoonotic diseases of dogs and
humans in Mexicali and leads community education programs
of Universidad Autónoma de Baja California.
References
1.
2.
3.
4.
5.
6.
7.
Biggs HM, Behravesh CB, Bradley KK, Dahlgren FS, Drexler NA,
Dumler JS, et al. Diagnosis and management of tickborne
rickettsial diseases: Rocky Mountain spotted fever and other
spotted fever group rickettsioses, ehrlichioses, and anaplasmosis—
United States. MMWR Recomm Rep. 2016;65(RR-1):1–44.
http://dx.doi.org/10.15585/mmwr.rr6502a1
Álvarez-Hernández G, Roldán JFG, Milan NSH, Lash RR,
Behravesh CB, Paddock CD. Rocky Mountain spotted fever in
Mexico: past, present, and future. Lancet Infect Dis. 2017;17:e189–
96. http://dx.doi.org/10.1016/S1473-3099(17)30173-1
Nicholson WL, Paddock CD, Demma L, Traeger M, Johnson B,
Dickson J, et al. Rocky Mountain spotted fever in Arizona:
documentation of heavy environmental infestations of
Rhipicephalus sanguineus at an endemic site. Ann N Y Acad Sci.
2006;1078:338–41. http://dx.doi.org/10.1196/annals.1374.065
Álvarez-Hernández G. La fiebre manchada de las Montañas Rocosas,
una epidemia olvidada. Salud Pública de México. 2010;52:1–3.
Regan JJ, Traeger MS, Humpherys D, Mahoney DL, Martinez M,
Emerson GL, et al. Risk factors for fatal outcome from Rocky
Mountain spotted fever in a highly endemic area—Arizona, 2002–
2011. Clin Infect Dis. 2015;60:1659–66. http://dx.doi.org/10.1093/
cid/civ116
Dantas-Torres F. Biology and ecology of the brown dog tick,
Rhipicephalus sanguineus. Parasit Vectors. 2010;3:26.
http://dx.doi.org/10.1186/1756-3305-3-26
Centers for Disease Control and Prevention. Rocky Mountain
spotted fever—statistics and epidemiology [cited 2017 Aug 1].
https://www.cdc.gov/rmsf/stats/index.html
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Rocky Mountain Spotted Fever in Mexicali
8.
Tinoco L. Diagnostico serologico y molecular de un brote
de riquetsiosis (Rickettsia rickettsii) en perros y un humano en la
cuidad de Mexicali, B.C. XXXIV Congreso Nacional de
Infectologia, México; 2009 Oct 7–10; Guadalajara, Jalisco State,
Mexico.
9. Gómez-Castellanos P, Tinoco-Gracia L, López-Valencia G,
Oshima S, Medina Basulto G. Deteccion de especies del genero
Rickettsia por PCR en pacientes del sector salud y analisis de
factores de riesgo en Mexicali Baja California. Rev Biomed.
2015;26:59.
10. Kato CY, Chung IH, Robinson LK, Austin AL, Dasch GA,
Massung RF. Assessment of real-time PCR assay for detection of
Rickettsia spp. and Rickettsia rickettsii in banked clinical samples.
J Clin Microbiol. 2013;51:314–7. http://dx.doi.org/10.1128/
JCM.01723-12
11. Anstead CA, Chilton NB. A novel Rickettsia species detected in
vole ticks (Ixodes angustus) from western Canada. Appl Environ
Microbiol. 2013;79:7583–9. http://dx.doi.org/10.1128/AEM.02286-13
12.
Webb L, Carl M, Malloy DC, Dasch GA, Azad AF. Detection of
murine typhus infection in fleas by using the polymerase chain
reaction. J Clin Microbiol. 1990;28:530–4.
13. Bustamante M, Varela G. Distribucion de las rickettsiasis en
Mexico. Rev Inst Salubr Enferm Trop. 1947;8:3–13.
14. Paddock CD, Denison AM, Lash RR, Liu L, Bollweg BC,
Dahlgren FS, et al. Phylogeography of Rickettsia rickettsii genotypes
associated with fatal Rocky Mountain spotted fever. Am J Trop Med
Hyg. 2014;91:589–97. http://dx.doi.org/10.4269/ajtmh.14-0146
15. Drexler N, Miller M, Gerding J, Todd S, Adams L, Dahlgren FS,
et al. Community-based control of the brown dog tick in a region with
high rates of Rocky Mountain spotted fever, 2012-2013. PLoS One.
2014;9:e112368. http://dx.doi.org/10.1371/journal.pone.0112368
Address for correspondence: Janet Foley, University of California,
Department of Medicine and Epidemiology, 1320 Tupper Hall, Davis,
CA 95616, USA; email: jefoley@ucdavis.edu
July 2013: V e ct or bor n e I n fe ct ion s
• Transmission of Streptococcus equi Subspecies
zooepidemicus Infection from Horses to Humans
• Schmallenberg Virus among Female
Lambs, Belgium, 2012
• Travel-associated Illness Trends and Clusters, 2000–2010
• Psychrobacter arenosus Bacteremia
after Blood Transfusion, France
• Quantifying Effect of Geographic Location on
Epidemiology of Plasmodium vivax Malaria
• Ciprofloxacin-Resistant
Campylobacter spp. in Retail
Chicken, Western Canada
• Asynchronous Onset of Clinical Disease in BSE-Infected
Macaques
• Prevalence of Nontuberculous Mycobacteria in Cystic
Fibrosis Clinics, United Kingdom, 2009
• Mutation in Spike Protein Cleavage Site and Pathogenesis
of Feline Coronavirus
• Pneumococcal Serotypes before and after Introduction
of Conjugate Vaccines, United States, 1999–2011
• Influence of Pneumococcal Vaccines and Respiratory
Syncytial Virus on Alveolar Pneumonia, Israel
• Avian Metapneumovirus Subgroup C Infection in
Chickens, China
• Reducing Visceral Leishmaniasis by Insecticide
Impregnation of Bed-Nets, Bangladesh
• Genetic Variants of Orientia tsutsugamushi in Domestic
Rodents, Northern China
• Undetected Multidrug-Resistant Tuberculosis Amplified
by First-line Therapy in Mixed Infection
• Clinical Findings for Early Human Cases of Influenza
A(H7N9) Virus Infection, Shanghai, China
• Human Alveolar Echinococcosis in Kyrgyzstan
• Multidrug-Resistant Atypical Variants of Shigella flexneri
in China
• Molecular Epidemiologic Source Tracking of Orally
Transmitted Chagas Disease, Venezuela
• MDR TB Transmission, Singapore
• Unique Clone of Coxiella burnetii Causing Severe Q
Fever, French Guiana
• Novel Bat-borne Hantavirus, Vietnam
• Human Infection with Marten Tapeworm
• Babesia microti Infection, Eastern Pennsylvania, USA
• Reemergence of Chikungunya Virus in Bo, Sierra Leone
• Novel Bartonella Agent as Cause of Verruga Peruana
https://wwwnc.cdc.gov/eid/articles/issue/19/7/table-of-contents
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1725
DI SPATCHES
Fa t a l Tick bor n e Ph le bovir u s I n fe ct ion
in Ca pt ive Ch e e t a h s, Ja pa n
Keita Matsuno, Noriyuki Nonoue,
Ayako Noda, Nodoka Kasajima, Keita Noguchi,
Ai Takano, Hiroshi Shimoda, Yasuko Orba,
Mieko Muramatsu, Yoshihiro Sakoda,
Ayato Takada, Shinji Minami, Yumi Une,
Shigeru Morikawa, Ken Maeda
Two captive cheetahs from a zoo in Japan died of a severe
fever with thrombocytopenia syndrome–like illness. Severe
fever with thrombocytopenia syndrome virus, an endemic
tickborne phlebovirus, was detected systemically with secretion of infectious viruses into the saliva. These cases
highlight the risk for exposure of captive animals to endemic
arthropodborne pathogens.
A
n emerging tickborne virus, severe fever with thrombocytopenia syndrome (SFTS) virus (SFTSV; genus
Phlebovirus, family Phenuiviridae [previously known as
family Bunyaviridae]) (1,2), causes severe and often fatal febrile illness in humans, especially in elderly patients.
SFTS cases have been identified in East Asia countries
(e.g., China, South Korea, and Japan), where the virus also
was detected in multiple species of ticks (3,4) and in domestic and wild animals (4,5). Ticks and animals play a
central role in maintaining the life cycle of SFTSV in the
environment and in the occasional transmission of SFTSV
to humans. The pathogenesis of SFTSV has been studied
in human (1,6) and animal models using immunocompromised mice that show a lethal SFTS-like illness (7,8).
In humans, SFTS begins with a high fever, marked
thrombocytopenia and leukocytopenia, and a high serum viral load, followed by multiorgan dysfunction,
which may be a consequence of systemic inflammatory
responses and disseminated intravascular coagulation
(9,10). Gastrointestinal symptoms, such as nausea and
Author affiliations: Hokkaido University, Sapporo, Japan
(K. Matsuno, Y. Sakoda, A. Takada); Hiroshima City Asa
Zoological Park, Hiroshima, Japan (N. Nonoue, A. Noda,
S. Minami); Hokkaido University Research Center for Zoonosis
Control, Sapporo (N. Kasajima, Y. Orba, M. Muramatsu, A.
Takada); Yamaguchi University, Yamaguchi, Japan (K. Noguchi,
A. Takano, H. Shimoda, K. Maeda); Okayama University of
Science, Imabari, Japan (Y. Une); National Institute of Infectious
Diseases, Tokyo, Japan (S. Morikawa)
DOI: https://doi.org/10.3201/eid2409.171667
1726
vomiting in the early phase and bloody diarrhea in the
later phase of the disease, have been frequently reported
(11). The serum viral load, which can be a prognostic
marker associated with a fatal outcome, remains high in
fatal cases but decreases in convalescent patients. Here
we report 2 fatal SFTS cases in cheetahs in a zoo in the
endemic area.
The Study
In July 2017, anorexia was first recognized in a 7-year-old
female cheetah (cheetah 1) in a group of 4 cheetahs sharing
the same outside enclosure; she was anesthetized for medical examination on day 3. Laboratory studies showed extremely low leukocyte and low platelet counts and slightly
elevated aspartate aminotransferase, alanine aminotransferase (ALT), and total bilirubin levels (Table). The animal
was confirmed negative for feline leukemia virus, feline
immunodeficiency virus, and feline panleukopenia virus
using rapid test kits (Checkman FIV, SNAP FIV/FeLV
Combo, Checkman FeLV, and Checkman CPV; Kyoritsu
Seiyaku Corporation, Tokyo, Japan). On day 4, cheetah 1
started vomiting with hemorrhage and then died after generalized convulsion. Pathologic analysis identified 4 ulcers
in the digestive tract, bleeding in the esophagus, and swollen spleen with white nodules.
Slightly abnormal behavior of a 6-year-old male cheetah (cheetah 2) was first observed at 10 and 15 days after
the death of cheetah 1. Obvious anorexia in cheetah 2 was
recorded at 20 days after cheetah 1 died (hereafter referred
to as day 1). Dragging of hind limbs was observed on day
2, and hematologic tests revealed a moderately low platelet count and elevated ALT (Table). A fecal sample was
negative for Helicobacter pylori antigen, enteric bacteria,
and ova-parasite. On day 3, slightly decreased leukocyte
count along with continued low platelet count and high
liver aspartate aminotransferase levels were detected. On
day 4, the gastroscopy test showed erosion and petechiae
in the stomach, and a blood-feeding tick was found and removed from the ear. In addition to the low leukocyte and
platelet counts, elevated ALT, creatine phosphokinase,
and lactate dehydrogenase levels were revealed by laboratory tests on day 6. Cheetah 2 vomited with hemorrhage
on days 6 and 7 and died on day 7. Similar to cheetah 1,
cheetah 2 had a swollen spleen with white nodules and
ulcers in the stomach. No clinical signs were observed in
the 2 other cheetahs.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Fatal Tickborne Phlebovirus Infection in Cheetahs
Table. Hematology and blood chemistry parameters in 2 fatal cases of severe fever with thrombocytopenia syndrome in cheetahs,
Japan, 2017
Cheetah 2‡
Cheetah 1,
day 3†
Laboratory value
Normal ( SD)*
Day 2
Day 3
Day 4
Day 6
Day 7§
10,350 (3,500)
1,700
12,500
10,700
6,900
3,900
4,800
Leukocytes/L
684 (106)
707
845
756
834
722
952
Erythrocytes, 103 cells/L
349 (119)
1
12.7
9.1
5.9
0.9
1.3
Platelets, 103/L¶
Hemoglobin, g/L
12.5 (1.9)
13.9
16.7
15
15.7
14
18.3
Hematocrit, %
37.9 (5.8)
38.4
58.6
43.1
47.4
39.5
54.4
Mean cell volume, fL
55.6 (5.5)
54.3
69.3
57
56.8
54.7
57.1
Aspartate aminotransferase, U/L
52 (35)
161
119
162
145
492
500
Alanine aminotransferase, U/L
98 (71)
157
412
377
284
501
471
Creatine phosphokinase, U/L
296 (311)
262
200
915
746
>2,000
>2,000
Lactate dehydrogenase, U/L
92 (87)
273
203
574
174
684
906
Total bilirubin, mg/dL
0.3 (0.2)
2.7
0.6
2.9
1.2
5.4
12.3
*Numbers are obtained from (12).
†After illness onset.
‡Day 1 was 20 days after cheetah 1 died.
§Blood was collected from the carcass.
¶Possible lower platelet counts due to blood collection using heparin.
We performed laboratory tests for virus detection using plasma from cheetah 1 and serum, spleen, and mesenteric lymph node samples from cheetah 2. SFTSV RNA
genomes were detected using a quantitative reverse transcription PCR (RT-PCR) targeting the S (small) segment
RNA in the spleen and lymph node but not in plasma and
serum (Figure 1, panel A). Quantitative RT-PCR showed
intensive replication of viral RNA in the popliteal lymph
nodes and salivary gland and moderate replication in the
brain and spleen. In addition to these tissues, the livers,
kidneys, and small intestines of both animals were positive for SFTSV RNAs by conventional RT-PCR. The
tissues were negative for flaviviruses, alphaviruses, and
canine distemper virus using conventional RT-PCR targeting these viruses.
We isolated infectious viruses using Huh-7 cells and
Vero E6 cells from the plasma and popliteal lymph node of
cheetah 1 and the spleen, lymph nodes, and brain of cheetah 2 but not from the serum of cheetah 2. Infected cells
were clearly stained in an immunofluorescence assay with
a monoclonal antibody YG1-7-3-3-4 raised against the recombinant SFTSV nucleoprotein of the Japanese prototype
strain YG1. Conditions of the plasma and serum samples
may result in negative RT-PCR results in the plasma and
negative RT-PCR results and virus isolation in the serum
because both samples were collected from animals supposed to cause viremia.
To assess the potential for virus shedding into the secretions of infected animals, infectious SFTSV of the salivary
gland, oral, nasal, and rectal swabs from cheetah 2 were
titrated using Huh-7 cells. Swab samples were collected
from the carcass after freeze and thaw. We detected virus
titers of ≈105 50% tissue culture infectious dose (TCID50)/g
or TCID50/mL in the salivary gland and oral swab samples,
respectively; however, virus was not detected in the nasal
and rectal swab samples (Figure 1, panel B).
We determined genomic sequences of 2 isolates
(SkrP/2017 from the plasma of cheetah 1 and ArtSp/2017
Figure 1. Detection of severe
fever with thrombocytopenia
syndrome virus (SFTSV) in
samples from 2 cheetahs,
Japan, 2017. A) RNA was
extracted from tissues, plasma,
and serum and subjected to
quantitative reverse transcription
PCR (RT-PCR). The amounts
of SFTSV RNA were quantified,
with a reference, as RNA copies/
mg for tissues and RNA copies/
mL for plasma and serum. The
mean of duplicate results is
shown in the graph. a, plasma;
b, popliteal lymph node (left);
c, serum; d, brain; e, salivary gland; f, spleen; g, mesentric lymph node; h, popliteal lymph node (left); i, popliteal lymph node (right). B)
The TCID50 of salivary gland (per mg) and swab specimens (per mL) for cheetah 2 was determined using Huh-7 cells. Virus proteins
were detected by an immunofluorescence assay with an anti-SFTSV N monoclonal antibody. a, salivary gland; b, oral swab sample;
c, nasal swab sample; d, rectal swab sample. ND, not done; TCID50, 50% tissue culture infectious dose.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1727
DISPATCHES
Figure 2. Phylogenetic analyses of severe fever with thrombocytopenia syndrome virus (SFTSV) isolates from 2 cheetahs, Japan, 2017.
The phylogenetic trees constructed based on large (A), medium (B), and small (C) segment RNA nucleotide sequences of isolates
SkrP/2017 from cheetah 1 and ArtSp/2017 from cheetah 2 (underlined) with representative SFTSV isolates. Isolates from human cases
reported in the same prefecture as the zoo are indicated with black dots. The trees were calculated using MrBayes version 3.2.6 (http://
mrbayes.sourceforge.net) with the general time reversible plus gamma plus invariate sites substitution model. Numbers beside nodes
indicate posterior probabilities. Scale bars indicate nucleotide substitutions per site.
from the spleen of cheetah 2) using MiSeq (Illumina, San
Diego, CA, USA) with NEBNext-Ultra RNA Library Prep
kit (NEB). De novo assembly on CLC Genomics Workbench (QIAGEN, Hilden, Germany) determined virtually
full-length sequences of all 3 RNA segments of 2 SFTSV
isolates. We manually edited the termini and remapped virus reads to contigs to define the complete full-length genome sequences (sequences deposited into GenBank under
accession nos. LC325234–9). We found only 1 synonymous nucleotide difference on the coding region of the L
(large) segment between the 2 isolates. Phylogenetic analyses of 3 RNA segments revealed that both cheetah isolates
were clustered together with an SFTSV isolate, SPL071A,
which had been reported in a human in the same prefecture
as the zoo (Figure 2) (13).
Conclusions
We found a fatal SFTS-like illness of 2 cheetahs naturally
infected with an endemic tickborne virus, SFTSV. Disease
progression of cheetah 2 was carefully tracked by daily
monitoring, providing important clinical information on
fatal SFTSV infection in animals. Because the genome sequences of 2 SFTSV isolates were almost identical to each
other, and closely related to those of a local isolate from
a human case, SFTSV circulating among ticks and wild
animals in the area may intrude into the zoo. That 2 cheetahs sharing the same outside enclosure were successively
1728
infected with SFTSV within a month of each other and that
they had the potential to shed infectious SFTSV into their
saliva indicates the virus might have been independently
transmitted to 2 cheetahs by ticks; however, the possibility of horizontal transmission through a bite of the animal
is undeniable. Further investigation on ticks and animals
around the zoo is ongoing. Our study highlights the zoonotic risk for SFTSV infection and the importance of monitoring this endemic arthropodborne disease in zoo animals,
as well as livestock, pets, and wildlife.
Acknowledgments
We thank Aiko Ohnuma, Chiaki Funaki, Hiroko Miyamoto,
and Hirofumi Sawa for their assistance in virologic tests in
laboratory; Keita Mizuma and Masatoshi Okamatsu for their
assistance in preparation of cells and the manuscript and all
the staff at Hiroshima City Asa Zoological Park for their help
and assistance. We are most grateful to Tadaki Suzuki, Hideki
Hasegawa, Kyoko Sawabe, and Shinji Kasai for their help and
advice in this study and for developing measures against ticks in
the zoo.
This study was partly supported by the Ministry of Education,
Culture, Sports, Science and Technology/The Japan Society for
the Promotion of Science [KAKENHI] (grant nos. JP16K18791,
JP16H06431, JP16H06429, JP16K21723, JP16H05805,
JP15K18778), the Japan Initiative for Global Research Network
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Fatal Tickborne Phlebovirus Infection in Cheetahs
on Infectious Diseases, the Japan Agency for Medical Research
and Development (AMED) (grant nos. JP18fm0108008 and
JP17fm0208001), AMED/Japan International Cooperation
Agency within the framework of the Science and Technology
Research Partnership for Sustainable Development, Fusion-H
program from Hokkaido University, and the Akiyama Life
Science Foundation.
About the Author
Dr. Matsuno is a lecturer with the Faculty of Veterinary
Medicine, Hokkaido University, Sapporo, Hokkaido, Japan. His
research interests are the epidemiology, ecology, and molecular
virology of tickborne viruses.
6.
7.
8.
9.
References
1.
2.
3.
4.
5.
Yu X-J, Liang M-F, Zhang S-Y, Liu Y, Li J-D, Sun Y-L, et al.
Fever with thrombocytopenia associated with a novel bunyavirus
in China. N Engl J Med. 2011;364:1523–32. http://dx.doi.org/
10.1056/NEJMoa1010095
Adams MJ, Lefkowitz EJ, King AMQ, Harrach B, Harrison RL,
Knowles NJ, et al. Changes to taxonomy and the International
Code of Virus Classification and Nomenclature ratified by the
International Committee on Taxonomy of Viruses (2017).
Arch Virol. 2017;162:2505–38. http://dx.doi.org/10.1007/
s00705-017-3358-5
Park S-W, Song BG, Shin E-H, Yun S-M, Han MG, Park MY,
et al. Prevalence of severe fever with thrombocytopenia syndrome
virus in Haemaphysalis longicornis ticks in South Korea. Ticks
Tick Borne Dis. 2014;5:975–7. http://dx.doi.org/10.1016/
j.ttbdis.2014.07.020
Oh S-S, Chae J-B, Kang J-G, Kim H-C, Chong S-T, Shin J-H,
et al. Detection of severe fever with thrombocytopenia
syndrome virus from wild animals and Ixodidae ticks in the
Republic of Korea. Vector Borne Zoonotic Dis. 2016;16:408–14.
http://dx.doi.org/10.1089/vbz.2015.1848
Niu G, Li J, Liang M, Jiang X, Jiang M, Yin H, et al. Severe fever
with thrombocytopenia syndrome virus among domesticated
10.
11.
12.
13.
animals, China. Emerg Infect Dis. 2013;19:756–63. http://dx.doi.org/
10.3201/eid1905.120245
Takahashi T, Maeda K, Suzuki T, Ishido A, Shigeoka T, Tominaga T,
et al. The first identification and retrospective study of severe
fever with thrombocytopenia syndrome in Japan. J Infect Dis.
2014;209:816–27. http://dx.doi.org/10.1093/infdis/jit603
Liu Y, Wu B, Paessler S, Walker DH, Tesh RB, Yu X-J. The
pathogenesis of severe fever with thrombocytopenia syndrome
virus infection in alpha/beta interferon knockout mice: insights
into the pathologic mechanisms of a new viral hemorrhagic fever.
J Virol. 2014;88:1781–6. http://dx.doi.org/10.1128/JVI.02277-13
Matsuno K, Orba Y, Maede-White K, Scott D, Feldmann F,
Liang M, et al. Animal models of emerging tick-borne
phleboviruses: determining target cells in a lethal model of
SFTSV infection. Front Microbiol. 2017;8(e3267):104.
http://dx.doi.org/10.3389/fmicb.2017.00104
Deng B, Zhou B, Zhang S, Zhu Y, Han L, Geng Y, et al. Clinical
features and factors associated with severity and fatality among
patients with severe fever with thrombocytopenia syndrome
Bunyavirus infection in northeast China. PLoS One.
2013;8:e80802. http://dx.doi.org/10.1371/journal.pone.0080802
Matsuno K, Matsuno K, Feldmann H, Ebihara H. Severe fever with
thrombocytopenia syndrome associated with a novel bunyavirus.
In: Ergonul O, Can F, Akova M, Madoff L, editors. Amsterdam:
Elsevier; 2014. p. 1–12.
Liu Q, He B, Huang S-Y, Wei F, Zhu X-Q. Severe fever with
thrombocytopenia syndrome, an emerging tick-borne zoonosis.
Lancet Infect Dis. 2014;14:763–72. http://dx.doi.org/10.1016/
S1473-3099(14)70718-2
Fowler ME, Miller RE, editors. Zoo and wild animal medicine.
5th ed. Philadelphia: W.B. Saunders; 2003.
Yoshikawa T, Shimojima M, Fukushi S, Tani H, Fukuma A,
Taniguchi S, et al. Phylogenetic and geographic relationships
of severe fever with thrombocytopenia syndrome virus in China,
South Korea, and Japan. J Infect Dis. 2015;212:889–98.
http://dx.doi.org/10.1093/infdis/jiv144
Address for correspondence: Keita Matsuno, Hokkaido University,
Department of Disease Control, Graduate School of Veterinary
Medicine, N18 W9, Sapporo 060-0818, Japan; email:
matsuno@vetmed.hokudai.ac.jp
Manage your email alerts so you only
receive content of interest to you.
Sign up for an online subscription:
wwwnc.cdc.gov/eid/subscribe.htm
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1729
DI SPATCHES
Eliza be t h k in gia a n oph e lis a n d Associa t ion
w it h Ta p W a t e r a n d H a n dw a sh in g, Sin ga por e
Chee-Fu Yung, Matthias Maiwald,
Liat H. Loo, Han Y. Soong, Chin B. Tan,
Phaik K. Lim, Ling Li, Natalie WH Tan,
Chia-Yin Chong, Nancy Tee,
Koh C. Thoon, Yoke H. Chan
We report an Elizabethkingia anophelis case cluster associated with contaminated aerators and tap water in a children’s intensive care unit in Singapore in 2017. We demonstrate a likely transmission route for E. anophelis to patients
through acquisition of the bacteria on hands of healthcare
workers via handwashing.
lizabethkingia anophelis is an emergent pathogen first
described from midgut specimens of the Anopheles
gambiae mosquito (1). To date, there have been 2 reported
confirmed E. anophelis outbreaks in humans. One occurred
in an adult critical care unit in Singapore; the second was
a large community outbreak in the United States (Wisconsin, Michigan, and Illinois) (2–5). Water sources have been
identified to harbor members of the genus Elizabethkingia,
but the source of the community outbreak in the United
States remains unknown (3,6). Effective interventions for
outbreak control and transmission routes of E. anophelis
remain unclear (3).
KK Women’s and Children’s Hospital (KKH) is the
single largest public tertiary-care specialist women’s and
children’s hospital in Singapore. The Children’s Intensive
Care Unit (CICU) is a 16-bed unit that provides advanced
monitoring and therapeutic technologies for critical pediatric cases. On May 30, 2017, an alert was triggered due
to the detection of 3 patients with Elizabethkingia spp.
within 13 days in the unit. The incidence rate of the cluster,
2.87/1,000 bed-days, was ≈4 times higher than the average rate in the previous 5 years, 0.63/1,000 bed-days (2012
through 2016). Initially, the strains were reported as E. meningoseptica, but subsequent testing confirmed the cluster
to be associated with E. anophelis. We conducted an epidemiologic investigation to identify the source of the cluster.
We also conducted a pragmatic experiment to test our hypothesis that E. anophelis could be transmitted by healthcare workers during handwashing with water contaminated
with E. anophelis.
E
Author affiliation: KK Women’s and Children’s Hospital, Singapore.
DOI: https://doi.org/10.3201/eid2409.171843
1730
The Study
We collated clinical and epidemiologic data using a
standardized spreadsheet for all patients testing positive
for Elizabethkingia species in the KKH CICU in 2017.
We also performed environmental sampling on all tap
outlets and sinks in the clinical areas. For each tap, we
swabbed the aerator and collected a water sample for
culture. The water source of KKH has no supplemental treatments and meets WHO guidelines for drinkingwater quality (7). To test our transmission hypothesis,
we had 2 volunteer nurses place their hands on agar
plates at 3 stages: before handwashing; after handwashing with chlorhexidine soap (4% wt/vol chlorhexidine
gluconate; Microshield 4 Chlorhexidine Surgical Handwash; Schülke, Norderstedt, Germany) and tap water
from the tap outlet in CICU known to be positive for
E. anopheles; and finally after hand hygiene using alcohol-based hand rub (ABHR) (70% vol/vol ethanol
and 0.5% wt/vol chlorhexidine gluconate; Microshield
Handrub; Schülke).
We tested samples using matrix-assisted laser
desorption/ionization time-of-flight (MALDI-TOF)
mass spectrometry (VITEK MS; bioMérieux, Marcyl’Étoile, France). We retested all samples positive for
Elizabethkingia spp. by using 16S rDNA PCR: we extracted bacterial DNA and amplified 16S rDNA using
primers 27f and 1492r (8). We performed sequencing
using standard protocols and used BLAST (https://
blast.ncbi.nlm.nih.gov/Blast.cgi) for comparison with
database sequences.
The 3 cluster cases were the only patients positive for
Elizabethkingia species in the CICU in 2017. All were detected from blind bronchial sampling (BBS) via endotracheal tube (ETT). (Table 1) Patient 3’s isolate was confirmed as E. anophelis. Unfortunately, the samples from the
first 2 cases were not available for follow-up confirmatory
testing. The patients were 2.8 months, 4.9 months, and 4.8
years of age, and all had significant underlying medical
conditions. The average number of days in CICU before
detection of Elizabethkingia species was 36 (range 11–66).
None of the patients had been moved since admission, and
2 were cared for in single rooms.
Of the 27 environmental samples collected from 9
tap outlets or sinks in the unit, 10 samples were positive
for E. anophelis and 1 positive for E. meningoseptica.
Only 1 room (single bed) in the unit was negative for
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
E. anophelis and Association with Handwashing
Table 1. Characteristics of Elizabethkingia cases in children admitted to the Children’s Intensive Care Unit, KK Women’s and
Children’s Hospital, Singapore, May 2017*
Category
Patient 1
Patient 2
Patient 3
Sample date
2017 May 15
2017 May 22
2017 May 28
Sample type
ETT, BBS
ETT, BBS
ETT, BBS
Bacterial identification
MALDI-TOF mass spectrometry
E. meningoseptica
E. meningoseptica
E. meningoseptica
16S rDNA
Isolate not available
Isolate not available
E. anophelis
Sex
M
F
F
Age, mo
4.9
2.8
57.9
Preterm birth
No
No
No
Underlying clinical condition
Duodenal atresia; small
Pulmonary atresia; Large
Thoracic tumor
atrial septal heart defect
ventral septal heart defect;
large patent ductus arteriosus
Outcome
Discharged
Discharged
Deceased
Days in hospital
11
83
33
CICU bed type
Single room
4-bed cubicle
Single room
Other beds used
No
No
No
Antimicrobial drug treatment within 72 h
Piperacillin/tazobactam,
Clindamycin
Piperacillin/tazobactam
before detection
ceftriaxone
History of immunosuppressive medication
No
No
Yes (chemotherapy)
On ECMO at time of detection
Yes
No
Yes
* BBS, blind bronchial sampling; CICU, Children’s Intensive Care Unit; ECMO, extracorporeal membrane oxygenation; ETT, endotracheal tube;
MALDI-TOF, matrix-assisted laser desorption/ionization time-of-flight.
Elizabethkingia bacteria. All 3 Elizabethkingia case-patients’ rooms or cubicles were confirmed positive for E.
anophelis from their respective tap outlets (aerator or water or both). The tap outlet from 1 cubicle not associated
with any of the cases was positive for both Elizabethkingia
species, E. meningoseptica in water and E. anophelis in
the aerator. The Figure illustrates the spatial distribution
of Elizabethkingia bacteria detected in tap outlets stratified by aerator, water, or sinks in the unit.
Our transmission experiment found that 1 staff member (staff B) acquired E. anophelis on her hands after
handwashing (Table 2). After hand hygiene using ABHR,
Figure. Spatial distribution of Elizabethkingia isolates by location (patients, tap water, aerators, and sinks) in children’s intensive care
unit, KK Women’s and Children’s Hospital, Singapore, May 2017.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1731
DISPATCHES
Table 2. Potential transmission route of E. anophelis via
handwashing for 2 hospital staff, Children’s Intensive Care Unit,
KK Women’s and Children’s Hospital, Singapore, May 2017
Hands culture result
Procedure
Staff A
Staff B
Before handwashing
CoagulaseCoagulasenegative
negative
Staphylococcus sp. Staphylococcus sp.
After handwashing
CoagulaseE. anophelis
with chlorhexidine
negative
soap
Staphylococcus sp.
After use of alcoholNo growth
No growth
based hand rub
both staff members had no detectable microbial growth
on their hands.
Upon detection of the case cluster, we reinforced
standard precautions, specifically hand hygiene compliance, and implemented environmental and patient-care
equipment cleaning. We had all aerators permanently removed from the tap outlets in the CICU following confirmation of Elizabethkingia bacteria. The water from all 5
tap outlets previously found to be positive for Elizabethkingia bacteria in aerator or water was negative upon repeat testing after the intervention. We also recommended
prioritizing hand hygiene using ABHR over handwashing
unless hands were visibly soiled. All staff were reminded
not to dispose of body fluids from patients into sinks used
for handwashing because this was previously identified to
be associated with Elizabethkingia tap colonization (2).
In addition, we ended the use of tap water for patient care
and allowed only sterile water. After these interventions,
no additional cases of Elizabethkingia occurred in the unit
for >4 months.
Conclusions
We report a confirmed E. anophelis case cluster affecting infants and children in the CICU of a pediatric hospital. Our investigation identified the likely source of E.
anophelis to be tap outlets with aerators. We confirmed
that removal of the aerators was effective in eliminating
E. anophelis from tap water sources. We also demonstrated a likely transmission route for E. anophelis to patients
through acquisition of the bacteria on hands of healthcare
workers via handwashing. Subsequent use of ABHR was
effective in eliminating the acquired E. anophelis from
workers’ hands.
Although 2 patients’ isolates were not available for
confirmatory testing, we detected E. anophelis in the tap
outlets where they were cared for, suggesting that the Elizabethkingia species detected in their samples was highly
likely to be E. anophelis. Isolates were initially misidentified as E. meningoseptica by MALDI-TOF mass spectrometry because E. anophelis was not represented in our
routine database and only present in research databases
of MALDI-TOF mass spectrometry systems (9). This
1732
discrepancy means that E. anophelis is probably overlooked in most diagnostic microbiology laboratories. There
is a clinical need to differentiate these species in light of
observations that E. anophelis infections tend to be more
severe and associated with more deaths than are E. meningoseptica infections (10).
We showed how handwashing, despite the use of
chlorhexidine soap, is a possible vehicle of transmission
for E. anophelis from an affected tap outlet via the hands
of healthcare workers to patients. Perinatal transmission of
E. anophelis was previously documented to have occurred
from a mother with chorioamnionitis to her neonate (11).
We confirmed that hand hygiene using ABHR was effective in removing E. anophelis from hands of healthcare
workers, which has implications for infection control. Although current hand hygiene guidelines prioritize ABHR
over handwashing when hands are not visibly soiled, there
is no requirement to perform ABHR in addition to handwashing (12). Therefore, most staff consider handwashing
as complying with hand hygiene requirements. Our findings support using ABHR as the primary hand-hygiene
method in clinical care, especially in critical care units
and in outbreak situations involving waterborne organisms
such as E. anophelis.
Acknowledgments
We thank hospital colleagues and staff, especially those from the
CICU, Infection Control Unit, Facilities Management, and
Environmental Services for their support and dedication in
controlling the cluster and ensuring safe care for patients.
About the Author
Dr. Yung is a consultant with the Infectious Disease Service,
KK Women’s and Children’s Hospital, Singapore. He has a
keen interest in infectious diseases, vaccines, outbreak control,
epidemiology, and public health.
References
1.
Kämpfer P, Matthews H, Glaeser SP, Martin K, Lodders N,
Faye I. Elizabethkingia anophelis sp. nov., isolated from the midgut
of the mosquito Anopheles gambiae. Int J Syst Evol Microbiol.
2011;61:2670–5. http://dx.doi.org/10.1099/ijs.0.026393-0
2. Balm MN, Salmon S, Jureen R, Teo C, Mahdi R, Seetoh T, et al.
Bad design, bad practices, bad bugs: frustrations in controlling an
outbreak of Elizabethkingia meningoseptica in intensive care units.
J Hosp Infect. 2013;85:134–40. http://dx.doi.org/10.1016/
j.jhin.2013.05.012
3. CDC. Multi-state cluster of Elizabethkingia anophelis in
Wisconsin, Michigan, and Illinois. 2016 [cited 2017 Sep 28].
https://www.cdc.gov/elizabethkingia/outbreaks/index.html
4. Perrin A, Larsonneur E, Nicholson AC, Edwards DJ,
Gundlach KM, Whitney AM, et al. Evolutionary dynamics and
genomic features of the Elizabethkingia anophelis 2015 to 2016
Wisconsin outbreak strain. Nat Commun. 2017;8:15483.
http://dx.doi.org/10.1038/ncomms15483
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
E. anophelis and Association with Handwashing
5.
6.
7.
8.
9.
Teo J, Tan SYY, Liu Y, Tay M, Ding Y, Li Y, et al. Comparative
genomic analysis of malaria mosquito vector–associated
novel pathogen Elizabethkingia anophelis. Genome Biol Evol.
2014;6:1158–65. http://dx.doi.org/10.1093/gbe/evu094
Moore LSP, Owens DS, Jepson A, Turton JF, Ashworth S,
Donaldson H, et al. Waterborne Elizabethkingia meningoseptica
in adult critical care. Emerg Infect Dis. 2016;22:9–17.
http://dx.doi.org/10.3201/eid2201.150139
World Health Organization. Guidelines for drinking-water
quality (GDWQ). 2017 [cited 2018 Jul 9]. http://www.who.int/
water_sanitation_health/water-quality/guidelines/en/
Maiwald M. Broad-range PCR for detection and identification of
bacteria. In: Persing DH, Tenover FC, Tang YW, Nolte FS,
Hayden RT, van Belkum A, editors. Molecular microbiology:
diagnostic principles and practice, 2nd ed. Washington: American
Society for Microbiology; 2011. p. 491–505.
Han MSKH, Kim H, Lee Y, Kim M, Ku NS, Choi JY, et al.
Relative prevalence and antimicrobial susceptibility of clinical
isolates of Elizabethkingia species based on 16S rRNA gene
sequencing. J Clin Microbiol. 2017;55:274–80. http://dx.doi.org/
10.1128/JCM.01637-16
10. Lau SK, Chow WN, Foo CH, Curreem SO, Lo GC, Teng JL, et al.
Elizabethkingia anophelis bacteremia is associated with clinically
significant infections and high mortality. Sci Rep. 2016;6:26045.
http://dx.doi.org/10.1038/srep26045
11. Lau SKP, Wu AKL, Teng JLL, Tse H, Curreem SO, Tsui SK, et al.
Evidence for Elizabethkingia anophelis transmission from mother
to infant, Hong Kong. Emerg Infect Dis. 2015;21:232–41.
http://dx.doi.org/10.3201/eid2102.140623
12. World Health Organization. WHO guidelines on hand hygiene in
health care. Geneva: The Organization; 2009.
Address for correspondence: Chee Fu Yung, KK Women’s and
Children’s Hospital, 100 Bukit Timah Rd, 229899, Singapore; email:
cheefu.yung@gmail.com
The David J. Sencer CDC Museum, a Smithsonian Affiliate,
uses award-winning exhibits and innovative programing to
educate visitors about the value of public health, and
presents the rich heritage and vast accomplishments of CDC.
Hours
Monday– Wednesday: 9 a.m.–5 p.m.
Thursday: 9 a.m.–7 p.m.
Friday: 9 a.m.–5 p.m.
Closed weekends
and federal holidays
The Refugee
Journey
to Wellbeing
Location
July 9 – October 5, 2018
Photograph by Ashley Gilbertson, courtesy of UNICEF
1600 Clifton Road NE
Atlanta, GA 30329
Phone 404-639-0830
Admission and parking free
Government–issued photo ID required
for adults over the age of 18
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1733
DI SPATCHES
M a r ipa Vir u s RN A Loa d a n d
An t ibody Re spon se in H a n t a vir u s
Pu lm on a r y Syn dr om e , Fr e n ch Gu ia n a
Séverine Matheus, Hatem Kallel, Alexandre Roux,
Laetitia Bremand, Bhety Labeau, David Moua,
Dominique Rousset, Damien Donato,
Vincent Lacoste, Stéphanie Houcke,
Claire Mayence, Benoît de Thoisy,
Didier Hommel, Anne Lavergne
We report viral RNA loads and antibody responses in 6
severe human cases of Maripa virus infection (2 favorable
outcomes) and monitored both measures during the 6-week
course of disease in 1 nonfatal case. Further research is
needed to determine prevalence of this virus and its effect
on other hantaviruses.
H
antaviruses are members of the genus Orthohantavirus (family Hantaviridae) and are carried by various
rodent species, depending on the strain. Humans can be infected by inhalation of aerosolized viruses excreted in the
urine or feces of infected rodents. New World hantaviruses
in the Americas cause hantavirus pulmonary syndrome
(HPS) in humans, characterized by fever, headache, cough,
myalgia, and nausea, evolving rapidly to pulmonary edema
(1,2). This respiratory insufficiency is associated with death
in 26%–39% of cases, depending on the New World hantavirus species (3,4).
Following the identification of Sin Nombre virus
(SNV) as the etiologic agent of HPS in the United States in
1993, many other hantaviruses have been identified in the
Americas (3–6). In French Guiana, a laboratory-confirmed
case of hantavirus infection was reported in a hospitalized
patient in 2008; the complete sequence analysis showed
that this was a novel hantavirus closely related to the Rio
Mamore species called Maripa virus (7,8).
We describe antibody responses to Maripa hantavirus
infection and viral RNA loads in the 6 laboratory-confirmed
human cases in French Guiana, measured at admission to
the hospital. We also report how these 2 markers evolved
Author affiliations: Institut Pasteur de la Guyane, Cayenne,
French Guiana (S. Matheus, L. Bremand, B. Labeau, D. Moua,
D. Rousset, D. Donato, V. Lacoste, B. de Thoisy, A. Lavergne);
Centre Hospitalier de Cayenne, Cayenne (H. Kallel, A. Roux,
S. Houcke, C. Mayence, D. Hommel)
DOI: https://doi.org/10.3201/eid2409.170223
1734
during the course of the disease in the most recent hospitalized case-patient, who had a favorable clinical outcome.
The Study
Since the time hantavirus diagnostic tools were set up at
French Guiana’s Institut Pasteur in 2008, a total of 6 severe
human cases of infection by native hantavirus have been
reported. All the patients were male; the mean age was
54.6 years (range 38–71 years). The mean time from onset
of the disease until admission to the hospital was 4.6 days
(range 2–7 days). The clinical outcome was favorable for 2
of the patients; 4 died (Table 1). The clinical and biologic
parameters of the first 5 confirmed hantavirus cases were
reported previously (9). The sixth patient was a 47-year-old
man who complained of fever, cough, myalgia, and sweating that had been developing over 6 days. He was admitted to the Andrée Rosemon General Hospital in Cayenne,
French Guiana, on August 31, 2017. He experienced respiratory failure, requiring rapid transfer to the intensive care
unit for intubation and mechanical ventilation. Thoracic
radiography revealed bilateral diffuse alveolar pulmonary
infiltrates. The patient remained under mechanical ventilation for 18 days and was discharged from the hospital
after 23 days with complete clinical recovery. The clinical
symptoms of the patient, and his outdoor activities making
the contact with rodents possible, led to suspicion of acute
hantavirus infection, which was confirmed by molecular
and serologic tests. The complete RNA coding sequence of
the S RNA segment (GenBank accession no. MG785209)
was also generated and compared with those of the other 5
previous hantavirus cases, showing that it corresponded to
a Maripa virus infection (9).
We tested serum samples from the 6 HPS case-patients
that were collected on admission at the intensive care unit
and the other 7 sequential serum samples provided from
case-patient 6 (6 samples during the hospitalization and 1
after discharge). We performed serologic IgM and IgG tests
and assayed them for viral RNA quantification (Tables 1,
2). We obtained informed consent from the patients, their
representatives, or both at admission and before discharge.
We assayed all serum samples by IgM capture and IgG
ELISA using the protocol described by Ksiazek et al. (10).
We tested samples against SNV antigen and control antigen using 4-fold dilutions, from 1:100 to 1:6,400. Because
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Hantavirus Pulmonary Syndrome, French Guiana
Table 1. Immune response and viral loads on admission in 6 confirmed hantavirus cases, French Guiana*
Characteristic
Patient 1
Patient 2
Patient 3
Patient 4
Patient 5
Year case reported
2008
2009
2010
2013
2016
Age, y
38
56
49
67
71
Days of disease at admission
7
4
2
4
4
SNV IgM
Positive
Positive
Positive
Positive
Positive
IgM sum OD†
1.02
1.70
4.72
0.92
2.23
SNV IgG
Negative
Negative
Negative
Negative
Positive
IgG sum OD†
0.05
0.01
0.01
0.01
2.05
Serum viral RNA load‡
5.8
6.6
6.4
5.9
6.0
Clinical evolution
Favorable
Death
Death
Death
Death
Patient 6
2017
47
7
Positive
1.79
Negative
0.73
6.4
Favorable
*OD, optical density; SNV, Sin Nombre virus.
†Adjusted sum OD values (dilution 1:100, 1:400, 1:1,600, and 1:6,400).
‡Virus copy number was determined as log10 copies/mL. Primers and TaqMan probe for quantitative PCR were Maripa_qRT2F
5'-GCAGCTGTGTCTACATTGGAGAA-3', Maripa_qRT2R 5'-CCACCAGATCCGCCAACT-3', and Maripa_Probe2 5'-FAM-AAACTTGCAGAACTCA-MGB-3'.
of antibody cross-reactivities, positive ELISA findings
with SNV antigens indicated infections with New World
hantaviruses. The positive criteria were similar to those described by MacNeil et al. (11).
The serologic investigations showed that all samples
collected at admission had detectable amounts of hantavirus IgM: minimum IgM titers >400 for patients 1, 2, 4, 5,
and 6 and a maximum titer of >16,00 for patient 3 (Table
1). These data were similar to those reported in previous
work (11,12). Only patient 5, who died 24 hours after admission, had serum samples positive for hantavirus IgG
(titer >6,400). Although the time from the onset of disease
and sample collection at admission was different for each of
the 6 patients, this single positive hantavirus IgG case may
be explained in part by the longer viral incubation period,
resulting in the induction of IgG before the appearance of
symptoms. A previous study reported that the presence of
hantavirus IgG during the first week of infection might be a
predictor of survival, but we found no evidence supporting
this view (11).
To determine the viral RNA load in each serum
sample, we performed real-time PCR. Each reaction was
performed in duplicate. For absolute quantification, we
calculated the exact number of copies of the gene of interest using a standard curve established with plasmid DNA
at dilutions from 5 to 5 × 107 copies/mL. The viral RNA
loads in the samples collected on admission were 5.8–6.6
log10 copies/mL (mean 6.2 ± 0.3 log10 copies/mL) (Table
1). These values were similar to those observed in patients
infected by other hantaviruses, including patients with mild
or moderate symptoms (13–15). We also observed that the
viral RNA load in the 4 fatal cases was 6.2 log10 copies/
mL, whereas in the 2 nonfatal cases it was 6.1 log10 copies/mL. A correlation between hantavirus RNA loads in
the serum during the acute phase of disease and the clinical outcome has been hypothesized (14,15); however, although our study includes only a small number of cases
and only severe cases, it provides no evidence supporting
this possibility. Presumably, the fatal or nonfatal outcome
depends not only on the hantavirus viral load but also on
other pathogenic or host factors.
The progression of these antibody responses and viral
RNA loads was also followed during the course of disease
for patient 6, from admission to the hospital (day 7) until
day 46 after the onset of disease (Table 2). IgM titers were
high at admission but decreased to become undetectable
by day 46. Conversely, seroconversion (IgM to IgG) was
observed between day 7 and day 12; these hantavirus IgG
titers then increased to 4.4 by day 46. Likewise, viral RNA
load evaluated in these 7 sequential serum samples showed
a high value at admission (6.4 log10 copies/mL), declining
by 7 days later to 4.7 log10 copies/mL (Table 2). Viral load
then remained around 4 log10 copies/mL in samples collected on days 20, 25, and 30 and was undetectable on day 46.
Conclusions
Although limited in sample size, this study found similar
results for viral load and immune response in the first 6
cases of Maripa virus infection reported in French Guiana
after laboratory-based surveillance began in 2008. Further
Table 2. Monitoring of hantavirus antibodies and viral RNA load in sequential serum samples from patient 6, French Guiana*
Days after symptom onset
Characteristic
Day 7
Day 12
Day 15
Day 20
Day 25
Day 30
Day 46
SNV IgM
Positive
Positive
Positive
Positive
Positive
Positive
Negative
IgM sum OD†
1.79
1.56
1.50
1.34
1.01
0.72
0.42
SNV IgG
Negative
Positive
Positive
Positive
Positive
Positive
Positive
IgG sum OD†
0.73
1.83
2.20
3.08
4.21
4.71
4.40
Serum viral RNA load‡
6.4
5.4
4.7
4.1
4.0
4.1
0
*OD, optical density; SNV, Sin Nombre virus.
†Adjusted sum OD values (dilution 1:100, 1:400, 1:1,600, and 1:6,400).
‡Virus copy number was determined as logs10 copies/mL. real-time PCR Primers and TaqMan probe for quantitative PCR were Maripa_qRT2F 5'GCAGCTGTGTCTACATTGGAGAA-3', Maripa_qRT2R 5'-CCACCAGATCCGCCAACT-3', and Maripa_Probe2 5'-FAM-AAACTTGCAGAACTCA-MGB-3'.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1735
DISPATCHES
work is needed to determine the overall prevalence of this
hantavirus in French Guiana and also the possible undetected mild or moderate cases induced by Maripa virus infection as reported for other New World hantaviruses (13–
15). Moreover, it would be informative to determine the
infectious potential of the virus in the sequential samples
to provide a better understanding of the pathophysiology
of this infection. Investigations of the immune response to
hantavirus, consequences of different viral loads, and the
pathologic characteristics of different hantavirus strains
would help identify the determinants of disease outcome.
4.
5.
6.
7.
8.
Acknowledgments
We thank Sandrine Fernandes-Pellerin and Nathalie Jolly for
their helpful expertise on ethics issues relevant to this study. In
addition, we acknowledge Thierry Carage for his assistance.
This study was supported in part by the Centre National de
Référence des Hantavirus Laboratoire Associé financed by the
Institut Pasteur de la Guyane and Santé Publique France
(Saint-Maurice, France). This study benefited from the
RESERVOIRS program, which is supported by the European
Regional Development Fund and Fonds Européen de
Developpement Régional, and received assistance from
Région Guyane and Direction Régionale pour la Recherche
et la Technologie and Investissement d’Avenir grants
managed by the Agence Nationale de la Recherche (CEBA
ANR-10-LABEX-25-01).
About the Author
Dr. Matheus is a research assistant at the Institut Pasteur de la
Guyane, Cayenne, French Guiana. Her research interests are the
diagnosis and pathophysiology of arboviruses, with special
interest in hantavirus circulation in French Guiana.
References
1.
2.
3.
1736
Jonsson CB, Figueiredo LT, Vapalahti O. A global perspective on
hantavirus ecology, epidemiology, and disease. Clin Microbiol Rev.
2010;23:412–41. http://dx.doi.org/10.1128/CMR.00062-09
Enria DA, Briggiler AM, Pini N, Levis S. Clinical manifestations
of New World hantaviruses. Curr Top Microbiol Immunol.
2001;256:117–34. http://dx.doi.org/10.1007/978-3-642-56753-7_7
Martinez VP, Bellomo CM, Cacace ML, Suarez P, Bogni L,
Padula PJ. Hantavirus pulmonary syndrome in Argentina,
1995–2008. Emerg Infect Dis. 2010;16:1853–60. http://dx.doi.org/
10.3201/eid1612.091170
9.
10.
11.
12.
13.
14.
15.
MacNeil A, Ksiazek TG, Rollin PE. Hantavirus pulmonary
syndrome, United States, 1993–2009. Emerg Infect Dis.
2011;17:1195–201. http://dx.doi.org/10.3201/eid1707.101306
Montoya-Ruiz C, Diaz FJ, Rodas JD. Recent evidence of
hantavirus circulation in the American tropic. Viruses.
2014;6:1274–93. 10.3390/v6031274 http://dx.doi.org/10.3390/
v6031274
Centers for Disease Control and Prevention. International HPS
cases. 2012 [cited 2017 Apr 1]. https://www.cdc.gov/hantavirus/
surveillance/international.html
Matheus S, Djossou F, Moua D, Bourbigot AM, Hommel D,
Lacoste V, et al. Hantavirus pulmonary syndrome, French Guiana.
Emerg Infect Dis. 2010;16:739–41. http://dx.doi.org/10.3201/
eid1604.090831
Matheus S, Lavergne A, de Thoisy B, Dussart P, Lacoste V.
Complete genome sequence of a novel hantavirus variant of
Rio Mamoré virus, Maripa virus, from French Guiana. J Virol.
2012;86:5399. http://dx.doi.org/10.1128/JVI.00337-12
Matheus S, Kallel H, Mayence C, Bremand L, Houcke S,
Rousset D, et al. Hantavirus pulmonary syndrome caused by
Maripa virus in French Guiana, 2008–2016. Emerg Infect Dis.
2017;23:1722–5. http://dx.doi.org/10.3201/eid2310.170842
Ksiazek TG, Peters CJ, Rollin PE, Zaki S, Nichol S,
Spiropoulou C, et al. Identification of a new North American
hantavirus that causes acute pulmonary insufficiency. Am J
Trop Med Hyg. 1995;52:117–23. http://dx.doi.org/10.4269/
ajtmh.1995.52.117
MacNeil A, Comer JA, Ksiazek TG, Rollin PE. Sin Nombre
virus-specific immunoglobulin M and G kinetics in hantavirus
pulmonary syndrome and the role played by serologic responses
in predicting disease outcome. J Infect Dis. 2010;202:242–6.
http://dx.doi.org/10.1086/653482
Bostik P, Winter J, Ksiazek TG, Rollin PE, Villinger F, Zaki SR,
et al. Sin Nombre virus (SNV) Ig isotype antibody response during
acute and convalescent phases of hantavirus pulmonary syndrome.
Emerg Infect Dis. 2000;6:184–7. http://dx.doi.org/10.3201/
eid0602.000213
Bellomo CM, Pires-Marczeski FC, Padula PJ. Viral load of patients
with hantavirus pulmonary syndrome in Argentina. J Med Virol.
2015;87:1823–30. 10.1002/jmv.24260 http://dx.doi.org/10.1002/
jmv.24260
Terajima M, Hendershot JD III, Kariwa H, Koster FT, Hjelle B,
Goade D, et al. High levels of viremia in patients with the
hantavirus pulmonary syndrome. J Infect Dis. 1999;180:2030–4.
http://dx.doi.org/10.1086/315153
Xiao R, Yang S, Koster F, Ye C, Stidley C, Hjelle B.
Sin Nombre viral RNA load in patients with hantavirus
cardiopulmonary syndrome. J Infect Dis. 2006;194:1403–9.
http://dx.doi.org/10.1086/508494
Address for correspondence: Séverine Matheus, Centre National de
Référence des Hantavirus, Institut Pasteur de la Guyane, 23 avenue
Pasteur, BP 6010 – 97306 Cayenne CEDEX, French Guiana; email:
smatheus@pasteur-cayenne.fr
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Se ve r e M a n ife st a t ion s of Ch ik u n gu n ya Fe ve r
in Ch ildr e n , I n dia , 2 0 1 6
Pradeep K. Sharma, Maneesh Kumar,
Girraj K. Aggarwal, Virender Kumar,
R.D. Srivastava, Ashish Sahani, Rohit Goyal
Chikungunya is a relatively benign disease, and a paucity
of literature on severe manifestations in children exists. We
describe a cohort of pediatric chikungunya fever patients in
New Delhi, India, who had severe sepsis and septic shock,
which can develop during the acute phase of illness.
C
hikungunya fever, regarded as a benign disease with
infrequent severe manifestations, has caused epidemics in many countries in the past decade. The worst epidemic of chikungunya fever in Delhi, India, occurred in 2016
(1). Severe manifestations of chikungunya fever in adults
have been reported recently (2–7); however, there is a paucity of similar data in children. The objective of our study
was to describe the characteristics of pediatric patients who
had atypical or severe forms of the disease and to search for
predictive factors for severe forms.
The Study
We conducted a retrospective, observational study in the
pediatric intensive care unit (PICU) and pediatric highdependency unit of a tertiary care hospital in New Delhi,
India. We included patients whose chikungunya infection
was diagnosed by positive real-time reverse transcription
PCR (RT-PCR) during September–December 2016. The
RT-PCR was done using a Gene Finder DENV/CHKV RealAmp Kit (Osang Healthcare, Gyeonggi-do, South Korea)
at Oncquest Laboratories (New Delhi, India). This qualitative assay uses a 1-tube RT-PCR technique with internal
control for amplification and detection of chikungunya virus RNA. The study protocol was approved by the hospital’s Institutional Research Council.
The information recorded consisted of demographic
features, clinical features, laboratory parameters, course,
organ dysfunction, ventilation days, inotropic days, hospital stay, and whether the patient died. We classified the
disease as severe in the presence of severe sepsis, septic
shock, or organ dysfunction, which were defined according
to standard definitions (8).
Author affiliation: Sri Balaji Action Medical Institute,
New Delhi, India
DOI: https://doi.org/10.3201/eid2409.180330
A total of 49 children had chikungunya fever; 36 had
nonsevere disease and 13 had severe disease. All patients
with severe disease were admitted to the PICU; 11 had illness consistent with the case definition of severe sepsis and
septic shock, and 2 had acute liver failure. Of the 36 patients
with nonsevere disease, 16 were admitted to the PICU (11
had seizures, 4 had fluid-responsive shock, 1 had peripheral
cyanosis and mottling) and 20 were admitted to the pediatric high-dependency unit (3 had bleeding manifestations,
4 had severe abdominal pain, 2 had underlying cyanotic
congenital heart disease, 2 had body temperature >40.3°C
with irrelevant talking, 7 had dehydration, and 2 had severe
rash). The median age was 12 years for patients with severe
disease and 6.5 years for patients with nonsevere disease;
male sex predominated in both groups (Table). Frequency
of fever, body ache, arthralgia, and vomiting were similar
for both groups. Peripheral cyanosis, along with mottling
of skin and encephalopathy, was significantly higher in the
group with severe disease. Serum albumin was significantly lower in the group with severe disease (3 vs. 3.75 g/dL).
Of the 11 children with septic shock, 8 were admitted to
the hospital within 24 hours of developing fever; 9 had hypotensive shock, and 2 had compensated shock. In this group,
6 children required 1 vasoactive agent, 3 children required
2 vasoactive agents, and 2 children required 3 vasoactive
agents. Dopamine was used in 8 patients, dobutamine in 5
patients, epinephrine in 2 patients, and norepinephrine in 2
patients. The median duration of vasoactive support was 56
hours (range 31–114 hours), and the median vasoactive inotropic score in the first 24 hours was 10 (range 5–90; score
>15–20 is considered serious). A vasoactive inotropic score
>20 was seen in 2 children. Mean pH was 7.26 (reference
range 7.35–7.45), mean lactate 5.1 mmol/L (reference range
<2 mmol/L), mixed venous saturation 55% (reference range
70%–80%), and mean base excess at admission –7.7 mEq
(reference range –2 to 2 mEq). Of the 2 children with acute
liver failure with encephalopathy, 1 had dengue virus (positive dengue IgM by enzyme immunoassay) and the other had
hepatitis E virus (reactive anti–hepatitis E IgM by enzyme
immunoassay) co-infection.
The usual symptoms of chikungunya are fever, rash,
and joint pain. Children can have features distinct from
adults, such as more frequent dermatological and hemorrhagic manifestations and less frequent rheumatologic
manifestations (7). Most patients with symptomatic disease have mild to moderate illness. A recent pediatric study
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1737
DISPATCHES
Table. Demographic, clinical, and laboratory features at admission of pediatric patients with severe and nonsevere chikungunya fever,
New Delhi, India, 2016*
Parameters
Nonsevere disease, n = 36
Severe disease, n = 13
p value†
Median age, y (range)
6.5 (0.75–15)
12 (0.5–14)
0.28
Male:female ratio
3.5:1
2.25:1
0.53
Age group
Infant, 1 mo–1 y
3 (8.3)
4 (30.7)
0.06
Toddler, 2–5 y
13 (36)
1 (7.7)
School age, 6–12 y
3 (8.3)
0
Adolescent, 13 to <18 y
17 (47.2)
8 (61.5)
Clinical profile
Fever
36 (100)
13 (100)
Body ache
10 (27.7)
4 (30.7)
0.83
Rash
15 (41.6)
8 (61.5)
0.22
Arthralgia
5 (13.9)
3 (23)
0.44
Vomiting
15 (41.6)
5 (38.4)
0.84
Seizures
11 (30.5)
1 (7.7)
0.14
Bleeding
3 (8.3)
4 (30.7)
0.16
Abdominal pain
4 (11)
5 (38.4)
0.25
0.00
Peripheral cyanosis and mottling of skin
2 (5.5)
10 (76.9)
0.01
Encephalopathy
0
3 (23)
Laboratory test results, median (range)
Hemoglobin, g/dL
12.2 (6.6–17.5)
11.6 (8–13.5)
0.08
White cell count/µL
8,195 (3,700–15,200)
11,200 (4,100–44,800)
0.058
203 (25–362)
192 (13–362)
0.61
Platelet count, 103/µL)
AST, IU/L
44 (22–174)
43 (16–8,837)
0.96
ALT, IU/L
20 (9–96)
24 (8–2,311)
0.26
0.006
Albumin
3.75 (3.5–4)
3.3 (1.6–3.5)
Urea, mg/dL
21 (11–55)
36 (13–87)
0.094
Creatinine, mg/dL
0.4 (0.3–1.2)
0.6 (0.2–1.3)
0.37
APTT, s, control 28.4 s
NA
41.7 (27–247)
PT, s, control 13.3 s
NA
22.3 (18.5–117)
International normalized ratio
NA
1.77 (1.3–12.4)
Organ dysfunction
Cardiovascular
0
11 (84.6)
Respiratory
0
3 (23)
Hematological
0
5 (38.4)
Neurologic
0
3 (23)
Renal
0
2 (15.3)
Hepatic
0
3 (23)
Course and outcome
Mechanical ventilation
0
3 (23)
Inotropic support
0
11 (84.6)
Renal replacement
0
2 (15.3)
0.0015
Hospital stay, d (range)
3 (2–7)
5 (2–13)
Death
0
1 (7.7)
*Values are no. (%) patients except as indicated. ALT, alaninine aminotransferase; APTT, activated partial thromboplastin time; AST, aspartate
aminotransferase; NA, not applicable; PT, prothrombin time.
†Categorical variables were compared using the 2 test or Fisher exact test, as appropriate, and continuous variables were compared by using the
nonparametric Mann-Whitney test. p values <0.05 were considered statistically significant and are shown in bold type.
reported severe disease in infants and neonates; however,
septic shock was not well defined (9). Recently, sepsis and
septic shock in adults have been described in the literature,
with relatively high death rates (36%–100%) (2–6).
Conclusions
Our study reports a cohort of pediatric chikungunya fever patients who had severe sepsis and septic shock. In our study,
children <1 year of age and 11–14 years of age were more
likely to have septic shock. Most of these children were admitted to the hospital within 24 hours of developing fever,
with peripheral cyanosis and cold extremities. Although children can have cold extremities during high fever, in our cohort
1738
central capillary refill time was also prolonged, and generalized skin mottling was present. In addition, these children had
hypotension or metabolic evidence of poor perfusion (high
lactate and low mixed venous saturation). Children with early
shock had generalized erythema and diffuse edema.
Although dopamine was the most used inotropic agent
overall, in infants dobutamine was more helpful in improving shock, both clinically and metabolically. Of the infants, 3
of 4 required only dobutamine; 1 required dopamine as well.
Shock in children who were admitted early usually
resolved around the time of mitigation of fever. All 3 children who were admitted late had multiorgan failure and required mechanical ventilation. Of these, 2 had myocardial
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Severe Chikungunya Fever in Children
dysfunction and required multiple inotropic agents and renal replacement therapy. Both of these children had severe
ascites; the child who died had bilateral pleural effusion,
pericardial effusion, generalized confluent ecchymosis, and
pregangrenous changes at peripheral sites.
Our cohort of septic shock patients did not reveal clinical or microbiological evidence of other infections. Results
of tests for dengue nonstructural protein 1 antigen, dengue
IgM and IgG (by enzyme immunoassay), leptospira IgM
and IgG (by immuno-chromatographic assay), Weil Felix
serology (by latex agglutination), blood cultures, and other
relevant cultures were all negative.
Although chikungunya usually has a mild course, severe life-threatening manifestations can occur. Clinicians
should be aware that these manifestations can develop
within 24 hours of the onset of illness, and a high index of
suspicion is required to establish diagnosis. In our study,
age <1 year and 11–14 years were predictive of severe
disease. Further studies are required to clarify the clinical
spectrum and risk factors associated with severe disease.
About the Author
Dr. Sharma is senior consultant and in charge of the pediatric
critical care and pulmonology unit at Sri Balaji Action Medical
Institute, Paschim Vihar, New Delhi, India. His research
interests are infectious diseases, antimicrobial drug resistance,
and antibiotic stewardship, especially in pediatric intensive care.
References
1.
Press Trust of India. Chikungunya outbreak in Delhi worst in last
six years: officials. 2016 [cited 2017 Dec 14]. http://www.ndtv.com/
delhi-news/chikungunya-outbreak-in-delhi-worst-in-last-six-yearsofficials-1460234
2.
3.
4.
5.
6.
7.
8.
9.
Rollé A, Schepers K, Cassadou S, Curlier E, Madeux B,
Hermann-Storck C, et al. Severe sepsis and septic shock
associated with chikungunya virus infection, Guadeloupe, 2014.
Emerg Infect Dis. 2016;22:891–4. http://dx.doi.org/10.3201/
eid2205.151449
Crosby L, Perreau C, Madeux B, Cossic J, Armand C,
Herrmann-Storke C, et al. Severe manifestations of chikungunya
virus in critically ill patients during the 2013–2014 Caribbean
outbreak. Int J Infect Dis. 2016;48:78–80. http://dx.doi.org/
10.1016/j.ijid.2016.05.010
Torres JR, Leopoldo CG, Castro JS, Rodríguez L, Saravia V,
Arvelaez J, et al. Chikungunya fever: atypical and lethal cases
in the Western Hemisphere: a Venezuelan experience. IDCases.
2015;2:6–10. http://dx.doi.org/10.1016/j.idcr.2014.12.002
Hoz JM, Bayona B, Viloria S, Accini JL, Juan-Vergara HS,
Viasus D. Fatal cases of chikungunya virus infection in Colombia:
diagnostic and treatment challenges. J Clin Virol. 2015;69:27–9.
http://dx.doi.org/10.1016/j.jcv.2015.05.021
Gupta A, Juneja D, Singh O, Garg SK, Arora V, Deepak D.
Clinical profile, intensive care unit course, and outcome of patients
admitted in intensive care unit with chikungunya. Indian J Crit
Care Med. 2018;22:5–9.
Ritz N, Hufnagel M, Gérardin P. Chikungunya in children.
Pediatr Infect Dis J. 2015;34:789–91. http://dx.doi.org/10.1097/
INF.0000000000000716
Goldstein B, Giroir B, Randolph A; International Consensus
Conference on Pediatric Sepsis. International pediatric sepsis
consensus conference: definitions for sepsis and organ
dysfunction in pediatrics. Pediatr Crit Care Med. 2005;6:2–8.
http://dx.doi.org/10.1097/01.PCC.0000149131.72248.E6
Pinzón-Redondo H, Paternina-Caicedo A, Barrios-Redondo K,
Zarate-Vergara A, Tirado-Pérez I, Fortich R, et al. Risk factors for
severity of chikungunya in children: a prospective assessment.
Pediatr Infect Dis J. 2016;35:702–4. http://dx.doi.org/10.1097/
INF.0000000000001135
Address for correspondence: Pradeep K. Sharma, Sri Balaji Action
Medical Institute, Pediatric Critical Care and Pulmonology, A-4, Paschim
Vihar, New Delhi, 110063, India; email: drsharma025@gmail.com
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1739
DI SPATCHES
Zik a Vir u s Se r oposit ivit y in 1 – 4 - Ye a r - Old
Ch ildr e n , I n don e sia , 2 0 1 4
R. Tedjo Sasmono, Rama Dhenni,
Benediktus Yohan, Paul Pronyk,
Sri Rezeki Hadinegoro, Elizabeth Jane Soepardi,
Chairin Nisa Ma’roef, Hindra I. Satari,
Heather Menzies, William A. Hawley,
Ann M. Powers, Ronald Rosenberg,
Khin Saw Aye Myint, Amin Soebandrio
We assessed Zika virus seroprevalence among healthy
1–4-year-old children using a serum sample collection assembled in 2014 representing 30 urban sites across Indonesia. Of 662 samples, 9.1% were Zika virus seropositive,
suggesting widespread recent Zika virus transmission and
immunity. Larger studies are needed to better determine endemicity in Indonesia.
Z
ika virus, first isolated in 1947 (1), is a flavivirus phylogenetically related to dengue virus (DENV) that is, like
DENV, also transmitted by Aedes mosquitoes. Because of
the epidemic that swept through the Americas in 2016, Zika
virus infection is known to cause microcephaly, as well as
other congenital defects and Guillain-Barré syndrome (2).
Zika virus has long been known to be endemic in
Southeast Asia (3,4), but laboratory confirmation of infection can be challenging. Acute infections are often asymptomatic. In those who are symptomatic, viral RNA
typically persists in blood <7 days and in urine <10 days
after symptom onset, limiting the usefulness of nucleic acid
testing (5). Zika virus antibody cross-reacting with DENV
can confuse results of tests conducted in regions where the
viruses co-circulate (6). Virus-specific neutralization assays can more accurately detect and measure Zika virus
Author affiliations: Eijkman Institute for Molecular Biology, Jakarta,
Indonesia (R.T. Sasmono, R. Dhenni, B. Yohan, C.N. Ma’roef,
K.S.A. Myint, A. Soebandrio); UNICEF Indonesia, Jakarta
(P. Pronyk); University of Witwatersrand School of Public Health,
Johannesburg, South Africa (P. Pronyk); Universitas Indonesia
Medical School, Jakarta (S.R. Hadinegoro, H.I. Satari); Cipto
Mangunkusumo Hospital, Jakarta (S.R. Hadinegoro, H.I. Satari);
Ministry of Health of the Republic of Indonesia, Jakarta
(E.J. Soepardi); Centers for Disease Control and Prevention,
Atlanta, Georgia, USA (H. Menzies, W.A. Hawley); Centers for
Disease Control and Prevention, Fort Collins, Colorado, USA
(A.M. Powers, R. Rosenberg)
DOI: https://doi.org/10.3201/eid2409.180582
1740
antibody, but because of their complex requirements, these
tests have seldom been used in epidemiologic studies (7).
Acute Zika virus cases have been reported in Indonesia (8), Singapore (9), Malaysia (10), Vietnam (11), and
Thailand (12). However, little is known about Zika virus
prevalence in the region. Limited retrospective testing of
archived specimens collected from clinically ill patients in
Thailand (12) and Cambodia (13) suggest that incidence
in these countries is low. However, given the limited number of samples tested and lack of confirmatory testing in
these studies, information on prevalence and distribution
is challenging to assess. Likewise, little is known about the
prevalence and geographic distribution of Zika virus in Indonesia, the biggest country in Southeast Asia.
DENV and chikungunya virus, also transmitted by
Aedes mosquitoes, are endemic throughout Indonesia, suggesting the ecologic conditions exist for Zika virus transmission as well. An estimated 80% of the population in
Indonesia is infected with >1 DENV by the age of 10 years
(14). In our study, we assessed Zika virus seroprevalence
among healthy 1–4-year-old children to determine the
prevalence and distribution of Zika virus in Indonesia.
The Study
We used serum samples collected during October–November 2014 for a previous population-based, cross-sectional
cluster survey conducted to assess DENV seroprevalence;
in the study, 3,312 samples were collected from 1–18-yearold children in 30 urban districts in 14 provinces of Indonesia (14). In our study, we assessed only the children 1–4
years (range 12–59 months) of age because these children
were least likely to have cross-reactive DENV antibodies.
Ethics clearance was obtained from the Health Research
Ethics Committee of the Faculty of Medicine, Universitas
Indonesia, and the US Centers for Disease Control and Prevention (CDC; Atlanta, Georgia, USA).
Plaque reduction neutralization tests (PRNTs) that
could differentiate Zika virus neutralizing antibodies from
those produced in response to DENV infection were adapted from protocols developed by the CDC (online Technical
Appendix,
https://wwwnc.cdc.gov/EID/article/24/9/180582-Techapp1.pdf). The challenge virus used in the PRNT
was Zika virus JMB-185, acquired from a patient in 2014
(8). Convalescent serum from this same patient was used
as a PRNT positive control. We subjected all specimens
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Zika Virus in 1–4-Year-Old Children, Indonesia
to 2 tiers of testing by PRNT90 (i.e., a PRNT in which serum samples suppressing >90% of challenge virus were
considered positive for neutralizing antibody). In the first
tier, we tested serum samples diluted 1:10. Samples that
suppressed >90% of Zika virus PFUs were considered potentially positive for Zika virus antibodies because DENVspecific antibodies, if present, could have cross-reacted and
neutralized Zika virus. We then subjected the specimens
considered potentially positive to a second PRNT90, in
which we tested serum samples against Zika virus and all 4
DENV serotypes (online Technical Appendix). Specimens
that tested positive for Zika virus neutralizing antibody and
negative for DENV neutralizing antibody by PRNT90 were
classified as Zika virus seropositive, as were specimens
that had Zika virus PRNT90 titers >4-fold higher than all
DENV PRNT90 titers. We categorized specimens as flavivirus seropositive when Zika virus neutralizing antibodies
were present but at titers <4-fold higher than any DENV
neutralizing antibody titer (online Technical Appendix
Table). We also tested a subset of samples for Japanese encephalitis virus antibody by PRNT90; none of the samples
tested had a titer >20, and none of the sample classifications were changed after testing.
In the initial PRNT90 screening, we detected possible
Zika virus antibody in 73 (11.0%) of the 662 serum samples (Table). Of these, 72 had a sufficient volume to undergo second-tier testing; 60 (83.3%) of 72 samples were Zika
virus seropositive, and 12 (16.7%) were flavivirus seropositive. Serum samples from 11 of 14 provinces were Zika
virus seropositive, and the collections from the provinces
ranged from ≈4.5% seropositive (North Sumatra, Banten,
East Kalimantan) to >18% seropositive (Central Java,
Jambi; Figure). Overall, Zika virus seroprevalence in the
1–4-year-old cohort was 9.1% (95% CI 3.95%–11.01%).
Our assessment, involving use of the PRNT90, which
is highly specific for Zika virus antibodies, indicates widespread, recent Zika virus infection in much of western and
central Indonesia. Our criterion for confirmed Zika virus
antibodies (i.e., PRNT90 titer for Zika virus >4-fold higher
than that for any DENV in the same specimen) is the international standard. In just 2% (12/662) of specimens, we
could not determine whether the antibodies were Zika virus or DENV specific. When using the more conservative
criterion of only classifying a sample as positive for Zika
virus antibodies if no DENV-specific neutralizing antibodies are detected, the number of Zika virus antibody–positive samples decreases by only 6, leaving 54 samples still
classified as Zika virus seropositive. Further evidence for
the validity of the PRNT90 was that DENV neutralizing antibody–positive samples were negative for the presence of
Zika virus neutralizing antibodies across a range of titers
(R.T. Sasmono, unpub. data).
Although our data provide some evidence regarding
geographic distribution, no information is presented regarding a specific threshold titer associated with clinical
illness or a correlation between geography and titer. Further studies involving larger sample sets would be necessary to address these topics. The single age group, relatively small number of specimens, and limited number of
sites, particularly from eastern parts of the country, do not
give a comprehensive picture of endemicity throughout Indonesia. The small numbers of specimens available from
most localities did not enable accurate estimation of the
proportional differences between localities. We could perform PRNT90 with samples from the remaining cohort (the
5–18-year-olds), but we expect higher percentages of nonspecific flavivirus seropositivity in the samples from this
older age group.
Table. Seropositivity of 14-year-old urban children for Zika virus and other flaviviruses, by province, Indonesia, October–
November 2014*
Serologic status, % (no. positive samples/total samples)
Province
Suspected Zika virus seropositive†
Confirmed Zika virus seropositive‡
Flavivirus seropositive§
Aceh
0 (0/22)
0 (0/22)
0 (0/22)
North Sumatra
9.1 (2/22)
4.5 (1/22)
4.5 (1/22)
West Sumatra
18.2 (4/22)
13.6 (3/22)
4.5 (1/22)
Jambi
18.2 (4/22)
18.2 (4/22)
0 (0/22)
Lampung
8.7 (2/23)
8.7 (2/23)
0 (0/23)
Banten
4.4 (2/45)
4.4 (2/45)
0 (0/45)
DKI Jakarta
10.6 (7/66)
10.6 (7/66)
0 (0/66)
West Java
11.1 (17/153)
8.5 (13/153)
2.0 (3/153)
Central Java
20.5 (18/88)
18.2 (16/88)
2.3 (2/88)
East Java
11.7 (13/111)
9.0 (10/111)
2.7 (3/111)
Bali
0 (0/22)
0 (0/22)
0 (0/22)
East Kalimantan
4.5 (1/22)
4.5 (1/22)
0 (0/22)
South Sulawesi
0 (0/22)
0 (0/22)
0 (0/22)
Southeast Sulawesi
13.6 (3/22)
4.5 (1/22)
9.1 (2/22)
All provinces
11.0 (73/662), 95% CI 5.34–13.32
9.1 (60/662), 95% CI 3.95–11.01
1.8 (12/662), 95% CI 0.23–3.35
*DENV, dengue virus; PRNT90, plaque reduction neutralization test with neutralization defined as >90% reduction in challenge virus PFUs.
†Serum samples that neutralized >90% of the challenge virus at a 1:10 dilution on initial Zika virus PRNT90 screening.
‡Serum samples that neutralized Zika virus only or had a PRNT 90 titer >4-fold higher for Zika virus than for any DENV.
§Serum samples that neutralized Zika virus and DENV and had a PRNT 90 titer for Zika virus that was <4-fold higher than that for any DENV.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1741
DISPATCHES
Figure. Geographic distribution of Zika virus–seropositive 1−4-year-old children, Indonesia, October–November, 2014. The values listed
for each province indicate the percentage of serum samples confirmed Zika virus seropositive (percentage serum samples suspected
to be Zika virus seropositive). Samples suspected to be Zika virus positive were those that were positive on initial Zika virus PRNT90
(plaque reduction neutralization test with neutralization defined as >90% reduction in challenge virus PFUs) screening when using a
1:10 serum sample dilution. Serum samples confirmed as Zika virus seropositive were those that neutralized Zika virus only or had a
PRNT90 titer for Zika virus that was >4-fold higher than the PRNT90 titer for any DENV.
Conclusions
Much has been published on epidemic Zika virus, but little
is known about the effect of Zika virus in endemic areas.
Determining the prevalence of Zika virus in Indonesia can
provide clues to its potential long-term public health significance in endemic settings. Mild or asymptomatic infection
is common, and confusion with dengue during diagnosis
probably accounts for how long Zika virus was unrecognized in Indonesia and other areas of Southeast Asia. Besides the need to better evaluate Zika virus incidence and
distribution, a high priority for future investigations will be
determining the extent of Zika virus–related birth defects.
If, like other flaviviruses, a primary Zika virus infection
results in lifelong immunity, infections during childhood
could reduce a person’s risk for infection later in life and
thus the incidence of Zika virus–related birth defects. This
knowledge provides clues for understanding future patterns
of Zika virus transmission in the Americas.
Acknowledgments
We thank Alain Bouckenooghe and the DNG26 team for
specimen collection. Help from Jeremy P. Ledermann and
Araniy Fadhilah regarding PRNTs was greatly appreciated.
This work was supported by the Ministry of Research,
Technology, and Higher Education of the Republic of Indonesia
and CDC, Atlanta, Georgia, USA. Funding for this work was
also provided by the Office of Infectious Diseases, Bureau for
Global Health, US Agency for International Development, under
the terms of an interagency agreement with CDC.
1742
About the Author
Dr. Sasmono is a senior research fellow at the Eijkman Institute
for Molecular Biology, Jakarta, Indonesia. His primary research
interests are dengue and other arboviral diseases.
References
1.
2.
3.
4.
5.
6.
7.
8.
Dick GWA, Kitchen SF, Haddow AJ. Zika virus. I. Isolations and
serological specificity. Trans R Soc Trop Med Hyg. 1952;46:509–
20. http://dx.doi.org/10.1016/0035-9203(52)90042-4
World Health Organization. WHO statement on the first meeting of
the International Health Regulations (2005) (IHR 2005) Emergency
Committee on Zika virus and observed increase in neurological
disorders and neonatal malformations. 2016 Feb 1 [cited 2018 Apr
4]. http://www.who.int/mediacentre/news/statements/2016/
1st-emergency-committee-zika/en/
Musso D, Gubler DJ. Zika virus. Clin Microbiol Rev. 2016;29:487–
524. http://dx.doi.org/10.1128/CMR.00072-15
Duong V, Dussart P, Buchy P. Zika virus in Asia. Int J Infect Dis.
2017;54:121–8. http://dx.doi.org/10.1016/j.ijid.2016.11.420
Paz-Bailey G, Rosenberg ES, Doyle K, Munoz-Jordan J,
Santiago GA, Klein L, et al. Persistence of Zika virus in body
fluids-preliminary report. N Engl J Med. 2017;NEJMoa1613108.
http://dx.doi.org/10.1056/NEJMoa1613108
Lanciotti RS, Kosoy OL, Laven JJ, Velez JO, Lambert AJ,
Johnson AJ, et al. Genetic and serologic properties of Zika
virus associated with an epidemic, Yap State, Micronesia, 2007.
Emerg Infect Dis. 2008;14:1232–9. http://dx.doi.org/10.3201/
eid1408.080287
Posen HJ, Keystone JS, Gubbay JB, Morris SK. Epidemiology
of Zika virus, 1947–2007. BMJ Glob Health. 2016;1:e000087.
http://dx.doi.org/10.1136/bmjgh-2016-000087
Perkasa A, Yudhaputri F, Haryanto S, Hayati RF, Ma’roef CN,
Antonjaya U, et al. Isolation of Zika virus from febrile patient,
Indonesia. Emerg Infect Dis. 2016;22:924–5. http://dx.doi.org/
10.3201/eid2205.151915
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Zika Virus in 1–4-Year-Old Children, Indonesia
9.
Ho ZJM, Hapuarachchi HC, Barkham T, Chow A, Ng LC,
Lee JMV, et al.; Singapore Zika Study Group. Outbreak of
Zika virus infection in Singapore: an epidemiological,
entomological, virological, and clinical analysis. Lancet
Infect Dis. 2017;17:813–21. http://dx.doi.org/10.1016/
S1473-3099(17)30249-9
10. Salehuddin AR, Haslan H, Mamikutty N, Zaidun NH, Azmi MF,
Senin MM, et al. Zika virus infection and its emerging trends in
Southeast Asia. Asian Pac J Trop Med. 2017;10:211–9.
http://dx.doi.org/10.1016/j.apjtm.2017.03.002
11. Chu DT, Ngoc VTN, Tao Y. Zika virus infection in Vietnam:
current epidemic, strain origin, spreading risk, and perspective.
Eur J Clin Microbiol Infect Dis. 2017;36:2041–2. http://dx.doi.org/
10.1007/s10096-017-3030-8
12. Buathong R, Hermann L, Thaisomboonsuk B, Rutvisuttinunt W,
Klungthong C, Chinnawirotpisan P, et al. Detection of Zika
13.
14.
virus infection in Thailand, 2012–2014. Am J Trop Med Hyg.
2015;93:380–3. http://dx.doi.org/10.4269/ajtmh.15-0022
Duong V, Ong S, Leang R, Huy R, Ly S, Mounier U, et al. Low
circulation of Zika virus, Cambodia, 2007–2016. Emerg Infect Dis.
2017;23:296–9. http://dx.doi.org/10.3201/eid2302.161432
Prayitno A, Taurel A-F, Nealon J, Satari HI, Karyanti MR,
Sekartini R, et al. Dengue seroprevalence and force of primary
infection in a representative population of urban dwelling
Indonesian children. [erratum in PLoS Negl Trop Dis.
2018;12:e0006467]. PLoS Negl Trop Dis. 2017;11:e0005621.
http://dx.doi.org/10.1371/journal.pntd.0005621
Address for correspondence: R. Tedjo Sasmono, Eijkman Institute for
Molecular Biology, Jl Diponegoro 69, Jakarta 10430, Indonesia;
email: sasmono@eijkman.go.id
EI D Podca st :
Probable Unusual
Transm ission of Zika Virus
Zika virus (ZIKV), a mosquito-transmitted flavivirus,
has been isolated from sentinel monkeys, mosquitoes, and sick persons in Africa and Southeast Asia.
Serologic surveys indicate that ZIKV infections can
be relatively common among persons in southeastern Senegal and other areas of Africa, but that
ZIKV-associated disease may be underreported or
misdiagnosed. In 2007, a large outbreak of ZIKV
infection occurred on Yap Island in the southwestern Pacific that infected ≈70% of the island’s
inhabitants, which highlighted this virus as an
emerging pathogen. The purpose of this study
was to investigate and report 3 unusual cases of
arboviral disease that occurred in Colorado in 2008.
Clinical and serologic evidence indicates that two
American scientists contracted Zika virus infections
while working in Senegal in 2008. One of the
scientists transmitted this arbovirus to his wife after his return home. Direct contact is implicated
as the transmission route, most likely as a sexually
transmitted infection.
Visit ou r w e bsit e t o list e n :
h t t ps:/ / w w w 2 c.cdc.gov/
podca st s/ pla ye r .a sp?f= 7 1 0 6 4 8 9
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1743
RESEARCH LETTERS
Tr ich odyspla sia Spin u losa
Polyom a vir u s in
Re spir a t or y Tr a ct of
I m m u n ocom pr om ise d Ch ild
Arwa A. Bagasi, Tasneem Khandaker,
Gemma Clark, Terry Akagha, Jonathan K. Ball,
William L. Irving, C. Patrick McClure
Author affiliations: King Saud University, Riyadh, Saudi Arabia
(A.A. Bagasi); University of Nottingham, Nottingham, UK
(A.A. Bagasi, T. Khandaker, T. Akagha, J.K. Ball, W.L. Irving,
C.P. McClure); Nottingham University Hospitals NHS Trust,
Nottingham (G. Clark, W.L. Irving)
DOI: https://doi.org/10.3201/eid2409.180829
Trichodysplasia spinulosa polyomavirus causes trichodysplasia spinulosa, a skin infection, in immunocompromised
persons, but the virus is rarely detected in respiratory samples. Using PCR, we detected persistent virus in respiratory
and skin samples from an immunocompromised boy with
respiratory signs but no characteristic skin spicules. This
virus may play a role in respiratory illness.
T
richodysplasia spinulosa is a rare skin disease that occurs exclusively in immunocompromised persons. It is
characterized by facial keratotic spicules formed by trichohyalin accumulation in the inner root sheath cells of affected hair follicles. In 1999, electron microscopy identified a
novel polyomavirus, subsequently named trichodysplasia
spinulosa polyomavirus (TSPyV) or human polyomavirus
8, in sections of skin spicules of a solid organ transplant
patient (1); in 2010, the virus was more completely characterized (2). TSPyV is 1 of 5 polyomaviruses associated
with human diseases, particularly those that affect immunocompromised persons (3). Although worldwide seroprevalence of TSPyV antibodies among the general population is estimated at 70% (4) and a respiratory route of
infection has been hypothesized (5,6), as of 2015, only 32
cases of trichodysplasia spinulosa had been reported (7),
suggesting that other pathology caused by TSPyV may
have gone undiagnosed. We describe PCR detection of
TSPyV in an immunocompromised boy with respiratory
signs and symptoms.
To elucidate potential causes of undiagnosed viral respiratory infection, during January 2015–February 2016,
we used a panpolyomavirus degenerate primer PCR to
screen archived samples for polyomavirus. The archived
samples were nucleic acid of respiratory specimens from
218 children 6 months to 5 years of age, previously negative
for typical respiratory viruses in a panel used for routine
1744
diagnosis (online Technical Appendix, https://wwwnc.cdc.
gov/EID/article/24/9/18-0829-Techapp1.pdf). Of the 218
samples screened in 22 pools, we obtained positive results
for polyomavirus in 1 pool and, subsequently, 1 sample
(from the patient reported here). Subsequent Sanger sequencing and BLAST (http://blast.ncbi.nlm.nih.gov/Blast.
cgi) analysis of the 274-bp degenerate primer PCR product
indicated that the sample contained TSPyV. The complete
genome of this TSPyV strain was amplified in 4 overlapping PCR fragments and Sanger sequenced (online Technical Appendix). Phylogenetic analysis of the assembled
complete 5,232-nt genome with all available 23 reference
sequences revealed that the TSPyV strain was most closely
related to TSPyV 1312, which had been isolated in 2012 in
Dallas, Texas, USA (online Technical Appendix), but bootstrap support was limited because of the highly conserved
nature of TSPyV genomes.
The patient from whom this TSPyV-positive sample
was collected was a 4-year-old boy in Nottinghamshire,
United Kingdom, who had common acute lymphoblastic
leukemia and was receiving maintenance chemotherapy
during the study period. Retrospective clinical analysis
for March 2014–February 2016 revealed that the child
had had frequent cough with fever and coryzal symptoms of varying severity (Table). Concurrently collected nasopharyngeal aspirate and throat swab specimens
were negative for bacterial and viral pathogens routinely
tested for, except at the start of the study period, when
rhinovirus and adenovirus were detected, and the end
of the period, when rhinovirus and respiratory syncytial
virus were detected (Table). No bacteria were cultured
from paired specimens. On this basis, in conjunction
with unremarkable physical examination and radiologic findings and stable neutrophil and leukocyte counts
(data not shown), the patient’s respiratory signs were
treated conservatively on an outpatient basis. However,
on 2 occasions (August and November 2015), the child
required hospital admission, without and with co-infection, respectively.
Further retrospective laboratory investigation found
that all 11 additional samples collected from this patient
during November 2014–2015 were positive for TSPyV,
with co-infection at the 4 time points (November and
December 2014, September and November 2015); testing showed fluctuating cycle threshold (Ct) levels on
quantitative PCR (Table; online Technical Appendix).
Of note, various forms of rashes appeared in different
anatomic regions of the patient but did not resemble
the characteristic appearance of trichodysplasia spinulosa and, thus, did not raise any clinical suspicion for
this condition. Indeed, retrospective testing found that
a single skin swab sample taken from a suspected viral
rash (site undocumented) that looked like blisters and
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
RESEARCH LETTERS
Table. Clinical and laboratory data from TSPyV-positive patient, Nottinghamshire, United Kingdom, November 2014–2015*
Collection
Signs and symptoms at
Documented skin
Viral/bacterial
TSPyV
date
lesion
co-infection
Ct value
Sample type time of sample collection
Hospital admission
2014
Nov
Throat swab Cough, sore throat, fever
Tiny skin colored
Not required
Rhinovirus
31.83
pustules on hand
Dec
NPA
Cough, fever
None
Not required
Adenovirus
31.17
2015
Jan
Skin swab
None recorded
Suspected varicella
Not required
None
24.97
zoster virus rash
Feb
NPA
Dry cough, fever
None
Not required
None
31.23
Mar
Throat swab
Dry cough,
None
Not required
None
21.43
coryzal symptoms
Jul†
Throat swab
Cough with runny nose
None
Not required
None
23.90
Jul†
NPA
Cough with runny nose
None
Not required
None
22.70
Jul‡
NPA
Dry cough, fever
Few blisters
Not required
None
22.30
on fingers
Jul‡
Throat swab
Dry cough, fever
Few blisters
Not required
None
25.37
on fingers
Aug
Throat swab
Cough, fever (high)
Erythematous
Hospitalized 4 d
None
21.47
rash with tiny white
center on face
Sep
NPA
Cough
None
Not required
Rhinovirus
26.87
Nov
Throat swab
Cough, wheeze, fever
Rash across chest
Hospitalized 5 d
Respiratory
23.45
(high), coryzal symptoms
syncytial virus
*Ct , cycle threshold; NPA, nasopharyngeal aspirate; TSPyV, trichodysplasia spinulosa polyomavirus; VZV, varicella zoster virus.
†Collected on the same date.
‡Collected on the same date.
was queried as chickenpox was positive for TSPyV with
a low Ct value of 24.97 (Table). Thus, it is conceivable
that this rash represented the early papular stages of a
trichodysplasia spinulosa lesion that did not progress to
the characteristic spicules.
Previously, TSPyV has almost exclusively been associated with pathology of the skin (4); but 4 reports
indicate its isolation from blood (6) and respiratory
samples, suggesting a potential transmission route (5,8–
10). However, respiratory signs and symptoms were observed only in patients co-infected with another virus.
In contrast, the patient we report had persistent respiratory signs and symptoms and concomitant TSPyV-positive (by PCR) respiratory samples in conjunction with
varying forms of skin lesion lacking the characteristic
spicule form of trichodysplasia spinulosa. However, it is
difficult to assess the virus pathogenicity in the absence
of any supportive cell culture results. Hence, the potential of TSPyV to cause respiratory signs and symptoms
needs further investigation and surveillance. The relatively low Ct values (and thus high viral loads) of TSPyV
DNA obtained from this patient in the absence of positive results for any other microbial agents may suggest
an etiologic role of the TSPyV in respiratory pathogenesis. The fact that TSPyV skin disease can be effectively
treated with antiviral medication, such as cidofovir (6),
presents potential for treatment of respiratory manifestations of TSPyV infection.
This study was funded internally by the University of
Nottingham, UK, as part of a master of science degree project.
About the Author
Ms. Bagasi is a PhD student at the University of Nottingham.
Her research interests are epidemiology and cellular entry of
viral infections.
References
1.
2.
3.
4.
5.
6.
7.
8.
Haycox CL, Kim S, Fleckman P, Smith LT, Piepkorn M,
Sundberg JP, et al. Trichodysplasia spinulosa—a newly described
folliculocentric viral infection in an immunocompromised host.
J Investig Dermatol Symp Proc. 1999;4:268–71. http://dx.doi.org/
10.1038/sj.jidsp.5640227
van der Meijden E, Janssens RW, Lauber C, Bouwes Bavinck JN,
Gorbalenya AE, Feltkamp MC. Discovery of a new human
polyomavirus associated with trichodysplasia spinulosa in an
immunocompromized patient. PLoS Pathog. 2010;6:e1001024.
http://dx.doi.org/10.1371/journal.ppat.1001024
Nguyen KD, Lee EE, Yue Y, Stork J, Pock L, North JP, et al.
Human polyomavirus 6 and 7 are associated with pruritic and
dyskeratotic dermatoses. J Am Acad Dermatol. 2017 76:932–40 e3.
http://dx.doi.org/10.1016/j.jaad.2016.11.035
Kazem S, van der Meijden E, Feltkamp MC. The trichodysplasia
spinulosa-associated polyomavirus: virological background and
clinical implications. APMIS. 2013;121:770–82. http://dx.doi.org/
10.1111/apm.12092
Bialasiewicz S, Byrom L, Fraser C, Clark J. Potential route of
transmission for trichodysplasia spinulosa polyomavirus. J Infect
Dis. 2017;215:1175–6. http://dx.doi.org/10.1093/infdis/jix078
van der Meijden E, Horváth B, Nijland M, de Vries K, Rácz EK,
Diercks GF, et al. Primary polyomavirus infection, not reactivation,
as the cause of trichodysplasia spinulosa in immunocompromised
patients. J Infect Dis. 2017;215:1080–4.
Wu JH, Nguyen HP, Rady PL, Tyring SK. Molecular insight into
the viral biology and clinical features of trichodysplasia spinulosa. Br
J Dermatol. 2016;174:490–8. http://dx.doi.org/10.1111/bjd.14239
Tsuzuki S, Fukumoto H, Mine S, Sato N, Mochizuki M,
Hasegawa H, et al. Detection of trichodysplasia
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1745
RESEARCH LETTERS
9.
10.
spinulosa-associated polyomavirus in a fatal case of myocarditis in
a seven-month-old girl. Int J Clin Exp Pathol. 2014;7:5308–12.
Siebrasse EA, Bauer I, Holtz LR, Le BM, Lassa-Claxton S,
Canter C, et al. Human polyomaviruses in children undergoing
transplantation, United States, 2008–2010. Emerg Infect Dis.
2012;18:1676–9. http://dx.doi.org/10.3201/eid1810.120359
Rockett RJ, Sloots TP, Bowes S, O’Neill N, Ye S, Robson J,
et al. Detection of novel polyomaviruses, TSPyV, HPyV6, HPyV7,
HPyV9 and MWPyV in feces, urine, blood, respiratory swabs and
cerebrospinal fluid. PLoS One. 2013;8:e62764. http://dx.doi.org/
10.1371/journal.pone.0062764
Address for correspondence: C. Patrick McClure, University of
Nottingham, School of Life Sciences, Queen’s Medical Centre,
West Block A Floor, Nottingham, NG7 2UH, UK; email:
patrick.mcclure@nottingham.ac.uk
W oh lfa h r t iim on a s
ch it in icla st ica Ba ct e r e m ia
in H ospit a lize d H om e le ss
M a n w it h Squ a m ou s
Ce ll Ca r cin om a
Yuichi Katanami, Satoshi Kutsuna,
Maki Nagashima, Saho Takaya, Kei Yamamoto,
Nozomi Takeshita, Kayoko Hayakawa,
Yasuyuki Kato, Shuzo Kanagawa, Norio Ohmagari
Author affiliation: National Center for Global Health and Medicine,
Tokyo, Japan
DOI: https://doi.org/10.3201/eid2409.170080
We report a case of Wohlfahrtiimonas chitiniclastica
bacteremia in an elderly man in Japan who had squamous
cell carcinoma. Blood cultures were initially negative for
W. chitiniclastica but were positive on day 20. Careful attention needs to be paid to this organism in patients who have
chronic wounds with maggots.
W
e report Wohlfahrtiimonas chitiniclastica bacteremia
in a 75-year-old man in Japan who had squamous
cell carcinoma on his shoulder. In September 2016, an
unidentified patient was found unconscious on the ground
by a passerby and admitted to the emergency department
of the National Center for Global Health and Medicine
(Tokyo, Japan). He had a necrotic lesion on his left shoulder
1746
with maggots. Blood analysis showed leukocytosis (26.61
× 109 cells/L [reference range 3.30–8.60 × 109 cells /L]),
thrombocytosis (626 × 109/L [reference range 158–348 ×
109/L]), anemia (hemoglobin, 9.6 g/dL [reference range
13.7–6.8 g/dL]), and elevated C-reactive protein (87.9
mg/L [reference range 0.00–1.40 mg/L]). Albumin was
2.4 g/dL (reference range 4.1–5.1 g/dL) and calcium was
12.6 mg/dL (reference range 8.8–10.1 mg/dL). He was
diagnosed with disturbance of consciousness caused by
hypercalcemia and was hospitalized.
After saline infusion and intravenous cefazolin (3
g/d) were initiated, the patient’s condition improved. A
blood culture taken at the time of admission grew Peptoniphilus harei. A swab culture of the ulcer site grew
Proteus mirabilis, Morganella morganii, and Kerstersia
gyiorum. A biopsy was performed on day 3, and the patient was diagnosed with squamous cell carcinoma. Enhanced computed tomography scanning revealed an ulcer
and ring-enhancing lesion on his left shoulder (which was
suspected of being a tumor or abscess) and multiple enlarged lymph nodes and 10-mm pulmonary nodules in the
right lung.
On day 20, the patient had fever and disturbance of
consciousness; therefore, he was transferred to the Infectious Disease department of the hospital. Intravenous
therapy with vancomycin (1.5 g/d), cefepime (3 g/d), and
metronidazole (1,500 mg/d) was initiated, and the patient’s
fever and consciousness improved. Two cultures of blood
taken on day 20 grew P. mirabilis, M. morganii, Streptococcus anginosus, Streptococcus agalactiae, Bacteroides
fragilis, and gram-negative rods. After we obtained the
culture results, vancomycin was stopped in accordance
with the susceptibility test results. We identified the gramnegative rods as W. chitiniclastica by using matrix-assisted
laser desorption/ionization time-of-flight mass spectrometry (Bruker Daltonics, Billerica, MA, USA), which showed
scores of 2.239. We further confirmed the isolate to be W.
chitiniclastica by using 16S rRNA sequencing; the isolate
was 99.08% identical to strain S5 (GenBank accession no.
AM397063). We assessed the isolate’s antimicrobial susceptibility profile (Table). The patient improved and was
later discharged to another hospital.
W. chitiniclastica is a gram-negative, short, facultative anaerobic, straight-rod gammaproteobacterium that
was first isolated from the parasitic fly Wohlfahrtia magnifica (1). This fly has not been reported in Japan. However, W. chitiniclastica has also been isolated from the
Chrysomya megacephala fly, and this species has been
reported in Japan (2), and from from the Musca domestica housefly, which is widely distributed all over the
world (3). Campisi et al. reported that the Lucilia sericata
fly might be a vector for W. chitiniclastica (4); this fly is
common and widely distributed throughout Japan, and a
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
RESEARCH LETTERS
Table. Antimicrobial susceptibility profile of Wohlfahrtiimonas
chitiniclastica from a blood culture from a patient treated at
the National Center for Global Health and Medicine, Tokyo,
Japan, 2016.
Antimicrobial drug
MIC mg/L, susceptibility profile
Piperacillin
≤8, S
Piperacillin/tazobactam
≤8, S
Ceftazidime
≤4, S
Cefepime
≤2, S
Aztreonam
≤4, S
Imipenem/cilastatin
≤1, S
Meropenem
≤1, S
Amikacin
≤8, S
Gentamicin
≤2, S
Tobramycin
≤2, S
Minocycline
≤2, S
Levofloxacin
1, S
Ciprofloxacin
1, S
Trimethoprim/sulfamethoxazole
≤2, S
*S, susceptible.
case of cutaneous myiasis on skin cancer was reported
(5). Unfortunately, we could not collect maggots from this
patient because they were rapidly discarded at the emergency department.
Worldwide, few human cases of W. chitiniclastica infection have been documented. W. chitiniclastica has been
described as a zoonotic pathogen (6) and reported from
Hungary, Egypt, Niger, Germany, India, France, China,
Argentina, Estonia, the United Kingdom, and the United
States (4,7,8). Rebaudet et al. (9) described the first human
case of bacteremia attributable to W. chitiniclastica, which
occurred in a 60-year-old homeless woman from southeastern France who had a history of alcoholism. Other human
cases of W. chitiniclastica bacteremia were reported from
Argentina (10) and the United Kingdom (4). Recently, a
bacteremia case in a 72-year-old man was reported from
Hawaii, USA (1).
Risk factors for W. chitiniclastica infection are poor
personal hygiene, alcoholism, peripheral vascular disease,
and chronic open wound (8). The patient we describe had
a chronic wound because of squamous cell carcinoma,
and the associated maggots were thought to be the transmission route. At admission, blood and swab cultures
grew polymicrobial isolates without W. chitiniclastica,
as confirmed by using matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry. However, a
blood culture on day 20 was positive for W. chitiniclastica. The patient probably was infected with W. chitiniclastica during hospitalization. Cases of W. chitiniclastica
infection (with or without bacteremia) were reported as
parts of polymicrobial infections (1,4,7,8). W. chitiniclastica might have first infected this patient’s ring-enhancing
lesion as part of a polymicrobial infection. Because W.
chitiniclastica was undetected in blood and swab cultures
at admission, the organism might have entered the bloodstream during hospitalization.
This patient improved after intravenous therapy with
cefepime and metronidazole. Previously reported W. chitiniclastica bacteremia cases were treated with combination antimicrobial therapies, including cefuroxime plus
metronidazole plus clarithromycin (4), ceftazidime plus
amikacin (10), piperacillin–tazobactam plus clindamycin
plus vancomycin (1), ceftriaxone monotherapy (9), and
meropenem monotherapy (1). Two of the 5 cases were
fatal (1,10).
Clinicians should be attentive to the possibility of
W. chitiniclastica infection in patients who have chronic
wounds with maggots and poor hygiene. Clinical suspicion
is warranted even if blood and swab cultures are initially
negative for W. chitiniclastica.
This work was supported by a grant from Japan’s National
Center for Global Health and Medicine (grant no. 29-1018).
About the Author
Dr. Katanami is a medical doctor at the National Center for
Global Health and Medicine, Disease Control Prevention Center.
His main research interest is tropical infectious diseases.
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
Nogi M, Bankowski MJ, Pien FD. Wohlfahrtiimonas chitiniclastica
infections in 2 elderly patients, Hawaii, USA. Emerg Infect Dis.
2016;22:567–8. http://dx.doi.org/10.3201/eid2203.151701
Mihara M, Kurahashi H. Base-line susceptibility of the
oriental latrine fly, Chrysomya megacephala (Diptera:
Calliphoridae), to five insecticides. Med Vet Entomol. 1991;5:51–4.
http://dx.doi.org/10.1111/j.1365-2915.1991.tb00520.x
Gupta AK, Nayduch D, Verma P, Shah B, Ghate HV, Patole MS,
et al. Phylogenetic characterization of bacteria in the gut of house
flies (Musca domestica L.). FEMS Microbiol Ecol. 2012;79:581–
93. http://dx.doi.org/10.1111/j.1574-6941.2011.01248.x
Campisi L, Mahobia N, Clayton JJ. Wohlfahrtiimonas
chitiniclastica bacteremia associated with myiasis, United
Kingdom. Emerg Infect Dis. 2015;21:1068–9. http://dx.doi.org/
10.3201/eid2106.140007
Chigusa Y, Shinonaga S, Kawaguchi T, Kawaguchi N, Kirinoki M,
Matsuda H. Cutaneous myiasis caused by Lucilia sericata
(Diptera: Calliphoridae) on skin cancer of the cheek. Medical
Entomology and Zoology. 2002;53:89–94. http://dx.doi.org/
10.7601/mez.53.89_1
Thaiwong T, Kettler NM, Lim A, Dirkse H, Kiupel M. First report
of emerging zoonotic pathogen Wohlfahrtiimonas chitiniclastica
in the United States. J Clin Microbiol. 2014;52:2245–7.
http://dx.doi.org/10.1128/JCM.00382-14
Kõljalg S, Telling K, Huik K, Murruste M, Saarevet V, Pauskar M,
et al. First report of Wohlfahrtiimonas chitiniclastica from soft
tissue and bone infection at an unusually high northern latitude.
Folia Microbiol (Praha). 2015;60:155–8. http://dx.doi.org/10.1007/
s12223-014-0355-x
de Dios A, Jacob S, Tayal A, Fisher MA, Dingle TC, Hamula CL.
First report of Wohlfahrtiimonas chitiniclastica isolation from
a patient with cellulitis in the United States. J Clin Microbiol.
2015;53:3942–4. http://dx.doi.org/10.1128/JCM.01534-15
Rebaudet S, Genot S, Renvoise A, Fournier PE, Stein A.
Wohlfahrtiimonas chitiniclastica bacteremia in homeless woman.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1747
RESEARCH LETTERS
10.
Emerg Infect Dis. 2009;15:985–7. http://dx.doi.org/10.3201/
eid1506.080232
Almuzara MN, Palombarani S, Tuduri A, Figueroa S, Gianecini A,
Sabater L, et al. First case of fulminant sepsis due to
Wohlfahrtiimonas chitiniclastica. J Clin Microbiol. 2011;49:2333–
5. http://dx.doi.org/10.1128/JCM.00001-11
Address for correspondence: Yuichi Katanami, National Center for
Global Health and Medicine, Disease Control and Prevention Center,
1-21-1, Toyama, Shinjuku, Tokyo 162-8655, Japan; email:
yuichi.katanami@gmail.com
Sym pt om a t ic D e n gu e du r in g
Pr e gn a n cy a n d Con ge n it a l
N e u r ologic M a lfor m a t ion s
Enny S. Paixão, Maria Glória Teixeira,
Maria da Conceição N. Costa,
Mauricio L. Barreto, Laura C. Rodrigues
Author affiliations: London School of Hygiene and Tropical
Medicine, London, United Kingdom (E.S. Paixão, L.C. Rodrigues);
Instituto de Saúde Coletiva, Salvador-Bahia, Brazil (E.S. Paixão,
M.G. Teixeira, M. da Conceição N. Costa, M.L. Barreto); Center
of Data and Knowledge Integration for Health (CIDACS),
Salvador-Bahia (M.L. Barreto, L.C. Rodrigues)
DOI: https://doi.org/10.3201/eid2409.170361
Dengue virus infection during pregnancy increased the
risk for any neurologic congenital anomaly in the infant by
roughly 50% and for other congenital malformations of brain
4-fold. Our results show an association between dengue
during pregnancy and congenital anomalies of the brain,
suggesting that flaviviruses other than Zika virus are associated with such malformations.
B
efore the causal relationship between Zika virus and
neurologic congenital anomalies (1), especially microcephaly (2), was established, no evidence associated flavivirus with congenital malformations in humans, although
postnatal complications have been described (3). We investigated whether dengue virus (DENV) infection during
pregnancy could be associated with neurologic defects in
the infant at birth.
We conducted a population-based study using routinely collected data from live births and from women who
1748
were notified and confirmed to have DENV infection during 2006–2012 in Brazil, before the introduction of Zika
virus. We probabilistically linked records of mothers of
live births with records of dengue notification to identify
women who were reported as having dengue during pregnancy. We excluded records with missing or implausible
names, multiple pregnancies, and births in municipalities
with no dengue notifications. We obtained ethics approval
from Federal University of Bahia, Salvador, Brazil (CAAE:
26797814.7.0000.5030) and from London School of Hygiene and Tropical Medicine (Ethics Ref:10269).
In the matching process, we used name, age, and place
of residence of the mother at time of delivery and notification. We included only links and nonlinks with a high
degree of certainty. We validated the linkage process in a
study that demonstrated 62% sensitivity (4).
We used an outcome definition of congenital malformation of the nervous system coded as Q00-Q07 in International Classification of Diseases, 10th Revision (ICD-10).
We defined dengue as a confirmed case of DENV infection
notified during a pregnancy that resulted in a live birth. We
estimated the association between symptomatic dengue
during pregnancy and neurologic congenital malformations
using the Firth method to reduce the small sample bias in
maximum-likelihood estimation.
The study parameters encompassed 16,103,312 live
births. Neurologic congenital anomalies are rare; they
occurred in 13,634 (0.08%) live births. Dengue during
pregnancy increased the odds of a neurologic congenital
anomaly by 50% (Table), but this result was not statistically significant (95% CI 0.97–2.27). We split the neurologic congenital defects into ICD-10 categories; the 95%
CI around the estimated odds ratios (ORs) was not statistically significant in 7 categories, including microcephaly
(OR 1.7, 95% CI 0.33–8.32). Two other types of neurologic congenital anomalies were >4 times more frequent in
women who had DENV infection during pregnancy: other
congenital malformations of spinal cord (OR 5.4, 95%
CI 1.0–26.9) and other congenital malformations of brain
(OR 4.5, 95% CI 1.7–11.3, which was statistically significant). We found no sign of space-time clusters or recording errors suggestive of a coding artifact in the 4 records
of other congenital malformations of brain wherein the
mother had DENV infection (online Technical Appendix
Table, https://wwwnc.cdc.gov/EID/article/24/9/17-0361Techapp1.pdf)
Symptoms of DENV infection occurred in the first trimester in 50% of patients. The specific diagnosis of those
among the nonexposed group were congenital malformation of corpus callosum (9%; 81/943), holoprosencephaly
(24%; 225/943), and septooptic dysplasia (0.6%; 6/943).
Our study showed an association between DENV infection during pregnancy and congenital anomalies of the
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
RESEARCH LETTERS
Table. Association between congenital anomalies and
symptomatic dengue virus infection during pregnancy, Brazil,
2006–2012
Congenital anomaly
Odds ratio (95% CI)
Neurologic congenital anomalies
1.5 (0.9–2.2)
Anencephaly
1.9 (0.8–4.4)
Encephalocele
1.4 (0.3–6.9)
Microcephaly
1.7 (0.3–8.3)
Congenital hydrocephalus
1.6 (0.8–3.2)
Other congenital malformations of
4.5 (1.7–11.3
brain
Spina bifida
0.8
Other congenital malformations of
5.4
spinal cord
Other congenital malformations of
Not available
nervous system
brain. Congenital anomalies of the brain detectable by routine examination at birth are so rare (6/100,000 live births
by our data) that it was necessary to assemble a cohort of
>16 million live births to detect an effect of dengue; even
then, we did not have sufficient power to confidently exclude associations with other neurologic abnormalities.
Because DENV infection had not been associated
with congenital anomalies, there is no established biologic
mechanism for its teratogenicity. However, there is evidence for postnatal neurotropism and virus isolation from
brain tissue (5) and for dengue virus crossing the blood–
brain and placental barriers (6,7). The pattern of anomalies
we described has similarities with congenital Zika syndrome. Brain images and autopsies from infants with Zika
and other infectious diseases have revealed abnormalities
similar to those we described (8,9).
Our study has limitations inherent to the linkage process. Rigorous evaluation of the linkage process showed
that it is unlikely to introduce bias and that it did not affect the magnitude of the association (4). Another potential
limitation was diagnosis of DENV infection. In notifiable
epidemics, not all cases are tested after the cause is established. DENV infection in Brazil is notified for the presence of clinical criteria, laboratory confirmation, or both.
Only ≈30% of notified DENV infections are laboratory
confirmed, which could lead to bias if unconfirmed cases
are not dengue. However, a previous article found no difference in pregnancy outcomes for women with notified
DENV infection with and without laboratory confirmation (10). We did not control for potential confounders, so
confounders such as maternal illness or environmental exposures may have contributed to the association between
dengue infection and neurologic malformations.
The association of symptomatic dengue during pregnancy and congenital anomalies of the brain in the infant,
while not as high frequency as the linkage with Zika, opens
the possibility of other flaviviruses causing congenital
malformations and raises questions about policy implications. We recommend careful observation and recording of
DENV infection in antenatal records and full investigation
of live births with neurologic malformations, as well as animal and in vitro research of teratogenic effects of dengue.
E.S.P. is funded by the National Council of Technological and
Scientific Development (CNPq), Brazil, and L.C.R. is partially
funded by the European Union’s Horizon 2020 research and
innovation program under Zika-PLAN grant agreement No.
734584. The funders of this study had no role in study design,
data collection, data analysis, data interpretation, or writing of
the report.
Authors’ contributions: E.S.P. carried out the analysis and wrote
the first draft of the article. L.C.R. and M.G.T. conceived the
study. M.da C.N.C. and M.L.B. contributed to the study design
and interpretation. All authors revised the manuscript and
approved the final version.
About the Author
Ms. Paixão is a PhD student at London School of Hygiene and
Tropical Medicine. Her main research interests are congenital
infections and use of routinely collected data.
References
1.
2.
3.
4.
5.
6.
7.
8.
Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR. Zika virus
and birth defects—reviewing the evidence for causality. N Engl J
Med. 2016;374:1981–7. http://dx.doi.org/10.1056/NEJMsr1604338
de Araújo TVB, Rodrigues LC, de Alencar Ximenes RA, de Barros
Miranda-Filho D, Montarroyos UR, de Melo APL, et al.;
investigators from the Microcephaly Epidemic Research Group;
Brazilian Ministry of Health; Pan American Health Organization;
Instituto de Medicina Integral Professor Fernando Figueira; State
Health Department of Pernambuco. Association between Zika
virus infection and microcephaly in Brazil, January to May,
2016: preliminary report of a case-control study. Lancet
Infect Dis. 2016;16:1356–63. http://dx.doi.org/10.1016/
S1473-3099(16)30318-8
John CC, Carabin H, Montano SM, Bangirana P, Zunt JR,
Peterson PK. Global research priorities for infections that affect
the nervous system. Nature. 2015;527:S178–86. http://dx.doi.org/
10.1038/nature16033
Paixão, ES, Harron K, Andrade K, Teixeira MG, Fiaccone RL,
Costa MDCN, et al. Evaluation of record linkage of two large
administrative databases in a middle income country: stillbirths
and notifications of dengue during pregnancy in Brazil. BMC Med
Inform Decis Mak. 2017;17:108.
Carod-Artal FJ, Wichmann O, Farrar J, Gascón J. Neurological
complications of dengue virus infection. Lancet Neurol. 2013;
12:906–19. http://dx.doi.org/10.1016/S1474-4422(13)70150-9
Chaturvedi UC, Dhawan R, Khanna M, Mathur A. Breakdown of
the blood-brain barrier during dengue virus infection of mice.
J Gen Virol. 1991;72:859–66. http://dx.doi.org/10.1099/
0022-1317-72-4-859
Castanha PMS, Braga C, Cordeiro MT, Souza AI, Silva CD Jr,
Martelli CM, et al. Placental transfer of dengue virus (DENV)–
specific antibodies and kinetics of DENV infection-enhancing
activity in Brazilian infants. J Infect Dis. 2016;214:265–72.
http://dx.doi.org/10.1093/infdis/jiw143
Martines RB, Bhatnagar J, de Oliveira Ramos AM, Davi HP,
Iglezias SD, Kanamura CT, et al. Pathology of congenital Zika
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1749
RESEARCH LETTERS
syndrome in Brazil: a case series. Lancet. 2016;388:898–904.
http://dx.doi.org/10.1016/S0140-6736(16)30883-2
9. Nunes ML, Carlini CR, Marinowic D, Neto FK, Fiori HH,
Scotta MC, et al. Microcephaly and Zika virus: a clinical and
epidemiological analysis of the current outbreak in Brazil.
J Pediatr (Rio J). 2016;92:230–40. http://dx.doi.org/10.1016/
j.jped.2016.02.009
10. Paixão ES, Costa MDCN, Teixeira MG, Harron K, de Almeida MF,
Barreto ML, et al. Symptomatic dengue infection during
pregnancy and the risk of stillbirth in Brazil, 2006–12: a matched
case-control study. Lancet Infect Dis. 2017;17:957–64.
http://dx.doi.org/10.1016/S1473-3099(17)30366-3
Address for correspondence: Enny S. Paixão, London School of Hygiene
and Tropical Medicine, Keppel St, London WC1E 7HT, UK; email:
enny.cruz@lshtm.ac.uk
Tr a ve le r s’ Act u a l a n d
Su bj e ct ive Kn ow le dge a bou t
Risk for Ebola Vir u s D ise a se
Isabelle Régner, Oana Elena Ianos,
Loucy Shajrawi, Philippe Brouqui,
Philippe Gautret
Author affiliation: Aix-Marseille Université, Marseille, France
(I. Régner); Méditerranée Infection Institute, Marseille (O.E. Ianos,
L. Shajrawi, P. Brouqui, P. Gautret)
DOI: https://doi.org/10.3201/eid2409.171343
To determine travelers’ actual and subjective knowledge
about risk for Ebola virus disease, we surveyed travelers
from France. Actual knowledge did not prevent irrational
perceptions or promote safe behavior. Rather, readiness to
adopt protective behavior depended on subjective knowledge and overconfidence in ability to self-protect.
T
he 2014–2016 epidemic of Ebola virus disease (EVD)
in West Africa was the largest ever recorded. As for
many other infectious diseases (1,2), surveys of knowledge,
attitudes, and practices report suboptimal knowledge and
misperceptions of risk for EVD among various populations
(3–6). Recommendations typically emphasize the need
to increase actual knowledge (what persons really know)
to reduce irrational beliefs and risky behavior. However,
subjective knowledge (what persons think they know),
which has been overlooked in EVD surveys, can lead to
the erroneous feeling that one has the requisite knowledge
1750
to avoid adverse events, resulting in a higher risk of
experiencing negative outcomes (7). To determine if
actual and subjective knowledge about EVD would lead
to differing perceptions of risk, we surveyed travelers
from France who had visited the International Vaccination
Center at North Hospital in Marseille, France, for pretravel
consultation during May 2015–February 2016.
A sample of 189 participants (93 women, 96 men; mean
age ± SD 37.78 ± 14.50 years) anonymously completed a
questionnaire about their knowledge and perceptions of risk
of acquiring EVD. Respondents reported their sociodemographic characteristics, destination, purpose of travel, date
of departure, and date of return. Questions about EVD actual knowledge included preventive measures, transmission
routes, epidemic status, affected countries, and presence of
EVD in the destination country. We used correct responses
to compute final scores (online Technical Appendix, https://
wwwnc.cdc.gov/EID/article/24/9/17-1343-Techapp1.pdf).
We used 5-point Likert scales (1 = strongly disagree to
5 = strongly agree) to record travelers’ self-reports pertaining to their subjective knowledge (7) and several risk perceptions about EVD (6,8,9): perceived seriousness of EVD,
awareness of EVD risk in the destination country, perceived
effectiveness of protective measures, fear of contracting
EVD in the country of destination, fear of contracting EVD
in Europe, and intentions to adopt preventive behavior. Personal control and unrealistic optimism were assessed as key
measures of positive illusions that typically lead persons to
overestimate their capabilities to protect themselves against
adverse events (8,9) (online Technical Appendix).
Among the 189 participants, 25.9% planned to travel to
West Africa (2.6% to an affected country, Guinea), 21.7%
to other African countries, and 52.4% to other countries
worldwide. Only 10.6% were able to correctly report the
3 countries affected by the EVD epidemic (Liberia, Sierra
Leone, Guinea), and many were unaware of preventive
measures (45%) and modes of Ebola virus transmission
(39.1%). The most frequent answers for preventive measures were practice careful hygiene (24.34%), avoid contact
with infected persons (23.28%), and wear protective equipment (21.16%). Answers about modes of Ebola virus transmission were body contact (31.22%), body fluids (30.16%),
and aerosol (12.17%; this answer is wrong). Overall, the
actual knowledge about EVD was very low (mean 3.57
correct responses; maximum possible score = 16). Simultaneously, subjective knowledge was low (mean ± SD 2.39
± 1.00; maximum possible score = 5.00) (online Technical
Appendix Table 3 for bivariate intercorrelations).
To go beyond bivariate correlations and to estimate
the associations between risk perceptions and each type
of knowledge, we used multiple regression analyses (Table). Findings showed that actual knowledge was far from
being as effective, as typically thought from knowledge,
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
RESEARCH LETTERS
Table. Results of multiple regression analyses for variables predicting actual and subjective knowledge of risk for Ebola virus disease*
Actual knowledge
Subjective knowledge
Risk perception variable
b
95% CI
b
95% CI
Perceived seriousness
0.12 (p<0.001)
0.05 to 0.20
0.08
–0.08 to 0.24
Risk awareness
–0.19 (p<0.001)
–0.26 to –0.11
–0.16 (p<0.05)
–0.33 to –0.01
Perceived effectiveness of protective measures
0.04
–0.02 to 0.10
0.22 p<0.01)
0.09 to 0.35
Positive illusions
–0.07
–0.14 to 0.01
0.16 (p<0.05)
0.01 to 0.33
Fear of contracting EVD in destination country
0.03
–0.07 to 0.12
0.02
–0.19 to 0.22
Fear of contracting EVD in Europe
–0.01
–0.09 to 0.07
-0.09
–0.26 to 0.08
Behavioral intention
0.04
–0.03 to 0.11
0.16 (p<0.05)
0.01 to 0.32
% variance explained by the model
Adj R2 = 0.32 (p<0.001)
Adj R2 = 0.21 (p<0.001)
*All regression coefficients are unstandardized coefficients that were adjusted for participants’ destination (Africa vs. other countries). Adj, adjusted; b,
unstandardized regression coefficients; EVD, Ebola virus disease.
attitudes, and practices studies (3–5). Actual knowledge
was associated only with higher perceived seriousness
of the disease and lower awareness of risk for EVD in
the country of destination, which reflects some rational
perceptions (EVD is indeed serious, and most destination
countries for this sample population were not affected
by the epidemic). However, travelers with greater actual
knowledge were not more likely to view protective measures as efficient, to avoid positive illusions, or to intend to
engage in protective behavior. On the contrary, travelers
with higher subjective knowledge reported confidence in
preventive measures and intention to adopt safe behavior,
while indicating illusions of having personal control and
unrealistic optimism. Results of a further analysis (online
Technical Appendix) revealed that positive illusions and
subjective knowledge were positively associated with behavioral intentions.
Our observations of suboptimal actual knowledge
about EVD replicated findings of past knowledge, attitudes, and practices studies (3–6); however, we went further by showing that relationships between actual versus
subjective knowledge and perceptions of risk for EVD
differed. The fact that subjective knowledge and positive
illusions, but not actual knowledge, were associated with
protective behavior intentions is problematic, especially
because actual knowledge was low. Persons’ belief that
they know how to protect themselves when they actually
do not and the feeling of knowing added to a feeling of
overconfidence in how to self-protect might result in risky
rather than safe behavior (7).
Our results indicate that not considering subjective
knowledge and positive illusions can lead to the erroneous
conclusion that increasing actual knowledge will necessarily translate into behavioral change and good practices.
EVD communication would benefit from research showing
that promoting behavioral change requires changing subjective evaluations of risk to make it self-relevant and to
induce a reappraisal of the perceived benefits of (or costs of
not) performing safe behavior (10).
About the Author
Dr. Régner is assistant professor at the Cognitive Psychology
Laboratory and head of the Centre of Social Sciences at the
Faculty of Sciences, Aix-Marseille Université, France. Her
research interests include social cognition and risk perceptions.
The Mediterranée Infection Institute is funded by the Agence
Nationale de la Recherche “Investissements d’Avenir”
(Méditerranée Infection 10-IAHU-03).
Address for correspondence: Isabelle Régner, Aix-Marseille Université,
CNRS, LPC, Site Saint-Charles, Case D, 3 Place Victor Hugo, 13331
Marseille CEDEX 3, France; email: isabelle.regner@univ-amu.fr
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
Sridhar S, Belhouchat K, Drali T, Benkouiten S, Parola P,
Brouqui P, et al. French Hajj pilgrims’ experience with
pneumococcal infection and vaccination: a knowledge, attitudes
and practice (KAP) evaluation. Travel Med Infect Dis. 2015;
13:251–5. http://dx.doi.org/10.1016/j.tmaid.2015.02.002
Tashani M, Alfelali M, Barasheed O, Fatema FN, Alqahtani A,
Rashid H, et al. Australian Hajj pilgrims’ knowledge about
MERS-CoV and other respiratory infections. Virol Sin.
2014;29:318–20. http://dx.doi.org/10.1007/s12250-014-3506-y
Rübsamen N, Castell S, Horn J, Karch A, Ott JJ,
Raupach-Rosin H, et al. Ebola risk perception in Germany, 2014.
Emerg Infect Dis. 2015;21:1012–8. http://dx.doi.org/10.3201/
eid2106.150013
Alqahtani AS, Wiley KE, Willaby HW, BinDhim NF, Tashani M,
Heywood AE, et al. Australian Hajj pilgrims’ knowledge, attitude
and perception about Ebola, November 2014 to February 2015.
Euro Surveill. 2015;20:21072. http://dx.doi.org/10.2807/
1560-7917.ES2015.20.12.21072
Merino JG. Response to Ebola in the US: misinformation, fear,
and new opportunities. BMJ. 2014;349. http://dx.doi.org/10.1136/
bmj.g6712
Sridhar S, Brouqui P, Fontaine J, Perivier I, Ruscassier P, Gautret P,
et al. Risk perceptions of MSF healthcare workers on the recent
Ebola epidemic in West Africa. New Microbes New Infect.
2016;12:61–8. http://dx.doi.org/10.1016/j.nmni.2016.04.010
Jaccard J, Dodge T, Guilamo-Ramos V. Metacognition, risk
behavior, and risk outcomes: the role of perceived intelligence
and perceived knowledge. Health Psychol. 2005;24:161–70.
http://dx.doi.org/10.1037/0278-6133.24.2.161
Schneider SL. In search of realistic optimism. Meaning,
knowledge, and warm fuzziness. Am Psychol. 2001;56:250–63.
http://dx.doi.org/10.1037/0003-066X.56.3.250
Peterson C, Stunkard AJ. Personal control and health promotion.
Soc Sci Med. 1989;28:819–28. http://dx.doi.org/10.1016/
0277-9536(89)90111-1
Dijkstra A, Rothman A. Social psychology of health and illness.
In: Steg L, Keizer K, Buunk AP, Rothengatter T, editors. Applied
Social Psychology. Cambridge (UK): Cambridge University Press;
2017. p. 214–34.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1751
RESEARCH LETTERS
Spr e a d of m cr - 1 – D r ive n
Colist in Re sist a n ce on
H ospit a l Su r fa ce s, I t a ly
Elisabetta Caselli, Maria D’Accolti, Irene Soffritti,
Micol Piffanelli, Sante Mazzacane
Author affiliation: Università Degli Studi di Ferrara, Ferrara, Italy
DOI: https://doi.org/10.3201/eid2409.171386
Plasmid-mediated colistin resistance driven by the mcr-1
gene is of great clinical concern. Its diffusion in the hospital
environment is unknown. We detected mcr-1–driven resistance in 8.3% of Enterobacteriaceae isolates from hospital
surfaces in Italy, which might represent a reservoir of threatening nosocomial pathogens.
T
he rapid and continuous growth of drug resistances is
of global concern and one of the most severe threats
for human health. Among those detected in recent years,
a plasmid-mediated colistin resistance, driven by the mcr1 gene (1), represents a serious clinical concern because
colistin was considered a last-resort drug against multidrugresistant (MDR) gram-negative bacteria.
Since its original isolation in an Escherichia coli strain
in China in 2016, the mcr-1 gene has been detected almost
globally in ≈10% of animal isolates (2) and in 0.1%–2% of
human isolates (3), suggesting that this plasmid-mediated
resistance spread efficiently from animals (where colistin has been used for years as a therapeutic drug or food
supplement) to humans through horizontal gene transfer.
Furthermore, the mcr-1 gene was found in different gramnegative bacteria, including Klebsiella pneumoniae, Enterobacter, Salmonella (1,4,5), and recently Citrobacter
(6). The emergence of mcr-1 in clinical Enterobacteriaceae
isolates appears particularly alarming because it frequently
occurs in MDR strains, further limiting current treatment
options for lethal infections sustained by carbapenem-resistant Enterobacteriaceae.
In Italy, mcr-1–driven colistin resistance was first reported in an E. coli strain in 2016 (7). However, colistin
resistance already had been reported previously in carbapenem-resistant Enterobacteriaceae from different peripheral
laboratories in Italy (8).
The mcr-1 gene has been detected in infected persons, but its epidemiology is poorly described, and data
are lacking about its presence in the microbial population
that persistently contaminates hospital environments. Surface contamination is known to contribute to the onset of
healthcare-associated infections, which are often sustained
by MDR or even pan–drug-resistant strains. Thus, based
on the need for information about this aspect, we aimed to
determine the diffusion of mcr-1–driven colistin resistance
in the hospital environment.
We searched for the presence of mcr-1 gene in our library of 300 Enterobacteriaceae samples collected from
the surfaces of 8 hospitals in Italy during 2016–2017. Surface samples were collected from 3 points in hospital rooms
(floor, bed footboard, and sink) as previously described
(9), then grown in MacConkey broth for 48 h at 37°C to
amplify the Enterobacteriaceae population. An aliquot of
grown bacteria was frozen in 50% sterile glycerol for subsequent identification and functional studies. The remaining bacterial suspension was used for total DNA extraction
(UCP-Pathogen Mini Kit; QIAGEN, Hilden, Germany)
and analyzed for mcr-1 gene presence by nested PCR.
We conducted first-round amplifications as previously described (1); nested PCR amplification was carried out using
the following primers and conditions: CLRn-F (5′-AAA
CCT ATC CCA TCG CGG AC-3′) and CLRn-R (5′-CCG
CGC CCA TGA TTA ATA GC-3′), for 35 cycles at 57°C,
originating a 147-bp amplification product, subsequently
confirmed by sequence analysis. Plasmid pBAD24::mcr-1
(3) was used as a positive control. We also conducted a universal panbacterial PCR as a control of DNA amplification
(9). Whole-genome sequence and mcr-1 location were not
analyzed here and might deserve future study.
Of 300 Enterobacteriaceae isolated from hospital surfaces, 25 (8.3%) harbored the mcr-1 gene. All positive samples were culturally isolated on MacConkey agar plates.
Table. Antimicrobial susceptibility of the mcr-1–carrying bacterial isolates from hospital surfaces, Italy*
Drug-resistant isolates, % (MIC, mg/L)
No.
isolates
Bacteria
F
AK
ATM
TZP
C
SXT
NET
Acinetobacter Iwoffii
4
50
25
50
50
25
50
25
Citrobacter freundii
1
0
0
0
0
100
0
0
Enterobacter cloacae
3
100
100
33.3
100
33.3
33.3
100
Enterobacter agglomerans
3
100
0
0
100
0
0
100
Escherichia coli
4
100
50
25
100
0
25
100
Klebsiella pneumoniae
6
100
100
33.3
66.6
66.6
0
100
K. oxytoca
2
100
100
0
0
0
0
100
Pseudomonas aeruginosa
1
0
100
0
100
100
0
100
P. putida
1
0
100
0
0
100
0
100
CTX
25
0
33.3
0
50
66.6
0
100
0
Col-R
7 (4–8)
4
16
5.3 (4–8)
10 (8–16)
13.3 (8–16)
16
4
8
*AK, amikacin 30 g; ATM, aztreonam 30 g; C, chloramphenicol 30 g; Col-R, colistin resistant; CTX, cefotaxime 5 g; F, nitrofurantoin 100 g; NET,
netilmicin 10 g; SXT, trimethoprim/sulfamethoxazole 25 g; TZP, piperacillin/tazobactam 36 g.
1752
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
RESEARCH LETTERS
We identified presumptive positive isolates at the species
level by biochemical typization (API-20E) and Vitek-2
system (BioMérieux, Florence, Italy) and tested them for
drug susceptibility by disc diffusion (Entero1 Multodisc;
Liofilchem,Teramo, Italy) and broth microdilution (SensiTest Colistin, Liofilchem).
Identification results indicated that different species harbored the mcr-1 gene, including K. pneumoniae,
K. oxytoca, E. coli, Acinetobacter Iwoffii, Enterobacter
cloacae, E. agglomerans, Citrobacter freundii, Pseudomonas aeruginosa, and P. putida (Table). These results suggest that this gene is silently spreading to many
gram-negative bacteria responsible for infections in
clinical settings.
All mcr-1–carrying isolates were colistin resistant by microdilution test (MIC 4 mg/L to >16 mg/L).
In addition, as judged by the results obtained by the
disc-diffusion method, all colistin-resistant isolates
were resistant to >2 antimicrobial drugs among those
effective against Enterobacteriaceae, exhibiting a
MDR phenotype.
Our data show that mcr-1–carrying Enterobacteriaceae can be detected on hospital surfaces with higher frequency than in clinical isolates, indicating that this plasmid
has the ability to spread, not only in vitro (1), in key human pathogens. Persistent surface contamination in hospitals might thus favor colistin resistance spread among
gram-negative bacteria, perhaps helped by selective pressure exerted by some antiseptics (i.e., chlorhexidine) (10).
Although this finding might represent a potential reservoir
of threatening nosocomial pathogens and favor their diffusion in hospitalized patients, currently no specific monitoring exists to control it. Thus, we suggest that surveillance
for mcr-1–driven colistin resistance might include not only
clinical samples but also environmental analyses and all
clinically relevant gram-negative species to control and
counteract the increase of untreatable infections.
About the Author
Dr. Caselli is a professor of microbiology and clinical
microbiology at the Faculty of Medicine of the University
of Ferrara. Her research interests include infectious diseases,
microbiology, virology, molecular virology, antiviral immune
response, autoimmunity, and healthcare-associated infections.
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J,
et al. Emergence of plasmid-mediated colistin resistance
mechanism MCR-1 in animals and human beings in China:
a microbiological and molecular biological study. Lancet
Infect Dis. 2016;16:161–8. http://dx.doi.org/10.1016/
S1473-3099(15)00424-7
Irrgang A, Roschanski N, Tenhagen BA, Grobbel M,
Skladnikiewicz-Ziemer T, Thomas K, et al. Prevalence of mcr-1
in E. coli from livestock and food in Germany, 2010–2015. PLoS
One. 2016;11:e0159863. http://dx.doi.org/10.1371/
journal.pone.0159863
Ye H, Li Y, Li Z, Gao R, Zhang H, Wen R, et al. Diversified
mcr-1–harbouring plasmid reservoirs confer resistance to
colistin in human gut microbiota. MBio. 2016;7:e00177.
http://dx.doi.org/10.1128/mBio.00177-16
Wong SC, Tse H, Chen JH, Cheng VC, Ho PL, Yuen KY.
Colistin-resistant Enterobacteriaceae carrying the mcr-1 gene
among patients in Hong Kong. Emerg Infect Dis. 2016;22:1667–9.
http://dx.doi.org/10.3201/eid2209.160091
Tse H, Yuen KY. Dissemination of the mcr-1 colistin resistance
gene. Lancet Infect Dis. 2016;16:145–6. http://dx.doi.org/10.1016/
S1473-3099(15)00532-0
Li XP, Fang LX, Jiang P, Pan D, Xia J, Liao XP, et al. Emergence
of the colistin resistance gene mcr-1 in Citrobacter freundii.
Int J Antimicrob Agents. 2017;49:786–7. http://dx.doi.org/
10.1016/j.ijantimicag.2017.04.004
Cannatelli A, Giani T, Antonelli A, Principe L, Luzzaro F,
Rossolini GM. First detection of the mcr-1 colistin resistance
gene in Escherichia coli in Italy. Antimicrob Agents
Chemother. 2016;60:3257–8. http://dx.doi.org/10.1128/
AAC.00246-16
Monaco M, Giani T, Raffone M, Arena F, Garcia-Fernandez A,
Pollini S, et al.; Network EuSCAPE-Italy. Colistin resistance
superimposed to endemic carbapenem-resistant Klebsiella
pneumoniae: a rapidly evolving problem in Italy, November
2013 to April 2014. Euro Surveill. 2014;19:20939.
http://dx.doi.org/10.2807/1560-7917.ES2014.19.42.20939
Caselli E, D’Accolti M, Vandini A, Lanzoni L, Camerada MT,
Coccagna M, et al. Impact of a probiotic-based cleaning
intervention on the microbiota ecosystem of the hospital
surfaces: focus on the resistome remodulation. PLoS
One. 2016;11:e0148857. http://dx.doi.org/10.1371/journal.
pone.0148857
Wand ME, Bock LJ, Bonney LC, Sutton JM. Mechanisms of
increased resistance to chlorhexidine and cross-resistance to
colistin following exposure of Klebsiella pneumoniae clinical
isolates to chlorhexidine. Antimicrob Agents Chemother.
2016;61:e01162-16. http://dx.doi.org/10.1128/AAC.01162-16
Address for correspondence: Elisabetta Caselli, Universita Degli Studi
di Ferrara Dipartimento di Scienze Mediche, Department of Medical
Sciences, Section of Microbiology, via Borsari 46 Ferrara, Ferrara 44121
Italy; email: csb@unife.it
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1753
RESEARCH LETTERS
Tr a n sve r se M ye lit is a n d
Gu illa in - Ba r r é Syn dr om e
Associa t e d w it h Ca t - Scr a t ch
D ise a se , Te x a s, USA, 2 0 1 1
Ramia Zakhour, Pedro Mancias, Gloria Heresi,
Norma Pérez
Author affiliations: American University of Beirut, Beirut, Lebanon
(R. Zakhour); University of Texas UT Health, Houston, Texas, USA
(R. Zakhour, P. Mancias, G. Heresi, N. Pérez)
DOI: https://doi.org/10.3201/eid2409.180008
We describe a case of coexisting transverse myelitis and
Guillain-Barré syndrome related to infection with Bartonella henselae proteobacterium and review similar serologyproven cases. B. henselae infection might be emerging as
a cause of myelitis and Guillain-Barré syndrome and should
be considered as an etiologic factor in patients with such
clinical presentations.
A
child with lower extremity weakness raises an increasingly complex diagnostic challenge; frequently no etiology is identified (1,2). We present a case of lower extremity weakness linked to cat-scratch disease (CSD, causative
agent Bartonella henselae proteobacterium).
In 2011, a 10-year-old girl was transferred to our hospital (UT Health, Houston, Texas, USA) from another hospital, where she had been treated for 2 days for abdominal
pain, vomiting, and urinary retention. Seven days before
admission to UT Health, she had a left cervical lymphadenopathy. During hospitalization, the patient had urinary
retention; lower extremity weakness; worsening headache;
neck pain; lower back pain; and a bilateral burning sensation in the wrists, knees, ankles, and feet.
Before her illness, she was healthy and fully immunized; her exposure history only included a cat at home
that frequently bit and scratched her. Physical examination
revealed a palpable lymph node (3 × 4 cm) at the left cervical lymph node, lower extremity strength of 4 on a 5-point
scale (https://www.ncbi.nlm.nih.gov/books/NBK436008/),
and decreased deep tendon reflexes. She reported hyperalgesia in her legs.
Peripheral blood cell counts and chemistry test values
were within reference ranges. Alanine aminotransferase
and aspartate aminotransferase were both mildly elevated
(48 U/L [0.8 µkat/L]). A magnetic resonance image (MRI)
of the brain showed a focus of increased T2 signal, and an
MRI of the spine showed a long centrally located segment
of increased T2 signal (Figure). Cerebrospinal fluid (CSF)
studies showed a leukocyte concentration of 58 cells/mm3
(reference range <10 cells/mm3), glucose of 46 mg/dL
(nonfasting reference range 45–100 mg/dL), and protein
of 55 mg/dL (reference range 15–45 mg/dL). We gave the
patient a diagnosis of myelitis and treated her empirically
with ceftriaxone and vancomycin, pending CSF culture
results. On day 11 of illness, we started administering rifampin and doxycycline for a possible CSD diagnosis; the
patient was positive for B. henselae IgG (1:152) and IgM
(1:160). Increases in B. henselae IgG and decreases in B.
henselae IgM were seen with subsequent serologic tests:
day 27 (IgG 1:256, IgM 1:40) and day 41 (IgG 1:512, IgM
1:20). Evaluation for other etiologies included bacteria culture with urine, blood, and CSF samples; CSF latex agglutination for bacterial antigen; virus culture with nasal washes; rapid plasma reagin test; CSF venereal disease research
laboratory testing; enterovirus, herpes simplex virus, and
mycobacteria PCR of CSF sample; Epstein-Barr virus and
Figure. Magnetic resonance images (MRIs) on day 10 of illness in a 10-year-old girl with transverse myelitis and Guillain-Barré
syndrome associated with cat-scratch disease, Houston, Texas, USA, 2011. A) Brain MRI. Arrow indicates focus of increased T2 signal
in the left posterior periventricular and deep white matter. B) Sagittal spine MRI. Arrow indicates long segment of increased T2 signal
centrally located within the spinal cord. C) Axial thoracic spine MRI. Arrow indicates increased central signal within the spinal cord.
1754
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
RESEARCH LETTERS
cytomegalovirus PCR of serum samples; and Mycoplasma
pneumoniae, West Nile virus, Borrelia burgdorferi, and
human T-cell lymphotropic virus I and II antibody testing,
all of which were negative for evidence of the respective
microbial agents. CSF angiotensin-converting enzyme and
IgG levels were in reference ranges. CSF myelin basic protein level (6.4 ng/mL [reference range <1.1 ng/mL]) was
elevated. Vitamin B12 and folate levels were in reference
ranges, and antinuclear antibody, rheumatoid factor antibody, and dsDNA antibodies were absent.
The patient completed a 14-day course of doxycycline;
rifampin was discontinued after 5 days because of rising liver enzyme levels. By day 34 of illness, the patient’s muscle
strength substantially improved, but she continued to have
difficulty voiding and severe lower extremity pain. A repeat
MRI showed resolution of the increased thoracic spinal cord
signal and a new enhancement of the cauda equina nerve
roots. Repeat lumbar puncture indicated a leukocyte concentration of 12 cells/mm3 (85% lymphocytes [reference range
62% ± 34%]). Nerve conduction studies revealed patchy
mixed demyelinating axonal motor and sensory neuropathy.
After intravenous immunoglobulin administration for possible Guillain-Barré syndrome (GBS), she showed tremendous improvement, with resolution of urinary retention and
a substantial decrease in pain and weakness; 4 months later,
she had only residual sensory deficits.
B. henselae proteobacterium is transmitted to humans
typically through cat scratches or bites (3). Neurologic
complications, usually self-limited, develop in 0.2%–3.0%
of CSD patients (4). The first case of CSD with neurologic
manifestations was described in 1952. By 1971, ≈40 cases
had been reported (5), 90% involving encephalitis and a
few myelopathy (6). The cases of myelopathy had slower
recovery courses than those of encephalitis, as well as more
residual deficits.
Four other serology-documented CSD-associated myelitis cases (3,4,7) and 1 other GBS-associated B. henselae
infection (in a 10-year-old girl) (8) have been described.
Carman et al. reported a case similar to the one we describe: myelitis and GBS in a 12-year-old boy (9).
Studies of the efficacy of treatments for CSD-associated neurologic manifestations are lacking, and thus, the
optimal regimen and duration of therapy are unknown.
However, we suggest that clinicians consider CSD early
in disease courses involving neurologic complications; the
possibility of GBS, myelitis, or both in the setting of possible CSD should prompt clinicians to initiate antimicrobial
treatment early and consider steroid or intravenous immunoglobulin therapy to prevent progression of disease.
This patient had an unusual presentation of CSD, with
evidence of myelitis, brain lesions, and peripheral nerve
involvement. Although few cases of CSD-associated transverse myelitis and GBS have been described, clinicians
should be aware of the existence of this clinical scenario
and include it as a differential diagnosis for these 2 syndromes in the pediatric age group.
About the Author
Dr. Zakhour is an assistant professor at the American University
of Beirut in Beirut, Lebanon. She has a special interest in
immune complications of infections.
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
Marx A, Glass JD, Sutter RW. Differential diagnosis of acute
flaccid paralysis and its role in poliomyelitis surveillance.
Epidemiol Rev. 2000;22:298–316. http://dx.doi.org/10.1093/
oxfordjournals.epirev.a018041
Centers for Disease Control and Prevention. AFM investigation.
2015 Apr [cited 2018 Jan 2]. https://www.cdc.gov/acute-flaccidmyelitis/afm-surveillance.html
Baylor P, Garoufi A, Karpathios T, Lutz J, Mogelof J, Moseley D.
Transverse myelitis in 2 patients with Bartonella henselae
infection (cat scratch disease). Clin Infect Dis. 2007;45:e42–5.
http://dx.doi.org/10.1086/519998
Salgado CD, Weisse ME. Transverse myelitis associated with
probable cat-scratch disease in a previously healthy pediatric
patient. Clin Infect Dis. 2000;31:609–11. http://dx.doi.org/
10.1086/313986
Lyon LW. Neurologic manifestations of cat-scratch disease. Report
of a case and review of the literature. Arch Neurol. 1971;25:23–7.
http://dx.doi.org/10.1001/archneur.1971.00490010033004
Lewis DW, Tucker SH. Central nervous system involvement in cat
scratch disease. Pediatrics. 1986;77:714–21.
Sendi P, Hirzel C, Bloch A, Fischer U, Jeannet N, Berlinger L,
et al. Bartonella-associated transverse myelitis. Emerg Infect Dis.
2017;23:712–3. http://dx.doi.org/10.3201/eid2304.161733
Massei F, Gori L, Taddeucci G, Macchia P, Maggiore G.
Bartonella henselae infection associated with Guillain-Barré
syndrome. Pediatr Infect Dis J. 2006;25:90–1. http://dx.doi.org/
10.1097/01.inf.0000195642.28901.98
Carman KB, Yimenicioglu S, Ekici A, Yakut A, Dinleyici EC.
Co-existence of acute transverse myelitis and Guillain-Barré
syndrome associated with Bartonella henselae infection. Paediatr
Int Child Health. 2013;33:190–2. http://dx.doi.org/10.1179/204690
5512Y.0000000044
Address for correspondence: Ramia Zakhour, American University
of Beirut Medical Center, Department of Pediatrics and Adolescent
Medicine, PO Box 11-0236, Riad El Solh 1107, 2020, Beirut, Lebanon;
email: rz17@aub.edu.lb
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1755
RESEARCH LETTERS
Co- Cir cu la t ion of 4 D e n gu e
Vir u s Se r ot ype s a m on g
Tr a ve le r s En t e r in g Ch in a
fr om M ya n m a r , 2 0 1 7
Binghui Wang,1 Yuebo Liang,1 Shuting Yang,
Yirong Du, Li-Na Xiong, Ting Zhao, Fang Yang,
Weihong Qin, Xueshan Xia
Author affiliations: Kunming University of Science and
Technology, Kunming, China (B. Wang, S. Yang, X. Xia); Care
Center for International Travel Health in Yunnan, Kunming
(Y. Liang, W. Qin); Ruili Entry-Exit Inspection and Quarantine
Authority, Ruili, China (Y. Du, L.-N. Xiong, F. Yang); First People’s
Hospital of Yunnan Province, Kunming (T. Zhao)
DOI: https://doi.org/10.3201/eid2409.180252
We report 301 dengue virus infections among cross-border
travelers entering Yunnan Province, China, from Myanmar
during 2017. Phylogenetic analysis of 99 strains found all
4 serotypes co-circulating; genetic characteristics have
also changed. This finding highlights the urgent need for
monitoring dengue virus cross-border transmission as early
warning of severe dengue fever.
D
engue virus (DENV) infection is one of the most serious threats to public health in tropical and subtropical
regions worldwide (1). Southeast Asia is the most seriously
affected region, with explosive outbreaks occurring frequently. In 2013, a small-scale DENV outbreak occurred
in Yunnan, the southeasternmost province in China, as a result of imported infection from neighboring Southeast Asia
countries (2,3). Ruili County is located in southwest Yunnan, bordering Myanmar on 3 sides. In this county, crossborder DENV transmission and endemic disease have become a serious challenge in the past decade.
In 2017, a total of 8.3 million cross-border travelers
who entered Yunnan Province through Ruili had their body
temperature measured using an intelligent infrared human body temperature measurement system. Persons with
a temperature >37°C were suspected to be infected with
DENV; infection was confirmed by NS1 antigen detection
(4). In total, 1,667 travelers were screened for DENV infection because of fever symptoms. Of these, 301 were confirmed to be DENV infected. The DENV-infected travelers
comprised 196 citizens of Myanmar and 105 citizens of
China; median age was 27 (range 1–71) years, and male/female ratio was 1.15:1 (161:140). The occurrence of DENV
infection was concentrated during August–November;
1
These authors contributed equally to this article.
1756
196 infections were detected in this period, accounting for
65.1% of DENV cases in 2017.
To further describe the genetic characteristics of these
DENV strains, we selected 100 DENV-positive plasma
samples for E gene amplification followed by phylogenetic
analysis (2). All participants were informed and provided
written consent before sample collection. This research was
approved by the Institutional Ethical Committee of Kunming University of Science and Technology. We randomly
enrolled 10 cases from each month; if there were <10 cases
in 1 month, we included all cases from that month. As a
result, 99 samples were successfully amplified; 1 sample
failed, possibly because of low viral load. We identified all
4 DENV serotypes in this population, although DENV-3 (4
cases) and DENV-4 (17 cases) had previously been undiscovered in Yunnan Province (2). DENV-1, the dominant serotype in 2013, continued to be the most prevalent serotype
in 2017 (77 cases), whereas only 1 case of DENV-2 was
detected. We found no significant difference in serotype
distribution based on sampling time.
We randomly selected 40 DENV-1 samples, 1 DENV2 sample, 4 DENV-3 samples, and 17 DENV-4 samples for
sequencing and phylogenetic analysis; we submitted the resulting sequences to GenBank (accession nos. MG933806–
MG933867). Phylogenetically, all DENV-1 strains of the
cross-border travelers in 2017 were classified as genotype
I (Figure), similar to earlier reports (2). Specifically, most
strains were closely related to the strains identified in 2013
in Dehong Prefecture and its neighboring country, Thailand
(Figure), which suggests the prolonged circulation of 2013
strains or stable importing from neighboring countries. The
only DENV-2 strain (D2-0022) was classified as the Asian I
genotype, forming a close cluster with 2013 strains and reference sequences from Myanmar and Thailand and strains
previously circulated in Yunnan Province. The DENV-3
strains detected in Ruili were classified as genotype I and
genotype III, which is substantially different from the genotype II strains identified during the DENV outbreak in the
southern prefecture of Xishuangbanna in 2013 (Figure) (2).
DENV-4 genotype II was once reported as a circulating serotype in Yunnan Province in 2015 but is now a long-term
epidemic in Myanmar and Thailand.
Among the travelers entering Yunnan Province from
Myanmar in 2017, dengue infections showed not only
inherited characteristics of previous epidemic DENV-1 and
DENV-2 but also the circulation of additional serotypes
and genotypes (DENV-3 genotypes I and III, DENV-4
genotype II). This importation of all serotypes of DENV
may result in simultaneous or sequential epidemics of the
local population in Yunnan Province. Co-circulation of
the 4 serotypes, considered a key indicator of progression
toward hyperendemic transmission (5,6), led to an alert for
a threatening DENV pandemic. Our findings also revealed
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
RESEARCH LETTERS
Figure. Phylogenetic tree of DENV serotypes identified in cross-border travelers entering Yunnan Province, China, from Myanmar
during 2017. A) DENV-1; B) DENV-2; C) DENV-3; D) DENV-4. The phylogenetic trees were constructed by the maximum-likelihood
method with a Kimura 2 parameter model using MEGA 7.0 software (https://www.megasoftware.net). Bootstrap values were set
for 1,000 repetitions. Black dots denote strains from this study, and black triangles denote strains from our previous study (2,3).
GenBank accession numbers for comparison isolates are provided. Scale bars indicate nucleotide substitutions per site. DENV,
dengue virus.
the continued changing of DENV genetic characteristics
in this float population (5,7,8), developed from fewer
genotypes/serotypes to the co-circulation of multifarious
serotypes/genotypes, from sporadic imported infection
to more local infection. In the past decade, or at least
since 2013, local DENV infection has occurred in border
regions of Yunnan Province. Thus, DENV undoubtedly
also exists in local mosquitoes. In the near future, we plan
to investigate DENV infection in mosquitoes and perform
genetic characterization of those strains from mosquitoes.
The cross-border population serves as a major vector for transmission of pathogens into China from neighboring countries in Southeast Asia. Because of the large
number of DENV infection cases in Yunnan Province and
neighboring countries, our research clearly demonstrates
that surveillance and control of dengue virus is a difficult
task, and south China is under the risk for an increase in
dengue infections.
Acknowledgments
The authors express immense gratitude to all patients associated
with this study.
This study was supported by grants from the National Natural
Science Foundation of China (grant no. 81460509), the
Science and Technology Project (grant no. 2016RA014), and
the Key Science and Technology Planning Project of the
Yunnan Provincial Science and Technology Department (grant
no. 2016FC005).
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1757
RESEARCH LETTERS
About the Author
Dr. Wang is a virology researcher at Kunming University of
Science and Technology. His research interests are molecular
epidemiology of infectious disease, focusing especially on
human immunodeficiency virus, hepatitis viruses, and
dengue virus.
References
1.
2.
3.
4.
5.
6.
7.
8.
Guzman MG, Harris E. Dengue. Lancet. 2015;385:453–65.
http://dx.doi.org/10.1016/S0140-6736(14)60572-9
Wang B, Yang H, Feng Y, Zhou H, Dai J, Hu Y, et al. The distinct
distribution and phylogenetic characteristics of dengue virus
serotypes/genotypes during the 2013 outbreak in Yunnan, China:
phylogenetic characteristics of 2013 dengue outbreak in Yunnan,
China. Infect Genet Evol. 2016;37:1–7. http://dx.doi.org/10.1016/
j.meegid.2015.10.022
Wang B, Li Y, Feng Y, Zhou H, Liang Y, Dai J, et al.
Phylogenetic analysis of dengue virus reveals the high
relatedness between imported and local strains during the 2013
dengue outbreak in Yunnan, China: a retrospective analysis.
BMC Infect Dis. 2015;15:142. http://dx.doi.org/10.1186/
s12879-015-0908-x
Fuchs I, Bin H, Schlezinger S, Schwartz E. NS1 antigen
testing for the diagnosis of dengue in returned Israeli travelers.
J Med Virol. 2014;86:2005–10. http://dx.doi.org/10.1002/
jmv.23879
Messina JP, Brady OJ, Scott TW, Zou C, Pigott DM, Duda KA,
et al. Global spread of dengue virus types: mapping the 70 year
history. Trends Microbiol. 2014;22:138–46. http://dx.doi.org/
10.1016/j.tim.2013.12.011
Villabona-Arenas CJ, de Oliveira JL, Capra CS, Balarini K,
Loureiro M, Fonseca CR, et al. Detection of four dengue serotypes
suggests rise in hyperendemicity in urban centers of Brazil.
PLoS Negl Trop Dis. 2014;8:e2620. http://dx.doi.org/10.1371/
journal.pntd.0002620
Zhang FC, Zhao H, Li LH, Jiang T, Hong WX, Wang J,
et al. Severe dengue outbreak in Yunnan, China, 2013.
Int J Infect Dis. 2014;27:4–6. http://dx.doi.org/10.1016/
j.ijid.2014.03.1392
Zhao Y, Li L, Ma D, Luo J, Ma Z, Wang X, et al. Molecular
characterization and viral origin of the 2015 dengue outbreak in
Xishuangbanna, Yunnan, China. Sci Rep. 2016;6:34444.
http://dx.doi.org/10.1038/srep34444
Address for correspondence: Xueshan Xia, Kunming University of
Science and Technology Faculty of Life Science and Technology, No
727 Jing Ming Rd, Chenggong District, Kunming City, Yunnan Province,
Kunming 650500, China; email: oliverxia2000@aliyun.com; Weihong
Qin, Health Care Center for International Travel in Yunnan, Kunming,
Yunnan, China; email: qinwh19@sina.com
1758
Ca se of M icr oce ph a ly a ft e r
Con ge n it a l I n fe ct ion w it h
Asia n Lin e a ge Zik a Vir u s,
Th a ila n d
Thidathip Wongsurawat,1 Niracha Athipanyasilp,1
Piroon Jenjaroenpun, Se-Ran Jun,
Bualan Kaewnapan, Trudy M. Wassenaar,
Nattawat Leelahakorn, Nasikarn Angkasekwinai,
Wannee Kantakamalakul, David W. Ussery,
Ruengpung Sutthent, Intawat Nookaew,2
Navin Horthongkham2
Author affiliations: University of Arkansas for Medical Sciences,
Little Rock, Arkansas, USA (T. Wongsurawat, P. Jenjaroenpun,
S.-R. Jun, D.W. Ussery, I. Nookaew); Siriraj Hospital, Mahidol
University, Bangkok, Thailand (N. Athipanyasilp, B. Kaewnapan,
N. Leelahakorn, N. Angkasekwinai, W. Kantakamalakul,
R. Sutthent, N. Horthongkham); Molecular Microbiology and
Genomics Consultants, Zotzenheim, Germany (T.M. Wassenaar)
DOI: https://doi.org/10.3201/eid2409.180416
We sequenced the virus genomes from 3 pregnant women
in Thailand with Zika virus diagnoses. All had infections
with the Asian lineage. The woman infected at gestational
week 9, and not those infected at weeks 20 and 24, had
a fetus with microcephaly. Asian lineage Zika viruses can
cause microcephaly.
A
lthough Zika virus has circulated in Asia longer than
in the Americas, only 3 confirmed cases of congenital
Zika virus infection with microcephaly have been reported
in Asia (2 Thailand, 1 Vietnam) (1). As of June 2018, the genomic sequences of the viruses from these 3 cases have not
been reported; thus, whether these cases were caused by an
Asian lineage or an imported American lineage is unknown.
Several mechanisms involving virus genome sequences have been proposed to explain how Zika virus
might cause microcephaly (2). Liang et al. (3) showed in
vitro that replication of both the African (strains MR766
and IbH30656) and American (strain H/PF/2013) lineage
viruses suppress Akt phosphorylation; this suppression is
caused by an accumulation of mutations in the Zika virus genome that increase the number of phosphorylation
sites on virus proteins that compete with host proteins for
phosphorylation. Yuan et al. proposed that a serine to asparagine substitution (S17N) in the premembrane protein
(stably conserved in the American lineage but not in the
1
These first authors contributed equally to this article.
2
These senior authors contributed equally to this article.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
RESEARCH LETTERS
Figure. Maximum-likelihood phylogenetic analysis of nonredundant Zika virus genomes including 7 isolates from patients in Thailand,
2016–2017, and amino acid changes corresponding with 3 evolutionary events (2). Circles indicate the Zika virus isolates from this report;
the Zika virus strains used by Liang et al. (3) are indicated by asterisks and Yuan et al. (4) by squares. The key amino acid residue changes
corresponding with the 3 evolutionary events (2) are shown, and the conserved amino acid substitution S17N, present in the American
lineage but not in the other lineages, is in bold. The amino acid residues of the 7 isolates from this report are identical to those of the other
Asian lineage isolates. C, capsid; prM, premembrane; NS, nonstructural protein. Scale bar indicates nucleotide changes per basepair.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1759
RESEARCH LETTERS
Asian) contributes to the onset of microcephaly (4). An increased frequency of retinoic acid response elements in the
American lineage genome versus the Asian lineage genome
has also been observed (2). We question these explanations
because we report a confirmed case of congenital Zika virus infection with microcephaly in Thailand caused by an
Asian lineage virus.
We sequenced 7 Zika virus genomes obtained from 5
patients, including 3 pregnant women (PW1–3), in 2016
and 2017. PW1 had fever, maculopapular rash, and mild
conjunctivitis at 24 weeks of gestation. Her urine sample
was positive for Zika virus (BKK05, GenBank accession
no. MG807647), and she gave birth to an infant without
birth defects at full term. PW2 had a suspected Zika virus
infection at 9 weeks’ gestation with high fever, maculopapular rash, and mild conjunctivitis. At 16 weeks, a sample
of the amniotic fluid was positive for Zika virus (BKK03,
GenBank accession no. MG548660). The pregnancy was
terminated at 17 weeks. Autopsy of the fetus demonstrated
a head circumference of 12.5 cm (less than the third percentile for this gestational age); Zika virus was detected in
the brain (BKK02, GenBank accession no. MF996804) and
placenta (BKK04, GenBank accession no. MG548661). No
other etiologic agents associated with birth defects (cytomegalovirus, herpes simplex virus types 1 and 2, rubella
virus, syphilis virus, Toxoplasma gondii, Treponema pallidum) were detectable by real-time PCR. PW2 had detectable hepatitis B viral surface antigen but no concurrent
medical conditions. These findings suggest that Zika virus
was the causative agent of this case of microcephaly. PW3
had a maculopapular rash without fever or conjunctivitis
and received a Zika virus diagnosis at 20 weeks’ gestation.
Her urine sample was positive for Zika virus (BKK07,
GenBank accession no. MH013290), and she gave birth
to a healthy infant at full term. The last 2 samples were
from a 6-year-old child with mild fever and maculopapular rash (BKK06, GenBank accession no. MG807647)
and a 64-year-old man with fever and maculopapular rash
(BKK01, GenBank accession no. KY272987).
We retrieved 121 nonredundant Zika virus genomes
(444 viruses, 99.9% nucleic acid identity cutoff) from GenBank to compare these isolates by phylogenetic analysis.
All 7 BKK Zika virus isolates grouped within the Asian
lineage (Figure). Virus from the amniotic fluid (BKK03),
fetal brain (BKK02), and placenta (BKK04) of PW2 closely resembled each other (5 mismatches in BKK04 and 6 in
BKK03, overall 99.898% identity). These 3 isolates were
separated on the tree from their closest neighbor, a 2016
isolate from Singapore, by 40 mismatches. The number of
retinoic acid response elements and predicted phosphorylation sites in BKK01–BKK07 was the same as the number
in other Asian lineage Zika viruses (2). Also, the S17N substitution in premembrane was absent in all 7 isolates. Thus,
1760
all 3 proposed mechanisms failed to explain the case of
congenital Zika virus infection with microcephaly in PW2.
This case clinically resembled that of a woman in Finland
infected during week 11 of pregnancy while traveling in
Mexico, Guatemala, and Belize (5); in that case, Zika virus
was detected in the brain of the aborted fetus at week 21.
The 3 cases in pregnant women described here support
the hypothesis that the timing of Zika virus infection during
pregnancy might be a key contributor to the development of
microcephaly during congenital Zika virus infection. PW2
was infected around week 9 of gestation, during embryonic
neurulation and cortical neurogenesis, which lay the foundation for the developing brain. Infection during weeks 20
(for PW3) and 24 (for PW1) of gestation did not lead to microcephaly. Our observations are in agreement with reports
involving American lineage Zika viruses that show a high
risk for microcephaly when infection occurs before week
21 (6), during weeks 7–14 (7), or during the first trimester
(8–10). Our findings show that Zika viruses circulating in
Asia can cause microcephaly, just like American strains.
This work was funded in part by Siriraj Research (grant no.
RO16034012), the Helen Adams & Arkansas Research Alliance
Endowed Chair, and the National Institute of General
Medical Sciences of the National Institutes of Health (award no.
P20GM125503).
About the Author
Dr. Wongsurawat is a postdoctoral research fellow at the
Arkansas Center for Genomic Epidemiology & Medicine in
Little Rock, Arkansas, USA. Her primary research interests
are applying next-generation and third-generation sequencing
technologies to perform DNA and RNA viral genome and
metagenome sequencing.
References
1.
2.
3.
4.
5.
Lim SK, Lim JK, Yoon IK. An update on Zika virus in Asia.
Infect Chemother. 2017;49:91–100. http://dx.doi.org/10.3947/
ic.2017.49.2.91
Jun SR, Wassenaar TM, Wanchai V, Patumcharoenpol P,
Nookaew I, Ussery DW. Suggested mechanisms for Zika virus
causing microcephaly: what do the genomes tell us? BMC
Bioinformatics. 2017;18(Suppl 14):471. http://dx.doi.org/10.1186/
s12859-017-1894-3
Liang Q, Luo Z, Zeng J, Chen W, Foo SS, Lee SA, et al.
Zika virus NS4A and NS4B proteins deregulate akt-mTOR
signaling in human fetal neural stem cells to inhibit neurogenesis
and induce autophagy. Cell Stem Cell. 2016;19:663–71.
http://dx.doi.org/10.1016/j.stem.2016.07.019
Yuan L, Huang XY, Liu ZY, Zhang F, Zhu XL, Yu JY, et al. A
single mutation in the prM protein of Zika virus contributes to fetal
microcephaly. Science. 2017;358:933–6. http://dx.doi.org/10.1126/
science.aam7120
Driggers RW, Ho CY, Korhonen EM, Kuivanen S, Jääskeläinen AJ,
Smura T, et al. Zika virus infection with prolonged maternal
viremia and fetal brain abnormalities. N Engl J Med.
2016;374:2142–51. http://dx.doi.org/10.1056/NEJMoa1601824
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
RESEARCH LETTERS
6.
7.
8.
9.
10.
Sohan K, Cyrus CA. Ultrasonographic observations of the fetal
brain in the first 100 pregnant women with Zika virus infection in
Trinidad and Tobago. Int J Gynaecol Obstet. 2017;139:278–83.
http://dx.doi.org/10.1002/ijgo.12313
Parra-Saavedra M, Reefhuis J, Piraquive JP, Gilboa SM,
Badell ML, Moore CA, et al. Serial head and brain imaging
of 17 fetuses with confirmed Zika virus infection in Colombia,
South America. Obstet Gynecol. 2017;130:207–12.
http://dx.doi.org/10.1097/AOG.0000000000002105
Kleber de Oliveira W, Cortez-Escalante J, De Oliveira WT,
do Carmo GM, Henriques CM, Coelho GE, et al. Increase in
reported prevalence of microcephaly in infants born to women
living in areas with confirmed Zika virus transmission during the
first trimester of pregnancy—Brazil, 2015. MMWR Morb
Mortal Wkly Rep. 2016;65:242–7. http://dx.doi.org/10.15585/
mmwr.mm6509e2
Cuevas EL, Tong VT, Rozo N, Valencia D, Pacheco O, Gilboa SM,
et al. Preliminary report of microcephaly potentially associated
with Zika virus infection during pregnancy—Colombia, January–
November 2016. MMWR Morb Mortal Wkly Rep. 2016;65:1409–
13. http://dx.doi.org/10.15585/mmwr.mm6549e1
Reynolds MR, Jones AM, Petersen EE, Lee EH, Rice ME,
Bingham A, et al.; U.S. Zika Pregnancy Registry Collaboration.
Vital Signs: Update on Zika virus–associated birth defects and
evaluation of all U.S. infants with congenital Zika virus exposure—
U.S. Zika Pregnancy Registry, 2016. MMWR Morb Mortal Wkly
Rep. 2017;66:366–73. http://dx.doi.org/10.15585/
mmwr.mm6613e1
Address for correspondence: Intawat Nookaew, Department of
Biomedical Informatics and Department of Physiology and Biophysics,
College of Medicine, University of Arkansas for Medical Sciences,
Little Rock, AR 72205, USA; email: inookaew@uams.edu; Navin
Horthongkham, Department of Microbiology, Faculty of Medicine,
Siriraj Hospital, Mahidol University, Wanglang Road, Bangkoknoi
Bangkok, 10700 Thailand; email: navin.hor@mahidol.ac.th
Dirofilaria repens N e m a t ode
Infection with Microfilaremia
in Tr a ve le r Re t u r n in g t o
Be lgiu m fr om Se n e ga l
Idzi Potters, Gaëlle Vanfraechem,
Emmanuel Bottieau
Author affiliations: Institute of Tropical Medicine Antwerp, Antwerp,
Belgium (I. Potters, E. Bottieau); Centre Hospitalier Interrégional
Edith Cavell Hospital Group, Brussels, Belgium (G. Vanfraechem)
DOI: https://doi.org/10.3201/eid2409.180462
We report human infection with a Dirofilaria repens nematode likely acquired in Senegal. An adult worm was extracted from the right conjunctiva of the case-patient, and blood
microfilariae were detected, which led to an initial misdiagnosis of loiasis. We also observed the complete life cycle of
a D. repens nematode in this patient.
O
n October 14, 2016, a 76-year-old man from Belgium
was referred to the travel clinic at the Institute of Tropical Medicine (Antwerp, Belgium) because of suspected
loiasis after a worm had been extracted from his right conjunctiva in another hospital. Apart from stable, treated arterial hypertension and non–insulin-dependent diabetes, he
had no remarkable medical history. For the past 10 years,
the patient spent several months per year in a small beach
house in Casamance, Senegal, and did not travel to any
other destination outside Belgium. His last stay in Senegal
was during October 2015–May 2016, during which time he
took care of dogs roaming on the beach.
On September 30, 2016, unilateral right conjunctivitis
developed in the patient, and he was referred to an ophthalmologist, who extracted a worm (length 10 cm, diameter
470 µm) (Figure, panel A). The patient did not report any
previous symptoms such as itching, larva migrans, or migratory swelling.
Results of a physical examination were unremarkable.
Blood analysis showed a leukocyte count of 8,330 cells/µL
and 16.8% eosinophils. All other first-line laboratory parameters, including total level of IgE, were within reference
ranges. A pan filaria IgG-detecting assay (Acanthocheilonema viteae ELISA Kit; Bordier Affinity Products SA,
Crissier, Switzerland) showed a positive result. All other
relevant serologic assays showed negative results. Blood
smear examination after Knott concentration showed 6 microfilariae of Dirofilaria sp./mL of blood.
Although treatment for such infections is not well
established, the patient was given ivermectin (200 µg/
kg, single dose) on October 15. The patient had general itching and fever (temperature up to 40°C) the next
day. Blood test results on October 26 showed a leukocyte count of 8,410 cells/µL and 27.9% eosinophils. The
patient recovered uneventfully. In September 2017, the
patient was free of symptoms, and his eosinophil count
was 470 cells/µL.
Human dirofilariasis is a mosquitoborne zoonosis
caused by filarial worms of the genus Dirofilaria, which
has 2 subgenera: Dirofilaria (the most common species is
D. immitis) and Nochtiella (the most common species is
D. repens). The main clinical manifestations are subcutaneous or ocular nodules, and a diagnosis is usually made by
biopsy or worm extraction. The risk for humans to acquire
dirofilariasis has increased because of climate changes and
larger distribution ranges of vectors (1).
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1761
RESEARCH LETTERS
Figure. Dirofilaria repens adult worm isolated from the right conjunctiva of a 76-year-old man who returned to Belgium from Senegal,
and microfilaria detected by using the Knott test. A) Macroscopic image of the adult. B) Microscopic image of the adult cuticle, showing
the typical longitudinal ridges. Scale bar indicates 200 µm. C) Eggs in utero, indicating that the adult is a gravid female worm. Scale bar
indicates 50 µm. Panel C has been cropped and contrast was increased to improve visibility of eggs. D) Microfilaria found in the blood of
the patient. In a Knott test, microfilariae usually appear stretched out and slightly longer than those observed in a Giemsa-stained blood
film. Scale bar indicates 100 µm.
Human dirofilariasis is currently considered an emerging zoonosis (2). D. repens nematodes have a large geographic distribution that includes Africa, Asia, and Europe
and have recently spread into colder regions (3). Studies of
primates indicate that D. repens nematodes need to develop
for ≈25–34 weeks before they are fully mature and produce
microfilariae (4). This finding suggests that the patient we
report acquired the infection in Senegal, possibly through
close contact with dogs.
Initially, loiasis was suspected as a diagnosis, given
the location of the adult worm and presence of microfilaremia. However, the length (10 cm) of the adult worm did
not correspond to a Loa loa worm, which can reach a maximum length of ≈7 cm. Microscopic examination of the
cuticle identified conspicuous longitudinal ridges, which
are typical for certain Dirofilaria spp. but absent in L. loa
worms (Figure, panel B). These ridges also ruled out D.
immitis worms.
When we took the largest diameter of the adult worm
(470 µm) into account, we made a diagnosis of D. repens
nematode infection (5). Eggs found in utero (Figure, panel
C) confirmed that the worm was a gravid adult female.
This diagnosis was supported by morphologic features of
the blood microfilariae: terminal extremities that did not
contain nuclei (L. loa microfilariae have nuclei extending
to the tip of the tail) and short cephalic spaces containing
2–4 nuclei (Figure, panel D; online Technical Appendix
Figure, https://wwwnc.cdc.gov/EID/article/24/9/18-0462Techapp1.pdf). We measured 25 larvae, and they had an
average length of 376 µm (range 357–395 µm) and an average diameter of 9.7 µm (range 7.5–10.0 µm), all features
compatible with D. repens microfilariae (6,7).
We attempted to provide molecular confirmation of the
infecting species by using 2 PCRs: 1 reported by Gioia et
al. in 2010 (8) and 1 reported by Latrofa et al. in 2012 (9).
Both techniques, which were performed with material from
the adult worm, did not confirm identification of infecting
species, probably because of prolonged preservation of the
worm in formaldehyde.
1762
D. repens worms seldom fully develop and produce
microfilariae in humans. To our knowledge, 5 such cases
have been reported: 3 with microfilariae in tissues surrounding adult worms and 2 with microfilariae in blood
(10). There might have been immune impairment in our patient with diabetes, which enabled completion of the worm
cycle, a phenomenon also observed in macaques with decreased immunity (4).
In conclusion, this case highlights the need for careful parasitologic examination when clinical and laboratory
findings (i.e., presence of an eye worm and microfilaremia)
lead to a diagnosis that is epidemiologically unexpected.
In addition, clinicians should be aware that similar clinical
presentations might also be increasingly observed in nontropical settings.
Acknowledgments
We thank all laboratory staff involved in the study for
providing technical assistance and Pierre Dorny, Renaud
Piarroux, and Anne-Cécile Normand for providing assistance
with the molecular techniques.
About the Author
Mr. Potters is a skills laboratory teacher and a medical laboratory
technologist at the national reference laboratory for parasitology
at the Institute of Tropical Medicine, Antwerp, Belgium. His
research interest is tropical parasitology.
References
1.
Diaz JH. Increasing risks of human dirofilariasis in travelers.
J Travel Med. 2015;22:116–23. http://dx.doi.org/10.1111/jtm.12174
2. Pampiglione S, Rivasi F, Angeli G, Boldorini R, Incensati RM,
Pastormerlo M, et al. Dirofilariasis due to Dirofilaria repens
in Italy, an emergent zoonosis: report of 60 new cases.
Histopathology. 2001;38:344–54. http://dx.doi.org/10.1046/
j.1365-2559.2001.01099.x
3. Pietikäinen R, Nordling S, Jokiranta S, Saari S, Heikkinen P,
Gardiner C, et al. Dirofilaria repens transmission in southeastern
Finland. Parasit Vectors. 2017;10:561. http://dx.doi.org/10.1186/
s13071-017-2499-4
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
RESEARCH LETTERS
4.
5.
6.
7.
8.
9.
10.
Wong MM. Experimental dirofilariasis in macaques. II.
Susceptibility and host responses to Dirofilaria repens of dogs
and cats. Am J Trop Med Hyg. 1976;25:88–93. http://dx.doi.org/
10.4269/ajtmh.1976.25.88
MacDougall LT, Magoon CC, Fritsche TR. Dirofilaria repens
manifesting as a breast nodule. Diagnostic problems and
epidemiologic considerations. Am J Clin Pathol. 1992;97:625–30.
http://dx.doi.org/10.1093/ajcp/97.5.625
Magnis J, Lorentz S, Guardone L, Grimm F, Magi M, Naucke TJ,
et al. Morphometric analyses of canine blood microfilariae isolated
by the Knott’s test enables Dirofilaria immitis and D. repens
species-specific and Acanthocheilonema (syn. Dipetalonema)
genus-specific diagnosis. Parasit Vectors. 2013;6:48.
http://dx.doi.org/10.1186/1756-3305-6-48
Liotta JL, Sandhu GK, Rishniw M, Bowman DD. Differentiation
of the microfilariae of Dirofilaria immitis and Dirofilaria
repens in stained blood films. J Parasitol. 2013;99:421–5.
http://dx.doi.org/10.1645/12-10.1
Gioia G, Lecová L, Genchi M, Ferri E, Genchi C, Mortarino M.
Highly sensitive multiplex PCR for simultaneous detection and
discrimination of Dirofilaria immitis and Dirofilaria repens in
canine peripheral blood. Vet Parasitol. 2010;172:160–3.
http://dx.doi.org/10.1016/j.vetpar.2010.04.027
Latrofa MS, Weigl S, Dantas-Torres F, Annoscia G, Traversa D,
Brianti E, et al. A multiplex PCR for the simultaneous detection
of species of filarioids infesting dogs. Acta Trop. 2012;122:150–4.
http://dx.doi.org/10.1016/j.actatropica.2012.01.006
Fontanelli Sulekova L, Gabrielli S, De Angelis M, Milardi GL,
Magnani C, Di Marco B, et al. Dirofilaria repens microfilariae
from a human node fine-needle aspirate: a case report. BMC Infect
Dis. 2016;16:248. http://dx.doi.org/10.1186/s12879-016-1582-3
Address for correspondence: Idzi Potters, Department of Clinical
Sciences, Institute of Tropical Medicine Antwerp, Kronenburgstraat 43/3,
2000 Antwerp, Belgium; email: ipotters@itg.be
Ru be lla Vir u s Ge n ot ype 1 E
in Tr a ve le r s Re t u r n in g t o
Ja pa n fr om I n don e sia , 2 0 1 7
Daiki Kanbayashi, Takako Kurata, Yuka Nishino,
Fumi Orii, Yuki Takii, Masaru Kinoshita,
Toshitake Ohara, Kazushi Motomura,
Takahiro Yumisashi
Author affiliations: Osaka Institute of Public Health, Osaka, Japan
(D. Kanbayashi, T. Kurata, K. Motomura, T. Yumisashi); Osaka
Prefectural Government Department of Health and Medical Care,
Osaka (Y. Nishino, F. Orii, Y. Takii, M. Kinoshita); Osaka
Prefectural Government Ikeda Healthcare Center, Osaka (T. Ohara)
DOI: https://doi.org/10.3201/eid2409.180621
Although rubella is epidemic in Indonesia, the phylogenetic
profile of circulating rubella virus strains has not been clarified. In 2017, rubella virus was detected in 2 travelers who
returned from Indonesia to Japan. These strains were classified into genotype 1E lineage 2, which may be an indigenous strain in Indonesia.
R
ubella is a mild contagious disease caused by the rubella
virus, genus Rubivirus, family Togaviridae (1). Fetal
death or congenital rubella syndrome (CRS) can occur when
infection arises in pregnant women (1). Rubella infections
and CRS cases have declined in many countries because of
vaccination (2); however, an estimated 110,000 CRS cases
occurred globally in 2010, with almost half developing in
Southeast Asia because routine immunization programs
against rubella virus had scarcely been introduced in these
countries at that time (3,4). As of 2016, of the 11 countries
in Southeast Asia, 8 (Bangladesh, Bhutan, Maldives, Myanmar, Nepal, Sri Lanka, Thailand, and Timor-Leste) had introduced routine immunization (5). However, large epidemics
still exist in Southeast Asia, mainly in India and Indonesia,
which had not introduced routine immunization as of 2016
(5). In addition, CRS cases in Indonesia were the highest
worldwide in 2016 (5). Contrarily, only 1 sequence of the
virus in Indonesia was registered in GenBank, from a patient
who returned to the United States in 2011 (Hendersonville.
NC.USA/15.11, accession no. JX477651). Although these
rubella-endemic countries greatly affect the efforts of neighboring countries to control the virus, genetic information of
epidemic strains in Southeast Asia remains unclear.
In October 2017, a 29-year-old man in Japan experienced a slight fever and sore throat. He had traveled to
Jakarta, Indonesia, in late September, 14 days before symptom onset. He was not previously vaccinated against rubella virus. On day 4 after onset, rashes appeared on his body.
Testing by real-time reverse transcription PCR did not detect the measles virus genome, but it detected rubella virus
genome via throat swab sample collected on day 7 after
onset (6). His illness was diagnosed as rubella; we strongly
suspected that he acquired the infection in Indonesia, because the incubation period of rubella virus is ≈14 days and
Japan has had no domestic rubella epidemic since 2013.
We amplified the E1 protein-coding region genome of
the virus and sequenced the molecular window region (739
nt) (7). We classified this rubella strain into genotype 1E
and deposited it into GenBank (RVs/Osaka.JPN/41.17[1E],
accession no. LC333396). We generated a phylogenetic
tree including 61 strains using the maximum-likelihood
method; it revealed that rubella virus can be classified into
5 distinct lineages (L0–L4), as previously described (7,8).
1E-L1 strains are mainly detected in China and Russia.
1E-L2 strains are mainly detected in or imported from Malaysia, China, and Japan. 1E-L3 strains are detected in or
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1763
RESEARCH LETTERS
imported from African countries, such as the Democratic
Republic of the Congo and Tunisia. 1E-L4 strains are detected in Sudan, Yemen, and Uganda. Both RVs/Osaka.
JPN/41.17[1E] and Hendersonville.NC.USA/15.11 belonged to 1E-L2; these sequences were closely related to the
recently identified 1E-L2 sequences. We also detected RVs/
Yokohama.JPN/3.17[1E] in a traveler who returned to Japan from Indonesia in January 2017 (deposited in GenBank
under accession no. LC215401) who had contact with a
local rubella patient. Our findings indicate that 1E-L2
strains may circulate as indigenous strains in Indonesia.
To verify rubella elimination, interruptions in transmission of indigenous or imported rubella virus strains must be
confirmed through effective surveillance systems (9). However, it is difficult to distinguish imported strains from endemic strains and to confirm the control status on the basis of
genotype information because the genotypes of global epidemic strains converge to genotypes 1E and 2B (3,7,8,10).
Figure. Maximum-likelihood
phylogram of the molecular
window region (739 nt) within
the E1 gene of rubella virus
genotype 1E from a 29-year-old
man in Japan who had traveled
to Indonesia (black circles). We
constructed a phylogenetic tree
using 61 strains, including the
genotype reference strains and
the candidate lineage reference
strains, using MEGA version
7.0 (http://www.megasoftware.
net) and the Tamura-Nei model.
Numbers at nodes indicate the
bootstrap support values, given as
a percentage of 1,000 replicates
(values <45 are omitted). The
genotype 1D reference strain (RVi/
Saitama.JPN/0.94/[1D]) is included
as an outgroup. White circles
indicate the genotype 1E strain
detected in patients returning to
the United States from Indonesia
in 2011. Black squares indicate
candidate genotype 1E lineage
reference strains. White squares
indicate the strains detected in
Japan from 2012–2017. Each
strain identification consists
of a 3-letter country name
abbreviation and detection year.
Accession numbers are shown in
parentheses. Scale bar indicates
nucleotide substitutions per site.
COD, Democratic Republic of the
Congo; FRA, France; JPN, Japan;
KAZ, Kazakhstan; CHN, China;
MYS, Malaysia; ROU, Romania;
RUS, Russia; SDN, Sudan; TWN,
Taiwan; TUN, Tunisia; UGA,
Uganda; UKR, Ukraine; USA,
United States of America.
1764
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
RESEARCH LETTERS
Therefore, several studies were conducted to subdivide the
genotypes on the basis of detailed phylogenetic analysis
(7,8). We reported that a large epidemic in Japan in 2013
might have occurred due to the transport of multiple lineages
of rubella virus from rubella-endemic countries (7). According to the National Epidemiological Surveillance of Infectious Diseases (NESID) of Japan, during 2015–2017, ≈100
cases of rubella, which is a notifiable disease in Japan, were
reported annually (5), and genotype 1E strains, including a
strain closely related to RVs/Osaka.JPN/41.17[1E], were detected. Although these strains might have been transported
from countries with endemic rubella, their origin remains
unclear because of insufficient genomic information.
Japan has a high risk for subsequent rubella epidemics because the proportion of persons susceptible to rubella
virus (≈9.0%) has not changed since 2013. In addition, an
epidemic can occur when rubella virus is transported from
rubella-endemic countries and the infection occurs in susceptible populations, as happened in Japan in 2013. Of the 11
imported cases of rubella to Japan reported in 2017, 4 were
from Indonesia, according to the NESID of Japan. In the case
we describe, we identified the rubella-exporting country and
clarified the genetic information of the strain, which may contribute to countermeasures for worldwide importation of rubella virus. Rubella control by 2020 is the flagship goal of the
World Health Organization South-East Asia region. Indonesia is conducting rubella immunization campaigns targeting
≈70 million children in 2017–2018. Therefore, constructing
effective surveillance systems, accumulating genetic information, and promoting immunization in rubella-endemic
countries are steps toward the global elimination of rubella.
Acknowledgments
We thank the staff of Osaka Prefectural Government, Yokohama
City Institute of Public Health, Yokohama City Public Health
Center, and Yokohama City Ward Health and Welfare Centers for
supporting our work. We thank Yoshio Mori for review of this
manuscript and Enago for the English language review.
This study was partially supported by JSPS KAKENHI grant
number 26860453, 18K17367 to D.K. and a grant-in-aid from
the Japan Agency for Medical Research and Development,
AMED (JP17fk0108213j).
About the Author
Mr. Kanbayashi is a researcher at the Osaka Institute of Public
Health. His research interests include rubella.
References
1
Reef S, Plotkin SA. Rubella vaccine. In: Plotkin SA, Orenstein W,
Offit P, editors. Vaccines, 6th ed. Philadelphia: Saunders; 2013. p.
688–717.
2. Plotkin SA. The history of rubella and rubella vaccination leading
to elimination. Clin Infect Dis. 2006;43(Suppl 3):S164–8.
http://dx.doi.org/10.1086/505950
3.
4.
5.
6.
7.
8.
9.
10.
Lambert N, Strebel P, Orenstein W, Icenogle J, Poland GA.
Rubella. Lancet. 2015;385:2297–307. http://dx.doi.org/10.1016/
S0140-6736(14)60539-0
Cutts FT, Vynnycky E. Modelling the incidence of congenital
rubella syndrome in developing countries. Int J Epidemiol.
1999;28:1176–84. http://dx.doi.org/10.1093/ije/28.6.1176
World Health Organization. WHO vaccine-preventable diseases:
monitoring system [cited 2018 Jul 10]. http://apps.who.int/
immunization_monitoring/globalsummary/
Okamoto K, Mori Y, Komagome R, Nagano H, Miyoshi M,
Okano M, et al. Evaluation of sensitivity of TaqMan
RT-PCR for rubella virus detection in clinical specimens.
J Clin Virol. 2016;80:98–101. http://dx.doi.org/10.1016/
j.jcv.2016.05.005
Mori Y, Miyoshi M, Kikuchi M, Sekine M, Umezawa M,
Saikusa M, et al. Molecular epidemiology of rubella virus
strains detected around the time of the 2012–2013 epidemic in
Japan. Front Microbiol. 2017;8:1513. http://dx.doi.org/10.3389/
fmicb.2017.01513
Rivailler P, Abernathy E, Icenogle J. Genetic diversity of currently
circulating rubella viruses: a need to define more precise viral
groups. J Gen Virol. 2017;98:396–404. http://dx.doi.org/10.1099/
jgv.0.000680
Framework for verifying elimination of measles and rubella. Wkly
Epidemiol Rec. 2013;88:89–99. PubMed
Abernathy ES, Hübschen JM, Muller CP, Jin L, Brown D,
Komase K, et al. Status of global virologic surveillance for
rubella viruses. J Infect Dis. 2011;204(Suppl 1):S524–32.
http://dx.doi.org/10.1093/infdis/jir099
Address for correspondence: Daiki Kanbayashi, Osaka Institute of Public
Health, 1-3-69 Nakamichi, Higashinari-ku, Osaka 537-0025, Japan;
email: kanbayashi@iph.osaka.jp
Spon dw e n i Vir u s in
Fie ld- Ca u gh t Culex
quinquefasciatus M osqu it oe s,
H a it i, 2 0 1 6
Sarah K. White,1 John A. Lednicky,
Bernard A. Okech, J. Glenn Morris, Jr.,
James C. Dunford
Author affiliations: University of Florida, Gainesville, Florida, USA
(S.K. White, J.A. Lednicky, B.A. Okech, J.G. Morris, Jr.); US Navy
and Marine Corps Public Health Center, Portsmouth, Virginia,
USA (J.C. Dunford)
DOI: https://doi.org/10.3201/eid2409.171957
1
Current affiliation: Brammer Bio, Alachua, Florida, USA.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1765
RESEARCH LETTERS
Spondweni virus (SPONV) and Zika virus cause similar
diseases in humans. We detected SPONV outside of Africa from a pool of Culex mosquitoes collected in Haiti
in 2016. This finding raises questions about the role of
SPONV as a human pathogen in Haiti and other Caribbean countries.
S
pondweni virus (SPONV) and Zika virus are closely
related flaviviruses that were first described in Africa in 1952 and 1947, respectively (1). Humans infected by these viruses have similar clinical manifestations;
asymptomatic infections are common, and illness is
generally self-limiting (1). In the 6 documented human
SPONV infections, fever occurred in all. Other symptoms included headache, nausea, myalgia, conjunctivitis, and arthralgia; only 1 SPONV-infected person had
maculopapular and pruritic rash (1). The similar clinical
presentations for these virus infections and reportedly
high serologic cross-reactivity have resulted in frequent
misdiagnosis (1).
Because of the 2015–2016 epidemic of Zika fever
in the Western Hemisphere and the link between microcephaly and Zika virus infection, Zika virus has been
studied more comprehensively than SPONV (1). SPONV
was first isolated from Mansonia uniformis mosquitoes
during virus surveillance in 1955 in South Africa (2). No
new reports of SPONV surfaced despite continued mosquito surveillance until 1958, when it was identified in
4 additional mosquito species, including Aedes circumluteolus, a tropical sylvatic mosquito found in Africa (2).
Little is known about possible vertebrate hosts, although
SPONV antibodies have been detected in birds, small
mammals, and ruminants (2). In a recent study by Haddow et al., strains of Ae. aegypti, Ae. albopictus, and Culex quinquefasciatus mosquitoes were not susceptible to
SPONV infection (3).
We detected SPONV from a pool of 7 mixed-sex Cx.
quinquefasciatus mosquitoes collected in July 2016 during ongoing arbovirus surveillance in Gressier, Haiti. During May–August 2016, we caught 1,756 mosquitoes using Biogents Sentinel traps (BioQuip Products, Rancho
Dominguez, CA, USA) within a 10-mile radius in Gressier,
a semirural setting. Trap locations were selected based on
environmental considerations, low risk for traps being disturbed, and known human arbovirus-caused illnesses in the
area (4). Trap bags were transported to a field laboratory in
Haiti, where mosquitoes were frozen at –20°C, then identified by species and sexed by trained technicians using morphologic keys and identification guides (5,6). After identification, the mosquitoes were pooled by location, collection
date, species (Ae. aegypti, Ae. albopictus, Cx. quinquefasciatus, and other), and sex. All pools were screened for
chikungunya virus, dengue virus (DENV) serotypes 1–4,
and Zika virus RNA by real-time reverse transcription PCR
(rRT-PCR) (online Technical Appendix Table 1, https://
wwwnc.cdc.gov/EID/article/24/9/17-1957-Techapp1.pdf),
as we previously have done with human specimens from
Haiti (4). Mosquito homogenates positive by rRT-PCR
were used for sequencing using primer walking and Sanger
sequencing methods as previously reported (4; online Technical Appendix Table 2). In addition, we confirmed Aedes
and Culex mosquito species by molecular methods (7,8). In
initial screens of a pool of 7 mixed-sex Cx. quinquefasciatus mosquitoes (non–blood-fed) collected on July 4, 2016,
rRT-PCR results suggested the presence of Zika virus RNA
(cycle threshold value 39), but this same pool was negative
for chikungunya virus and DENV RNA by rRT-PCR. After
unsuccessful attempts to amplify Zika virus–specific amplicons using previously described Zika virus sequencing
primers, we used an unbiased sequencing approach after
treatment of virions in mosquito homogenate with cyanase
(4). Because we suspected a closely related virus, we next
Table. Comparison of nucleotide and amino acid identities of representative strains of SPONV and Zika virus, Haiti*
Nucleotide identity, %
SPONV, GenBank accession no.
Zika virus, GenBank accession no.
Virus type and nucleotide GenBank
accession no. (country of origin, year)
MG182017
DQ859064
KX227369
KY989511
KU501215
MF384325
SPONV MG182017 (Haiti, 2016)
100
98.8
96.8
70.7
70.4
70.4
SPONV DQ859064 (South Africa, 1954)
100
97.8
70.9
70.6
70.7
SPONV KX227369 (Nigeria, 1952)
100
71.1
70.8
70.8
Zika virus KY989511 (Uganda, 1947)
100
89.0
89.0
Zika virus KU501215 (Puerto Rico, 2015)
100
99.6
Zika virus MF384325 (Haiti, 2016)
100
Amino acid identity, %
SPONV, GenBank accession no.
Zika virus, GenBank accession no.
Virus type and protein GenBank
accession no. (country of origin, year)
AVD68687
ABI54480
AOZ57820
ARM59240 AMC13911
ASF57880
SPONV AVD68687 (Haiti, 2016)
100
98.8
98.3
74.1
74.0
74.1
SPONV ABI54480 (South Africa, 1954)
100
99.1
74.9
74.7
74.8
SPONV AOZ57820 (Nigeria, 1952)
100
74.9
74.8
74.9
Zika virus ARM59240 (Uganda, 1947)
100
96.9
96.9
Zika virus AMC13911 (Puerto Rico, 2015)
100
99.8
Zika virus ASF57880 (Haiti, 2016)
100
*SPONV, Spondweni virus.
1766
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
RESEARCH LETTERS
tested random hexamers and SPONV-specific primers (online Technical Appendix Table 3), which resulted in formation of virus-specific amplicons (online Technical Appendix). Thereafter, using SPONV primers, we determined
a 10,290-nt nearly complete genome and deposited it in
GenBank (accession no. MG182017).
The SPONV genome from Haiti shared 10,174
(98.8%) of 10,290 nt identity with a SPONV isolate from
mosquitoes in South Africa in 1954 (GenBank accession
no. DQ859064) and 9,958 (96.8%) of 10,287 nt identity
with the SPONV Chuku strain from blood of a febrile human patient in Nigeria in 1952 (accession no. KX227369)
(Table). When compared with the Zika virus reference
strain from Uganda (accession no. KY989511), a strain
from Puerto Rico (accession no. KU501215), and a strain
from Haiti in 2016 (accession no. MF384325), Zika virus and SPONV clearly continue to diverge because the
nucleotide and amino acid identities of SPONV are less
similar to more recent strains of Zika virus (Table). Few
SPONV sequences have been deposited into GenBank,
resulting in insufficient information to predict how and
when SPONV was introduced in Haiti.
In the Americas and the Caribbean, SPONV is a potential emergent arbovirus and public health threat that
manifests clinically with symptoms and signs similar to
those of Zika virus infection (2,9). Misdiagnosis has been
documented, and it is possible that SPONV has caused
human infection in Haiti but has been misidentified as
infection from DENV or other arboviruses (9). Little is
known about SPONV pathogenesis, host range, and vector competency, especially with vectors present in the
Western Hemisphere. Our detection of SPONV in Cx.
quinquefasciatus mosquitoes raises questions about the
role of this species as a vector for this virus and highlights
the need for ongoing surveillance for SPONV infection
among humans in the Caribbean, combined with studies
of potential vector populations.
Acknowledgments
We thank the field technicians for setting traps and collecting and
identifying mosquitoes in Haiti.
This work was funded in part by the Armed Forces Health
Surveillance Branch, Global Emerging Infections Surveillance
Section, Proposal Management Information System (PROMIS)
ID P014517E2, and a grant from the National Institutes of
Health to J.G.M. (R01 AI26357-01S1).
The views expressed in this article are those of the authors and
do not necessarily reflect the official policy or position of the
Department of the Navy, Department of Defense, nor the US
Government. Dr. Dunford is a military service member; this
work was prepared as part of his official duties. Title 17, U.S.C.,
§105 provides that copyright protection under this title is not
available for any work of the US Government. Title 17, U.S.C.,
§101 defines a US Government work as a work prepared by a
military service member or employee of the US Government as
part of that person’s official duties.
About the Author
Dr. White is a senior scientist in Assay Development and
Analytic, and Small Scale Development at Brammer Bio.
During this study, she was a postdoctoral associate in the
Department of Environmental and Global Health at the
Emerging Pathogens Institute, University of Florida, under the
mentorship of Dr. John Lednicky. Her primary research interests
include emerging arboviruses, influenza D virus, and novel viral
vector therapeutics.
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
Haddow AD, Woodall JP. Distinguishing between Zika and
Spondweni viruses. Bull World Health Organ. 2016;94:711–711A.
http://dx.doi.org/10.2471/BLT.16.181503
McIntosh BM, Kokernot RH, Paterson HE, De Meillon B. Isolation
of spondweni virus from four species of culicine mosquitoes and
a report of two laboratory infections with the virus. S Afr Med J.
1961;35:647–50.
Haddow AD, Nasar F, Guzman H, Ponlawat A, Jarman RG,
Tesh RB, et al. Genetic characterization of Spondweni and Zika
viruses and susceptibility of geographically distinct strains of
Aedes aegypti, Aedes albopictus and Culex quinquefasciatus
(Diptera: Culicidae) to Spondweni virus. PLoS Negl Trop Dis.
2016;10:e0005083. http://dx.doi.org/10.1371/journal.pntd.0005083
Lednicky J, Beau De Rochars VM, El Badry M, Loeb J, Telisma T,
Chavannes S, et al. Zika virus outbreak in Haiti in 2014: molecular
and clinical data. PLoS Negl Trop Dis. 2016;10:e0004687.
http://dx.doi.org/10.1371/journal.pntd.0004687
Rueda LM. Pictoral keys for the identification of mosquitoes
(Diptera: Culicidae) associated with dengue virus transmission.
Zootaxa. 2004;589:33–41.
Unit WRB. Mosquito ID: Culex (Cux.) quinquefasciatus [cited 2017
May 1]. http://www.wrbu.org/mqID/mq_medspc/AD/CXqui_hab.html
Smith JL, Fonseca DM. Rapid assays for identification of members
of the Culex (Culex) pipiens complex, their hybrids, and other sibling
species (Diptera: culicidae). Am J Trop Med Hyg. 2004;70:339–45.
Das B, Swain S, Patra A, Das M, Tripathy HK, Mohapatra N,
et al. Development and evaluation of a single-step multiplex PCR
to differentiate the aquatic stages of morphologically similar Aedes
(subgenus: Stegomyia) species. Trop Med Int Health. 2012;17:235–
43. http://dx.doi.org/10.1111/j.1365-3156.2011.02899.x
Wolfe MS, Calisher CH, McGuire K. Spondweni virus infection in
a foreign resident of Upper Volta. Lancet. 1982;2:1306–8.
http://dx.doi.org/10.1016/S0140-6736(82)91511-2
Address for correspondence: Sarah K. White, Brammer Bio, 13859 Progress
Blvd, Alachua, FL 32615, USA; email: sek0005@tigermail.auburn.edu
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1767
RESEARCH LETTERS
Flu con a zole - Re sist a n t
Candida parapsilosis
Bloodst r e a m I sola t e s w it h
Y1 3 2 F M u t a t ion in ERG1 1
Ge n e , Sou t h Kor e a
Yong Jun Choi,1 Yae-Jean Kim,1 Dongeun Yong,
Jung-Hyun Byun, Taek Soo Kim, Yun Sil Chang,
Min Ji Choi, Seung Ah Byeon, Eun Jeong Won,
Soo Hyun Kim, Myung Geun Shin, Jong Hee Shin
Author affiliations: Chonnam National University Medical School,
Gwangju, South Korea (Y.J. Choi, M.J. Choi, S.A. Byeon,
E.J. Won, S.H. Kim, M.G. Shin, J.H. Shin); Samsung Medical
Center, Sungkyunkwan University School of Medicine, Seoul,
South Korea (Y.-J. Kim, Y.S. Chang); Yonsei University College of
Medicine, Seoul (D. Yong, J.-H. Byun); Seoul National University
Hospital, Seoul (T.S. Kim)
DOI: https://doi.org/10.3201/eid2409.180625
We recently observed the emergence of fluconazole-resistant
Candida parapsilosis bloodstream isolates harboring a Y132F
substitution in Erg11p in South Korea. These Y132F isolates
had a higher propensity to cause clonal transmission than other fluconazole-resistant isolates and persisted within hospitals
for several years, as revealed by microsatellite typing.
andida parapsilosis is the second most common species
isolated from patients with Candida bloodstream
infections (BSIs) in Latin America and eastern Asia (1,2).
Although uncommon, fluconazole-resistant C. parapsilosis
isolates harboring the Y132F substitution in Erg11p (referred
to as Y132F isolates) have been reported in Brazil, the
United States, and Kuwait (3–6). The precise reason for the
emergence of C. parapsilosis Y132F isolates has yet to be
defined; it may be related to selective drug pressure, and the
mutation at position 132 may be a hot spot for resistance
mediated by ERG11, a gene encoding the azole target (3).
Alternatively, C. parapsilosis Y132F isolate emergence may
be associated with exogenous clonal transmission (4). We
recently observed the emergence and nosocomial spread
of Y132F isolates in South Korea. In this study, we report
a greater increase in the clonal spread of C. parapsilosis
Y132F BSI isolates than of non-Y132F fluconazole-resistant
isolates within hospitals during the past several years.
We assessed the first 47 C. parapsilosis BSI isolates
that were fluconazole-resistant (MIC ≥8 mg/L) according
to the Clinical and Laboratory Standards Institute (CLSI)
species-specific clinical breakpoint (7,8). All 47 isolates
C
1
These authors contributed equally to this article.
1768
were obtained from multicenter surveillance cultures from
8 university hospitals (A–H) during 2005–2016. For all
fluconazole-resistant isolates, we examined genotypic relationships using microsatellite typing. We defined >2 isolates with identical genotypes according to microsatellite
typing as clonal isolates. We sequenced the ERG11 gene
and 3 transcription factor genes: TAC1, which can lead to
the upregulation of CDR; MRR1, which can lead to the
upregulation of MDR; and UPC2, which can lead to the
upregulation of ERG11 (5); we compared the results with
those of 20 fluconazole-susceptible (MIC 0.5–2 mg/L) isolates. This study was approved by the Institutional Review
Board of Chonnam National University Hospital (IRB
CNUH-2014-290).
Of the 47 C. parapsilosis fluconazole-resistant
isolates, 30 (63.8%) had the Y132F substitution in
Erg11p; however, none of the 20 fluconazole-susceptible isolates had the Y132F mutation in ERG11. Recently, 31%–57% of fluconazole-resistant C. parapsilosis
isolates from different parts of the world were reported
to be Y132F isolates, but the Y132F mutation was absent in all fluconazole-susceptible isolates (3–6). These
data confirm that a Y132F substitution in Erg11p is the
predominant fluconazole resistance mechanism for C.
parapsilosis worldwide.
Microsatellite typing revealed that 4 clonal Y132F
isolates (M1–4) were persistently recovered in 2 hospitals
(A and B) over a period of 3–7 years, and the proportion of clonal isolates was much higher in Y132F isolates
(86.7%, 26/30) than in non-Y132F fluconazole-resistant
isolates (11.8%, 2/17) (Table). In a previous microsatellite
study from a US surveillance study by Grossman et al. (4),
no hospital specificity was detected among 13 non-Y132F
fluconazole-resistant isolates; however, 2 notable clusters
of isolates from 17 Y132F isolates were found over 8or 18-month periods. The results obtained in our study
and those of Grossman et al. indicate that Y132F isolates
may have a higher propensity to cause clonal transmission and persist in particular hospitals than do non-Y132F
fluconazole-resistant isolates. The Y132F substitution in
Erg11p has also been detected in C. auris isolates from
Pakistan (10/16 isolates), India (12/17 isolates), and Venezuela (5/5 isolates); these isolates are strongly associated
with clonal transmission (9). Further studies are needed
to determine whether the Y132F mutation in Erg11p has
a direct effect on clonal transmission of C. parapsilosis or
C. auris isolates.
Two previous studies conducted in the United States
detected the Erg11p Y132F substitution in combination with
the Erg11p R398I substitution in almost all C. parapsilosis
BSI isolates (4,5). In addition, no Y132F isolates
detected in a US surveillance study contained an MRR1
polymorphism, according to MRR1 sequence analysis
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
RESEARCH LETTERS
Table. Molecular characterization of 47 fluconazole-resistant isolates and 20 fluconazole-susceptible isolates of Candida parapsilosis,
South Korea*
MICs, mg/L‡
Amino acid substitutions§
Microsatellite
No.
genotypes†
isolates
Hospital
FLC
VRC
Erg11p
Mrr1p
Tac1p Upc2p Isolation year (no. patients)
Fluconazole-resistant with Y132F in Erg11p, n = 30 isolates
M1
A
8
8–32
0.25–0.5
Y132F K177N
2006 (1), 2009 (1), 2010 (2),
2011 (2), 2012 (1), 2013 (1)
B
3
16–32
0.5
Y132F K177N
2012 (2), 2013 (1)
M2
A
10
8–32
0.125–0.5
Y132F K177N
2012 (1), 2016 (9)
M3
A
3
8–16
0.25
Y132F K177N,
2007 (1), 2011 (1), 2012 (1)
Q1053*
M4
A
2
8–>64
0.5–4
Y132F K177N
2013 (1), 2016 (1)
M5
A
1
32
0.25
Y132F K177N
2012 (1)
M6
A
1
8
0.5
Y132F K177N
2013 (1)
M7
A
1
8
0.25
Y132F K177N
2016 (1)
M8
C
1
64
2
Y132F
2016 (1)
Other fluconazole-resistant, n = 17 isolates
M9
D
2
>64
1
G583R
2007 (1), 2009 (1)
M10
E
1
16
0.5
R398I
L877P
2005 (1)
M11
A
1
8
0.25
2006 (1)
M12
E
1
8
0.25
R398I
L877P
2011 (1)
M13
F
1
16
0.06
R398I
L877P
2011 (1)
M14
E
1
8
0.125
R398I
L877P
2012 (1)
M15
G
1
8
0.125
R398I
L877P
2012 (1)
M16
G
1
8
0.06
R398I
L877P
2012 (1)
M17
E
1
8
0.125
N900D
2012 (1)
M18
C
1
8
0.125
R398I
P250S
L877P
2012 (1)
M19
C
1
8
0.25
R398I S1081P L877P
2012 (1)
M20
D
1
8
0.125
R398I
D394N
2012 (1)
M21
E
1
32
0.5
R398I
P295R
L877P
2015 (1)
M22
E
1
16
0.125
R398I
2015 (1)
M23
H
1
32
0.125
K128N W872C
2015 (1)
M24
E
1
16
0.25
G927D
2016 (1)
Fluconazole-susceptible controls
M3
A
1
1
0.03
K177N,
2010 (1)
Q1053*
M25
C
2
0.5
0.03
R398I
2012 (2)
M26
F
2
0.5
0.03–0.06
R208G
2012 (1), 2013 (1)
M27
A
1
2
0.06
2010 (1)
M28
A
1
0.5
0.03
K177N,
2011 (1)
Q1053*
M29
A
1
1
0.06
L877P
2011 (1)
M30
A
1
1
0.03
R208G
2012 (1)
M31
A
1
0.5
0.03
R208G
2012 (1)
M32
E
1
2
0.03
2012 (1)
M33
G
1
0.5
0.03
R208G
2012 (1)
M34
G
1
0.5
0.03
2012 (1)
M35
A
1
0.5
0.03
R208G
2013 (1)
M36
A
1
1
0.06
R398I
D394N
2013 (1)
M37
A
1
0.5
0.03
R398I
2013 (1)
M38
D
1
0.5
0.06
R398I
2014 (1)
M39
D
1
0.5
0.06
R208G
2014 (1)
M40
E
1
0.5
0.03
R208G
2015 (1)
M41
A
1
1
0.03
R398I
L877P
2015 (1)
*CLSI, Clinical and Laboratory Standards Institute; FLC, fluconazole; VRC, voriconazole.
†For microsatellite typing, each strain was characterized by a genotype resulting from combination of the sizes of the 4 markers (CP1, CP4, CP6, and B).
See the Technical Appendix Figure (https://wwwnc.cdc.gov/EID/article/24/9/18-0625-Techapp.pdf) for results of microsatellite genotyping presented as an
UPGMA tree.
‡Antifungal MICs were determined by the CLSI M27–A3 broth microdilution method (7). The fluconazole MICs of 30 Y132F isolates determined by Etest
were ≥8 mg/L. All 67 isolates tested were susceptible to amphotericin B (MIC 0.25–1 mg/L) and micafungin (MIC 0.25–2 mg/L) according to the CLSI
method.
§All were homozygote alleles except for 6 heterozygote alleles (Q1053,* G583R, P250S, P295R, W872C, and G927D) in Mrr1p.
results (4). However, a single Y132F substitution in Erg11p
was found in all 30 fluconazole-resistant isolates from
South Korea hospitals. The same K177N substitution in
Mrr1p was found in all Y132F isolates except 1; none of
the Y132F isolates showed missense mutations in Tac1p or
Upc2p (Table). Taken together, these findings demonstrate
low genetic diversity among Y132F isolates from the same
country (the United States or South Korea).
In our study, 76.7% (23/30) of patients with Y132F
isolates had no antifungal exposure within 30 days before
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1769
RESEARCH LETTERS
candidemia detection, and their clonal transmission
was not detected by routine hospital surveillance, partly
because more than half of the patient hospitalizations did
not overlap. These findings indicate that clonal Y132F isolates may be dormant over long periods and can survive
and persist outside their host on hospital environmental
surfaces, which may be similar to the behavior of C. auris
(10). Although our study was limited by the relatively low
number of isolates, our data suggest that C. parapsilosis
Y132F isolates should be identified in clinical microbiology laboratories to prevent further clonal transmission of
BSI caused by Y132F isolates.
9.
Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J,
Chowdhary A, Govender NP, et al. Simultaneous emergence of
multidrug-resistant Candida auris on 3 continents confirmed by
whole-genome sequencing and epidemiological analyses. Clin
Infect Dis. 2017;64:134–40. http://dx.doi.org/10.1093/cid/ciw691
10. Welsh RM, Bentz ML, Shams A, Houston H, Lyons A, Rose LJ,
et al. Survival, persistence, and isolation of the emerging
multidrug-resistant pathogenic yeast Candida auris on a plastic
health care surface. J Clin Microbiol. 2017;55:2996–3005.
http://dx.doi.org/10.1128/JCM.00921-17
Address for correspondence: Jong Hee Shin, Chonnam National
University Medical School, Department of Laboratory Medicine,
42 Jebong-ro, Dong-gu, Gwangju 61469, South Korea; email:
shinjh@chonnam.ac.kr
This research was supported by the Basic Science Research
Program through the National Research Foundation
of Korea funded by the Ministry of Education
(NRF-2016R1A2B4008181).
About the Author
Dr. Y.J. Choi is a clinical pathologist at Chonnam National
University Hospital, Gwangju, South Korea. His current research
interest is molecular epidemiology of fungal infections.
Reference
1.
2.
3.
4.
5.
6.
7.
8.
1770
Pfaller MA, Jones RN, Doern GV, Sader HS, Messer SA,
Houston A, et al.; The SENTRY Participant Group. Bloodstream
infections due to Candida species: SENTRY antimicrobial
surveillance program in North America and Latin America,
1997–1998. Antimicrob Agents Chemother. 2000;44:747–51.
http://dx.doi.org/10.1128/AAC.44.3.747-751.2000
Sandven P. Epidemiology of candidemia. Rev Iberoam Micol.
2000;17:73–81.
Souza AC, Fuchs BB, Pinhati HM, Siqueira RA, Hagen F,
Meis JF, et al. Candida parapsilosis resistance to fluconazole:
molecular mechanisms and in vivo impact in infected Galleria
mellonella larvae. Antimicrob Agents Chemother. 2015;59:6581–7.
http://dx.doi.org/10.1128/AAC.01177-15
Grossman NT, Pham CD, Cleveland AA, Lockhart SR.
Molecular mechanisms of fluconazole resistance in Candida
parapsilosis isolates from a U.S. surveillance system. Antimicrob
Agents Chemother. 2015;59:1030–7. http://dx.doi.org/10.1128/
AAC.04613-14
Berkow EL, Manigaba K, Parker JE, Barker KS, Kelly SL,
Rogers PD. Multidrug transporters and alterations in sterol
biosynthesis contribute to azole antifungal resistance in Candida
parapsilosis. Antimicrob Agents Chemother. 2015;59:5942–50.
http://dx.doi.org/10.1128/AAC.01358-15
Asadzadeh M, Ahmad S, Al-Sweih N, Khan Z. Epidemiology
and molecular basis of resistance to fluconazole among
clinical Candida parapsilosis isolates in Kuwait. Microb
Drug Resist. 2017;23:966–72. http://dx.doi.org/10.1089/
mdr.2016.0336
Clinical and Laboratory Standards Institute. Reference method
for broth dilution antifungal susceptibility testing of yeasts—
third edition: approved standard (M27–A3). Wayne (PA): The
Institute; 2008.
Clinical and Laboratory Standards Institute. Reference method
for broth dilution antifungal susceptibility testing of yeasts:
fourth informational supplement (M27–S4). Wayne (PA): The
Institute; 2012.
Borrelia miyamotoi D ise a se
in a n I m m u n ocom pe t e n t
Pa t ie n t , W e st e r n Eu r ope
Dieuwertje Hoornstra,1 Joris Koetsveld,1
Hein Sprong, Alexander E. Platonov,
Joppe W. Hovius
Author affiliations: Academic Medical Center, Amsterdam, the
Netherlands (D. Hoornstra, J. Koetsveld, J.W. Hovius); National
Institute for Public Health and the Environment, Bilthoven,
the Netherlands (H. Sprong); Central Research Institute of
Epidemiology, Moscow, Russia (A.E. Platonov)
DOI: https://doi.org/10.3201/eid2409.180806
Borrelia miyamotoi disease is a hard tick–borne relapsing
fever illness that occurs across the temperate climate zone.
Human B. miyamotoi disease in immunocompetent patients
has been described in Russia, North America, and Japan.
We describe a case of B. miyamotoi disease in an immunocompetent patient in western Europe.
A
72-year-old woman in the Netherlands sought
treatment in her third day of fever (<38.6°C) and
reported myalgia, arthralgia, headache, and a 2.5-kg weight
loss. Three weeks earlier she had noticed a tick bite after
gardening. Several days later, an erythematous lesion
appeared, increasing to palm size within 1.5 weeks and
dissolving in a similar period. Full medical history was not
1
These authors contributed equally to this article.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
RESEARCH LETTERS
suggestive of other causes of fever. Her previous medical
history included cervical carcinoma and breast cancer,
curatively treated.
Physical examination showed a moderately ill patient with a temperature of 36.7°C, heart rate of 59 bpm,
blood pressure of 100/72 mmHg, an erythematous skin
lesion (1.5 cm in diameter) on the thigh, and mild generalized lymphadenopathy. Initial laboratory tests revealed
increased C-reactive protein (22.7 mg/L), leukopenia (2.1
× 109 cells/L), elevated monocytes (11%), and thrombocytopenia (144 × 109 platelets/L) (reference ranges in online
Technical Appendix Table 1, https://wwwnc.cdc.gov/EID/
article/24/9/18-0806-Techapp1.pdf). All other test results,
including urinalysis, were unremarkable. Molecular tests
of blood and skin biopsy and serologic testing for Borrelia
burgdorferi sensu lato and syphilis were repeatedly negative, except for a C6 EIA IgM/IgG seroconversion (Immunetics, Boston, MA, USA) in convalescent-phase serum
samples that was positive but could not be confirmed by either IgM or IgG immunoblot (Mikrogen, Neuried, Germany) (online Technical Appendix Table 2). We did not admit
the patient to the hospital, and we did not initiate antimicrobial drug treatment because her symptoms had largely
resolved. At a 2-month follow-up visit, the patient had fully
recovered, and laboratory test results were normal.
On the basis of the patient’s description, we suspect that
she was bitten by an Ixodes ricinus tick, the most prevalent
tick species in western Europe (1), which can potentially
carry several tickborne pathogens: Borrelia burgdorferi
s.l., B. miyamotoi, Rickettsia helvetica and R. monacensis,
Anaplasma phagocytophilum, Babesia divergens and B.
microti, Neoehrlichia mikurencis, and tick-borne encephalitis virus (2). Specific molecular and serologic diagnostic
tests for all of these pathogens were negative, expect for
1 (false-positive) tick-borne encephalitis virus IgM ELISA
result in convalescent-phase serum samples (online Technical Appendix Table 2).
B. miyamotoi, a relapsing fever Borrelia species
uniquely found in Ixodes spp. ticks in Eurasia and North
America, is the causative agent of Borrelia miyamotoi disease (BMD), a tickborne febrile disease (3,4). Diagnosis of
BMD relies on detection of spirochetes by quantitative PCR
of blood and experimental serology based on glycerophosphodiester phosphodieasterase (GlpQ) antigen detection
(3,5). GlpQ is present in relapsing fever Borrelia but not in
B. burgdorferi s.l. and therefore can discriminate between
the 2 types (4). In a well-described cohort of PCR-positive
patients in Russia, characteristic clinical symptoms were
fever, myalgia, nausea, and headaches; laboratory findings
showed thrombocytopenia and diffuse organ damage (3).
In this patient, results of pan–relapsing fever Borrelia
PCR and B. miyamotoi–specific PCR (6) of blood drawn at
the day of clinical visit were negative. However, the fever
and symptoms had subsided, which probably impeded these
direct diagnostic tests. We tested for anti-GlpQ and anti–
variable major proteins (Vmps) IgM and IgG using ELISA
Figure. Results of GlpQ
and variable major proteins
(Vmps) IgM and IgG ELISA
and confirmatory Western blot
tests in testing of a 72-year-old
woman in the Netherlands who
showed evidence of Borrelia
miyamotoi disease.
A) Anti-GlpQ and anti–Vmps
IgM ELISA results representative
of 3 individual ELISAs.
B) Confirmatory IgM Western
blot results of samples taken
at 3 different time points with
recombinant proteins.
C) Anti-GlpQ and anti–Vmps
IgG ELISA results representative
of 3 individual ELISAs.
D) Confirmatory IgG Western
blot results of samples taken
at 3 different time points
with recombinant proteins.
GlpQ, glycerophosphodiester
phosphodieasterase; Vlp,
variable large protein; Vsp,
variable small protein.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1771
RESEARCH LETTERS
and Western blot in serum samples taken on the day of the
hospital visit (3 days after disease onset), after 5 weeks (38
days), and after 3 months (88 days). Results demonstrated
a clear seroconversion for predominantly IgG against GlpQ
(Figure). We had previously shown that Vmps are highly
immunogenic in patients with BMD (7) and that the presence
of antibodies against GlpQ combined with antibodies against
Vmps had 100% specificity for IgM and 98.3% for IgG
(8). In this case, we could demonstrate antibodies against
multiple Vmps over time (Figure). Finally, our findings were
further confirmed by preferential IgM and IgG reactivity to
lysates of the B. miyamotoi strain HT31 (tick isolate, Japan)
and Izh-16 (clinical isolate, Russia) compared with reactivity
to the B. afzelii strain PKo (skin isolate, Germany) and B.
hermsii HS-1 (tick isolate, United States) control lysates
(online Technical Appendix Figure).
These findings, combined with the established presence
of B. miyamotoi in I. ricinus ticks throughout Europe,
clinical presentation, and laboratory findings, strongly
suggest that B. miyamotoi was the causative agent of the
patient’s symptoms. That the patient recovered even without
antimicrobial treatment is consistent with a recent BMD
case described in the United States (9). Because of the initial
skin rash, we did not completely rule out B. burgdorferi s.l.
co-infection; however, prior evaluation by an independent
dermatologist, a negative B. burgdorferi s.l. immunoblot
despite high C6 reactivity, and a negative PCR on DNA
obtained from the skin biopsy argue against co-infection.
Regardless, the clinical picture of fever and mild leukopenia
and thrombocytopenia is compatible with BMD and not with
Lyme borreliosis. Of interest, C6 reactivity in combination
with a negative B. burgdorferi s.l. immunoblot has been
described in BMD patients in the United States (10).
This case identifies B. miyamotoi as an emerging
tickborne pathogen in western Europe. Because of the
widespread presence of multiple other tickborne pathogens
across Europe, more attention and awareness for other
tickborne diseases is warranted.
Acknowledgments
We thank Barbara Johnson and Volker Fingerle for providing
B. miyamotoi strain HT31. Furthermore, we thank Alex
Wagemakers, Tal Azagi, and Bob de Wever for their
contributions to the manuscript.
This study was supported by ZonMW as part of the project
“Ticking on Pandora’s Box, a study into tickborne pathogens in
Europe” (project no. 50-52200-98-313) to D.H. and J.W.H.
The contribution of A.E.P. was supported by a grant of the
Russian Science Foundation (project 15-15-00072).
1772
About the Authors
Dr. Hoornstra and Dr. Koetsveld are PhD students at the
University of Amsterdam at the Department of Infectious
Diseases in Professor Joppe W. Hovius’s laboratory. They focus
on tickborne pathogens, and their work has been key in research
on B. miyamotoi disease.
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
Steere AC, Strle F, Wormser GP, Hu LT, Branda JA, Hovius JW,
et al. Lyme borreliosis. Nat Rev Dis Primers. 2016;2:16090.
http://dx.doi.org/10.1038/nrdp.2016.90.
Michelet L, Delannoy S, Devillers E, Umhang G, Aspan A,
Juremalm M, et al. High-throughput screening of tick-borne
pathogens in Europe. Front Cell Infect Microbiol. 2014;4:103.
http://dx.doi.org/10.3389/fcimb.2014.00103
Platonov AE, Karan LS, Kolyasnikova NM, Makhneva NA,
Toporkova MG, Maleev VV, et al. Humans infected with
relapsing fever spirochete Borrelia miyamotoi, Russia. Emerg
Infect Dis. 2011;17:1816–23. 10.3201/eid1710.101474
http://dx.doi.org/10.3201/eid1710.101474
Molloy PJ, Telford SR III, Chowdri HR, Lepore TJ, Gugliotta JL,
Weeks KE, et al. Borrelia miyamotoi disease in the northeastern
United States: a case series. Ann Intern Med. 2015;163:91–8.
http://dx.doi.org/10.7326/M15-0333
Krause PJ, Narasimhan S, Wormser GP, Rollend L, Fikrig E,
Lepore T, et al. Human Borrelia miyamotoi infection in the United
States. N Engl J Med. 2013;368:291–3. http://dx.doi.org/10.1056/
NEJMc1215469
Hovius JW, de Wever B, Sohne M, Brouwer MC, Coumou J,
Wagemakers A, et al. A case of meningoencephalitis by the
relapsing fever spirochaete Borrelia miyamotoi in Europe.
Lancet. 2013;382:658. http://dx.doi.org/10.1016/
S0140-6736(13)61644-X
Wagemakers A, Koetsveld J, Narasimhan S, Wickel M, Deponte K,
Bleijlevens B, et al. Variable major proteins as targets for specific
antibodies against Borrelia miyamotoi. J Immunol. 2016;196:
4185–95. https://dx.doi.org/10.4049/jimmunol.1600014
Koetsveld J, Kolyasnikova NM, Wagemakers A, Stukolova OA,
Hoornstra D, Sarksyan DS, et al. Serodiagnosis of Borrelia
miyamotoi disease by measuring antibodies against GlpQ
and variable major proteins. Clin Microbiol Infect. 2018;
S1198-743X(18)30215-5.
Sudhindra P, Wang G, Schriefer ME, McKenna D, Zhuge J,
Krause PJ, et al. Insights into Borrelia miyamotoi infection from
an untreated case demonstrating relapsing fever, monocytosis
and a positive C6 Lyme serology. Diagn Microbiol Infect Dis.
2016;86:93–6. http://dx.doi.org/10.1016/j.diagmicrobio.
2016.06.015
Molloy PJ, Weeks KE, Todd B, Wormser GP. Seroreactivity to the
C6 peptide in Borrelia miyamotoi infections occurring in the
northeastern United States. Clin Infect Dis. 2018;66:1407–10
http://dx/doi.org/10.1093/cid/cix1023. http://dx.doi.org/10.1093/
cid/cix1023
Address for correspondence: Dieuwertie Hoornstra, Academic
Medical Center, Center for Experimental and Molecular Medicine,
Meibergdreef 9 Amsterdam 1105 AZ, the Netherlands; email:
d.hoornstra@amc.uva.nl
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
LETTER
Se r opr e va le n ce of
Ch ik u n gu n ya Vir u s a ft e r
I t s Em e r ge n ce in Br a zil
Patrick Gérardin,1 André Ricardo Ribas Freitas,1
Daouda Sissoko1
Author affiliations: Centre Hospitalier Universitaire Réunion,
Saint Pierre, France (P. Gérardin); Unité Mixte 134 Processus
Infectieux en Milieu Insulare Tropical, Sainte Clotilde, France
(P. Gérardin); São Leopoldo Mandic School of Medicine,
Campinas, Brazil (A.R.R. Freitas); Biomerieux Africa Cluster,
Abidjan, Côte d’Ivoire (D. Sissoko)
DOI: https://doi.org/10.3201/eid2409.180724
To the Editor: In their well-designed and timely serosurvey, Dias et al. provide evidence of high prevalence
of East/Central/South African (ECSA) genotype chikungunya virus (CHIKV) (seropositivity rate 51.0%) in population subsets of 2 urban communities in Bahia state, Brazil
(1). The authors found a high proportion of asymptomatic
CHIKV patients (63.2%; 268/424). In addition, the prevalence of chronic arthralgia among infected persons (26.4%;
112/424) was lower or within the expected range of previously reemerging clades of CHIKV, namely ECSA diverged
(Indian Ocean lineage) or Asian lineage, respectively. However, a high proportion of the symptomatic participants in
Dias et al. reported chronic symptoms lasting >3 months
(71.8%; 112/156). We comment on these findings.
First, Dias et al. report that the selected locations were
at the epicenter of the transmission area and, therefore, the
data cannot be extrapolated to other cities. To better understand the dynamics of the disease, it would be useful to
select locations more representative of other infected areas.
Second, the modest participation at the study locations
(66.5%; 831/1250) could be related to using the more painful venipuncture method instead of a fingerstick to draw
blood. In comparison, the participation rate was ≈80% in
1
All authors contributed equally to this article.
a Réunion Island serosurvey for CHIKV for which the fingerstick method was used (2). The participation level suggests the possibility of self-selection bias toward infected
patients, who might be more interested in knowing their
serologic status. Self-selection bias might explain the high
proportion of symptomatic patients who self-reported having a chronic form of chikungunya.
Last, because of their unreliable discriminatory performance, using fever and arthralgia to identify symptomatic patients might have increased the proportion of
patients misclassified as asymptomatic (i.e., patients with
symptoms other than fever and arthralgia being falsely
classified as negative) (3). These limitations being specified, the prevalence of chronic arthralgia among symptomatic patients in Dias et al. falls within the expected
range of the Asian lineage of CHIKV, the other clade
circulating in the Americas (4,5), which confers external
validity to the study.
References
1.
2.
3.
4.
5.
Dias JP, Costa MDCN, Campos GS, Paixão ES, Natividade MS,
Barreto FR, et al. Seroprevalence of chikungunya virus after its
emergence in Brazil. Emerg Infect Dis. 2018;24:617–24.
http://dx.doi.org/10.3201/eid2404.171370
Gérardin P, Guernier V, Perrau J, Fianu A, Le Roux K, Grivard P,
et al. Estimating Chikungunya prevalence in La Réunion Island
outbreak by serosurveys: two methods for two critical times
of the epidemic. BMC Infect Dis. 2008;8:99. http://dx.doi.org/
10.1186/1471-2334-8-99
Sissoko D, Ezzedine K, Moendandzé A, Giry C, Renault P,
Malvy D. Field evaluation of clinical features during
chikungunya outbreak in Mayotte, 2005–2006. Trop Med Int
Health. 2010;15:600–7.
Chang AY, Encinales L, Porras A, Pacheco N, Reid SP,
Martins KAO, et al. Frequency of chronic joint pain following
chikungunya virus infection: a Colombian cohort study. Arthritis
Rheumatol. 2018;70:578–84. http://dx.doi.org/10.1002/art.40384
Paixao ES, Rodrigues LC, Costa MCN, Itaparica M, Barreto F,
Gérardin P, et al. Chikungunya chronic disease: a systematic review
and meta-analysis. Trans R Soc Trop Med Hyg. 2018. Jul 11.
Address for correspondence: Patrick Gérardin, INSERM CIC 1410
Clinical Epidemiology, Centre Hospitalier Universitaire, Groupe
Hospitalier Sud Réunion, BP 350, 97448 Saint Pierre CEDEX, Reunion,
France; email: patrick.gerardin@chu-reunion.fr
Cor r e ct ion : Vol. 2 4 , N o. 8
The author list was incorrect in Death from TransfusionTransmitted Anaplasmosis, New York, USA, 2017 (R. Goel et al.),
and a name was missing from the acknowledgments. Melissa M.
Cushing should have been listed as senior author. Ljljana V. Vasovic
provided assistance with the article. The article has been corrected
online (https://wwwnc.cdc.gov/eid/article/24/8/17-2048_article).
Cor r e ct ion : Vol. 2 4 , N o. 9
Several corrections to the text were needed in Phenotypic
and Genotypic Characterization of Enterobacteriaceae
Producing Oxacillinase-48–Like Carbapenemases,
United States (J.D. Lutgring et al.). The article has been
corrected online (https://wwwnc.cdc.gov/eid/article/24/4/
17-1377_article).
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1773
AN OTH ER D I M EN SI ON
Em e r gin g I n fe ct iou s Lit e r a t u r e s a n d t h e Zom bie Con dit ion
Joanna Verran,1 Xavier Aldana Reyes1
The book club format has enabled expert and nonexpert
exploration of infection and epidemiology as encountered
in popular literature. This exploration reveals that fiction
focusing on apocalyptic disease often uses the zombie as
embodiment of infection, as well as an exemplar of current
knowledge on emerging disease.
Author affiliation: Manchester Metropolitan University,
Manchester, UK
discussions, particularly for books that they have suggested.
The meeting leader prepares questions before the meeting
to guide discussion and publishes them online on the book
club’s website after the meeting, but usually conversation
does not require prompting. Meeting reports are also posted
online, enabling themes to be identified across books and
genres, as well as establishing a rich, freely accessible
resource that has informed much of the content of this
article.
Our findings, based on the reports accessible from the
book club’s website, show that fiction content in epidemiologic narratives is often influenced by epidemiologic outbreaks—authors absorbing and recasting what have been
called “outbreak narratives” (8) within plotlines—as well as
by the pervading rhetoric of fear that surrounds pandemics
in the media (9). We found that the representation of vampires and, particularly, zombies as agents of infection was
frequent; these monsters appeared often as epidemiologic
avatars (10–12). This article therefore examines the role
of the zombie as a metaphor for infectious disease and the
emergence of new literature describing apocalyptic disease
as examples of the ways in which fiction can lead to a widespread discussion and understanding of pandemics. We use
examples from books discussed in our book club meetings.
The Zombie Research Society defines a zombie as “a
relentlessly aggressive human or reanimated human corpse
driven by a biologic infection” (http://zombieresearchsociety.com/about-us). This description neatly summarizes the
current state of zombies, both narratively (in the stories told
about them) and in terms of how they might become useful in our understanding of pandemics, contagion patterns,
and prevention. One aim of the book club is to redress the
balance between fear of infection and the importance of
a working knowledge of microbiology, but zombies also
provide a useful means for examining concerns about
fast-spreading diseases in the first world, the “shock doctrine” used in the reporting of pandemics (13), emerging
disease, and, more recently, the impact of antimicrobial
resistance. Indeed, Bishop (14) proposes that “post-9/11
anxieties about potential terrorist attacks via anthrax, avian
influenza, swine flu, and other forms of biologic warfare”
may be responsible for this emergence and suggests that
apocalyptic contagion narratives might outlive interest in
the zombie.
DOI: https://doi.org/10.3201/eid2409.170658
1
T
he Bad Bugs Book Club (https://www2.mmu.ac.uk/
engage/what-we-do/bad-bugs-bookclub/) was established in 2009 (1). This reading group meets every 2 months
to discuss works of literary fiction from any genre that features infectious disease. The aim of these meetings is to
engage scientists and nonscientists in discussions about
epidemiology and infection and to consider what the texts
tell us about our perception of science and its advances.
Book clubs, or reading groups, have increased in
popularity since the late 1990s. Estimates in 2003 were of
≈50,000 book clubs in Britain and ≈500,000 in the United
States (2). Some clubs are specialized groups whose members read restricted genres such as crime fiction, science
fiction, or the classics. Fiction and nonfiction texts focusing
on microbiology have been incorporated into the book club
format, led primarily by academics for student education
(3–5), but no evidence has been found in the literature for
such groups for the general public.
Adults have been identified as 1 of 3 key underserved
audiences in terms of engagement with science (6). The
reading group format addresses this need and contrasts
with unidirectional science communication activities from
scientists (experts) to members of the public (nonexperts)
(7) in that reading groups provide an opportunity for adults
to contribute their knowledge, experience, and perceptions
about the reading subject matter on a level platform.
Bad Bugs Book Club meetings take place in an
informal environment (a bar) in the evening, typically
comprising up to 8 participants, of whom around half have
been members since 2009. New members are welcome;
meetings are advertised online, as well as through an email
group. At each meeting one book is discussed, selected by
the group at the previous meeting. Discussions tend to be
led by the group leader (J.V.), but all members can lead
1774
The authors contributed equally to this article.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Emerging Infectious Literatures
The Zombie as Allegory of Infectious
Disease Epidemiology
In fiction focusing on infectious disease, the invisible
pathogen is an embodiment of the unknown, existing in
intimate contact with us, yet beyond the boundaries of our
senses. The infection is carried by its host and transmitted to another; its effects become apparent as symptoms
develop. The pathogen as a microscopic Gothic presence
can be represented metaphorically and macroscopically in
the figure of the zombie, much as the ghost, the undead (the
vampire), and the “weird creature” have traditionally acted
as springboards for the exploration of the beyond and the
numinous (15–17). In the zombie, internal damage to the
host becomes externalized, and contagion patterns among
populations are demonstrated as the zombie hordes rampage. With no subclinical manifestation, the zombie makes
the apocalypse visible, enabling us to physically map the
spread of infection. In other words, the zombie becomes an
“allegory of infectious disease” and a “metaphor of ubiquitous contagion” (18). In their hordelike structure, zombies
also operate metonymically, standing in for large swaths of
the population (the infected), or viruses (the infection). The
mathematics of zombie outbreaks has therefore also been
explored as an education tool to represent contagion patterns and containment strategies (19,20).
In 1996, the influential horror survival video game
Resident Evil was developed by Capcom (Capcom USA,
San Francisco, CA, USA); this release was the first zombie game to rely on infection as the catalyst for the zombie
state. Since then, and particularly after 2002, when a spate
of infection-zombie texts emerged (such as the Resident
Evil movie series [2002 onward; directed by Paul W.S. Anderson], 28 Days Later [directed by Danny Boyle, 2002],
and The Walking Dead comic series [2003–present] [21]),
infection has tended to become the primary cause of the
zombie condition itself. A blurring of the lines between
the traditional zombie and the rabid human has shortened
the distance between fantasy and reality (22). The zombie
dominates the horror fiction landscape because it has adapted well to the real-life scenario of pandemic outbreaks as
represented by and in the media. Like microorganisms
themselves, zombies respond well to selection pressures.
Other parallels between the infection process and the
infectious zombie text are apparent. In 2007’s 28 Weeks
Later (directed by Juan Carlos Fresnadillo), a woman and
son appear to be immune to infection but carry the Rage
virus to susceptible populations. The novel I Am Legend
(10) describes the scientific methods applied to isolate the
cause of the undead plague, but ultimately it is the evolution of the agent of zombie infection that enables the survival of the host and the pathogen in the novel (although
the monsters are infected with the “vampiris bacillus,” their
behavior by night is zombie-like). Likewise, in The Girl
with All the Gifts (23), airborne fungal spores ultimately
bring about the extinction of the human race: the new world
is populated by partially immune, but infected, children.
Killing the host limits spread of infection and survival of
the pathogen. In these novels, symbiosis is advantageous to
both partners in the host–parasite relationship.
Tolerance of infection leads to recovery in the novel
Warm Bodies (24); the immune response is stimulated
when the host begins to interact socially with humans.
Breathers: A Zombie’s Lament (25) is narrated by a zombie
who regains his self-confidence through attendance at “Undead Anonymous” meetings and becomes a champion for
zombie rights (with a taste for human flesh). In comparable
texts in other media, such as the television series In the
Flesh (written and produced by Dominic Mitchell, 2013–
2014) and iZombie (directed by Rob Thomas, 2016–present), zombies are also likable main characters who suffer at
the hands of a society that does not understand them. This
cross-media development suggests that the zombie condition is evolving heterogeneously, sometimes (especially
in melodrama and romance fiction) moving away from
the image of the monstrous apocalyptic vector and into a
more individually focused host–parasite relationship. The
sentient zombie of Breathers or Warm Bodies can cohabit
the same cultural space as the more traditional aggressors
of Seth Grahame-Smith’s book Pride and Prejudice and
Zombies (26) and Darren Shan’s Zom-B (27) series, and
even zombie-like creatures, such as the rabid attackers of
David Moody’s Hater (28). What unites all these zombies
is a similar approach to the cause of their ontological status,
namely, infection as the point of origin.
In contemporary zombie fiction, 3 different contagion
outcomes predominate that parallel the pathogenesis of
infection: success of the predator, mutualism, or a defeat
of the predator. Our innate knowledge of real disease epidemiology is thus illustrated in much zombie literature by
the behavior of the humans who are under threat. In the
absence of any treatment strategy, options are restricted to
quarantine (isolation of the infected, as in Cherie Priest’s
Boneshaker [29]), immunization strategies (protection of
the uninfected in Warm Bodies, Charlie Higson’s The Enemy [30], and Jonathan Maberry’s Rot and Ruin [31]), and
control (extermination of the agent in Max Brooks’ World
War Z [32]). As zombies become the manifestation of virulent infection, they do not just address our fear of pandemic
disease and apocalypse; they also allow us to explore coping strategies.
Pathogens Influencing Zombie Epidemiology
Viruses are the perfect mechanistic microbiological comparison for the zombie, whose sole function is essentially
to replicate/transmit the infection. Although some bacterial infections have had an impact on a global scale, viral
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1775
ANOTHER DIMENSION
pandemics are a greater threat: viruses replicate inefficiently, frequently creating different versions of themselves
against which we have reduced or no immunological defense (33). The attributes of airborne transmission, high
infection rate, and high virulence are the worst possible
outcome for humanity because airborne transmission is
extremely difficult to control or prevent, a high infection
rate ensures high numbers of cases, and high virulence results in high rates of illness and death (as depicted in the
2011 infectious disease–themed movie Contagion, directed
by Steven Soderbergh). In addition, the incubation period
needs to be sufficiently long to enable others to become
infected. These patterns have been followed in popular
fictional narratives. For example, Ebola virus disease has
varying infectivity and virulence: in the 1976 Zaire and Sudan outbreaks, infectivity was relatively low (contact with
infected fluids was the route of infection), but fatality rates
were high, approaching 90%, whereas in the 2014 outbreak, the fatality rate was 50% (34). Ebola epidemiology
enabled dramatic scenarios in the book The Hot Zone (35)
and the movie Outbreak (directed by Wolfgang Petersen,
1995). The zombie apocalypse draws from such scenarios,
yet simultaneously eclipses them all in its scale.
The epidemiology of viral infection we have described
may not always be directly applicable to the spread of the
zombie condition (e.g., airborne infection happens only
when the zombie origin is fungal), but noteworthy patterns
do emerge. The novel World War Z (as opposed to the 2013
movie of the same name, directed by Marc Forster, which
bears little resemblance to the novel) is a good example of
how zombie fiction uses real epidemiologic scares to shape
the ultimate viral zombie horror narrative. In microbiological terms, the book describes the emergence and spread of
a pandemic whose infection and mortality rates are 100%,
with an incubation period of a few days, whose symptoms
make those infected extremely dangerous to society, and
for which there is no treatment. Inactivation of infected
persons by destruction of the brain becomes the only solution and prevention strategy. The infection is not airborne;
rather, it is transmitted by biting or entry of infected tissue through injured skin and via transplants. Still, its other
traits correlate with those of several true infectious agents,
such as rabies virus, Creutzfeldt-Jakob prion disease, cytomegalovirus, herpes virus, and HIV (33). The zombie incubation period in the novel is also extended (“slow burns”)
if a major blood vessel is missed during biting. This particular aspect of the virus is itself borrowed from rabies, in
which a longer incubation period results from a bite to the
leg rather than a bite to the neck. As with many influenza
pandemics and severe acute respiratory syndrome, World
War Z’s pandemic begins in China. In this novel, there are
other localized outbreaks, but the pandemic develops via
misinformation and obfuscation—as occurred with the
1776
spread of severe acute respiratory syndrome from China.
Politics plays a major part in the spread of the pandemic.
The zombie, an insentient creature with a tendency to
swarm, has been used in several disciplines in recent years
to shed light on the dynamics of economics, capitalism, and
international politics and to channel fears connected to social alienation, especially as a result of digital and communication technologies and overpopulation (22,36–38). In
contrast to the intellectual and allegorical use of the zombie
in such disciplines, articles describing the epidemiologic
properties and preventive measures in the event of a “zombie outbreak” have been presented in the scientific literature in a more ironic tone, nevertheless taking cues from
emerging public interest in zombies. For example, BMJ has
provided information on epidemiology, treatment, and prevention (39). However, the use of zombie epidemiology as
an education tool requires careful planning; for instance,
the CDC’s section on “zombie preparedness” (http://www.
cdc.gov/phpr/zombies.htm) has been accused of “trivialization” of the preparedness topic (40).
At least 1 of the popular reimaginings of the late postmillennial zombie proposes that zombified humans may
have a “new strain of prion disease.” In the novel Zombie Autopsies: Secret Notes from the Apocalypse (41), the
private notes of a neurodevelopmental biologist written
in a remote laboratory setting “where the world community could focus its efforts on the scientific study of ANSD
[Ataxic Neurodegenerative Satiety Deficiency Syndrome]”
describe the dissections of 3 zombie subjects before the
author succumbs to the disease himself. This narrative is
framed as the main section of a highly confidential memorandum from the United Nations outpost. Two working hypotheses on the nature of the pandemic are proposed. The
first is that ANSD may be caused by an airborne engineered
plague, a symbiosis that would result in 3 contagions operating through a single vector, specifically a combination of
influenza and prion and a third unknown infectious agent.
The second option is that humans may be faced “with
something new… with distinct and adaptive properties.
Something that hijacks the host.”
Two different fictional worlds, in Charlie Higson’s The
Enemy series (2009–2015) (30) and The Girl with All the
Gifts (23), adopt and modify the “zombie fungus” Ophiocordyceps unilateralis as the apocalyptic zombie agent. In
both cases, airborne fungal spores provide an inescapable
source of infection, with the sporulation cycle being critical
to the plot. Mira Grant’s novel Feed (42) is the first volume in a series following life in a postapocalyptic America
where a third of the population has succumbed to the KellisAmberlee virus; zombies are a result of an ecoterrorism act
that “released a half-tested ‘cure for the common cold’ into
the atmosphere.” The novel’s dormant pathogen is based
on Toxoplasma gondii, a pathogen that would not wipe out
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Emerging Infectious Literatures
the entire susceptible population. In all these new novels,
the aim is to provide a microbiologically accurate backdrop
and story in which the population either succumbs to infection or learns to cope with a pathogen—for example, in
Feed, through out-of-bounds contamination areas, complex
decontamination routines, and constant screening.
Books like Zombie Autopsies shows how new infectious zombie texts act as virological repositories. The opposite is also true; since I Am Legend, several publications
have attempted to use the symptoms of zombieism to explain the workings of specific pathogens and scientific principles. Many examples exist; a particularly notable one is
Do Zombies Dream of Undead Sheep? A Neuroscientific
View of the Zombie Brain (43), largely an introduction to
neurology, in which consciousness deficit hypoactivity
disorder (CDHD) is deemed to be the result of infection
from external pathogens that hijack human systems, which
could be caused by either Cordyceps-style fungi (as in The
Girl with All the Gifts), prion disease, or evolved brain
tapeworms (parasites or protozoans). The zombie status is
used here to explain viral attacks on the brain, as well as
to describe how this organ generally operates. A book like
Do Zombies Dream of Undead Sheep? shows both the tremendous reach of the zombie in the 21st century and how
fiction may, in turn, end up delivering the very science it
uses as inspiration.
Conclusion: Zombies and Emerging
Infectious Literatures
New infectious zombie texts evince the main shifts in
fictional representations of infection narratives; in them,
symptoms and epidemiology are often based on real infections. We have termed the wider phenomenon within which
the zombie narrative has manifested “emerging infectious
literatures,” an echo of the term “emerging infectious diseases.” Generically, emerging infectious literatures are
varied: some show clear horrific leanings, whereas others
are more obviously defined as science fiction or thrillers.
Influenza is a particularly malleable candidate for such
narratives; the varying possible rates of transmission and
virulence have been used to frame different postapocalyptic
scenarios since the publication of Stephen King’s The Stand
(44). For example, in Immunity (45), 4% of the population
is lost in a matter of months, and screening is deployed to
detect the infected, coupled with immunization of selected
persons. In Station Eleven (46), a much more virulent strain
almost wipes out humanity; survivors are few and required
to construct new, small, civilizations. Yet another book,
Not Forgetting the Whale (47), focuses on how an isolated
Cornish community manages to avoid succumbing to an
outbreak affecting the urban environment. Novels about the
future impact of antimicrobial resistance are as yet few and
far between, but no less interesting: A Fierce Radiance (48)
describes the industrial production of antimicrobial drugs
during World War II, the prioritization of combat troops to
receive treatment, and the impact of antimicrobial drugs
on public health, and The Deep Zone (49) is concerned
with the discovery of new antimicrobial drugs in unusual
environments (caves), couched in industrial and political
espionage. More recently, short stories (for example, Infectious Futures, published by NESTA [http://www.nesta.
org.uk/search?search_api_views_fulltext=Infectious%20
futures]), comic books (50), and other public information
efforts are attempting to raise awareness and change behavior. Perhaps Zika virus and Middle East respiratory syndrome will provide inspiration for the next epidemiologic
antiheroes. Zombies will likely remain a returning concern
for epidemiologically inclined writers.
To return to our initial premise, the book club format
successfully allows discussion between experts and nonexperts about the overlaps between pandemic fact and fiction.
Through these discussions, participants can focus on key
messages about disease and infection that underpin the fiction narrative. Meeting reports and reading guides posted
on the Bad Bugs Book Club website over the past 9 years
provide evidence of the success of multiway discussion,
and are a rich resource for others wishing to engage in similar activities. Book club discussions have enabled identification of different themes emerging from such texts, the
most notable of which has, for us, been the zombie infection narrative. In the case of the novels discussed throughout this article, our meetings helped us come to grips with
the contemporary significance, porosity, and ubiquity of the
zombie as contemporary monster. The zombie has enabled
the exploration of our behaviors when confronted with infection and served as an indication of how fiction reflects
current knowledge about pandemics. In the same way that
the changing virulence of pathogens has occurred throughout history, the zombie trope is flexible, something that has
enabled its survival in 21st century literature. Emerging infectious diseases and their management likewise provide a
rich lode for continuous exploration of the microbiological
present and potential future in fiction.
About the Authors
Dr. Verran is a professor of microbiology at Manchester
Metropolitan University, Manchester, UK. Her laboratorybased research focuses on the interactions occurring between
microorganisms and inert surfaces, but she also investigates
how art and literature can facilitate discussion and enhance
understanding of infectious disease epidemiology among
students and public audiences.
Dr. Aldana Reyes is a senior lecturer in English literature and
film at Manchester Metropolitan University and a founding
member of the Manchester Centre for Gothic Studies.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1777
ANOTHER DIMENSION
References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
1778
22.
Verran J. The Bad Bugs Book Club: science, literacy, and
engagement. J Microbiol Biol Educ. 2013;14:110–2.
http://dx.doi.org/10.1128/jmbe.v14i1.507
Hartley J. The reading groups book. Oxford: Oxford University
Press; 2002.
Calman KC, Downie RS, Duthie M, Sweeney B. Literature
and medicine: a short course for medical students. Med Educ.
1988;22:265–9. http://dx.doi.org/10.1111/j.1365-2923.1988.
tb00752.x
Aaronson LR. The “novel approach”: popular fiction as a teaching
tool in undergraduate microbiology courses. Focus Microbiol Educ.
2008;15:2–4.
Aune JE, Evans LL, Boury N. Using non-fiction narratives in an
English course to teach the nature of science and its importance to
communicating about science. J Microbiol Biol Educ. 2018;19:1–6.
http://dx.doi.org/ 0.1128/jmbe.v19i1.1435
Lloyd R, Neilson R, King S, Dyball M. Review of informal science
learning. London: Wellcome Trust; 2012.
Fogg-Rivers LA, Hickman M. The people, the people, the people,
the people: engaging underserved audiences. In: Collected
thoughts: essays inspired by the annual science communication
conference. London: British Science Association; 2014.
Wald P. Contagious: cultures, carriers and the outbreak narrative.
Durham (NC, USA): Duke University Press; 2008.
Alcabes P. Dread: how fear and fantasy have fueled epidemics from
the black death to the avian flu. New York: Public Affairs; 2009.
Matheson R. I am legend. London: Orion; 1954.
Stoker B. Dracula. London: Rider and Company; 1897.
Del Toro G, Hogan C. The strain. London: Harper Collins; 2009.
Klein M. The shock doctrine. The rise of disaster capitalism.
London: Penguin; 2008.
Bishop KW. American zombie gothic: the rise and fall (and rise)
of the walking dead in popular culture. Jefferson, NC, USA:
McFarland; 2010.
Smith A. The ghost story, 1840–1920: a cultural history.
Manchester, UK: Manchester University Press; 2012.
McDonald BE. The vampire as numinous experience: spiritual
journeys with the undead in British and American literature.
Jefferson, NC: McFarland; 2004.
Varnado SL. Haunted presence: the numinous in Gothic fiction.
Tuscaloosa, AL, USA: University of Alabama Press; 1987.
Lauro SJ, Embry K. A zombie manifesto: the nonhuman condition
in the era of advanced capitalism. Boundary 2. 2008;35:85–108.
http://dx.doi.org/10.1215/01903659-2007-027
Munz P, Hudea I, Imad J, Smith RJ. When zombies attack!
Mathematical modelling of an outbreak of zombie infection.
In: Tchuenche JM, Chiyaka C, editors. Infectious disease
modelling research progress. New York: Nova Science Publishers;
2009. p. 133–50.
Verran J, Crossley M, Carolan K, Jacobs N, Amos M. Monsters,
microbiology and mathematics: the epidemiology of a zombie
apocalypse. J Biol Educ. 2013;48:98–104. http://dx.doi.org/
10.1080/00219266.2013.849283
Kirkman R, Moore T. The walking dead. Berkeley (CA, USA):
Image Comics Inc.; 2003.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
Botting F. Zombie London: unexceptionalities of the new world
order. In: Phillips L, Witchard A, editors. London Gothic: place,
space and the gothic imagination. London: Continuum; 2010.
p. 153–70.
Carey MR. The girl with all the gifts. London: Orion; 2014.
Marion I. Warm bodies. London: Vintage; 2010.
Browne SA. Breathers: a zombie’s lament. London:
Piatkus; 2009.
Grahame-Smith S. Pride and prejudice and zombies. Philadelphia,
PA: Quirk Productions Inc.; 2009.
Shan D. Zom-B. London: Simon and Schuster; 2012.
Moody D. Hater. New York: St Martin’s Press; 2006.
Priest C. Boneshaker. New York: Tor Books; 2009.
Higson C. The enemy. London: Puffin; 2008.
Maberry J. Rot and ruin. London: Simon and Schuster; 2010.
Brooks M. World war Z. London: Gerald Duckworth and
Co. Ltd.; 2006.
Flint J, Rancaniello VR, Rall GE, Skalka AM. Principles of
virology. 4th ed. Washington: ASM; 2015.
Centers for Disease Control and Prevention. Outbreaks
chronology: Ebola virus disease. 2017 [cited 2018 May 4].
https://www.cdc.gov/vhf/ebola/outbreaks/history/chronology.html
Preston R. The hot zone. London: Doubleday; 1994.
Harman C. Zombie capitalism: global crisis and the relevance of
Marx. Chicago: Haymarket; 2010.
Giroux HA. Zombie politics and culture in the age of casino
capitalism. New York: Peter Lang; 2011.
Whitman G, Dow J. Economics of the undead: zombies,
vampires and the dismal science. Lanham (MD, USA): Rowman
and Littlefield; 2014.
Smith TC. Zombie infections: epidemiology, treatment, and
prevention. BMJ. 2015;351:h6423. http://dx.doi.org/10.1136/
bmj.h6423
Houghton F, Del Monte K, Glessner D, Goff J, Hopkins E,
Loney K, et al. Zombie pandemic preparedness: a cautionary
observation. N Z Med J. 2016;129:97–9.
Scholzman SC. The zombie autopsies: secret notebooks from the
apocalypse. London: Bantam Press; 2011.
Grant M. Feed. London: Orbit Books; 2010.
Verstynen T, Voytek B. Do zombies dream of undead sheep?
A neuroscientific view of the zombie brain. Princeton (NJ, USA):
Princeton University Press; 2014.
King S. The stand. London: Hodder and Stoughton; 1990.
Antrim T. Immunity. New York: Regan Arts; 2015.
St. John Mandel E. Station eleven. London: Picador; 2015.
Ironmonger J. Not forgetting the whale. London: Weidenfeld
and Nicolson; 2015.
Belfer L. A fierce radiance. New York: Harper Collins; 2010.
Tabor JM. The deep zone. New York: Ballantine Books; 2012.
Kenney S, Watkiss J. Surgeon X. Berkeley (CA, USA): Image
Comics Inc.; 2016.
Address for correspondence: Joanna Verran, Manchester Metropolitan
University School of Healthcare Science, Chester Street, Manchester M1
5GD, UK; email: J.Verran@mmu.ac.uk
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
ABOUT TH E COVER
Paul Klee (1879–1940), Tropische Dämmerung (Tropical Twilight), 1921. Oil on white primer on paper on cardboard; 13.5 in × 9.1
in/33.5 cm × 23 cm. Fondation Beyeler, Riehen/Basel, Switzerland; Beyeler Collection; Photo: Robert Bayer.
Tr opica l Su n se t Blu e s
Byron Breedlove and Paul M. Arguin
“C
olor is the place where our brain and the universe
meet,” according to painter, printmaker, draftsman,
and teacher Paul Klee. This month’s cover image, Tropische
Dämmerung (Tropical Twilight), is a shimmering example
of Klee’s early work during his very productive decade
at the German art school Bauhaus. In this painting, Klee
uses colors, shapes, and forms that defy expectations for
a tranquil twilight in the tropics, in some ways suggestive
of the peculiar, imaginary plant kingdom envisioned half a
Author affiliation: Centers for Disease Control and Prevention,
Atlanta, Georgia, USA
DOI: https://doi.org/10.3201/eid2409.AC2409
century later in Leo Lionni’s book Parallel Botany. Brisk,
pale brushstrokes make up the broad leaves and twitching
tendrils of vegetation set against a menacing crimson sunset. A crosshatched fence bisects the canvas and is repeated
again in the lower left. Hieroglyphic shapes, particularly a
starlike symbol, contrast with his organic forms, creating
additional tension to the scene. The viewer scans, ruminates, and ponders how Klee’s iconography, arrangement,
and color form a seamless and foreboding snapshot of the
tropics at that moment when colors fade into darkness.
Klee was born in Münchenbuchsee, Switzerland, in
1879. According to a Tate Museum biography, “Klee came
from a generation that would shape the modern world.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1779
ABOUT THE COVER
Albert Einstein . . . was born in March 1879, Georges
Braque and Pablo Picasso in 1880 and 1881 respectively.”
Klee is remembered as a prodigious artist, caring teacher,
talented violinist, and thoughtful writer. His father, Hans
Wilhelm Klee, a German music teacher, and his mother,
Ida Marie Klee, a Swiss singer, no doubt nurtured his interest and instruction in music, but Klee shifted his attention to visual arts while a teenager and, starting in 1898,
he studied drawing and painting in Munich, Germany.
Early in his career, Klee struggled to find his path as an
artist, noting after a trip to Italy “that a long struggle lies
in store for me in this field of color.”
When he returned to Munich in 1911, Klee became involved with Der Blaue Reiter (The Blue Rider), an organization of diverse artists founded by Wassily Kandinsky and
Franz Marc. Those associations and travels to Paris in 1912
exposed the young artist to emerging, new theories about color and art forms and lead to his discovery of work by Pablo
Picasso and Georges Braque. It was during a brief excursion
to Tunisia in 1914, however, that Klee experienced an epiphany about color, attributed to the quality of light there, leading him to boldly proclaim, “Colour has taken possession of
me; no longer do I have to chase after it, I know that it has
hold of me forever... Colour and I are one. I am a painter.”
Klee taught at the Bauhaus from 1921 to 1931, and in 1923,
Kandinsky and Klee formed Die Blaue Vier (The Blue Four).
His influences and his output reveal a gracious fluidity
in his vast trove of artwork, thought to comprise 9,000–
10,000 works. Identifying Klee by a single category or
school of art—whether cubist, abstract, surrealist, expressionist, or perhaps Dadaist—is simply not possible. Klee
worked simultaneously on multiple projects in various media, and those could also be quite dissimilar in style and
approach. (Klee was also ambidextrous: he used his left
hand to paint, his right hand to write.) Alexxa Gotthardt,
staff writer and editor for Arsty, explains that “Klee’s body
of work isn’t easily bucketed into a single category, thanks
in large part to the system of throbbing forms, mystical hieroglyphs, and otherworldly creatures that he developed to
populate his compositions.”
Whether Klee’s rendering of a tropical twilight came
from a place he visited or imagined does not matter. But
Klee asserted in his 1920 Creative Confession that “Art
does not reproduce the visible, rather, it makes visible.” We
1780
see the tropical twilight through his eyes as both the natural
beauty and the hidden dangers together.
It is at this juncture between day and night when crepuscular fauna are active and the stealthy nocturnal denizens of the tropics begin to stir. Before you can see them,
the sting of that first sandfly bite is often the signal that
you have lingered too long watching the sunset and it is
time to head inside for the evening. Tiny female Anopheles mosquitoes also become active at this time, seeking
a blood meal for sustenance while perpetuating the devastating cycle of malaria infections. Alphonse Laveran, the
scientist who discovered the malaria parasite Plasmodium
falciparum, died in 1922, the year after Klee finished this
arresting painting that evokes the world’s tropical areas. By
2050, according to the report State of the Tropics, more than
half of the world’s population and 60% of children will live
in the tropics. Within the tropics, malaria, the World Health
Organization’s 17 neglected tropical diseases, and numerous other zoonotic infections such as leptospirosis and human trypanosomiasis are leading causes of death and disability in humans.
Bibliography
1.
2.
3.
4.
5.
6.
7.
8.
9.
Gotthardt A. A brief history of Bauhaus master and father of
abstraction Paul Klee [cited 2018 Jul 15]. https://www.artsy.net/
article/artsy-editorial-what-you-need-to-know-about-paul-klee
Hemingway J. Health in the tropics. In: State of the Tropics, 2014
report; p. 275–7 [cited 2018 Jul 22]. https://www.jcu.edu.au/
state-of-the-tropics/publications/2014/2014-essay-pdfs/
Essay-3-Hemingway.pdf
James Cook University. State of the tropics 2017 sustainable
infrastructure report [cited 2018 Jul 22]. https://www.jcu.edu.au/
state-of-the-tropics
Klee P. Creative confessions. London: Tate Publishing; 2013.
Klee P, Grohmann W. Paul Klee, 1879–1940: a retrospective
exhibition [cited 2018 Jul 18]. https://archive.org/details/
paulklee1879klee
Lionni L. Parallel Botany. New York: Alfred A. Knopf; 1977.
Paul Klee biography [cited 18 July 2018]. https://www.biography.
com/people/paul-klee-9366304
Rewald S. Paul Klee (1879–1940) [cited 2018 Jul 15].
https://www.metmuseum.org/toah/hd/klee/hd_klee.htm
Tate Museum. A–Z of Paul Klee [cited 2018 Jul 18].
https://www.tate.org.uk/art/artists/paul-klee-1417/a-z-paul-klee
Address for correspondence: Byron Breedlove, EID Journal, Centers for
Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop H16-2,
Atlanta, GA 30329-4027, USA; email: wbb1@cdc.gov
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
N EW S AN D N OTES
Upcoming Infectious
Disease Activities
September 23–26, 2018
Upcoming Issue
• Molecular Evolution, Diversity, and Adaptation
of Influenza A(H7N9) Viruses in China
• Influenza Transmission Dynamics in Nicaragua
Households
• Rapid Increase in Carriage Rates of Enterobacteriaceae
Producing Extended-Spectrum β-Lactamases in Healthy
Preschool Children, Sweden
• Evaluation of Nowcasting for Detection and Prediction of
Local Influenza Epidemics, Sweden, 2009–2014
• Identification of Influenza C Virus in Cattle with
Respiratory Disease in the United States, 2016–2018
• Multilocus Sequence Typing of Mycoplasma
pneumoniae, Japan, 2002–2016
• Simple Estimates for Local Prevalence of Latent
Tuberculosis Infection, United States, 2011–2015
• Circulation of Influenza A(H5N8) Virus, Saudi Arabia
• Diagnosis of Haemophilus influenzae Pneumonia by
Nanopore 16S Amplicon Sequencing of Sputum
• Staphylococcus argenteus Sequence Type 2250
Community-Acquired Bone and Joint Infection,
France 2017
• Severe Respiratory Illness Outbreak Associated with
Human Coronavirus NL-63 in Long-Term Care Facility
• Psychrobacter sanguinis Wound Infection Associated
with Marine Environment Exposure, Washington, USA
• Protective Measures for Humans against Avian Influenza
A(H5N8) Outbreaks in 22 European Union/European
Economic Area Countries and Israel, 2016–17
• VisiEAU 2018—A Vision for Water in Haiti, 2018
Complete list of articles in the October issue at
http://www.cdc.gov/eid/upcoming.htm
ASM Conference on Rapid Applied
Mirobial Next-Generation
Sequencing and Bioinformatic Pipelines
Tysons, VA, USA
https://www.asm.org/
October 1–3, 2018
International Conference on
Migration Health
Sponsored by the International
Society of Travel Medicine
Rome, Italy
http://www.istm.org/ICMH2018
October 3–7, 2018
ID Week
San Francisco, CA, USA
http://www.idweek.org/
October 14–18, 2018
Keystone Symposia Conference
Hong Kong, China
www.keystonesymposia.org/18S2
October 28–30, 2018
International Society for Vaccines
2018 Annual Congress
Atlanta, GA, USA
www.ISVCongress.org
October 28–November 1, 2018
ASTMH
American Society of Tropical
Medicine and Hygiene
New Orleans, LA, USA
http://www.astmh.org/
October 31—November 4, 2018
11th International Respiratory
Syncytial Virus Symposium
Asheville, NC USA
http://rsvsymposium.com/
November 9–12, 2018
ProMED
International Society for
Infectious Diseases
7th International Meeting on
Emerging Diseases and Surveillance
Vienna, Austria
http://imed.isid.org/index.shtml
Email announcements to EIDEditor
(eideditor@cdc.gov). Include the event’s
date, location, sponsoring organization, and
a website. Some events may appear only on
EID’s website, depending on their dates.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
1781
Ea r ning CM E Cre dit
To obtain credit, you should first read the journal article. After reading the article, you should be able to answer the following, related, multiple-choice questions. To complete the questions (with a minimum 75% passing score) and earn continuing
medical education (CME) credit, please go to http://www.medscape.org/journal/eid. Credit cannot be obtained for tests completed on paper, although you may use the worksheet below to keep a record of your answers.
You must be a registered user on http://www.medscape.org. If you are not registered on http://www.medscape.org,
please click on the “Register” link on the right hand side of the website.
Only one answer is correct for each question. Once you successfully answer all post-test questions, you will be able to
view and/or print your certificate. For questions regarding this activity, contact the accredited provider, CME@medscape.
net. For technical assistance, contact CME@medscape.net. American Medical Association’s Physician’s Recognition Award
(AMA PRA) credits are accepted in the US as evidence of participation in CME activities. For further information on this award,
please go to https://www.ama-assn.org. The AMA has determined that physicians not licensed in the US who participate in
this CME activity are eligible for AMA PRA Category 1 Credits™. Through agreements that the AMA has made with agencies
in some countries, AMA PRA credit may be acceptable as evidence of participation in CME activities. If you are not licensed
in the US, please complete the questions online, print the AMA PRA CME credit certificate, and present it to your national
medical association for review.
Ar t icle T it le
N a t ion a l Su r ve illa n ce for Clostridioides difficile
I n fe ct ion , Sw e de n , 2 0 0 9 – 2 0 1 6
CM E Que st ions
1. You are advising a large Swedish hospital regarding
anticipated needs for Clostridioides difficile infection
(CDI). According to the analysis of data from the
Swedish national surveillance program by Rizzardi
and colleagues, which of the following statements
about CDI incidence rates and resistance from 2012 to
2016 is correct?
A.
National CDI incidence increased by 22% from 2012
to 2016
B. The proportion of multidrug-resistant (MDR) isolates
increased by 18% from 2012 to 2016
C. Among European countries, Sweden still has a
comparatively high CDI incidence
D. From 2012 to 2016, geographical variation in
incidence among counties increased
2. According to the analysis of data from the Swedish
national surveillance program by Rizzardi and
colleagues, which of the following statements about
distribution of CDI types, including known outbreaks
from 2012 to 2016, is correct?
A.
B.
1782
High incidence of CDI in Sweden is best explained by
nationwide outbreaks
RT017 was the most common polymerase chain
reaction (PCR) ribotype throughout the whole period
from 2012 to 2016
C.
D.
Ribotypes frequently associated with MDR isolates
were most common in 2014 and 2015
A clonal outbreak not always apparent in clinical
practice or in infrequent surveillance programs could
explain geographical clustering of MDR isolates
3. According to the analysis of data from the Swedish
national surveillance program by Rizzardi and
colleagues, which of the following statements about
the impact of diagnostic methods on CDI incidence
and other possible reasons for changes in incidence
and resistance is correct?
A.
A decrease in CDI incidence and resistance is caused
exclusively by decreased antibiotic use
B. The disappearance of geographical clusters of
specific C. difficile PCR ribotypes indicates reduced
nosocomial spread
C. Use of stand-alone nucleic acid amplification testing
(NAAT) explains higher CDI incidence
D. Minimal inhibitory concentration distributions of
isolates collected in Sweden between 2009 and
2016 were very similar to those from the European
Committee on Antimicrobial Susceptibility Testing
(EUCAST) for all tested antibiotics
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 9, September 2018
Em e rging I nfe c t ious Dise a se s is a peer-reviewed journal established expressly to promote the recognition of new and
reemerging infectious diseases around the world and improve the understanding of factors involved in disease emergence, prevention, and elimination.
The journal is intended for professionals in infectious diseases and related sciences. We welcome contributions from infectious disease specialists in
academia, industry, clinical practice, and public health, as well as from specialists in economics, social sciences, and other disciplines. Manuscripts in all
categories should explain the contents in public health terms. For information on manuscript categories and suitability of proposed articles, see below and
visit http://wwwnc.cdc.gov/eid/pages/author-resource-center.htm.
Sum m a r y of Aut hors’ I nst ruc t ions
Authors’ Instructions. For a complete list of EID’s manuscript guidelines, see the
author resource page: http://wwwnc.cdc.gov/eid/page/author-resource-center.
Manuscript Submission. To submit a manuscript, access Manuscript Central from
the Emerging Infectious Diseases web page (www.cdc.gov/eid). Include a cover letter
indicating the proposed category of the article (e.g., Research, Dispatch), verifying the
word and reference counts, and confirming that the final manuscript has been seen and
approved by all authors. Complete provided Authors Checklist.
Manuscript Preparation. For word processing, use MS Word. Set the document
to show continuous line numbers. List the following information in this order: title page,
article summary line, keywords, abstract, text, acknowledgments, biographical sketch,
references, tables, and figure legends. Appendix materials and figures should be in
separate files.
Title Page. Give complete information about each author (i.e., full name, graduate
degree(s), affiliation, and the name of the institution in which the work was done). Clearly
identify the corresponding author and provide that author’s mailing address (include phone
number, fax number, and email address). Include separate word counts for abstract and text.
Keywords. Use terms as listed in the National Library of Medicine Medical
Subject Headings index (www.ncbi.nlm.nih.gov/mesh).
Text. Double-space everything, including the title page, abstract, references, tables,
and figure legends. Indent paragraphs; leave no extra space between paragraphs. After
a period, leave only one space before beginning the next sentence. Use 12-point Times
New Roman font and format with ragged right margins (left align). Italicize (rather than
underline) scientific names when needed.
Biographical Sketch. Include a short biographical sketch of the first author—both
authors if only two. Include affiliations and the author’s primary research interests.
References. Follow Uniform Requirements (www.icmje.org/index.html). Do not
use endnotes for references. Place reference numbers in parentheses, not superscripts. Number citations in order of appearance (including in text, figures, and tables).
Cite personal communications, unpublished data, and manuscripts in preparation or
submitted for publication in parentheses in text. Consult List of Journals Indexed in
Index Medicus for accepted journal abbreviations; if a journal is not listed, spell out
the journal title. List the first six authors followed by “et al.” Do not cite references in
the abstract.
Tables. Provide tables within the manuscript file, not as separate files. Use the MS
Word table tool, no columns, tabs, spaces, or other programs. Footnote any use of boldface. Tables should be no wider than 17 cm. Condense or divide larger tables. Extensive
tables may be made available online only.
Figures. Submit editable figures as separate files (e.g., Microsoft Excel, PowerPoint).
Photographs should be submitted as high-resolution (600 dpi) .tif or .jpg files. Do not embed
figures in the manuscript file. Use Arial 10 pt. or 12 pt. font for lettering so that figures, symbols, lettering, and numbering can remain legible when reduced to print size. Place figure
keys within the figure. Figure legends should be placed at the end of the manuscript file.
Videos. Submit as AVI, MOV, MPG, MPEG, or WMV. Videos should not exceed 5
minutes and should include an audio description and complete captioning. If audio is
not available, provide a description of the action in the video as a separate Word file.
Published or copyrighted material (e.g., music) is discouraged and must be accompanied
by written release. If video is part of a manuscript, files must be uploaded with manuscript submission. When uploading, choose “Video” file. Include a brief video legend in
the manuscript file.
Type s of Ar t icle s
Perspectives. Articles should not exceed 3,500 words and 50 references. Use of
subheadings in the main body of the text is recommended. Photographs and illustrations are encouraged. Provide a short abstract (150 words), 1-sentence summary, and
biographical sketch. Articles should provide insightful analysis and commentary about
new and reemerging infectious diseases and related issues. Perspectives may address
factors known to influence the emergence of diseases, including microbial adaptation and
change, human demographics and behavior, technology and industry, economic development and land use, international travel and commerce, and the breakdown of public
health measures.
Synopses. Articles should not exceed 3,500 words in the main body of the text
or include more than 50 references. Use of subheadings in the main body of the
text is recommended. Photographs and illustrations are encouraged. Provide a short
abstract (not to exceed 150 words), a 1-line summary of the conclusions, and a brief
biographical sketch of first author or of both authors if only 2 authors. This section
comprises case series papers and concise reviews of infectious diseases or closely
related topics. Preference is given to reviews of new and emerging diseases; however, timely updates of other diseases or topics are also welcome. If detailed methods
are included, a separate section on experimental procedures should immediately follow the body of the text.
Research. Articles should not exceed 3,500 words and 50 references. Use of subheadings in the main body of the text is recommended. Photographs and illustrations are
encouraged. Provide a short abstract (150 words), 1-sentence summary, and biographical
sketch. Report laboratory and epidemiologic results within a public health perspective.
Explain the value of the research in public health terms and place the findings in a larger
perspective (i.e., “Here is what we found, and here is what the findings mean”).
Policy and Historical Reviews. Articles should not exceed 3,500 words and 50 references. Use of subheadings in the main body of the text is recommended. Photographs
and illustrations are encouraged. Provide a short abstract (150 words), 1-sentence summary, and biographical sketch. Articles in this section include public health policy or historical reports that are based on research and analysis of emerging disease issues.
Dispatches. Articles should be no more than 1,200 words and need not be divided
into sections. If subheadings are used, they should be general, e.g., “The Study” and
“Conclusions.” Provide a brief abstract (50 words); references (not to exceed 15); figures
or illustrations (not to exceed 2); tables (not to exceed 2); and biographical sketch. Dispatches are updates on infectious disease trends and research that include descriptions
of new methods for detecting, characterizing, or subtyping new or reemerging pathogens.
Developments in antimicrobial drugs, vaccines, or infectious disease prevention or elimination programs are appropriate. Case reports are also welcome.
Research Letters Reporting Cases, Outbreaks, or Original Research. EID
publishes letters that report cases, outbreaks, or original research as Research Letters.
Authors should provide a short abstract (50-word maximum), references (not to exceed
10), and a short biographical sketch. These letters should not exceed 800 words in the
main body of the text and may include either 1 figure or 1 table. Do not divide Research
Letters into sections.
Letters Commenting on Articles. Letters commenting on articles should contain a
maximum of 300 words and 5 references; they are more likely to be published if submitted
within 4 weeks of the original article’s publication.
Commentaries. Thoughtful discussions (500–1,000 words) of current topics.
Commentaries may contain references (not to exceed 15) but no abstract, figures, or
tables. Include biographical sketch.
Another Dimension. Thoughtful essays, short stories, or poems on philosophical
issues related to science, medical practice, and human health. Topics may include science and the human condition, the unanticipated side of epidemic investigations, or how
people perceive and cope with infection and illness. This section is intended to evoke
compassion for human suffering and to expand the science reader’s literary scope.
Manuscripts are selected for publication as much for their content (the experiences they
describe) as for their literary merit. Include biographical sketch.
Books, Other Media. Reviews (250–500 words) of new books or other media on
emerging disease issues are welcome. Title, author(s), publisher, number of pages, and
other pertinent details should be included.
Conference Summaries. Summaries of emerging infectious disease conference activities (500–1,000 words) are published online only. They should be submitted no later
than 6 months after the conference and focus on content rather than process. Provide
illustrations, references, and links to full reports of conference activities.
Online Reports. Reports on consensus group meetings, workshops, and other activities in which suggestions for diagnostic, treatment, or reporting methods related to
infectious disease topics are formulated may be published online only. These should not
exceed 3,500 words and should be authored by the group. We do not publish official
guidelines or policy recommendations.
Photo Quiz. The photo quiz (1,200 words) highlights a person who made notable
contributions to public health and medicine. Provide a photo of the subject, a brief clue
to the person’s identity, and five possible answers, followed by an essay describing the
person’s life and his or her significance to public health, science, and infectious disease.
Etymologia. Etymologia (100 words, 5 references). We welcome thoroughly researched
derivations of emerging disease terms. Historical and other context could be included.
Announcements. We welcome brief announcements of timely events of interest to
our readers. Announcements may be posted online only, depending on the event date.
Email to eideditor@cdc.gov.